

NATIONAL QUALITY FORUM

+ + + + +

ATTRIBUTION: PRINCIPLES AND APPROACHES COMMITTEE  
IN-PERSON MEETING

+ + + + +

WEDNESDAY  
JUNE 15, 2016

+ + + + +

The Committee met at the National Quality Forum, 9th Floor Conference Room, 1030 15th Street, N.W., Washington, D.C., at 9:00 a.m., Ateev Mehrotra, Chair, presiding.

PRESENT:

ATEEV MEHROTRA, MD, MPH, Chair

MICHAEL BARR, MD, MBA, MACP, National Committee  
for Quality Assurance

JENNY BEAM, MSc, Humana

ELIZABETH DRYE, MD, SM, Yale Center for Outcomes  
Research and Evaluation (CORE)

TROY FIESINGER, MD, Village Family Practice of  
Fort Bend

CHARLES HAWLEY, MA, Utah Department of Health

ARI HOUSER, AARP Public Policy Institute

KEITH KOCHER, MD, MPH, MPhil, University of  
Michigan

ROBERT KROPP, MD, MBA, MACP, Aetna Accountable  
Care Solutions

DANIELLE LLOYD, MPH, Premier, Inc.

IRA MOSCOVICE, PhD, University of Minnesota  
School of Public Health

JENNIFER NOWAK, RN, MSN, Blue Cross Blue Shield  
Association

JENNIFER PERLOFF, PhD, Heller School for Social  
Policy and Management, Brandeis  
University\*

BRANDON POPE, PhD, Baylor Scott & White Health

LAUREL RADWIN, PhD, RN, VA Boston Healthcare  
System

MICHAEL SAMUHEL, PhD, Booz Allen Hamilton

ROBERT SCHMITT, FACHE, FHFMA, MBA, CPA, Gibson  
Area Hospital & Health Services

NATHAN SPELL, Emory University School of  
Medicine

SRINIVAS SRIDHARA, PhD, MS, The Advisory Board

BHARAT SUTARIYA, MD, FACEP, Cerner Corporation

**NQF STAFF:**

HELEN BURSTIN, MD, MPH, Chief Scientific Officer

DONNA HERRING, MPH, Project Analyst

KIM IBARRA, Project Manager

ELISA MUNTHALI, MPH, Vice President, Quality  
Measurement

ERIN O'ROURKE, Senior Director

ASHLIE WILBON, RN, MPH, Senior Director

**ALSO PRESENT:**

TAROON AMIN, PhD, Independent Advisor

SOPHIA CHAN, PhD, MPH, Center for Clinical  
Standards & Quality

DAN MULDOON, MA, Federal Liaison, Center for  
Medicare & Medicaid Innovation

ANDREW RYAN, PhD, University of Michigan School  
of Public Health

\* present by teleconference

CONTENTS

Review Work from Day 1 and Day 2 Objectives

Ateev Mehrotra . . . . .24

Deep Dive into Results of Environmental Scan of Attribution Approaches

Andrew Ryan. . . . .35

Determining the Merits of Attribution Approaches

Andrew Ryan. . . . .103

Public Comment . . . . .174

How Can Attribution Models be Improved . . . . .175

Revisiting Draft Framework and Principles . . . . .236

Meeting Recap and Next Steps . . . . .271

Adjourn

1 P-R-O-C-E-E-D-I-N-G-S

2 9:07 a.m.

3 DR. AMIN: All right. Well, welcome  
4 everybody to day 2 of the Attribution meeting.  
5 Thank you for all of your contributions  
6 yesterday. We look forward to another exciting  
7 day of discussion on attribution.

8 Before we get started I just wanted to  
9 introduce Jennifer Perloff. Are you on the  
10 phone?

11 MEMBER PERLOFF: Yes, I'm here.

12 CHAIR MEHROTRA: Great. Would you  
13 mind introducing yourself to the Committee and if  
14 you have any disclosures to make.

15 MEMBER PERLOFF: Okay. Sure. So I'm  
16 a health physicist researcher at Brandeis, and  
17 the vast majority of my work in the last four  
18 years has been on episodes of care. And in that  
19 context, we are doing a lot of active work right  
20 now on attribution. And so, I think that would  
21 probably be my only disclosure is that we're  
22 actively funded to be developing attribution

1 methodology.

2 CHAIR MEHROTRA: Great. Thank you,  
3 Jennifer.

4 So with that, I think I'll turn it  
5 over to Ateev to walk through yesterday, some of  
6 the key guiding principles that we have in draft  
7 form, and then we will get started with -- oh,  
8 Ashlie, I apologize. And we have our  
9 commissioned author with us today.

10 Andy Ryan, if you wouldn't mind just  
11 doing a quick introduction?

12 DR. RYAN: Sure. Hi, everyone. It's  
13 a pleasure to have the chance to meet with all of  
14 you today. I am a health economist/health  
15 services researcher. I work at the University of  
16 Michigan, although here I'm here as an  
17 individual. And so, I'll talk about our approach  
18 to our report and what we did and what we found,  
19 but I'm just looking forward to engaging with you  
20 on these topics.

21 MS. WILBON: Thanks, Andy.

22 So before we get started on the review

1 of the draft principles, I thought it might be a  
2 helpful foundation for today as we kind of wrap  
3 up some of the discussions for over the two days  
4 on this issue to kind of give everyone a sense of  
5 what we're expecting or what our plan is at the  
6 end of the two-day meeting, the product that will  
7 come out, that will go out for public comment,  
8 and then ultimately the product that we're  
9 looking to have at the end of the project, which  
10 might help frame some of our discussions and kind  
11 of where it's going.

12 Because you guys have great  
13 discussion, and it's not just going into the air;  
14 we're capturing it all. We are still actively  
15 figuring out how to frame it all and put it into  
16 a product, but just basically the principles that  
17 we've come up with today or over the last couple  
18 of days, we've identified that some of these may  
19 fit better as recommendations. We're going to be  
20 parsing them out as we have more discussion to  
21 figure out what may fit better as a  
22 recommendation versus as a principle.

1           So the product that Andy has produced,  
2       which is the environmental scan, which will also  
3       include some elements of the discussion of the  
4       Committee to build on some of the work that he's  
5       done in the scan and the results and summary of  
6       that and evaluation of those methods.

7           We'll also be producing -- I won't say  
8       a separate report, but a supplemental report that  
9       summarizes some of the other discussions that  
10      we've had, particularly on day one about how to  
11      frame this issue, the elements to be thinking  
12      about when you're just thinking about the issue  
13      of attribution, that will go out as one product  
14      with the environmental scan as an appendix.

15          So the structure of that, exactly what  
16      it looks like we're still working through, but  
17      just wanted to give you guys a sense of the  
18      product that will come out, and that will go out  
19      for comment after this meeting.

20          When we reconvene in August, that  
21      meeting we hope to be more focused on specific  
22      recommendations to measure developers, to NQF, to

1       measure implementers. And that will again build  
2       on the report that we put out for comment after  
3       this meeting and ultimately will be one big, one  
4       large report that includes all of it.

5               We also discussed this morning the  
6       idea of having some kind of smaller, shorter,  
7       like maybe a one or two-page summary that would  
8       be put out for public consumption to kind of  
9       summarize some of the key ideas that have come  
10      out of this group, because it is a lot of  
11      information. It's a very dense topic. There's a  
12      lot of complexity to it. So figuring out how we  
13      can distill that down for broader public  
14      consumption to be put out as well in some mode.

15             So do you have any other --

16             CHAIR MEHROTRA: Yes, if I could just  
17      clarify actually. So what's going to go out for  
18      public comment, just to repeat, is going to be:  
19      this is why attribution is important.

20             MS. WILBON: Yes.

21             CHAIR MEHROTRA: Here is how  
22      attribution is being used out there. That's



1       Andy's work, or his team's work. And that's all,  
2       or the principles also?

3               MS. WILBON: The principles will also  
4       go out for comment.

5               CHAIR MEHROTRA: Okay.

6               MS. WILBON: And at the end of the  
7       next meeting we will add the recommendations, and  
8       that will also go out for comment after the  
9       second. So we'll have kind of two separate  
10      comment periods that the public and members will  
11      get to reflect on after the Committee's  
12      discussion after both meetings, but ultimately  
13      the report kind of builds on itself as we go  
14      through the project.

15              CHAIR MEHROTRA: Sounds good. Okay.

16              MS. WILBON: Does that make sense?

17              CHAIR MEHROTRA: Any questions on  
18      that? Okay. Go ahead, Elizabeth.

19              MEMBER DRYE: Just a question about  
20      like the level that you're thinking about having  
21      the principles at. Are they going to be like a  
22      sentence or two like we were -- as we first threw

1       them up there, or would we be doing any  
2       refinement to that --

3               MS. WILBON: We will definitely be --

4               MEMBER DRYE: -- before public  
5       comment?

6               MS. WILBON: Yes, we will definitely  
7       be doing more refinement. This is all kind of  
8       between the end of the meeting last night and  
9       this morning, so we've digested as much as we  
10      could, but there will definitely be more  
11      refinement. And I suspect as we put together a  
12      report, it will be probably one sentence and then  
13      maybe like a couple of sentences explaining where  
14      that came from and why we think it's an important  
15      principle. But we anticipate them being rather  
16      brief.

17              CHAIR MEHROTRA: And this level, too?

18              MS. WILBON: Yes.

19              CHAIR MEHROTRA: This is kind of what  
20      you were -- okay.

21              MEMBER SAMUHEL: Yes, thanks. I think  
22      this is all good as a starting point with the

1 environmental scan and the principles and so on,  
2 but I don't know if it's a concern, but I'm  
3 having a hard time getting my head around maybe  
4 what the final report is going to look like. And  
5 specifically I guess what I'm wondering about is  
6 there's work going on in developing methods for  
7 attribution in various scenarios. Some in terms  
8 of clinical attribution. The colleague from  
9 Brandeis mentioned the work that they're doing.  
10 There's work going on for CMS in terms of program  
11 attribution. And I'm wondering how we're going  
12 to -- or if we want to reflect the current status  
13 of these things in the report.

14 MS.WILBON: So that is actually what  
15 the environmental scan is intended to capture.  
16 So any additional -- so we'll go over what Andy  
17 and his team have been able to capture so far,  
18 but if there's any additional things that we  
19 think are missing or that some additional work or  
20 approaches that we think should be captured, I  
21 think that this is prime time to discuss that and  
22 figure out how to get that captured in an

1 environmental scan so that it is part of our  
2 catalog of what is going on in terms of current  
3 state.

4 CHAIR MEHROTRA: And just to clarify,  
5 so there will be that front section where it will  
6 be sort of the state of the literature, what we  
7 know so far, and what it's --

8 MS.WILBON: Yes.

9 CHAIR MEHROTRA: Okay.

10 DR. AMIN: And also just to add to  
11 that, Mike, I mean, part of today's discussion is  
12 to actually get the current state discussion, but  
13 then also just to orient folks. The purpose of  
14 our meeting, which we started to do even  
15 yesterday in terms of the table that we discussed  
16 and whether that is an approach or not, but  
17 essentially the purpose of the next meeting is to  
18 really get concrete in terms of recommendations  
19 in particular applications.

20 And so, we're not going to get to the  
21 level of this is the attribution approach you  
22 should select for X program, but rather an

1 approach that one might want to consider for each  
2 of these different use cases. And I would  
3 welcome input here as well from CMS and others in  
4 terms of what they would find particularly  
5 helpful as we get to that point.

6 Our approach is going to be very  
7 consistent. Now how detailed we get I think will  
8 be based on how comfortable we feel about making  
9 what level recommendation and given where other  
10 users may want input from this group as well.

11 So, Dan, I don't know if you have  
12 anything else to add to that.

13 MR. MULDOON: No, I think that sounds  
14 right. And what we'd be looking for is not --  
15 like you said, we wouldn't be looking for this is  
16 the approach to use in this situation, but sort  
17 of, I think when we were talking about the table,  
18 it would be helpful if you sort of, for those  
19 examples, went through what some serious  
20 considerations were for each of the -- as you  
21 move down the rows sort of, oh, do you want to do  
22 this on an episodic basis versus a patient basis?

1 And sort of rather than being prescriptive just  
2 sort of going through the sort of serious  
3 considerations and things to think through as you  
4 work through whatever specific program or measure  
5 or other scenario you are in fact designing the  
6 attribution rule for.

7 DR. AMIN: Right. And so, sorry, to  
8 just to keep going on this, I think it's a really  
9 important point. Where we want to end today so  
10 we can feel comfortable leaving today that we've  
11 done our work is to have just generally our  
12 approach for how we're going to do that, which is  
13 we could put this table together to get a sense  
14 of how well this is going to work. If not, how  
15 we're going to start working on that. But then  
16 really the deep dive is going to be next time we  
17 meet in August to really do basically just want  
18 Dan just described.

19 CHAIR MEHROTRA: And just to be clear,  
20 at least two -- well, first a question just so I  
21 understand the process. We're going to have  
22 these principles, we're going to have this

1 environmental scan. I think the NQF staff is  
2 going to put it all together. And then are you  
3 going to send it out to all of us for input  
4 before it goes out for public comment? And how  
5 does that process work usually?

6 MS. WILBON: Yes, we can do that. And  
7 I have to look to Kim to see. I don't know the  
8 timeline in that much detail, but we can  
9 certainly build in time for after staff has had  
10 time to write for the Committee.

11 CHAIR MEHROTRA: So what's the norm,  
12 though? So I mean, I'm sure everyone in the room  
13 is like, oh, of course they want to look at it,  
14 but then everyone's busy.

15 MS.WILBON: Yes.

16 CHAIR MEHROTRA: So, I mean, what's  
17 the -- I mean, I don't want to like foist work  
18 upon the Committee members here.

19 MS.WILBON: No, we could certainly --  
20 we have the SharePoint website, so that's  
21 probably the best way to communicate. Everyone's  
22 looking at the same draft at the same time.

1 People can add comments to that. We would give  
2 you guys probably about a week. We can plan and  
3 let you know in advance when that week would be  
4 so that you can try to build in time if you need  
5 to to review it. And then we would take  
6 everyone's comments.

7 We do also have a conference call that  
8 we put on the schedule, although I'm not sure of  
9 the timing. Oh, yes, the timing's not going to  
10 work. We wouldn't have it written by next week.  
11 But we can certainly figure out how best to do  
12 that, whether it's a call that some folks might  
13 be able to hop on to give input or whether we do  
14 it online. It would be a SharePoint or email.

15 MS. IBARRA: And just to add to that,  
16 if for some reason you're unable to make a  
17 comment before we put it out for public comment,  
18 you're still able to make comments throughout and  
19 to view the rest of the public comments, add  
20 anything at that point. So it's not just the  
21 right before it gets published. There's going to  
22 be continuous opportunities for you to review and



1 help us refine these products.

2 CHAIR MEHROTRA: Great. And then the  
3 last point is that, and this is a preview of a  
4 conversation we'll have later, just to reflect  
5 where we were yesterday, I think there's a  
6 desire, I think an appropriate desire for us to  
7 be a little bit more concrete. We discussed this  
8 table as a potential way. And Danielle, Srinivas  
9 and others had put some time into that yesterday  
10 and this morning. And we'll have to see how we  
11 feel about it, because I do want to go in that  
12 direction, because I do think it would be useful,  
13 but we'll have to -- I think responding to the  
14 table and getting your input will be very  
15 important in terms of whether that's something  
16 that will go into the final report.

17 I think there were some questions.  
18 Troy, you had a point?

19 MEMBER FIESINGER: Quick housekeeping  
20 question. I love that you guys have put together  
21 this list. At what point will the draft  
22 principles be sent out? Meaning, will we get a

1 chance to look over it, think about it on the  
2 flight home, respond back?

3 CHAIR MEHROTRA: Right. So I think  
4 we're hoping today to have real-time input on  
5 these principles and provide input, but I do  
6 think that after we leave you can also provide  
7 input. And we'd I think be happy to share.

8 DR. AMIN: Absolutely.

9 MS.WILBON: Yes, we can actually print  
10 -- once we have some discussion about them, we'll  
11 do kind of like a working session I guess, if you  
12 will, on them, and then we can have them printed  
13 out and hand them out before you --

14 DR. BURSTIN: I think hand them out  
15 before we have the discussion.

16 MS.WILBON: Oh, before?

17 DR. BURSTIN: I think it's really hard  
18 for people to look at things on a screen without  
19 -- it's just for a lot of people you have to see  
20 visual -- I think we'll just do it before. Then  
21 you could mark it up, and it's just easier, yes.

22 MEMBER FIESINGER: I'm old-fashioned.

1 I need a piece of paper and a pencil.

2 DR. BURSTIN: Yes, we can do pen and  
3 paper and electronic.

4 MEMBER FIESINGER: But I have a lot of  
5 friends who I'm thinking asking them, in this  
6 scenario, how would this play out for you in your  
7 job situation? And I want to get some more  
8 feedback to help me formulate my thoughts.

9 CHAIR MEHROTRA: Nate, you had a  
10 point?

11 MEMBER SPELL: Yes, I'm struggling,  
12 too, with this tension between how concrete to be  
13 versus the limitations of the evidence in some  
14 sense. And there are some paradigms out there  
15 that we might think about using. So for  
16 instance, the Preventive Services Task Force will  
17 grade the evidence. And we're about to hear what  
18 the collection of evidence is as we look at the  
19 draft of the paper, but thinking ahead a little  
20 bit we might want to, as we create something like  
21 a table, be able to also give a sense of our  
22 level of confidence in these particular

1 approaches, or at least a guidance of the rigor  
2 we would expect in testing as people try to apply  
3 it.

4 CHAIR MEHROTRA: That's interesting,  
5 right, because -- has NQF ever done that? So are  
6 you familiar with the U.S. Preventive -- they'll  
7 say something, right? Yes, so how --

8 DR. BURSTIN: Yes. Of course.

9 CHAIR MEHROTRA: Oh. So Helen knows  
10 it well.

11 (Laughter.)

12 CHAIR MEHROTRA: Is that something  
13 you've ever done in the NQF process? Would that  
14 be -- I mean, I don't know if we have to copy the  
15 A, Bs and so on and so forth, but --

16 DR. BURSTIN: Yes, I mean, so I used  
17 to oversee the U.S. Preventive Services Task  
18 Force, so this is something I know well from my  
19 AHRQ days. I still shudder sometimes at the  
20 thought.

21 (Laughter.)

22 DR. BURSTIN: But I am not sure

1       whatever we're going to talk about today is at  
2       that level of evidence, and I think that's going  
3       to be a question here. But I think a lot of this  
4       is more this is what's out there.

5               I'm not sure how much the  
6       recommendations are tied to evidence, so I think  
7       that is one particular question. I mean,  
8       certainly on the measure evaluation side, we have  
9       a very strict evaluation of the quality, quantity  
10      and consistency of evidence for all of our  
11      measures, but I think we need to think through  
12      with Andy in particular, since that's the part  
13      that's likely going to be the one that's most  
14      driven by evidence, how we want to assess maybe  
15      at least some categorization of personal  
16      information, evidence-based information for the  
17      literature just to provide some of that guidance.

18             But I think this is going to be a  
19      blend of consensus opinion, which is not very  
20      high evidence as many of you know, but important,  
21      along with some evidence from the literature of  
22      what Andy can provide.

1                   MEMBER SPELL: And I think that's  
2 fine. We just ought to be clear about what  
3 evidence we reviewed, the state of the  
4 literature, what is our consensus based on? And  
5 then I think we can provide some guidance going  
6 forward about the degree of testing that should  
7 be expected for measures coming forward.

8                   CHAIR MEHROTRA: Troy?

9                   MEMBER FIESINGER: Sort of a follow-on  
10 to Nate's point. It's exciting, the last few  
11 years there's actually finally research on a lot  
12 of these ideas on this P4P work, which incentives  
13 drive which behaviors. One area, if you want to  
14 be aspirational, would be, can we draw that  
15 process a little farther forward, that there  
16 should be some evidence to support what people  
17 do? Because I just have this disquieted feeling  
18 that people are out there just trying all kinds  
19 of stuff to see what works, or even just trying  
20 stuff. It would be nice to do it a little more  
21 scientifically.

22                  DR. BURSTIN: I do think it's

1 important to stay in scope about attribution. I  
2 mean, that could go pretty far afield in terms of  
3 the full evidence of P4P, et cetera. I think  
4 keeping it within scope of attribution, that  
5 would be fine.

6 CHAIR MEHROTRA: So let me just review  
7 where we are now. So we're going to go over  
8 these principles just to kind of set, kind of  
9 refresh where we are. We will have lots of time  
10 to discuss these, but just right now I'm just  
11 going to plant the seed, and then we'll go right  
12 to Andy, and then we'll come back to these  
13 principles later on, but just as a recap of where  
14 we were.

15 So the first idea was, we kind of  
16 switched a little with this first principle,  
17 which is really the goal of attribution is to  
18 drive the system, the healthcare system towards  
19 shared accountability and to advance the goals of  
20 the National Quality Strategy. And this is  
21 trying to incorporate some of the discussion we  
22 had about this tension between attribution and

1 accountability, and what's the goal of this? And  
2 we can discuss this, obviously. I think this  
3 will raise some controversy within the Committee.

4 The second point we want to do is  
5 really emphasize the point here. Attribution is  
6 an essential part of measure specification and  
7 policy and program design, and measures and  
8 programs should be tested with more than one  
9 attribution approach to ensure accuracy and  
10 fairness. We made the point that when we do that  
11 process -- I can't remember, I think it was Jenny  
12 who said make sure we get provider and patient  
13 input on attribution rules to make sure they have  
14 face validity. Consider alignment of the  
15 attributed and measure population so we didn't  
16 have some of the issues that folks were  
17 frustrated with about attribution in the past.  
18 And consider alignment of the purpose of  
19 attribution, the attribution approach and measure  
20 concept.

21 And I think that really builds into  
22 the third principle here, which is that you've



1 got to be transparent about the goals of your  
2 attribution rule and why you chose the method you  
3 did. And you also have to really consider the  
4 unintended consequences that might arise as  
5 providers respond to the attribution method. And  
6 I think this was articulated well by Elizabeth  
7 yesterday when we were discussing the smoking  
8 rate in the county. Why the heck would you  
9 attribute that to hospitals? Articulate why you  
10 might consider that.

11 Attribution can be a big deal. It can  
12 impact reliability, validity, score results of an  
13 individual provider overall.

14 The other point that we wanted to make  
15 is this is not a static issue, that as time goes  
16 on, new data sources come on board, health system  
17 itself changes, that we have to think about how  
18 attribution rules will evolve.

19 We really emphasize that attribution  
20 rules, at least algorithms that are used using  
21 claims-based, could be considered -- is not the  
22 only way to do things, and provider and patient

1 self-selection of the responsible provider may be  
2 preferable in some cases. And we discuss some of  
3 the limitations of self-selection.

4 To drive the system forward is  
5 necessary to challenge current norms of  
6 attribution including desire to identify a single  
7 clinician or provider versus assigning to  
8 multiple providers.

9 And this last point is that simplicity  
10 and consistency of attribution rules are the  
11 ideal, however, flexibility is necessary to align  
12 the attribution method and the use case. And the  
13 idea here was is that we needed a lot -- there's  
14 no one single attribution rule out there that can  
15 be used across everything.

16 And then I think this is a preview of  
17 some of the conversation in the rows of the  
18 table, if we want to call it this, which is when  
19 we think about the attribution approach we should  
20 take, here are some different elements that you  
21 should be thinking about: the environmental  
22 context that was important. Emphasize the time

1 frame, how far back you look, the services  
2 included, the geographic context, the measure  
3 use, the focus of the measure, the payment model,  
4 the care delivery model, provider eligibility  
5 criteria, patient eligibility criteria and locus  
6 of control.

7 Those are all some elements, and we're  
8 probably going to play with some of these and  
9 refine, but it at least gives you a sense of at  
10 least some of the thoughts were, reflecting on  
11 the conversation yesterday.

12 So, I was now going to turn to Andy,  
13 but any, I'm going to say, burning thoughts on  
14 this as we -- go ahead, Brandon.

15 MEMBER POPE: I was going to ask do we  
16 feel like we captured enough this concept that --  
17 we talked about a lot of different terms not  
18 being accountability or the varying level of  
19 stakes, but I thought we sort of consistently hit  
20 on the fact that, look, initially it might be for  
21 the purpose of aspiration, and then it's for  
22 performance, and then it's for payment, and then

1       it's for even participation and that there's  
2       these increasing levels of stakes, and just being  
3       thoughtful about -- I think we talked a little  
4       bit the intent of what we're going to do with  
5       this attribution, but being clear and transparent  
6       about that. I just didn't know if people felt  
7       like that was --

8               CHAIR MEHROTRA: Maybe we can add  
9       that. My own reaction to what you said, Brandon,  
10      is, it's important, and I would say that going  
11      back up to that one where it's No. 3 now, I  
12      guess, about you want -- like why are you doing  
13      this? And maybe the couple sentences that Ashlie  
14      described that would go into that segment. But I  
15      think it's an important point.

16              Does that reflect what you were  
17      thinking?

18              MEMBER POPE: I think so. You could  
19      sort of roll it up into several of those, so I  
20      think if we call it out there, it will be great.

21              CHAIR MEHROTRA: Okay. I think, so,  
22      Bob, you had your -- oh, I'm sorry. Oh, you're

1 -- oh, look at --

2 MS.WILBON: Mike, Bob and Troy.

3 CHAIR MEHROTRA: Mike? Oh, Mike.

4 Yes.

5 MEMBER SAMUHEL: Hiding me again  
6 today.

7 (Laughter.)

8 MEMBER SAMUHEL: Actually, it's kind  
9 of the same point I raised yesterday. I keep  
10 reacting to the term provider. And maybe we need  
11 some definitions here. I think we all understand  
12 what we mean by provider, but it has a pretty  
13 broad definition in the current state of  
14 healthcare, public health that I'd like to see us  
15 leave in here. It still feels to me like  
16 attending physician when I read this. Could be  
17 just me. I don't know.

18 CHAIR MEHROTRA: No, I think it's a  
19 good point. Often reports like this have a  
20 glossary, but maybe in this particular case we  
21 need to be a little bit more -- for a couple of  
22 the key terms really say when we're talking about

1 attribution, these are the kind of terms we're  
2 talking about. Accountability might be another  
3 term. So those are a couple key areas. Because  
4 I think you're right, we're very loose sometimes  
5 in the terminology.

6 MEMBER RADWIN: So just a point of  
7 information. On page 2 of the draft report there  
8 is a glossary, and providers is defined there.  
9 Now, I don't know if that's the kind of  
10 definition that's clarifying, but that is set out  
11 as -- I can read it, if you want, but --

12 MEMBER SAMUHEL: I didn't quite catch  
13 where the reference was.

14 MEMBER RADWIN: It's on page 2 of the  
15 draft report. I don't know if it needs to be --  
16 if people feel it needs to be fine-tuned, but it  
17 has been defined.

18 CHAIR MEHROTRA: And I think there's  
19 something to be said for maybe even in this  
20 report avoiding the word provider, because --  
21 maybe just being more clear. Clinician versus  
22 health system or practice. Because I think

1 sometimes we use a term broadly and that adds  
2 confusion. But that's a -- we can discuss that  
3 later.

4 I think Troy?

5 MEMBER FIESINGER: One thing I thought  
6 of adding to the components to consider for these  
7 attribution rules would be vulnerability to  
8 manipulation, meaning -- you can call it gaming,  
9 cherry picking, whatever word you want to use.  
10 We can't design the perfect system --

11 CHAIR MEHROTRA: So right now it is  
12 unintended consequences, but, yes, I think you're  
13 saying maybe it would be more forceful with that  
14 term.

15 (Laughter.)

16 MEMBER FIESINGER: There may be people  
17 out there who are trying to create consequences.  
18 I'm thinking even seeing ACO formation, you think  
19 about how you formulate an ACO and which patients  
20 you want to attribute because you're thinking  
21 about your benchmark and potential for savings.  
22 That's part of the calculation people make as

1       they predict what profits they think they can  
2       make. If we assume everyone's a rational  
3       economic actor, people are going to either  
4       consciously or unconsciously attempt to  
5       manipulate the system. There may also be people  
6       who intentionally manipulate the system.  
7       Anything we can do to make that a little more  
8       difficult or make it sort of more resilient would  
9       help.

10               CHAIR MEHROTRA: Great. No, I think  
11       it's a great point. We'll have to be careful  
12       with what we say there, but I do think your point  
13       is well taken. I'm with you 100 percent that if  
14       you don't consider the gaming, then you're in big  
15       trouble, because almost in every system it's  
16       going to have that.

17               Bob, were you set? You put your card  
18       -- oh.

19               MEMBER KROPP: Yes. Yes, thank.  
20       First of all, great job paraphrasing these -- or  
21       actually editing these principles. I think that  
22       this is clear progress since we left yesterday



1 evening, so thank you to you and staff for that.

2 My question is on page 6 of the draft  
3 report, and this is maybe for Andy, Andy's gone  
4 ahead, between lines 15 and 31, listed some ways  
5 in which the existing attribution methods have  
6 been arrayed. And I'm thinking that that  
7 integrates in some way, shape or form with our  
8 principles.

9 So my question is to what extent will  
10 the paper reflect the deliberations of the  
11 Committee upon which we're arraying some of the  
12 cardinal aspects of these principles -- methods?

13 CHAIR MEHROTRA: Yes, I think it's a  
14 great point, and I think hopefully as we hear  
15 from Andy, that will feed into how we refine  
16 this. But I do want to really emphasize this is  
17 just an iterative process to try to get to  
18 something. And I think we should have -- it  
19 should be consistent.

20 I think was Elizabeth.

21 MEMBER DRYE: A couple of the  
22 principles -- I think 7 was we should challenge

1 norms, like maybe a single provider, and then the  
2 general principle of supporting shared  
3 accountability in the National Quality Strategy  
4 are -- they feel like they're on conflict with  
5 Group 1's proposed progression from shared  
6 accountability down to a single provider over  
7 time. So I raised that yesterday, but I don't  
8 know if this is a good to under -- I don't know  
9 if anyone -- if that conflicts or I'm just  
10 misjudging that.

11 CHAIR MEHROTRA: No, no. And let me  
12 -- so I feel we're already -- let me ask a favor,  
13 if this seems reasonable to you, that maybe --  
14 this is exactly the conversation we want to have,  
15 but I think there was a thought that -- get  
16 Andy's thoughts out there first. So could I hold  
17 -- I know Srinivas, Ari and Michael had some  
18 thoughts, and Ira, and then maybe come back to  
19 you guys? Would that be okay? Okay. So can I  
20 on that note --

21 (Laughter.)

22 DR. RYAN: Yes, right. So thanks. I

1 certainly hope that my comments about what we did  
2 -- I reviewed the principles, and hearing this  
3 discussion I think it very much will be an input  
4 to this process. It's certainly not meant to be  
5 external or something that is trying to put a  
6 form on these discussions that isn't already  
7 there.

8           So with that, I'll just kind of try to  
9 talk about what we did, why we did it, what we  
10 found and kind of my own view about some of the  
11 tensions and issues going forward with  
12 attribution. Again, we talked a little bit this  
13 morning. I think it's pretty consistent with  
14 where the group was yesterday.

15           So just as some background, I think  
16 this discussion is reflected in the principles,  
17 but attribution is really essential to drive  
18 value-based accountability in healthcare. We  
19 have an uncoordinated fragmented system, and  
20 there's -- first order problems associated with  
21 this are bad care for patients, but a kind of  
22 second order of problem with these uncoordinated

1 systems is kind of not knowing which provider is  
2 responsible for which patients, particularly from  
3 a measurement perspective. And this is really  
4 where attribution comes in. And so we really  
5 view this as the process through which providers,  
6 and using the word that might be in question --

7 (Laughter.)

8 DR. RYAN: -- but nonetheless  
9 providers are made responsible from a measurement  
10 perspective for some aspect of care they provide.  
11 So this is clearly necessary to drive value-based  
12 accountability.

13 But I think the reason why we're doing  
14 this project, the reason why we're all here is  
15 there isn't really clear guidance for how this  
16 should be done. Even some of the basic  
17 parameters of attribution haven't really been  
18 well-defined or considered or thought about how  
19 they should apply under different circumstances.

20 So that's really what we were trying  
21 to do with this report is think about what are  
22 the relevant dimensions of attribution? Why

1 might these dimensions -- how could they be  
2 thought of applying differentially to different  
3 types of care settings? And I think in a broad  
4 kind of way, what's good attribution? How can we  
5 think about criteria that -- attribution  
6 approaches that have desirable outcomes at a  
7 program level and also at a provider level? And  
8 so, these are some of the issues I think that we  
9 try to bring out a little bit in our scan.

10 So what we did is we performed an  
11 environmental scan to identify the attribution  
12 methods that have been proposed or are currently  
13 in use. So this is done with our team, which is  
14 Kristin Maurer, Ariel Linden, Rachel Werner and  
15 Brahmajee Nallamotheu.

16 So our strategy for the search was we  
17 started with kind of a typical lit review search  
18 with MeSH headings and key words, but we found  
19 that this was really leading to too many false  
20 positives. We were getting way too many articles  
21 that were not sufficiently relevant. So instead  
22 what we did was we took some -- a number of what

1 we found to be key articles about attribution  
2 that were in the literature, and kind of saw what  
3 articles were citing the key articles and what  
4 articles were cited by the key articles, and then  
5 used that to kind of snowball and bring in  
6 additional approaches for attribution.

7           So we're currently supplementing this  
8 with a more traditional search method, key words  
9 to bring in additional approaches that we may  
10 have missed with our search strategy. But  
11 nonetheless, the bottom line is that today, our  
12 strategy identified 70 different sources, so  
13 either reports or published articles that  
14 describe 163 different attribution models that  
15 have currently been used or are currently being  
16 used in accountability programs.

17           And so, I'll just tell you that a  
18 model is not a discrete thing. It's really just  
19 a combination of different elements. And what we  
20 did is we defined the attribution models based on  
21 these eight dimensions. So one of them was  
22 clinical circumstances, the type of provider that

1 was attributed, the programmatic circumstances,  
2 the timing of the attributions. So this is a  
3 retrospective versus prospective issue.

4 The exclusivity of attribution. So  
5 this gets at the single versus multiple provider  
6 attribution issue. The period of over time -- of  
7 time over which the attribution, the provider was  
8 responsible for care for a given patient. The  
9 minimum requirements that were the minimum  
10 requirement to make an attribution. And this  
11 gets into the issue of kind of pluralities versus  
12 majorities.

13 And then the measure that was used in  
14 attribution. So an example here is whether  
15 attribution was best based on kind of spending or  
16 whether it was based on visits, for instance.

17 CHAIR MEHROTRA: But I think I'm still  
18 having difficulty wrapping my head around the  
19 difference between a model and a rule, so could  
20 you go through that one more time? We started  
21 using the word attribution model. I'm trying to  
22 get a sense still. If you could do it one more

1 time, what does it mean to you, a model?

2 DR. RYAN: What I would say a model is  
3 an integrated approach. So it's a way that you  
4 can -- it's a combination of different elements  
5 that are put together and that the resulting  
6 product of that is an algorithm that is used to  
7 attribute patients to a provider.

8 CHAIR MEHROTRA: Okay. Got it. So  
9 just to be very concrete, I know there are many  
10 elements, but let's just say one element is you  
11 used visits, and you used a 30 percent cutoff,  
12 and it had to be the plurality. Those would be  
13 the different elements. And then those together  
14 would make an algorithm or model that you were  
15 using. Is that --

16 DR. RYAN: That's exactly right. So  
17 we haven't further condensed the idea of a model  
18 and say, okay, we found five models. Basically,  
19 we haven't gotten beyond just identifying what we  
20 call the 70 separate ways that these elements  
21 were brought together to identify a specific  
22 algorithm for attribution.



1 CHAIR MEHROTRA: Okay.

2 DR. RYAN: All right. So we had to  
3 make some assumptions. Not all the relevant  
4 elements were defined in each of the approaches  
5 that we reviewed, but for instance, if someone's  
6 using a claims-based approach for attribution, we  
7 presumed that that's retrospective as opposed to  
8 prospective attribution.

9 So this boils down to 163 separate  
10 approaches or models. Again, some language  
11 slippage here. I'll just talk about -- try to  
12 stick with the word model. And of these 70, 83  
13 percent have been proposed, and 17 percent have  
14 been implemented in some fashion. So the vast  
15 majority of these models have used retrospective  
16 attribution, 89 percent, compared to 6 percent  
17 using prospective attribution. One of our  
18 readings from the Dartmouth team talked about  
19 some of the, I think, advantages of retrospective  
20 attribution that might be good to talk about as a  
21 group.

22 Attribution approaches tend to require

1 attribution to only one provider, so that was  
2 about 77 percent of approaches compared to those  
3 that required -- multiple providers could be  
4 attributed for a given patient.

5 So visits and spending were the two  
6 most common measures used to attribute patients  
7 to providers, so visits were somewhat more  
8 likely, 42 percent, and 31 percent of models used  
9 spending as a way -- as the kind of measure for  
10 attribution. And I think interestingly, and  
11 hopefully this is something we can discuss as a  
12 group, there's really quite a bit of variation  
13 with respect to the minimum criteria required for  
14 attribution. For instance, a plurality was  
15 required in -- that was most common in 30 percent  
16 of cases. Specific thresholds were used in about  
17 30 percent of other cases. So I think deciding  
18 whether -- what's the minimum determination used  
19 for a match is really crucial.

20 And our team tried to say, okay, we  
21 see all these different elements together. Are  
22 there common groupings of elements that we can

1 see in the data? And we tried to do some kind of  
2 cluster analysis to identify these, but so far we  
3 really haven't coalesced on saying there's 5  
4 approaches or 10. This is still preliminary.  
5 But to us the difficulty identifying kind of  
6 common clusters speaks to the high variability of  
7 the different elements that have been applied in  
8 the extant models.

9 So that's kind of a high-level  
10 perspective about what we did. And so I just  
11 want to kind of comment on what I see as some of  
12 the important issues moving forward. I think  
13 that it sounds like the discussion yesterday was  
14 great, and I really agree with a lot of the  
15 principles that were talked about or established  
16 yesterday.

17 I think one of the things that we  
18 found is that there are some common features of  
19 existing attribution approaches like the use of  
20 retrospective attribution, but many other  
21 features really vary considerably. And I think  
22 having the group discuss even just conceptually

1       about why -- when different attribution methods,  
2       for instance, thresholds for attribution, how  
3       they should be thought of and enforced under  
4       different circumstances I think will be really  
5       important.

6               To me the key issue is really about  
7       how attribution approaches affect reliability and  
8       validity of, I'll just say profiling at both the  
9       program and provider level. So I'd say at the  
10      program level -- when I say that, I mean just say  
11      ACO program or say the MIPS or some kind of PCMH  
12      program. It seems to me that we need, for  
13      instance, some minimum number of patients to be  
14      attributed to providers for the approach to have  
15      tractability. If we developed -- if there's an  
16      attribution algorithm in which only five percent  
17      of patients are being attributed, we just think  
18      this isn't good enough; this doesn't work for  
19      program purposes.

20             At the same time if only 20 percent of  
21      providers are being attributed under a given  
22      programmatic -- under attribution rules, it just

1 seems like the whole program itself is not going  
2 to be able to meet the goals of accountability.  
3 So I think reflecting on how attribution -- how  
4 the individual provider attribution rules kind of  
5 roll up at a program level and affect the ability  
6 to the program for the program to do -- achieve  
7 its purpose is something that's important.

8 And I think Ateev's paper that was  
9 circulated among the Committee really highlights  
10 some of this, that if you apply different  
11 thresholds, you can have vastly different numbers  
12 of patients and providers that end up being  
13 attributed. And this is really crucial.

14 I mean, one way to think about solving  
15 a problem like this, and I don't want to get too  
16 deep in the weeds here, is kind of extending the  
17 window over which attribution can occur, to  
18 extending a time frame, to saying instead of  
19 looking at say 12 months, we could look at a  
20 longer period. That's really what CMS has done  
21 with other performance measures whether  
22 readmission or mortality, to get to greater

1 signal. That's often what's done.

2           So at the provider level, I think  
3 there's the real -- where the rubber meets the  
4 road here has to do with sensitivity and  
5 specificity. So if attributions are too  
6 sensitive and not specific enough, I think  
7 validity could be undermined. So if an algorithm  
8 can assign a patient to a physician just based on  
9 a single visit, and it's very sensitive, all  
10 patients end up getting attributed, for instance,  
11 but you have some poor matches. Physicians that  
12 have very little in common with certain patients  
13 that are attributed to them. I think that's a  
14 problem.

15           At the same time, if a measure is too  
16 -- if an attribution model is too specific, we  
17 could have this -- and attribution is only made  
18 when -- to say all the care of a patient is  
19 provided by a certain provider and otherwise  
20 attribution wouldn't be made. Then we'll have  
21 too few attributed patients to too few providers  
22 and that will kind of undermine the attribution

1 at program level.

2 So I just really think that that's a  
3 central contrast that I see. A central issue is  
4 sensitivity and specificity of attribution and  
5 how it relates to reliability and validity.

6 I think something that I've also been  
7 reflecting on is the importance of these  
8 different attribution rules to -- and we'll talk  
9 about use cases later today, but I see that what  
10 makes sense for ACOs and what might make sense  
11 for PCMHs or even PCPs really might not make  
12 sense for specialists.

13 And so, if we just think about for  
14 instance the one patient/one provider rule, so  
15 the exclusivity of attribution, I think this can  
16 make sense in the context of trying to drive  
17 accountability in a system where it hasn't been  
18 there. So an ACO, a patient gets attributed to a  
19 single ACO and then is responsible for all that  
20 patient's care, I think that really does make  
21 sense. But that really to me doesn't make sense  
22 for lots of specialists. Specialists should

1       probably just not ever really be responsible for  
2       all a patient's care.

3               And so as a result, that one patient  
4       to one provider rule could really make sense in  
5       an outpatient, primary care setting. But for I  
6       think specialist-based attribution considering  
7       multiple providers being responsible for multiple  
8       patients, getting rid of that exclusivity I think  
9       is probably more practical.

10              So I think that's just more kind of an  
11       example, and a lot follows from that. So if it's  
12       exclusivity, one-to-one attribution, then that's  
13       typically what follows is that that provider is  
14       responsible for all the patient's care, whereas  
15       if a physician might not have exclusive  
16       attribution, but it might be multiple providers  
17       are responsible for different patients under  
18       different circumstances, that makes more sense  
19       for kind of episodic care. So an orthopedist  
20       might be responsible for cost and quality  
21       outcomes within some defined window of an index  
22       event. So again, I think those are issues that



1 really map onto some of the key policy and  
2 accountability programs that are underway.

3           So I think just to kind of summarize  
4 our literature scan, we really saw a large  
5 variation in the approaches that were being used,  
6 the models/approaches for attribution. We see  
7 these in both the proposed and the implemented  
8 models. I think there's a tension about  
9 sensitivity and specificity and the trade-offs  
10 there with attribution and how that effects  
11 reliability and validity. I agree with the  
12 Committee's call for flexibility, and I see a key  
13 dimension of this really being related to kind of  
14 specialty care versus kind of more population-  
15 based accountability.

16           And then finally, I think some issues  
17 that really deserve attention in thinking about  
18 recommendations or even principles have to do  
19 with the exclusive versus non-exclusive  
20 attribution and kind of the resulting  
21 responsibility for episode-based cost and quality  
22 versus kind of program year cost and quality.

1                   So and then I think finally this isn't  
2                   an issue that's really going to be solved, but  
3                   how to say whether an attribution approach is  
4                   good, what are the criteria to say this model is  
5                   moving us to where we want to be better than this  
6                   other model, I think remains critical and  
7                   important to discuss, and I just look forward to  
8                   further discussion about these issues with the  
9                   group. So thank you.

10                  CHAIR MEHROTRA: Thanks, Andy. This  
11                  is great. I think just seeing these different  
12                  models laid out in this format and so forth, I  
13                  think this would be really helpful, is also  
14                  helpful. Encourage you to publish these results  
15                  in the peer-reviewed literature. That would be  
16                  really helpful, because I think a lot of people  
17                  are looking for these kind of different models  
18                  also. So a lot of rich stuff here.

19                  Let me open up to the Committee for  
20                  discussion and input. And we had some comments  
21                  about the principles. Maybe if I could -- I have  
22                  that list here, I do promise, but maybe we could

1 just focus right now on Andy's comments. So if  
2 you -- so starting there?

3 (Laughter.)

4 CHAIR MEHROTRA: Okay. There you go.  
5 But I will get back to folks.

6 Jenny, you had some thoughts?

7 MEMBER BEAM: Yes. Thanks, Andy, for  
8 your summary. I guess one of the things that  
9 keeps coming back is in talking about attributing  
10 to a single provider versus multiple providers,  
11 and one of the things I think when looking at --  
12 it goes back to the intent of why we're  
13 attributing. If you're attributing for the  
14 purpose of an incented program or some type of  
15 payment program, I guess from what I've heard,  
16 you don't want patients in multiple provider  
17 buckets because then therefore you are rewarding  
18 for the patient more than once. So that was the  
19 intent in trying to do a single provider  
20 attribution, whereas if you're doing a  
21 performance evaluation to attribute patients to  
22 multiple providers, then that becomes much more

1 relevant at that point.

2 I guess I was wondering from Andy --  
3 I don't know if those type of things have been  
4 looked at as far as in the literature review to  
5 look at the purpose, the intent of each of the  
6 studies. Like what was their goal? Was it on  
7 payment or an incentive versus performance  
8 evaluation; kind of more of that profiling, and  
9 then what method did they use from there?

10 DR. RYAN: Well, we did some work to  
11 define this, particularly in the -- for the  
12 implemented programs how the attribution, how the  
13 elements of that attribution varied across  
14 implemented programs. Because some of the  
15 proposed approaches like what Ateev did in his  
16 paper, it was just stuff that researchers came up  
17 with. So there wasn't so deep in there. There's  
18 probably very little thinking at all.

19 CHAIR MEHROTRA: It was very random,  
20 so --

21 (Laughter.)

22 DR. RYAN: And so, I'd be happy to

1 think about -- we can certainly discuss kind of  
2 what the approaches have been for those extant  
3 programs that have kind of -- and then into some  
4 practice.

5 But your first point about the goals  
6 and beyond what we can try to presume is the goal  
7 from the nature of the accountability program, I  
8 think that's something that we have a hard time  
9 discerning in the kind of literature review,  
10 right? We don't see the -- and what we're  
11 pulling from the papers is not -- in general  
12 there's very little detail about the like genesis  
13 of the program and kind of the thought process  
14 through which accountability did occur.

15 I think these can be gleaned a little  
16 bit by just seeing what's happened in practice  
17 and reflecting on why. And I think that probably  
18 would be --

19 CHAIR MEHROTRA: That's a good point.  
20 Nate?

21 MEMBER SPELL: Just first a  
22 housekeeping thing. I'm having trouble hearing

1 with the construction noise, so just a reminder  
2 to everyone to either speak close to your  
3 microphone or in a loud voice so I can follow it  
4 better. Thanks.

5 CHAIR MEHROTRA: That's a good point.

6 MEMBER SPELL: To the exclusivity  
7 question, I think it gets to the confusion we had  
8 coming out of Group 1 yesterday, and Elizabeth  
9 brought it up earlier. I have a colleague who  
10 likes to refer to his ideal state as the joint  
11 and several liability plan for accountability,  
12 which is that in fact if we are -- in looking at  
13 the future state for some measures, if you really  
14 want to drive a change in how people work  
15 together and form teams, you might intentionally  
16 want to share accountability across providers.  
17 Now, you don't want to pay more than once, so I  
18 think the payment is different, but the  
19 accountability might be shared.

20 So the example is again that diabetic  
21 patient who goes to the orthopedic surgeon let's  
22 say with something that is -- the patient ends up

1 given a prescription for steroids, which of  
2 course could drive the diabetes out of control.  
3 Well, if there's some accountability shared for  
4 diabetic control, it might for instance  
5 incentivize the orthopedist to communicate with  
6 the endocrinologist or primary care doctor around  
7 the care of the glucose management while on  
8 steroids.

9 So that's just that sort of example  
10 where we ought to be thinking about the  
11 implications of one versus another. And I'm not  
12 sure how much we can say what the downstream  
13 impact will be. We can simply describe the  
14 relative merits of one versus another.

15 CHAIR MEHROTRA: That's a really good  
16 point. I think it also builds on the  
17 conversation yesterday about how sometimes  
18 attribution -- I think just it's sometimes  
19 aspirational. We also discussed the case of the  
20 hospital and the 30 days follow-up. I think that  
21 right now it may be thought to be that the  
22 hospital doesn't have much to do with what

1 happens 28 days afterwards, but we're hoping  
2 through attribution to drive them to be. And so  
3 that whole locus of control issue, it's not  
4 today, it's the future.

5 Let's see. Danielle?

6 MEMBER LLOYD: So I was starting to go  
7 along Jenny's line, and I guess the 138 proposed  
8 kind of scared me, because that's a lot --

9 DR. RYAN: It's 163.

10 (Laughter.)

11 MEMBER LLOYD: Well, proposed. Sixty-  
12 three is within use though, right? So it  
13 doesn't matter. So I think part of what I was  
14 also trying to think is could we take some of the  
15 in-use ones -- because they're in use I give them  
16 a little more credibility. Sorry, Ateev. And  
17 maybe I had actually gotten some private payers  
18 to in a blinded fashion give their current  
19 attribution models. And then we also -- I don't  
20 think I see in here the LAN paper, attribution  
21 paper. And maybe that's because it's not  
22 officially published yet. Is it officially



1 published?

2 But there was such a huge appendix,  
3 maybe I missed it. But I think maybe if we took  
4 that because it was a broad effort that's recent  
5 and we took some of the payers and you took the  
6 28 or whatever in use, maybe we would find some  
7 more commonalities. Or maybe if you only took --  
8 I think to what Jenny was saying, let's look at  
9 the ones that are specific to ACOs or let's look  
10 at the ones that are specific to episodic or  
11 something. That might help us make a little bit  
12 more sense of this, because I was having trouble.

13 And I'm glad you're confirming because  
14 I couldn't really find a pattern. So I'm glad  
15 you're sort of saying the same thing. But I  
16 think maybe we need to take a couple more passes  
17 to try to glean some more specifics out of this.

18 You'd specifically asked about --

19 CHAIR MEHROTRA: Danielle, just if I  
20 could clarify. So what I'm sensing from you is  
21 that what you're asking for is almost like some  
22 analyses for specific real world applications;

1 ACOs would be an example, PCMHs, and to see if  
2 you go down to that level there's more  
3 consistency about the rules that are currently in  
4 use.

5 MEMBER LLOYD: So I would even say how  
6 they have the percent table, do that for only the  
7 28 implemented plus the ones that you didn't find  
8 in literature review because they weren't  
9 actually published, the ones that are actually in  
10 use, and rerun these numbers and see if you see  
11 something.

12 CHAIR MEHROTRA: So this is like table  
13 3?

14 MEMBER LLOYD: But that's not the ones  
15 that aren't published, right?

16 CHAIR MEHROTRA: Oh, I see.

17 MEMBER LLOYD: So implemented, but the  
18 things that aren't published is the problem,  
19 right, because --

20 CHAIR MEHROTRA: So it's a combination  
21 of table 2 and table 3 that focus only on those  
22 --

1                   MEMBER LLOYD: Everything seemed to be  
2                   cited, so it didn't seem like the collected  
3                   private payers or the LAN papers was in that. Or  
4                   no? Everybody's flipping.

5                   DR. RYAN: Well --

6                   MEMBER LLOYD: We don't have to answer  
7                   this right now. Just let's think about it. And  
8                   then --

9                   CHAIR MEHROTRA: Can I just -- on that  
10                  point?

11                  MEMBER LLOYD: Yes.

12                  CHAIR MEHROTRA: So, Danielle, I will  
13                  come right back to you. But do you -- Danielle  
14                  is proposing the idea of going to certain private  
15                  payers and specifically  
16                  getting --

17                  MEMBER LLOYD: No, I already did it.

18                  CHAIR MEHROTRA: Oh, okay.

19                  MEMBER LLOYD: I already did it and  
20                  gave it to them.

21                  CHAIR MEHROTRA: Oh, you already have  
22                  those? Okay. You incorporated them?

1                   MEMBER LLOYD: At least four of them.  
2 I didn't get Aetna because I think they weren't  
3 -- somebody was previously on the panel from  
4 there.

5                   MEMBER KROPP: Yes, I used to work for  
6 them, but --

7                   MEMBER LLOYD: So I assumed you'd get  
8 it, Bob.

9                   (Laughter.)

10                  MEMBER KROPP: I said used to.

11                  MEMBER LLOYD: You've got some phone  
12 numbers.

13                  MEMBER KROPP: I'd give it a shot.

14                  MEMBER LLOYD: Yes.

15                  MEMBER KROPP: They're pretty  
16 sensitive about --

17                  DR. RYAN: Well, Danielle, I think  
18 that's a great idea. So apologies if we didn't  
19 integrate stuff that we could have or should  
20 have, but we can certainly do that on the next  
21 round. We didn't limit to published. We looked  
22 in the gray literature, too, so it didn't have to

1 be peer reviewed approaches.

2 MEMBER LLOYD: Yes.

3 DR. RYAN: But surely there are some  
4 that we left out and we would love to supplement  
5 with existing -- other programs that we didn't  
6 include there. So again, I apologize if --

7 MEMBER LLOYD: No, no apologies  
8 necessary. I think it's always good to start  
9 specifically with peer reviewed and stuff, but  
10 since we've kind of got 165 or whatever you're  
11 saying --

12 DR. RYAN: Yes, yes.

13 MEMBER LLOYD: -- and we don't have a  
14 lot of semblance of cohesion around certain  
15 things, it might be another option.

16 DR. RYAN: Yes.

17 MEMBER LLOYD: But you had  
18 specifically asked about retrospective and  
19 prospective, and I guess this is part of why I  
20 think we -- at least I've been leaning towards  
21 here's the specific things you need to think  
22 about and steps you need to take and the things

1       that you need to make transparent to us, but you  
2       don't necessarily have to do one model or  
3       another, and that you need to test multiple  
4       models is because -- for instance, our members  
5       have always been, at least for ACO purposes,  
6       supportive of retrospective because we knew from  
7       our claims analysis it was more accurate, but the  
8       problem is it is not as easily implementable by  
9       the provider.

10               And the other thing here is that some  
11       payers will only give you legal waivers and such  
12       if you know who the beneficiaries are in advance.  
13       So there are other policy considerations that are  
14       then tied to that attribution choice, but I  
15       wouldn't want us to say retrospective is more  
16       accurate and that's the way we're going, right?

17               DR. RYAN: Great. Great point.

18               CHAIR MEHROTRA: Mike?

19               MEMBER SAMUHEL: Yes, I had a reaction  
20       to Andy's point about sensitivity and  
21       specificity, and it got me thinking, because my  
22       background is a statistician. And I think we

1       need to remember that attribution -- what we're  
2       talking about are estimates. We're not talking  
3       about exact engineered numbers. And so, since we  
4       have estimates, estimates have errors. And I  
5       think we need to recognize that fact. And it is  
6       possible to measure error in probably most of the  
7       underlying statistical methods that are at play  
8       in these models or algorithms. And I think it  
9       would be important to do so, and maybe even a  
10      principle here. And it might avoid some  
11      controversy down the road as we try to give some  
12      guidelines about -- especially when we try to  
13      attribute cost and quality to individuals or  
14      enterprises, or whatever.

15               DR. RYAN: I really like that point,  
16      and that gets me thinking that applying different  
17      models would change the individual providers  
18      estimates of kind of their cost and quality. And  
19      the different models would then -- there would be  
20      some variation derived from the application of  
21      different models and that could perhaps provide  
22      some balance or some notion of the error or

1 variation in different approaches.

2 I mean, imagine if we had like 10 ways  
3 of 10 models and that they varied with respect to  
4 sensitivity and specificity, but they all would  
5 generate estimates for the same provider. But  
6 then there would also -- there might be a one-  
7 point estimate or some way to combine those, but  
8 then there could be bounds around that and that  
9 could perhaps be information that's part of the  
10 profile and part of the description of  
11 performance. So anyway, I think I find that  
12 intriguing.

13 CHAIR MEHROTRA: Just one quick point,  
14 which I think it's an interesting idea, which is  
15 here's the truth who's responsible and here's a  
16 measure method to try to find that responsible  
17 provider.

18 But I think I forwarded you that paper  
19 that was done by some folks at Mass General where  
20 they tried to use an algorithm to try to figure  
21 out who was in a physician's panel and then they  
22 went to the physicians and said Sally Jones, in



1 your panel or not in your panel? And one of the  
2 things I came away with was like, oh, the truth  
3 is kind of fuzzy, right? Because you would go to  
4 the doc and you'd say is he or she in your panel?  
5 Some two years ago, I don't know, sort of. I  
6 think she's sort of still coming to me.

7 I mean, there were some that were very  
8 clear-cut, but there was a huge amount of gray  
9 area also in who is your patient, because they  
10 just haven't been seen. So I just want to  
11 reflect that the truth isn't so clear-cut either  
12 if you actually go to the providers themselves.

13 DR. RYAN: Can I ask you --

14 (Simultaneous speaking.)

15 MEMBER PERLOFF: This is Jen on the  
16 phone. Can I jump in on that point?

17 CHAIR MEHROTRA: Yes, of course.

18 MEMBER PERLOFF: I think I picked up  
19 on the sensitivity and specificity part as well  
20 being more methodological, but you could think  
21 about attribution as a negotiated relationship to  
22 some extent. So you might when you're setting up

1 a model -- we negotiate the bundle that providers  
2 are going to go at risk for. We might also  
3 negotiate the attribution methodology that  
4 someone's willing to enter into. So in that way  
5 you define the T, the truth against which you  
6 estimate the error, but it's just one dimension  
7 to the conversation.

8 I just wanted to throw in this idea  
9 that it is a design dimension that you could  
10 negotiate and have. There are different truths  
11 at play and different interpretations. So the  
12 MGH example is excellent. That's all.

13 CHAIR MEHROTRA: Yes. No, that's  
14 great. Truthiness, right?

15 (Laughter.)

16 CHAIR MEHROTRA: Bharat, you had a  
17 comment?

18 MEMBER SUTARIYA: So I think my  
19 comments are two comments, one related to the  
20 just conversation going on right now, which is  
21 it's one thing to find commonality or prevalence  
22 of types of models being used right now, but I

1 would think that since this experimentation or  
2 shift has been going on for now three to five  
3 years, there would be expectation that if we were  
4 to come up with a new model, it should be based  
5 on what do we know scientifically on whether  
6 things worked or not, not just here's what's in  
7 place, but did it produce intended results or  
8 not?

9 And in that regard I wonder if the  
10 author of this paper found any event -- just a  
11 high-level conclusion on what methods worked in  
12 producing the intended result, which is kind of  
13 what we're talking about, the sensitivity,  
14 specificity, not just theoretically but did it  
15 actually produce, which is a hard question. So  
16 one related to that.

17 Second, there's a second obligation I  
18 think we have as a committee, which is whatever  
19 we produce has to be implementable. That means  
20 the data to drive the logic has to be at least  
21 readily available in some form or fashion because  
22 each one of us are smart enough to probably

1 design a perfect algorithm, then to just go into  
2 the real world and not being implementable.

3 For example, right now; I'll share my  
4 own experience, across 50-plus clients that we're  
5 trying to implement attribution algorithm today  
6 for various different ACO efforts and private  
7 payer efforts, my team now has reached up to nine  
8 layers of logic. We're inching toward artificial  
9 intelligence, honestly, in trying to get the  
10 algorithms implementable for all scenarios for  
11 which the client is taking risk on today because  
12 the doctors don't want to be told on here's for  
13 your MSSP, here's for your bundle. They just  
14 want to know who is my panel and how does it  
15 work?

16 So sum it all up to a simple question  
17 out of that, one, any conclusion on what do you  
18 think actually worked in producing the result;  
19 and two, any challenges you saw in the literature  
20 or in anecdotal discussion about what is  
21 implementable and not implementable.

22 DR. RYAN: Well, if we say what has

1 worked from the perspective of improving system-  
2 based accountability -- so I'd be open to other  
3 people's interpretation of the evidence, but  
4 there's two papers that say that the Pioneer ACO  
5 program resulted in reductions in cost growth.  
6 And I actually don't recall the quality results,  
7 but I think improvements in quality as well. And  
8 there's also positive evidence of the alternative  
9 quality contract ACO model that Blue Cross Blue  
10 Shield implemented with respect to both cost  
11 growth and quality. So those are --

12 CHAIR MEHROTRA: But, Andy, is that  
13 worked for the program or worked for the  
14 attribution rule, or model? Because I feel like  
15 those are different.

16 DR. RYAN: Well, I think that the  
17 question was -- wasn't the question about when  
18 has this been applied, and then there's been a  
19 good system outcome?

20 MEMBER SUTARIYA: Yes, I'm not so much  
21 on the result generated from a cost savings. I  
22 think the charge really is did we attribute the

1 right patient to the right doctor?

2 DR. RYAN: Oh, okay.

3 MEMBER SUTARIYA: Or right team,  
4 right, because that's the first step. And then  
5 there's a complex mix of how do you measure  
6 quality and how do you attribute quality and how  
7 do you weight quality and so on to change  
8 behavior, right?

9 DR. RYAN: Yes.

10 MEMBER SUTARIYA: So I'm more  
11 interested in the first part, probably.

12 DR. RYAN: Okay. Well, then I think  
13 probably the evidence there is, to the extent  
14 that we have any, would come from attribution  
15 rules that are established and then patient and  
16 physician reports of how consistent those are.

17 I mean, as Ateev mentioned, there's I  
18 think potential sources of error on kind of what  
19 both -- there's really no gold standard there.  
20 And so, I mean, my read of the evidence is that  
21 we don't have a whole lot to tell us what's  
22 really -- what has worked, when has attribution

1 given the right patient to the right provider?  
2 And I think some of the discussions we've talked  
3 about it depends on a lot of other contextual  
4 factors, too. So that sounds like a total dodge,  
5 but I don't see existing evidence saying too much  
6 when as this model resulted in the kind of  
7 correct or best attribution.

8 CHAIR MEHROTRA: So, Andy, I think I'm  
9 with you just to be in -- when we were writing  
10 this paper, we had this sea of metrics and we  
11 were like which one's the best? And there was no  
12 single metric by which we could judge that. And  
13 it's very difficult.

14 And so, but I do think you made a  
15 point earlier in your presentation and, Bharat,  
16 your comment really emphasized for me, is that we  
17 have a -- currently; and we could discuss whether  
18 we want to include this principle, a principle  
19 that you got to test a couple. And as I think  
20 about that a little bit, that's a little bit --  
21 we -- it's a bit bogus what we're saying, right,  
22 because then, okay, I tested two or three or

1 four, but how do I know which one seems to be  
2 better?

3 And so, we might think about I think  
4 for August meeting, at least from my sense, would  
5 be to think about what are the criteria by which  
6 you might judge that? So you've made one, which  
7 I thought was well-said, which was how much of  
8 the care/money/patients were attributed to any  
9 provider? And a program that only attributes  
10 only five percent probably isn't sufficient. We  
11 probably don't want 100 percent because that has  
12 some issues. But somewhere in the middle.  
13 That's one metric.

14 But what are the other metrics by  
15 which you judge how well an attribution rule is  
16 working? And we can probably at least start to  
17 get there, at least put something in the report  
18 about what those criteria might be. I don't know  
19 if we're going to get an exact answer because the  
20 gold standard, who is responsible? We often  
21 don't know the answer, so we're using proxies or  
22 other metrics to look at that.



1 DR. RYAN: Just the one thing I would  
2 add to that is that different -- say we're using  
3 a spending metric and all Medicare spending is  
4 our measure that we're trying to profile and  
5 different ways of attributing patients to  
6 providers could result in different reliability  
7 and validity of a metric. So in theory you could  
8 test the reliability and validity of the same  
9 performance measure that uses different  
10 attribution approaches. And that might be one  
11 way then to back out what it means how good the  
12 difference attribution --

13 (Simultaneous speaking.)

14 CHAIR MEHROTRA: That's a fair point.  
15 Yes, you could test at least some of those  
16 metrics. That's a good point. I'm talking too  
17 much.

18 Ira?

19 MEMBER MOSCOVICE: I had one comment,  
20 but you just convinced me that this testing thing  
21 raises the amount of work to do testing to an  
22 incredible level. And we really need -- it's not

1 going to be easy unless we make simple rules that  
2 really don't apply. If we're really going to  
3 test, we'll see what principles or criteria we  
4 come up with, but it's -- that raises the scope  
5 of what testing in my mind really means.

6 But the question -- comment I had was  
7 I'm not sure what the scope of Andy's work is  
8 with NQF, but given Danielle's and everybody  
9 else's comments there's not doubt to me that a  
10 real contribution would be to come up with a  
11 taxonomy for attribution systems. And it may  
12 well be that of your 168, well, only 100 fit into  
13 -- and you still have 68 sort of wild cowboys out  
14 there --

15 (Laughter.)

16 MEMBER MOSCOVICE: -- but it still  
17 seems to be -- I mean, a real value would be to  
18 say, at least for the guts of the ones we have,  
19 here are the five or six or seven that seem to be  
20 used a lot. And then we get at Bharat's comments  
21 and other comments in terms of, well, okay,  
22 what's the impact of those systems? Is it really

1 working? And so, it's sort of like what Shortell  
2 did with the ACO and Elliott Fisher. That would  
3 be a tremendous contribution, rather than saying  
4 here's all the different attributes. And I don't  
5 know if it's within the scope of what you have.

6 CHAIR MEHROTRA: Is this -- Ira, if I  
7 could push, I had thought that this table or the  
8 table before was that taxonomy that you were  
9 looking for. So if you could make the  
10 distinction between the two, like what beyond  
11 these elements, which all these rule are  
12 classified, what other elements would you put --

13 (Simultaneous speaking.)

14 MEMBER MOSCOVICE: Well, he said they  
15 did some cluster -- I mean, I want to take these  
16 elements -- let's assume these are the right  
17 elements. I want to take the ones that seem to  
18 be used a lot and then say how frequently are  
19 they being -- what are the five -- the  
20 combinations of these elements and really come up  
21 with a taxonomy saying here's the prevalent sets  
22 of these elements that are out there.

1 CHAIR MEHROTRA: So if I could frame  
2 that just slightly differently just to make sure  
3 I understood, which was here are the different  
4 elements, but what you're looking for is at the  
5 end put them all together and give me the most  
6 common models which are a combination of these  
7 elements.

8 MEMBER MOSCOVICE: And that's --

9 CHAIR MEHROTRA: Is that kind of --

10 MEMBER MOSCOVICE: That's in essence  
11 what cluster analysis tries to do. If it comes  
12 out by the way you can't do it, that's an  
13 important piece of information that says the  
14 report will even be more important if it can  
15 provide us to lead towards that in terms of the  
16 work we're doing. Because if there really is 168  
17 different systems, so be it, but let's know that,  
18 because we need to put some structure around this  
19 I think if it's going to be meaningful.

20 CHAIR MEHROTRA: But I would make one  
21 point that -- and I think Bharat said this also,  
22 which is that I want to be careful. Let's say --

1 I don't remember what it was, let's say ACOs, and  
2 86 percent of them use this model. The  
3 implication could be, well, that's a good model  
4 because 86 percent of them are using it. And do  
5 I want to question that assumption, because that  
6 might be just because they all kind of copied  
7 each other. But it was a bad model to start  
8 with.

9 So I think we should -- I agree with  
10 your point that it's useful to make that point if  
11 there are some clusters. I also just do want to  
12 question the assumption that that's a good model  
13 because it's used frequently.

14 MEMBER MOSCOVICE: Yes. No, I'm not  
15 saying it's -- we can test whether it's a good  
16 model if you have this taxonomy. Without the  
17 taxonomy we're working on individual cases one by  
18 one by one. It may well be that a very prevalent  
19 model might well work and accomplish the things  
20 that Bharat was talking about half the time and  
21 half the time it doesn't. And that's important  
22 also to understand as Danielle is saying in what

1 environments is it working and what it isn't.  
2 But without the taxonomy we're looking at  
3 individual cases, and that's not -- I don't know  
4 what to do with that if I'm a person out there  
5 trying to say how do I do this?

6 CHAIR MEHROTRA: So, Srinivas?

7 MEMBER SRIDHARA: So one, I would  
8 support that completely and then sort of dovetail  
9 back to sort of a conversation we started with  
10 the principles and the table or whatever and sort  
11 of align this with sort of use case scenarios. I  
12 mean, you brought up the primary care versus  
13 specialty care, but I really think that we need  
14 some way to assess that in certain types of use  
15 cases that certain models are prevalent and are  
16 they effective? I think that's the part two that  
17 I think you were asking is, well, is this a good  
18 way to do it? And I think we need to be able to  
19 answer that.

20 And so, if we are indeed then -- if I  
21 were to envision how that would lay out is we  
22 would say here are the common models as they

1 align to common use cases and our commentary on  
2 were these effective or not. And then the end  
3 result from all of this are our considerations in  
4 how to build an appropriate model. Some may be  
5 the individual factors that were listed at the  
6 end of this sheet that we talked about today, and  
7 with maybe some more, or maybe combinations that  
8 work and we can say these sets are the things you  
9 should consider as they align to certain use  
10 cases. So that to me seems like a logical flow  
11 of what your presentation might be, and our  
12 recommendations would then make sense as to why  
13 we landed on certain considerations or  
14 combinations of them aligned to use cases.

15 CHAIR MEHROTRA: I'm just going to  
16 keep on going. Jen, you had a comment, but then  
17 you jumped in earlier. Was that the point you  
18 wanted to make or was there something else?  
19 We're happy to have anything else.

20 MEMBER PERLOFF: Sure. The one other  
21 thing I wanted to mention, in our work we're  
22 looking a lot at MACRA and MIPS and beginning to

1 think about role-based attributions. So when you  
2 do a lot of the single, multiple attribution  
3 techniques that we're talking about, you focus on  
4 specific kinds of services that providers bill  
5 for. So evaluation and management services. But  
6 we're beginning to think more about patient  
7 relationships such as ancillary services,  
8 supporting services, surgical services.

9 And so, I just wanted to mention that  
10 because it's a kind of emerging aspect of  
11 attribution that probably isn't in the literature  
12 yet, but really important as we look at the  
13 future policy environmental and horizon. So that  
14 was the thing I wanted to throw into the mix.

15 CHAIR MEHROTRA: It's a good point,  
16 especially with MIPS coming on board and  
17 different providers.

18 MEMBER PERLOFF: Yes. And the MACRA  
19 five patient relationship categories, the  
20 supporting, ancillary, episodic, primary and  
21 principal.

22 CHAIR MEHROTRA: So I have a number of



1 folks on the list here, but I also wanted to do a  
2 quick time check because we can go on for a long  
3 time and I don't -- do we have public comment or  
4 something coming up?

5 DR. AMIN: So we're breaking at 11:00.

6 CHAIR MEHROTRA: 10:30 or 11:00?

7 MS.WILBON: I have 10:30 on my  
8 schedule.

9 CHAIR MEHROTRA: All right. So I  
10 think what I would say as we now move forward,  
11 let's continue this conversation. We have about  
12 35 minutes and then we'll have a break at 11:00.  
13 Does that work for folks? Okay. So let's keep  
14 on going. This is great.

15 Brandon, you were next on the list.

16 MEMBER POPE: Yes, some unpublished  
17 data from the trenches, if you will, to the  
18 concern about attributing all the patients or  
19 attributing patients on the basis of one single  
20 visit.

21 So we recently sort of completed our  
22 complaint process where we told the providers

1       their performance, how it impacted their pay,  
2       complaints about patients you feel shouldn't have  
3       been attributed to you, etcetera. Probably 90  
4       percent of those patients were providers  
5       complained. This was where the attribution was  
6       on the basis of something reported to us by the  
7       payer where it was either an HMO where the  
8       patient had to select a payer or it was  
9       essentially the patient and payer went off and  
10      figured out who the provider was, right? And it  
11      wasn't based on claims or the EMR or anything  
12      like that.

13               So just some sort of anecdotal  
14      evidence. That may just be one data point.

15               CHAIR MEHROTRA: So your point really  
16      kind of emphasizes the caveats we were making  
17      yesterday about the self-selection bias, because  
18      to the degree that those were the patients  
19      choosing their provider it sounds like 90 percent  
20      of the -- well, at least 90 percent of your  
21      complaints were providers going that was wrong.

22               MEMBER POPE: Yes, especially when you

1 say who's your PCP? Well, I don't have one.

2 Well, choose one anyways, right? I mean, some of  
3 the -- literally work off that --

4 DR. BURSTIN: And some plans assign  
5 principles.

6 MEMBER POPE: Yes, absolutely.

7 DR. BURSTIN: That's actually a big  
8 issue here. I think a lot of those complaints  
9 are probably plan assignation --

10 (Simultaneous speaking.)

11 MEMBER POPE: Absolutely. Plan  
12 assignment. And when you ask the plan can you  
13 tell us specifically how that came to be, even if  
14 it was randomly -- and literally you cannot get  
15 an answer.

16 Anyways, another observation about  
17 sample size there was a comment, well, if you  
18 don't have enough sample size, you can look  
19 farther back. An alternative to that that we've  
20 taken is to say, well, if you don't have a  
21 sufficient number of patients, what we'll do is  
22 we'll give you a community-based performance,

1 right? We won't give you your 8 out of 10  
2 because we don't think 10 patients is enough.  
3 Instead we'll give you 850 out of 1,000, which is  
4 the sort of ACO performance or something like  
5 that. So just a different approach dealing with  
6 sample size.

7 But I did want to comment on this idea  
8 that, well, we should judge them versus the gold  
9 standard or what's the right attribution, and  
10 wanted to make sure we're clear that that's  
11 really only an interesting thing to do when you  
12 consider the temporal nature of attribution,  
13 right? Because, yes, at any one point in time,  
14 sure, we can go figure out, okay, this was good  
15 versus that, but it's really that when healthcare  
16 is delivered over the course of a year, then --  
17 and things happen where I change doctor, I change  
18 insurance plan. Different things happen where  
19 it's the temporal nature of it that really makes  
20 it more challenging than just if we could pause  
21 time and figure it all out and then we've got it  
22 right. So just to comment on when we test

1 things, you have to test them is sort of a  
2 temporal aspect, not just at a point in time.

3 CHAIR MEHROTRA: It's an important  
4 point.

5 Ari?

6 MEMBER HOUSER: So I wanted to respond  
7 to a couple of things recently, the idea of the  
8 measuring error and of developing a taxonomy.  
9 And I think both of those are great ideas.

10 I think the error is probably not  
11 quite as easy to measure as you think because why  
12 does the sensitivity of attribution matter? It  
13 matters because people are worried about being  
14 assigned somebody who has a bad outcome who  
15 perhaps shouldn't be assigned to them.

16 Alternately, from a system perspective  
17 we could also -- we don't want to assign people  
18 who have good outcomes to people who didn't have  
19 responsibility for those good outcomes, but no  
20 provider is going to complain about that going  
21 the other way.

22 But so, the uncertainty in attribution

1 is really an issue based on the uncertainty of  
2 the measure itself. If you have a highly  
3 variable measure, a little bit of sensitivity in  
4 the attribution could lead to very big  
5 differences in -- or a lot of uncertainty in the  
6 provider level score, whereas if the measure's --  
7 there's not a lot of uncertainty in the measure,  
8 then you can tolerate quite a bit of uncertainty  
9 in the attribution because the scores are all  
10 going to be about the same. So it's really the  
11 -- the uncertainty that matters is not just the  
12 uncertainty in attribution. It's the whole  
13 uncertainty of measurement.

14 And then for taxonomy I think if  
15 you're not making any headway with a cluster  
16 analysis, which is really a data-driven approach  
17 to figuring out what the patterns are, is inject  
18 some theory and say let's create a hierarchy of  
19 characteristics. And it seems to me perhaps the  
20 top level could be the type of provider, like a  
21 model that attributes to an individual physician  
22 is a different type of model than one that would

1 attribute to an ACO. And so, you can create that  
2 -- maybe that's the first step in the hierarchy.  
3 You pick a second, pick a third and then see what  
4 your buckets look like after that.

5 So instead of making the data do the  
6 work, develop empirically or -- not empirically,  
7 conceptually that hierarchy. And then you'll  
8 probably have to do it a couple different ways,  
9 but see what makes the most sense.

10 DR. AMIN: I totally agree with your  
11 point about the interaction between measure  
12 uncertainty and attribution uncertainty, and the  
13 attribution uncertainty could just magnify  
14 inherent uncertainty in spending or other  
15 measures we look at.

16 I also think you're right about  
17 thinking about classification approaches  
18 conceptually to try to not just do the data work,  
19 but actually think a little bit, too, is probably  
20 a good idea. So thanks.

21 CHAIR MEHROTRA: Jenny?

22 MEMBER BEAM: Yes. No, I just want to

1       -- and again, I kind of expand on Brandon as far  
2       as what he was saying as far as the look-back  
3       period. And when we increase the length of time  
4       for that, that can also increase the error.  
5       Because again, if somebody had a bad year in the  
6       prior year and they saw certain physicians a lot  
7       and then maybe they were relatively healthy in  
8       the most recent year -- so again, if you expand  
9       that period to -- if claims are available or  
10      whatever method to look at the most recent year  
11      first. And then if nothing is available, then to  
12      go back another year to make sure we don't  
13      increase our margin for error there.

14               And also, in listening -- I mean, and  
15      I know we have to look at what's available to us,  
16      which is published, but we know a lot of work has  
17      been done that is not published. And so, I guess  
18      -- and in looking at places I've worked before,  
19      probably team members 5 to 10 people working on  
20      this year 'round for over 5 years.

21               So is there any thought to this  
22      Committee to reach out to them to have some



1       conversations about what they're findings have  
2       been? Because they're not published, but yet  
3       again thinking you have teams of people that have  
4       been doing this and working on reliability and  
5       validity and they know all of these pitfalls,  
6       maybe things that we haven't even thought of yet.  
7       Is there any thought to reaching out to having a  
8       meeting with them? And I could help facilitate  
9       one.

10               CHAIR MEHROTRA: So that's an  
11       interesting point because I do -- I'm getting the  
12       -- I think reasonable is that Andy and his team  
13       were limited by you've got to find some gray  
14       literature, published peer reviewed literature.  
15       You can only get so much. And I see the appeal  
16       of talking to other folks who have done this,  
17       both in describing their rule as well as what  
18       they've learned. I'm also trying to be  
19       protective of Andy and his team and scope creep.  
20       And so, I'm a little bit -- I think it's  
21       important.

22               DR. RYAN: Well, one thing I'll say is

1 part of what is part of -- is part of our scope  
2 of work is to do some key informant interviews.  
3 And so, it sounds like I should talk to you.

4 (Laughter.)

5 DR. RYAN: Because that was part of  
6 what helped when we've done this work in the past  
7 is that can provide a deeper perspective that  
8 doesn't just kind of come out with what's out  
9 there in the world. So what we have done in the  
10 past is this -- the kind of -- the group meeting  
11 can provide some kind of leads as to who can --  
12 where that good information could come from.

13 CHAIR MEHROTRA: So could I -- would  
14 this be fair to -- for -- I mean, it was a very  
15 impressive amount of work that all of you have  
16 done regarding attribution in the roles that you  
17 all played. Would it be fair just to have -- if  
18 you have an idea on a lead, potentially send it  
19 to Kim and then Kim can kind of collect all those  
20 and send them off to Andy? And then you can  
21 choose -- I know with the resources that you have  
22 which informants, key informants that you might

1 speak with? Would that sound reasonable?

2 PARTICIPANT: That sounds good.

3 CHAIR MEHROTRA: Okay. That is a  
4 great idea. That's a good point, because there  
5 is a lot of knowledge out there. It's just how  
6 do you get to that knowledge in a quick way?

7 Elizabeth, I think you're next. Did  
8 you want -- your card was down and then up.

9 MEMBER DRYE: Yes, I was trying to  
10 look something up before I put my card up. So I  
11 did want to say something.

12 CHAIR MEHROTRA: Your mic. Hit it.

13 MEMBER DRYE: Actually I just wanted  
14 to go back to a comment you made awhile ago about  
15 potentially having not just principles, but  
16 criteria is the word that you used. And I don't  
17 think that's super defined, but I agree with that  
18 direction, because I think if we got to the point  
19 where we could list somewhat evaluative criteria  
20 that were still pretty high level, that would  
21 allow people to think through, well, does my  
22 attribution approach meet these criteria?

1                   And I was just pulling a precedent  
2                   which I'll just send around. In the early stages  
3                   of using outcomes to profile quality the American  
4                   Hospital Association and American College of  
5                   Cardiology put together a consensus paper on the  
6                   preferred attributes of models essentially for --  
7                   basically models used for publically reported  
8                   outcomes. And to this day we use this paper.  
9                   This is from 2006, and it's incorporated into the  
10                  NQF -- the principles stayed -- run true to the  
11                  NQF guidance and CMS' Blueprint and other  
12                  documents.

13                  And they're very simple. Things like  
14                  clear and explicit definition of the appropriate  
15                  patient sample. There's only seven. Use of an  
16                  appropriate outcome in a standardized period of  
17                  assessment, application of an analytic approach  
18                  that it takes into the count the data structure.  
19                  I mean, they're short, and then expanded on in  
20                  the paper.

21                  But so, I think there is a kind of  
22                  middle ground that we could shoot for between

1 just principles to get a little bit more towards  
2 criteria that people could run their approach  
3 through.

4 CHAIR MEHROTRA: Right, and it's  
5 actually a good point. So first, if you could  
6 share that, because I do find that -- at least my  
7 own experience is that if you have an example of  
8 something that has had traction and success  
9 before and has actually been used by many people  
10 in the future, that's at least what I want here,  
11 because we want to have something that's as  
12 useful to anyone who's in this space moving  
13 forward here. So a concrete example in another  
14 space would be very useful.

15 And then I also think it's -- I'm not  
16 sure exactly what you're saying, but at least one  
17 thing I took away is that when I had mentioned  
18 the word "criteria," I said that you have two  
19 different rules. And now we've got the two  
20 different rules and you run them. How do you  
21 know the criteria by which you compare?

22 But I think what you're making -- at

1 least what I'm taking away from one of your  
2 points is that you can also have criteria that go  
3 beyond just comparing the empirics about it, but  
4 more of a series of questions you need to ask  
5 yourself as you compare these two different  
6 rules. And they may be not a number answer, but  
7 more just a process by which you're going through  
8 to make sure that you're choosing the right rule.

9 MEMBER DRYE: Right, and the setting  
10 for this was people didn't think it was fair to  
11 evaluate quality using outcomes. And so, this  
12 was about how could you make sure the -- this  
13 isn't that long ago, right, but how can you make  
14 sure that the approach is fair? And I think  
15 underlying this attribution discussion is this  
16 notion that we're trying to set up a system  
17 that's fair and is driving towards things we  
18 agree on. So anyway, I can just send it around  
19 as a model.

20 CHAIR MEHROTRA: So I'm getting a  
21 sense; maybe it's just me, but the energy -- like  
22 we've been here for awhile here, so why don't, if

1 I do this, take two more -- one more comment and  
2 then take a break, refresh, and then maybe we can  
3 then decide how we want to take the rest of the  
4 time that we have together today in terms of  
5 energy.

6 So, Troy?

7 MEMBER FIESINGER: Elizabeth, actually  
8 you gave me great setup. In September after I  
9 have to get up in front of about 300 family docs  
10 two different times and talk about attribution as  
11 part of a Medicare education project. So there's  
12 the disclosure. And trying to decide what do I  
13 say, as I'm thinking one would approach would be,  
14 well, here are the rules, deal with it. You can  
15 imagine how that will go over.

16 (Laughter.)

17 MEMBER FIESINGER: But the question;  
18 this is more to Andy, is have we already or can  
19 we within your scope, within your time and  
20 funding look at end user impact? And I'm  
21 thinking on multiple levels as I try to get at  
22 the unintended consequences issue. Do we know

1 enough about any of these, I'll call them models  
2 to know how they're impacting clinician behavior,  
3 organization behavior, patient behavior? Because  
4 I'm thinking we're all in the middle of this  
5 grand decade-long experiment and none of us have  
6 any idea how it's going to come out. But in 20  
7 years what am I going to wish I'd said  
8 differently today? And I don't know.

9 And that's a big level question, but  
10 is there any way to tease out even just one  
11 quality measure, walk it all the way through and  
12 compare three or four models was there any  
13 difference? And I'm thinking of some of the P4P  
14 studies where they said, okay, we'll apply it in  
15 a 30 rule. Here's how things change or here's  
16 how it's going to performance change. But can we  
17 do a step further? Did behavior change? Because  
18 ultimately what I want to do in an ACO in a  
19 clinic is guide team behavior to improve patient  
20 health.

21 DR. RYAN: Well, my own comment on  
22 that is as has been coming up with these



1 programs, we say, okay, did an ACO program --  
2 like did it work? And there's how many different  
3 factors go into it working? All kinds of things,  
4 right? And one of them is the attribution. The  
5 other thing is the measures. The other thing is  
6 the incentives. The other thing is the existing  
7 structure before they even start it.

8 And so, I think we could say something  
9 about the application of different attribution  
10 models to successful enterprises, but of course  
11 you know the caveat always needs to be there  
12 that, who knows, at least that attribution  
13 approach didn't make everything go wrong. Maybe  
14 that's the best that could be said for it.

15 But on your other point, I think the  
16 end user impact could be a good -- that could  
17 really be a good thing to go after in the key  
18 informant interviews and to try to understand how  
19 to approach just, I'll say qualitatively how  
20 different approaches have been used and what was  
21 the response from physicians or patients there,  
22 or whoever. I think that might be a good way to

1 pursue that question to at least get some  
2 suggestive evidence that we can draw on from the  
3 expertise here.

4 MEMBER FIESINGER: And I think clearly  
5 that would answer my question is when I think of  
6 this potential audience, what are they going to  
7 think and feel? And if your conclusion on the  
8 first issue is that attribution doesn't really  
9 affect the measures, I'm okay with that. Then I  
10 know I don't sweat that as much. Let's worry  
11 about other stuff.

12 CHAIR MEHROTRA: And so, I mean, one  
13 of the things I took away from the HealthPartners  
14 paper or report that we looked at was that was  
15 one of the conclusions for that at least specific  
16 application, which was it didn't seem to make  
17 that much of a difference, the different  
18 attribution rules. So that might be a key point.

19 Another thing I might wonder as we  
20 think about -- so we've got challenges,  
21 principles and recommendations. And one of the  
22 recommendations that at least is coming to my

1 mind is that for some certain really key programs  
2 and/or situations where attribution is really  
3 thorny that there is a -- to make a call for if  
4 there is this idea that it's all about the  
5 responsible provider, that there could be  
6 research studies that would evaluate -- and maybe  
7 this has been done; I don't think it has been  
8 done, where they actually go and talk to the  
9 providers and the patients and say, okay, here's  
10 what the algorithm says is who your -- Troy's of  
11 doc. What do you think? Or who is your doc and  
12 say how often it's Troy and they match up.  
13 And that kind of work would -- at least for  
14 certain key programs, has some -- try to capture  
15 that gold standard and that potential bias there.

16 I recognize it's not perfect and I  
17 understand why, but as we think about that it  
18 does appear to me that kind of research is really  
19 critical. That's at least my thought. Do others  
20 like that recommendation or not?

21 MEMBER LLOYD: I actually thought that  
22 Atrius and some other folks who'd done a joint

1       workgroup in Massachusetts to try to get some  
2       commonalities across their attribution methods  
3       did a study like that, and I'm emailing people as  
4       we're talking- trying to get copies

5                   CHAIR MEHROTRA:   But, it's a good  
6       point.

7       I apologize for interrupting you.   It's a good  
8       point that I did see.   What they did is they took  
9       some of the commercial ACO algorithms and  
10      actually looked at to see whether, if I remember  
11      right -- and then they went back.   And my memory  
12      is that they went into their health system  
13      records and their EHRs and said, hey, Ms. Jones  
14      was assigned to Troy based on the algorithm.  
15      Let's look at what we have, which is a little bit  
16      richer data, and does that make sense?   And so,  
17      that's one of evaluating.

18                   The other one would be to go to the  
19      doc itself or the patient itself, because the one  
20      other person going -- if I could speak for Carol,  
21      the patient's voice was not included in that.  
22      But that kind of work.   I'm sorry for cutting you

1 off, Danielle.

2 Others like that idea? Bad idea?

3 Good -- oh, Helen?

4 DR. BURSTIN: I think it's an  
5 intriguing idea. I think it all depends on how  
6 you define "research." We don't really have a --  
7 prospective research is not something we could do  
8 here, however, one of the advantages of doing  
9 this work in the context at NQF is we do have 435  
10 members of NQF representing every single stripe  
11 of what we're talking about the healthcare  
12 system, and we might have capacity to go to them  
13 and at least do something qualitative to build on  
14 this to bring to the process.

15 CHAIR MEHROTRA: Right, and I wasn't  
16 implying that NQF should do that work, but maybe  
17 a general statement that this literature, the  
18 knowledge base is relatively weak and therefore  
19 in general this kind of work needs to be done to  
20 better understand --

21 DR. BURSTIN: Yes, I agree.

22 CHAIR MEHROTRA: -- whether these

1 algorithms or models are working to capture what  
2 this underlying truth or truthiness is.

3 (Laughter.)

4 MEMBER RADWIN: Actually, I just  
5 wanted to note that some really good  
6 recommendations came out before the break, and I  
7 made a list of them because I think they're worth  
8 pursuing and documenting. And we really want to  
9 develop a glossary or taxonomy that there are  
10 criteria, as Elizabeth mentioned, for inclusion  
11 of models like what criteria do we choose on?  
12 And you can use both of those above to cluster  
13 models that are out there and analyze each  
14 cluster for strengths, weaknesses, opportunities  
15 and threats and then think about aspirational  
16 models like MIPS and MACRA, what effect they'll  
17 have on the models that are described. And I  
18 think that kind of organizational framework could  
19 be really useful moving forward, and all those  
20 ideas came out this morning.

21 CHAIR MEHROTRA: Great. Thank you for  
22 that summary. That's really helpful. I

1 appreciate that.

2 All right. So let me propose a break.  
3 Why don't we come back just after -- make it  
4 easier, 11:00. Would that be okay?

5 PARTICIPANT: Yes.

6 CHAIR MEHROTRA: All right. We'll see  
7 you back then.

8 (Whereupon, the above-entitled matter  
9 went off the record at 10:47 a.m. and resumed at  
10 11:05 a.m.)

11 MS. WILBON: So we're going to go ahead  
12 and get started, and I think I'll go ahead and  
13 just give the group an overview of what we talked  
14 about.

15 CHAIR MEHROTRA: So we just what -- so  
16 we have till 2:30, so three-and-a-half hours,  
17 going non-stop, no breaks, no lunch. I'm just  
18 joking.

19 The thought is to for the next 45  
20 minutes, an hour just try to think. We had  
21 talked a lot about this table has become, you  
22 know, legendary now, so we're going to talk a

1 little bit about the table and the idea of how  
2 does this work in terms of trying to take our  
3 principles, our recommendations, these criteria,  
4 a lot of different ideas and try to make it a  
5 little bit more concrete because we do want  
6 something that's helpful to the larger audience.

7 So we'll go over that, respond, react  
8 to that.

9 Then what I'd like to do, then we'll  
10 have lunch, and then after that our next step is  
11 to really go over the principles, go back to  
12 where we were before, and to try to hammer those  
13 out and to semi-finalize or finalize them to the  
14 point where we'd put them out for public comment  
15 and getting people's reaction. And then we'll  
16 wrap up from there.

17 That's at least the current plan,  
18 subject to change as we get your input from the  
19 end reaction Does that sound reasonable?  
20 Thoughts, concerns?

21 Shaking of heads or at least no  
22 negative.



1                   So let's get started. What do you  
2 think, Kim, should I keep on talking?

3                   MS. IBARRA: Well, yes, keep talking.  
4 We're trying to project the table for everyone  
5 but we're having some difficulties.

6                   CHAIR MEHROTRA: Yes, so why don't we  
7 do that. That sounds like a great idea. So we  
8 have some comments that were left over regarding  
9 the principles, so let's at least start that  
10 conversation now while we deal with the sort of  
11 technical issues.

12                   So this is a little hard, so I know  
13 I'm going to like pick on people like Srinivas  
14 right now, who might have had a comment for two  
15 hours. What were you thinking about two hours  
16 ago, Srinivas? Do you remember? Or I can skip  
17 around a little, too.

18                   MEMBER SRIDHARA: Well, yeah, I mean I  
19 think, I thought the summary was great, sort of  
20 paring down the longer list and subsetting them.

21                   I think, you know, one of the comments  
22 that was really related to these considerations

1 and -- sorry, I'm trying to pull up my earlier  
2 list -- but there might be some other  
3 considerations that we should think about. For  
4 example, one that's missing here was our question  
5 about unitive analysis of, you know, single  
6 provider versus organizations of ACOs or  
7 otherwise. That wasn't in this list of  
8 considerations. I think that's something we  
9 should probably --

10 CHAIR MEHROTRA: And that probably  
11 would go under -- I don't know if this is a good  
12 principle, because it doesn't sound very  
13 principally, but challenging some of the ideas of  
14 like always attribute to one provider. Maybe it  
15 also could be right there a challenge to assign  
16 to more than one.

17 MEMBER SRIDHARA: Yeah, yeah. No, so  
18 I don't think it's necessarily a principle. It  
19 was sort of a list that followed that said  
20 considerations --

21 CHAIR MEHROTRA: No, but I appreciate  
22 you bringing that back up. Yes.

1                   MEMBER SRIDHARA: You know, so I think  
2                   that was one that I thought should be added here.

3                   And then in terms of principles,  
4                   otherwise I actually thought this was a pretty  
5                   good list. I mean I think we've talked about  
6                   some of the other comments that we've had today  
7                   about sort of, you know, how we frame our testing  
8                   or, you know, the appropriateness for a use case.  
9                   I think those you can roll into some of these  
10                  others.

11                  So I don't think I have any other  
12                  principle comments for now. But probably as we  
13                  dive in deeper on the considerations and how to  
14                  tune them to use cases though.

15                  CHAIR MEHROTRA: All right. I know  
16                  this is a little awkward but let's stop the  
17                  conversation now and let's go to the table which  
18                  has emerged on our screens here.

19                  Do we have that hand mike?

20                  MEMBER LLOYD: Okay, the infamous  
21                  table. The only problem is I can't move it on  
22                  the screen. So will you guys move it down a

1       tiny, tiny bit? You're missing a row. No, no,  
2       other way. I want to see the top.

3               There we go. You were missing a row.

4               Okay, so as we discussed yesterday,  
5       this is by no means a baked product. This was as  
6       we were talking to try to classify or narrow down  
7       some of the discussions we were having. Not to  
8       say that if somebody -- you know, that this is a  
9       must. Right? Not that if you want to do ACO  
10      attribution you must use these criteria, this was  
11      if you're doing -- if you're doing attribution,  
12      what are some of the things you need to think  
13      through and you need to be transparent about, per  
14      our conversations yesterday.

15              So we started over here with a lot of  
16      these you can see, because it was off the top of  
17      our heads, right. A lot of these were things that  
18      were in the paper we discussed this morning.  
19      It's not perfectly one for one. But these are  
20      sort of the steps, we think.

21              And then up on the top we've got four  
22      different use cases just as examples, okay. Straw

1 man. So the idea was to make them somewhat  
2 different from each other to also highlight that  
3 you might make a different choice, depending what  
4 the use case is. Right? Because we stumbled a  
5 couple times yesterday saying, well yeah, that's  
6 true, but only in this case. Or that's true in  
7 these two out of four cases, or whatever.

8 So the first one is more primary care  
9 oriented. The second one is more specialty  
10 oriented. The third one is more about the quality  
11 improvement aspects, not necessarily tied to a  
12 payment program. But maybe it could be some sort  
13 of value-based payment, but basically not an  
14 alternative payment model.

15 And then the last one is institutional  
16 because, as we discussed there also, you know, if  
17 it's something like a hospital readmissions  
18 measure it's a little bit easy -- easier, right?  
19 Either they were at that hospital or they  
20 weren't. You're not trying to split it up or  
21 weight things or anything like that, right?

22 So there's a case study line here that

1 gives an example within.

2 CHAIR MEHROTRA: Danielle, this is a  
3 very minor point, but what's ACO Track 2?

4 MEMBER LLOYD: So that's what I'm  
5 getting to. So this box right here -- so the  
6 case study line is different scenarios that could  
7 fall under any of those categories: the primary,  
8 specialty, et cetera.

9 So primary care, a lot of the  
10 attributions, whether it's a primary care medical  
11 home, an accountable care organization, or even  
12 maybe just a primary care group, it could be  
13 similar. The issue though is that the  
14 attribution places an emphasis on primary care.

15 So the example here is an ACO Track 2.  
16 The reason it got so specific on Track 2 is  
17 because that's one of the risk-bearing tracks.  
18 Really the only reason. And it has -- we  
19 actually probably should have put Track 3 now  
20 that I think about it. Right, that -- because I  
21 should have picked it to put to show prospective  
22 alignment here. No, but the point is to show

1 differences, right?

2 So the only reason Track 2 is there is  
3 because you'll see in one of the later columns  
4 it's risk bearing. Okay? So think ACO.

5 The example for joint replacement --  
6 I mean for specialty was joint replacement. The  
7 example for quality improvement was an  
8 endocrinologist and profiling, right? An  
9 endocrinologist profiling. And then  
10 institutional was skilled nursing facility  
11 readmission.

12 Now, there was some thought that it  
13 would be great if you could pick one measure and  
14 so you could see the differences with one measure  
15 across all of these. But to be honest, we ran  
16 out of time. So this is what you're going to  
17 get. Okay?

18 So if we -- if we just, for instance,  
19 picked complications and showed you how  
20 complication attribution would differ under each  
21 of these models, that would be great. We just  
22 didn't have time to do that.

1           So one of the first steps is what's  
2     the pool that you have established, like who's  
3     eligible for attribution. Who is it that is  
4     within the pool. You may or may not have  
5     inclusions and exclusions for a beneficiary  
6     population. It just depends. Not required.

7           So when you guys were talking about --  
8     when Elizabeth was presenting on the smoking  
9     measures, it had to be within a certain county,  
10    so there was a geographic limitation. Right? So  
11    the inclusion is only for the county, and it's  
12    only Medicare beneficiaries.

13           But there are some cases where there  
14    could be exclusions. So if you're under the  
15    specialty column and you're looking at joint  
16    replacement, you may have inclusions for joint  
17    replacement bundle that's Medicare only, but you  
18    might have exclusions to say we don't want to  
19    deal with fractures in that population, so we're  
20    going to take them out and we're not going to  
21    attribute for those patients. Right?

22           So I'm not going to go through the



1 whole table. But you can see sort of examples of  
2 we're just trying to show that you might make a  
3 different decision in one of these boxes or  
4 another based on the model. Okay?

5 So a couple -- let me give just a  
6 couple other examples. So the accountable unit,  
7 we talked about that a lot yesterday. So if  
8 you're looking at an accountable care  
9 organization the idea might be that you're doing  
10 the measurement and the attribution across all of  
11 the TINs. So it's a collective tax I.D. number,  
12 so it's collectively at the model level, the  
13 whole ACO that you're doing this attribution,  
14 right? You're not splitting them and doing a  
15 spending target for one, and a spending target  
16 for one, and a spending target for one, you're  
17 doing it as an ACO, right? At that level.

18 But when you get quality improvement,  
19 this is where we might do the over-tagging,  
20 right? Where you can have multiple different  
21 positions who are tagged with attribution. You  
22 have to make a choice depending on where you are.

1                   When you get to the institutional  
2                   level for that one it's pretty easy because  
3                   you're either you were at the SNF or you weren't.  
4                   Right.

5                   Okay. Let me give you one more  
6                   example and then we'll stop and see if this is  
7                   making any sense to anybody. And if not, we'll  
8                   go back and try it with complications only.

9                   We put a line in for stakes because a  
10                  lot of people wanted to know, that's why we put  
11                  Track 2, that it's a risk model. So if it's a  
12                  risk model you might want some -- I'm looking  
13                  over there because I'm struggling with I'm not  
14                  going to use the right scientific term --  
15                  precision accuracy, validity, stability, I don't  
16                  know. All of the above. You might want all of  
17                  the above if it's a risk model instead of just  
18                  the quality. Like that's where some of that --  
19                  the scientific perspective might play more of a  
20                  role in that line, right?

21                  We don't have beneficiary attestation  
22                  really yet, but we put it in there as that

1 marker, the three- to five-year marker that we  
2 talked about in group one yesterday of showing,  
3 well, we want people to consider that and see if  
4 you go there.

5 So let me skip down to a couple other  
6 ones. So data on which the attribution is based.  
7 This is, you know, is it -- you want to get in  
8 here is it prospective, is it retrospective, is  
9 it one year of data, is it two year of data? You  
10 know, what are -- what are the differences that  
11 might be about the time period or the data you're  
12 using.

13 And then some other examples here is  
14 that this concept of is it services, number of  
15 services, is it costs, right, is it expanded  
16 E&Ms? You might do the expanded E&Ms in that --  
17 I think it was C-1 in that paper, right? Because  
18 it's in the primary care you want to use primary  
19 care codes in this one. But you're not going to  
20 use primary care codes in the specialty column,  
21 you're going to want to use something that's  
22 specific to joints, right? And that's where the

1 exclusions and the services are going to match  
2 for a specialty because you want to make sure you  
3 pull in the specialists.

4 And, you know, we've got an eligible  
5 provider line but it's -- that's where you would  
6 decide, is it the orthopedist, is it the  
7 hospitalist, is it more than one of them? You  
8 know, and it just depends on which scenario  
9 you're doing.

10 And then one of the other factors is  
11 the -- down here on determination is it plurality  
12 of services, do you have to have at least X many  
13 percent services, is it to a single doc, you  
14 know, multiple docs, et cetera? So it's trying  
15 to start getting some examples in one place by  
16 case.

17 CHAIR MEHROTRA: Danielle, this is --  
18 first, thank you to yourself and others who  
19 worked on this. It's, I think, really useful for  
20 us to put something concrete on the table. And I  
21 really do like that we went really concrete with  
22 the case studies. And that's helpful. And I

1 thought the choices that you made were good  
2 illustrations of this.

3 My quick reaction is, is that the  
4 framework for me -- there's a lot of benefits.  
5 But I think the part that I was wondering -- as I  
6 look at this and I react to your comments and  
7 your input, is that what I'm looking for to  
8 expand this is the logic.

9 And so what I almost might start with  
10 -- and it may not -- so as I think it through it  
11 may not even look like a table. But let's say we  
12 take the ACO Track 2 or the joint replacement  
13 bundle. We start with that first, which is our  
14 principle 3 I think now, which is the  
15 transparency, what was the goal of the joint  
16 replacement bundle, for example? Like why --  
17 what are we trying to capture with attribution?

18 And then for each of the boxes -- and  
19 again maybe this is why it's text as opposed to a  
20 set, because you can only put so much in a little  
21 Excel spreadsheet -- for example when you have  
22 here services related to conditions with

1 exclusions, that makes sense to me. But I almost  
2 wonder whether it's useful to add the logic  
3 process.

4 So one could in this case focus on  
5 only the CPT codes or E&M services with an  
6 orthopedic surgeon. Or one could look at the  
7 actual CPT codes related to the procedure, or  
8 some combination of the two. Given the goal of  
9 this is to capture the -- let's say it's the  
10 hospital that's most attributable, we chose to --  
11 we thought you might want to focus on X. But  
12 basically for each of these cells you lay out a  
13 couple of options and then think through, for the  
14 reader who might be going through this for  
15 another application, how we thought about it as a  
16 committee and then provide that input.

17 So it's kind of a -- it's the logic  
18 model by which we got to it. And in each of  
19 these cells we'd lay out a couple of options.

20 Another example would be for the ACO  
21 Track 2, ACO collection of TINs. The whole goal  
22 of this is to try to decrease smoking in the

1 county. You could either attribute this to an  
2 ACO, an individual physician, a hospital. Why  
3 would you choose the following? Well, we thought  
4 the ACO was most applicable because we thought  
5 here's where you could put resources into it and  
6 actually do the smoking cessation services, while  
7 maybe the hospital makes less sense because they  
8 don't have -- they're not touching a lot of these  
9 patients in encounters.

10 So that was kind of my quick reaction  
11 to the table. I'm curious what others thought of  
12 that.

13 MEMBER LLOYD: Can I just respond to  
14 that for a second?

15 CHAIR MEHROTRA: Yes.

16 MEMBER LLOYD: I think part of it is  
17 right, we didn't -- we kind of had to cut off  
18 yesterday. But this is why there's sort of this  
19 challenges column now, too, where at least I  
20 noted the -- you know, this is risk taking  
21 entity, you know, choose the -- you know, so  
22 there are some notes that you could put. I

1 agree. We couldn't really fit it into the table.  
2 But I think the table was to try to start showing  
3 those cells where there might be some overt  
4 choice you need to make or, you know, reason that  
5 it might be different.

6 Or I mean it could be that we -- if we  
7 find out that there is starting to be some major  
8 models, you could say these are the most  
9 prevalent. Like if they're clustering remarks,  
10 these are the most prevalent. But here's a note  
11 in each of these of why you're going to have to  
12 make a decision, the advantages or disadvantages  
13 of prospective versus retrospective and cite the  
14 study, or something like that.

15 But you're absolutely correct, we  
16 couldn't really fit it in a table.

17 CHAIR MEHROTRA: So first, again thank  
18 you very much for doing this.

19 So I'd love other people to react on  
20 is this the right direction, is it not. Because,  
21 again, the whole goal is to try to provide  
22 something concrete to the audience.



1           So let me start with Srinivas and then  
2           Ira and then a bunch of other people put their  
3           tags up. Yes.

4           MEMBER SRIDHARA: So before -- so just  
5           to step back a little bit because I think we do  
6           want to get to the specificity and the logic that  
7           you described, but I would use this sort of  
8           activity as not to get to the final how do we  
9           present everything, but rather think of a  
10          framework to understand the environmental scan or  
11          the literature or anything else out there.

12          I think it is -- there are sort of the  
13          combination of say goals and use cases that --  
14          that you have that drive what attribution  
15          approach you might take. And based on that, how  
16          you choose the combination of considerations  
17          vary. And so I guess I would just keep that in  
18          the back of the mind that I think if you start  
19          going down and saying specifically for a CJR, for  
20          an ACO, for a specific measure, I think there's a  
21          lot of nuance to each of these.

22          And I guess what I would hope is that

1 we agree on a framework for understanding this  
2 and then get to exactly what you're saying, which  
3 is, okay, in the scenario that I'm an ACO trying  
4 to implement my smoking cessation program, or  
5 what is the difference between, say, you are  
6 looking at a CJR-type joint replacement episode,  
7 but it's an employed hospital model and  
8 physicians versus an ACO, how does that defer and  
9 how you might do attribution.

10 I mean I think there are questions  
11 that you can then disentangle, so why you might  
12 choose different considerations. So that's at  
13 least to me this should be an activity of how do  
14 you understand the framework and parse the  
15 information.

16 CHAIR MEHROTRA: And then on that note  
17 -- and I think this is an open question for  
18 others so I just want to prompt it here as I go  
19 to other people in the room -- are these the  
20 right criteria? What do you think?

21 MEMBER SRIDHARA: No I mean, I think  
22 you're going to have more, for the folks here.

1 CHAIR MEHROTRA: All right. Good.

2 MEMBER SRIDHARA: I think there's a lot  
3 more. And I think this is just sort of a quick  
4 list of examples. And I think you have some  
5 others on this list here that was presented this  
6 morning, and I bet others will have more to pull  
7 on. And I think to Ira's point, it may be that  
8 we say that there is a combination of  
9 considerations that generally bundle together  
10 that one should think about, or whatever.

11 So I think there's thinking to be done  
12 but this may be a framework to think about it.

13 CHAIR MEHROTRA: Okay.

14 MEMBER MOSCOVICE: Yes, I found this  
15 really useful. And I could see it being used in  
16 two ways in the report. One way which would be -  
17 - in the previous reports I've been involved with  
18 you had some concrete examples and really in very  
19 micro-level detail went through just sort of what  
20 Srinivas said in terms of how decisions were made  
21 and so forth.

22 And they would be, I don't know, sort

1 of dark boxes on the right-hand side that would  
2 point out here's a case study, so forth, so  
3 forth.

4 But to me this is the beginning of we  
5 could think about what Ari was saying, if they  
6 don't want to be data driven for a taxonomy let's  
7 think about this conceptually. And it seems to  
8 me the first level is really the purpose. Then  
9 underneath that is the accountable unit. And  
10 then beneath that then -- you know, I wrote down  
11 the three things that seemed to be important were  
12 the termination rule, the data source, the time  
13 frame. But there's a whole host, as have been  
14 pointed out, of other characteristics.

15 And the details are below that. But  
16 I think there's a couple levels on top that  
17 really drive this. And then the details get you  
18 into the nuances of people.

19 So I think this kind of approach could  
20 be real helpful in both ways, both in terms of  
21 conceptually thinking about what is the right  
22 framework but also then drilling down and giving

1 some specific examples in the report.

2 CHAIR MEHROTRA: That's interesting.  
3 So even right from the beginning of the report  
4 you'd have like almost a little sidebar, MedPAC  
5 style, where you'd say here's -- let me give you  
6 some context so then we can refer it back to it  
7 and try to make it more concrete. That's  
8 interesting. As well as I appreciate the other  
9 point.

10 Brandon.

11 MEMBER POPE: So applaud your all's  
12 bravery in that, you know, fitting a multi-  
13 dimensional taxonomy into a two-dimensional table  
14 is -- you know, it's always going to be a tough  
15 thing. And, frankly, getting this volume and  
16 variety of people to converge on a mental model  
17 of a taxonomy is in itself going to be really  
18 challenging. Maybe we want to figure out how  
19 much time we want to devote to that.

20 But would echo I think Ira and  
21 Srinivas' comments that this is a really useful  
22 direction. And -- but I think we ought to -- you

1 know, here we've got a lot going on. I would  
2 probably try and condense it a little bit.

3 I think, again, the five things that  
4 I wrote down are -- you know, and to use the term  
5 attribution model to refer to some of the details  
6 about what data, what time period, frequency, all  
7 those sorts of things. I think if we can group  
8 that into sort of calling that the attribution  
9 model, and that becomes one along with the  
10 measure, the unit of analysis, the unit of  
11 receiving attribution, and the stakes which we  
12 talked about these different levels of  
13 aspiration, reporting, payment -- you know,  
14 there's some different stakes.

15 I mean I would maybe even propose that  
16 as you could use that taxonomy to characterize  
17 both all of these use cases as well as, you know,  
18 talk through sort of like you said, like if  
19 you're thinking overall I want to decrease  
20 smoking, right? So let's start thinking about,  
21 okay, well you know you can go these directions  
22 of some of these aspects of this taxonomy, so.

1 CHAIR MEHROTRA: That's great. Thank  
2 you.

3 Troy is next.

4 MEMBER FIESINGER: Sorry. Thank you  
5 for taking this on. I definitely believe in  
6 jumping in and working through it. So thanks for  
7 putting this together. I'll throw a couple  
8 questions out there, and if I missed that part of  
9 the explanation, I apologize.

10 One of the exclusions, should that be  
11 handled at the attribution level or can that  
12 reside in the quality measure level, for example,  
13 since for those we always have denominators,  
14 numerators, the inclusion/exclusion criteria. I  
15 didn't quite specifically see cost measures  
16 versus quality measures. But we talked a lot in  
17 our group a clinical case about cost measures  
18 might have different attribution needs than  
19 quality measures.

20 And the other thought is we can  
21 discuss more ways to handle it, there's different  
22 good approaches. We thought maybe tell a story,

1 so pick a patient or a scenario and walk them  
2 through all of these situations. Because the two  
3 things that affect me that I don't quite see  
4 explicitly here would be the chronic disease  
5 patient with multiple doctors, sites of care, et  
6 cetera. How does he or she play into this? Add  
7 in transitions of care to that, SNFs, LTACs,  
8 hospitals, readmissions. I know you're trying to  
9 get at that from the measure perspective. An  
10 alternative might be do we tell that story and  
11 then wave it in from that direction.

12 CHAIR MEHROTRA: Great. Thank you.

13 Laurie, I think I skipped you. But  
14 my apologies.

15 MEMBER RADWIN: Actually Troy made my  
16 point which is that I think we need to bring the  
17 patient perspective back into this graphic. And  
18 I really appreciate being able to categorize  
19 things.

20 But exactly as Troy said, I think the  
21 cases that we use to apply this schemata should  
22 be a patient trajectory. And I'm thinking of



1 case 2 that we talked about where the gentleman  
2 began in primary care, ended up a couple times in  
3 specialty care. Who's accountable, responsible?  
4 To whom should you attribute the dropping the  
5 ball in terms of preventive care? Who picks up  
6 the responsibility? To whom is attributed the  
7 safety of the heart attack care?

8 And without marching a patient through  
9 this, it becomes a schemata, taxonomy for how we  
10 deliver care, not how we attribute patients.

11 MEMBER LLOYD: Can I just say on that  
12 I think -- and we did talk about this a little  
13 bit. I think Jenny might have brought it up. A  
14 single patient could be in any and all of these  
15 at the same time, yeah.

16 And to your point, Dan, yesterday,  
17 there's overlapping attribution in all of these.

18 MEMBER RADWIN: I think that's the --

19 MEMBER LLOYD: Then you get into like  
20 four-dimensional.

21 MEMBER RADWIN: No, but you -- we're  
22 agreeing vehemently that you need to address that

1 overlap because otherwise it becomes about the  
2 organizational unit and not about the person  
3 who's being attributed to whatever. And so we  
4 are -- I think we're agreeing.

5 CHAIR MEHROTRA: These are both good  
6 points.

7 Michael.

8 MEMBER BARR: First of all, I agree  
9 with everybody's comments that this is a great  
10 start. I can't help but think that with all the  
11 comments, building on Brandon and Ira's, implied  
12 by our conversation is sort of a flow diagram  
13 with branching logic and stuff.

14 And I wonder in the final report if  
15 there's an opportunity for this to be an  
16 interactive type of web-based toolkit where you  
17 could take a use case and build all the different  
18 sort of the logic model behind what the choices  
19 were referenced -- linked to references.

20 I mean just think if it becomes  
21 another PDF report it's going to be in the stack  
22 right here, whereas if it's online some of the

1 sort of challenges we're facing can be presented  
2 and have people make choices, see where they wind  
3 up, starting with the purpose and how do we drill  
4 down further and further. I think that would be  
5 really interesting.

6 I don't know if it's in the scope in  
7 terms of NQF, but I think it would be a really  
8 interesting exercise and could be very useful for  
9 people kind of dealing with similar issues.

10 CHAIR MEHROTRA: You guys want to  
11 comment back?

12 Helen, we want a video with you and  
13 like interactive and an interpretative dance of  
14 attribute.

15 (Laughter.)

16 DR. BURSTIN: We don't want the dance  
17 part. But I'm glad that this conversation is  
18 happening. And, you know, Sophia in addition to  
19 being an expert on, you know, what she was able  
20 to present yesterday from CMMI is also the person  
21 who leads our contracts. So we're delighted she  
22 heard this conversation. And we'll certainly

1 follow up and see what we can do within scope.

2 CHAIR MEHROTRA: But I think your  
3 point's well taken because we want to make this  
4 useful.

5 Ari was next.

6 MEMBER HOUSER: So I like the idea of  
7 having this table. And I like -- especially with  
8 a narrative that explains the thought process.

9 Looking at the table, however, I'm  
10 getting very distracted by the particulars of the  
11 case study. And I think the suggestion is we  
12 have to do a -- be very careful in our selection  
13 of what the case study is.

14 I look at the first case study with  
15 the smoking measures and I can't get past the  
16 fact that that's -- it seems like totally like  
17 you can't -- I grew up in California. My county  
18 that I was born in has two million people. Los  
19 Angeles County has eight million people. It's  
20 just -- it's like pissing in the ocean to  
21 attribute smoking rates to any group of  
22 providers.

1           If the providers could even make a  
2       difference in a small area I don't know. But I,  
3       you know, I can't get -- I can't get past that.  
4       And so what we have to do is we have to select  
5       cases where there aren't those kind of hang-ups.

6           MEMBER LLOYD: Yeah. And we did -- we  
7       did discuss that. And that's part -- one reason  
8       why we were trying to think like could we do  
9       complications, like something straightforward  
10      that's across all of them. But I think you could  
11      also easily just do primary versus specialty or  
12      something because it's just illustrative. You  
13      don't need the whole kit and caboodle, you don't  
14      need every single line.

15          MEMBER HOUSER: Right.

16          MEMBER LLOYD: So two columns and, you  
17      know, six lines like Ira's six or something like  
18      that. Just pare it down.

19          MEMBER HOUSER: It reminds me of, you  
20      know, when I started -- when I've written a book  
21      chapter with like an explanatory data example.  
22      Like, oh, this is easy. But then I have to run

1       like 200 models to get one that actually has the  
2       -- you know, where everything that I'm showing  
3       has to show up in the data and not, well, I know.  
4       So, you know, that doesn't fit well, but  
5       whatever.

6                       So it's --

7                       CHAIR MEHROTRA: So I think the point's  
8       well taken about which example do we want to  
9       choose. Is this a good example because it's  
10      particularly thorny and has some issues? Or is  
11      it so far afield that it probably distracts the  
12      reader?

13                      So let me just see if I can summarize  
14      and then I'll turn to both Mike and Elizabeth.

15                      If I'm hearing correctly, so the first  
16      is thank you to those who worked on this table.  
17      What I'm getting a sense of is that this is a  
18      useful framework. And at least where my thinking  
19      is -- and now I want to get people's reaction --  
20      is as we look at this report what I'm envisioning  
21      is we have a set of principles, and then we have  
22      a set of recommendations. And part of those

1 recommendations -- or are they separate, is it  
2 almost a set of a checklist or criteria list  
3 where we say here's when you -- whoever is out  
4 there, state, health plan, federal level, is  
5 considering the next program or quality measure.  
6 Here is a checklist that you should go through in  
7 thought process.

8           And we lay out that checklist. And  
9 then we say to help anybody who is going through  
10 this we're going to give you some examples of  
11 going through that checklist with some case  
12 studies. And we'll go through that process for -  
13 - and whether it's these four or not, and then  
14 we'll go through some of that logic model for  
15 each of those.

16           And then what I'm also hearing from  
17 the group is as we look at these criteria here,  
18 right now we have, I don't know, 11 rows, maybe  
19 if we can try to simplify those -- not simplify  
20 but at least consolidate those a little bit so  
21 that the checklist doesn't become too long. But  
22 at least -- and again give that logic -- that

1 process by which we hope others will go through  
2 for other quality measures or programs.

3 Is that -- am I capturing the vibe of  
4 the group or not is a question I would love to  
5 know. So let me turn to both Mike and Elizabeth  
6 and then others if they want to jump in.

7 MEMBER SAMUHEL: Actually that was kind  
8 of the lines of a comment that I was going to  
9 make is what you're saying. It's a useful  
10 framework. And, you know, there are some missing  
11 parts, like you mentioned logic models that  
12 describe each of these programs.

13 But I also want to emphasize in the  
14 choice of the examples what Ira's point was to  
15 get clarity around the purpose of the case study,  
16 its goals, data sources and so on. We can't  
17 model the entire healthcare system. So the  
18 choice of the columns I think is important.

19 Well, I think what we're trying to do  
20 is lay out some guiding principles, bring -- you  
21 know, make people aware of some methods,  
22 checklists as you described it. And I think



1       that's a good contribution to the state of the  
2       knowledge.

3               CHAIR MEHROTRA: Elizabeth.

4               MEMBER DRYE: Yeah, I think that your  
5       summary is a good one. And I agree with what  
6       Mike said also. And I really like -- thank you  
7       so much for putting this table down because I  
8       know it wasn't easy, because I was working over  
9       here while you guys were doing it.

10              But I had a -- I had a thought that I  
11       think is consistent with an interactive sort of  
12       set of flows, and it's modeled off of this AHA  
13       scientific statement I just sent around, of  
14       making those -- that first column more normative.  
15       So instead of, you know, saying eligible bennies  
16       or stakes or whatever, we just have a series of -  
17       - like you were saying, a series of questions.

18              And I'm going to try to articulate it,  
19       and it's only like seven things so I will go  
20       pretty fast. But the first one could be the goal  
21       of the use trace is clearly articulated. So it's  
22       quality reporting, you know, pay for performance,

1 QI or whatever. I would -- that one column, the  
2 QI column I think is probably that, I think  
3 that's a goal of an intended use versus, you  
4 know, the other three which are good examples of  
5 a type of care that you're trying to assess.

6 So the goal to use case is clearly  
7 articulated. The goal reflects patient and  
8 provider input. That would be number two. You'd  
9 say, okay, yeah I got that, or not. The level of  
10 attribution is a line with the goal by level, I  
11 mean ACO or hospital or whatever.

12 The goal -- the eligible beneficiaries  
13 are clearly identified. And the eligible  
14 providers are clearly identified. I really like  
15 how you stated that. And then you could also  
16 have like a sub thing, inappropriate exclusions  
17 are well defined.

18 So this is number five, would be the  
19 determination rule reflects the goals of -- the  
20 goals of the program. And alternative attribution  
21 strategies that are consistent with the goals  
22 were also evaluated, so that captures -- the time

1 frame is clearly articulated. Because I totally  
2 agree with Brandon on that. The data source  
3 supports the approach.

4 That was basically my list. And  
5 that's more normative as opposed to, you know,  
6 element based. We're saying, you know, not just  
7 do you have a time frame, but the time frame  
8 reflects -- you know, is clearly articulated, so.

9 CHAIR MEHROTRA: That's interesting.  
10 I like that.

11 I mean so I'll make one quick point  
12 and reaction. So I like that. I think I respond  
13 to -- it's building on that, but I do like the  
14 way you do it in a normative way.

15 And it's also kind of an interesting  
16 idea. I was going back to a study that we did  
17 last week -- sorry, yesterday, of the smoking  
18 cessation -- smoking rates in the county, should  
19 they be attributed to the hospital? And as we go  
20 through that framework, based on the conversation  
21 that we had we would say probably no. Because  
22 really the group that's most likely to act upon

1 this is the outpatient providers.

2 And so that -- I don't remember which  
3 number it was, but it's an interesting question  
4 to go through as you go -- as you think that  
5 through, which is it could change the way we --  
6 who you attribute to and a criteria.

7 MEMBER DRYE: Right. I would -- I just  
8 want to articulate that slightly differently  
9 which is, you know, was your goal to get the --  
10 you know, the goal was, was the goal to get the  
11 hospital to act? We said that could be a goal  
12 but it would be a very like -- you know, I want  
13 easier words. That would be a real reach.

14 (Laughter.)

15 So anyway, yeah, that's what I meant  
16 by goals, not would you attribute to the hospital  
17 but is the goal to get the hospital to act?  
18 Because whoever you're attributing to I think  
19 you're doing it to get them to do -- to act in a  
20 certain way.

21 CHAIR MEHROTRA: Troy.

22 MEMBER FIESINGER: I think it's a good

1       idea. I think your approach you recently laid  
2       out, you modified, I think makes sense as far as  
3       how to describe this.

4               I was talking to a gentleman down the  
5       road from Illinois with the issues in my  
6       profession in my state is what do rural  
7       physicians and rural critical access hospitals  
8       do. So I think with an end user we could get a  
9       bunch of rural physicians together who say, hey,  
10      we want to make an ACO. They need to consider  
11      attributions. They're not experts. They don't  
12      live and breathe this stuff and read it for fun  
13      at night like we do. How can then -- how could  
14      this help them walk through it?

15             And Planned Parenthood has a great  
16      little app on their website where you can choose  
17      your birth control. They'll walk you through it.  
18      Do you smoke? How old are you? Are you going to  
19      remember to take a pill? Yada, yada, yada, you  
20      end up with here's your choice.

21             We don't have to go as far as an app.  
22      But if a group of healthcare providers,

1 hospitals, et cetera, could access this document,  
2 start at a very superficial level, read it and  
3 understand it, that would help. And if you think  
4 of who they're going to have to go talk to,  
5 chambers of commerce, business leaders in the  
6 community, politicians. I guarantee you I lost  
7 the politicians as soon as this file went up  
8 there. They started texting their offices.

9           So we would need a really simple way  
10 to tell the story but we have to interact with  
11 them to get permission, legal waivers, et cetera.  
12 So to really push for at least the top level of  
13 simplicity, but narrative that can be  
14 communicated, then people can dive down in deeper  
15 levels of usability.

16           CHAIR MEHROTRA: So I like where the  
17 conversation is going here. I might reflect upon  
18 one concern or one thing that is on my mind is  
19 that when we've looked at, Andy, your paper and  
20 some of the -- as well as some of the other stuff  
21 that was shared, much of the places where at  
22 least people could empirically evaluate things,

1       which was like do you use 30 percent or 50  
2       percent. Or is it based on visits, and so forth.  
3       It's interesting, like there's almost this  
4       interesting disconnect between our criteria here  
5       and some of those criteria.

6               So it sounds like that would be almost  
7       like the third or fourth order issue that you  
8       might address. And I'm curious what your  
9       reaction is because it's almost as -- again, to  
10      see if I can articulate this well, there's a  
11      disconnect between what the literature has looked  
12      at and what we're arguing you should be looking  
13      at for attribution.

14             DR. RYAN: Well, I love Elizabeth's  
15      idea. And the way I see it is this is like the,  
16      you know, maybe necessary but not sufficient  
17      conditions for an attribution model that -- well,  
18      your kind of concept. It should do all these  
19      things. But -- and we were talking about this --  
20      if it does all these things it doesn't mean that  
21      that's it and that's the only way to do it. But  
22      it should -- it should certainly do these things.

1 And the list should make you reflect on what some  
2 of the tradeoffs should be about the specific  
3 ways that the attribution is formulated.

4 But even within meeting these  
5 criteria, there's other ways -- there's  
6 alternative ways to specify, you know, an  
7 attribution method, which has been kind of the  
8 more kind of maybe technical in the way we --  
9 ways that the literature has looked at this. And  
10 I still think, you know, we need to think about  
11 those -- those kind of second order criteria as  
12 well. That these things need to be met when you  
13 implement an attribution method, but we could  
14 still test alternative approaches that meet all  
15 these -- these criteria using, you know, these  
16 measures, these metrics.

17 So that's how I -- I don't see it as  
18 being inconsistent but just maybe kind of a order  
19 -- kind of an order thing about criteria.

20 CHAIR MEHROTRA: Then one of the things  
21 I had raised before was a set of empirical  
22 evaluations. So now you've gone through the



1 first four steps and now you're to, okay, now  
2 I've got to get down to some of these relatively  
3 weedy issues. What are the numbers I should  
4 generate for the two attribution rules? And that  
5 would -- do you have a sense of what those --  
6 what would you measure to see -- you said how  
7 many people are attributed or what fraction of  
8 care, and how does the reliability of the metric  
9 change under the two rules. Are there others?

10 DR. RYAN: So I think what we've talked  
11 about today and what our group has thought about  
12 is kind of the share of eligible patients that  
13 get attributed, the share of eligible providers  
14 that get attributed. And then the -- so those  
15 are two, you know, basic ideas.

16 And then the other issues we discussed  
17 are the holding the measure constant, the effects  
18 of alternative attribution approaches on  
19 reliability and validity of given performance  
20 measurements.

21 Now, you know validity is always  
22 something that we struggle with. You know,

1       that's always when we do the NQF and evaluate  
2       measures that's the one where it's most  
3       controversial, and testing validity is more  
4       challenging. But reliability at least is  
5       something that we're more comfortable with.  
6       There's common measures to do that.

7               And, you know, in theory if we can do  
8       -- you know, we know how to do reliability tests,  
9       and if we did the same tests but apply different  
10      attribution algorithms to the data and redo those  
11      tests, I think that's honestly pretty  
12      straightforward. So I see no like major  
13      technical challenges to at least doing  
14      reliability.

15             CHAIR MEHROTRA: Another one might be  
16      really just -- I think what I hear from providers  
17      that has been most compelling is to show the  
18      correlation or just a comparison of people's  
19      performance under two attribution rules. We know  
20      that they're going to be different. But then to  
21      look at those and see which one just on face  
22      validity reasons you like better. But just

1 comparing the two I think is a useful exercise to  
2 go to which would go then into reliability.

3 I'm just trying to think of concretely  
4 what would a person do under that step in our  
5 criteria is what I wanted to explore.

6 Some cards are up. So Nate and then  
7 maybe Elizabeth.

8 MEMBER SPELL: Yeah, I was just  
9 thinking -- thinking this through as you framed  
10 it. Maybe if we're having someone have a guide  
11 that is in a way a model, attribution model  
12 builder. So you've got your -- you're designing  
13 through this table might be designing a candidate  
14 model, but you're then going to put it through  
15 the performance testing phase. And maybe as you  
16 do some performance testing within that test  
17 criteria by which, you know, you should be  
18 judging that.

19 And maybe you come up with several  
20 candidates you want to test. Or maybe you test  
21 one and, boy, it fails on one or more measures,  
22 you're going to go back and tweak the model.

1 CHAIR MEHROTRA: So just let me  
2 summarize where we are from 45 minutes ago when  
3 we started this. Sounds like there's enthusiasm  
4 for this idea. We've refined it. We've  
5 discussed changing it into a more normative  
6 framework and trying to at least decrease the  
7 number of criteria or steps you might go through  
8 by either consolidation or addressing this.

9 Let me --

10 DR. AMIN: Sorry.

11 CHAIR MEHROTRA: Oh, no, no. Go ahead.

12 DR. AMIN: Sorry, were you done? I --

13 CHAIR MEHROTRA: No, no, I think --

14 DR. AMIN: I think in terms of summary  
15 as well, I'm just sort of -- yeah, I'm sort of  
16 thinking through, you know, as we talked about  
17 these first order of criteria, I think we can  
18 refine these in the time between this meeting and  
19 August and maybe do some surveys to just confirm  
20 that we're good.

21 What Andy's got in his paper will help  
22 us define sort of the second level criteria that,

1     you know, once you have the, you know, candidate  
2     models as Nate described them. We talked a  
3     little bit about empirical analysis that you  
4     might do to sort of test the different models.

5             I guess the one question I'm still  
6     trying to understand is as we try to make this  
7     concrete for our audience, what are some  
8     suggestions about the columns here that make this  
9     as concrete as possible in terms of the use  
10    cases?

11            And Dan again, not to pick on you  
12    again, but I guess I'm sort of thinking through,  
13    you know, are there some, you know, concrete  
14    examples that we can provide that are  
15    particularly -- you know, some that are more  
16    straightforward but some that are particularly  
17    thorny or irrelevant to the discourse or the  
18    policy discourse right now that might be helpful  
19    to walk through to provide, you know, some level  
20    of guidance, you know, as we look at the  
21    potential case studies that we might consider for  
22    discussion during our next meeting.

1                   MR. MULDOON: Yes, so I think I'd  
2                   probably want to confer with Sophia before making  
3                   specific recommendations. In terms of thinking  
4                   about the broadest would be like the use cases  
5                   that might be most helpful to CMS but also trying  
6                   to be mindful of that if we want this to be more  
7                   broadly applicable it might not just -- we  
8                   wouldn't want to solicit only our, you know, CMS  
9                   or other payers' feedback.

10                  I think one thing that sort of  
11                  occurred to me as we're talking about doing the  
12                  empirical analysis and criteria, one thing I  
13                  think would be helpful to reflect in here is that  
14                  I think, depending on the goals of whatever the  
15                  specific use case is, sometimes how you -- like  
16                  what you might be looking for in that empirical  
17                  analysis, comparing the different attribution  
18                  methodologies could -- could differ.

19                  And so like, again, it makes me wonder  
20                  how -- again how -- like as we move to make this  
21                  concrete do we also then lose -- maybe it's if  
22                  we're trying to walk through the logic cases you

1 don't lose some of the sort of breadth of issues  
2 that you might want to consider, but sort of  
3 thinking about if depending on -- I guess I'm  
4 having trouble articulating it exactly, but if  
5 you have two different programs, you know, with  
6 an ACO attributing maybe for the entire year to -  
7 - if you're attributing a beneficiary's care for  
8 a whole year to an ACO you want to make sure that  
9 you're getting the beneficiary attributed to the  
10 provider, group of providers that are responsible  
11 for that beneficiary's care.

12 But, you know, for like the joint  
13 replacement -- the joint replacement bundle we  
14 talked about here, you know, there's more of a  
15 balance there between do we want to attribute it  
16 to maybe the hospitalist or someone who's  
17 attending and managing that care versus the  
18 orthopedist who performed that surgery.

19 Like trying to think about, right,  
20 either -- if you can attribute to either of those  
21 physicians I think, you know, if they're -- if  
22 there's a difference there. But there's like

1 different -- depending on what the goal of sort  
2 of assigning that episode to a provider is you  
3 might have, you know, even though you could  
4 attribute it in either scenario and you have an  
5 empirical analysis that shows, oh, if we  
6 attribute to the attending physician when it's  
7 different, we attribute to the attending  
8 physician versus the orthopedist, depending on  
9 the goals like which one -- which way does --  
10 what of those empirical results do you want to  
11 put more weight on based on what the program is  
12 trying to achieve.

13           So I'm not sure if that's clear. I'm  
14 having trouble articulating it. But that was  
15 sort of occurring to me.

16           CHAIR MEHROTRA: But, yeah, so I  
17 appreciate that point. And -- but I do think  
18 that I do want to -- while we certainly don't  
19 want all four cases to be CMS, I think having one  
20 or two that are the most thorny for you probably  
21 is going to both be compelling for the audience  
22 of this report because that's going to seem that



1 much more relevant to them because what you do  
2 impacts so many providers, as well as we do want  
3 to make this helpful.

4 So given these kind of bins that I  
5 thought Danielle had created, I think, you know,  
6 if you and Sophia want to tweak or so forth we'd  
7 be I think very open to that.

8 Yes, so Brandon and then Ira.

9 MEMBER POPE: I just want to -- Taroon,  
10 you're asking about what's a good thought process  
11 on how we choose the columns of this, which are  
12 really examples of how our sort of taxonomy plays  
13 out. Yeah. I mean my thought was it's obviously  
14 a pretty big space. And the best way to explore  
15 a big space in my mind is choose, you know, one  
16 of the most salient characteristics.

17 I think you can go a different --  
18 couple of different directions. Whether you're  
19 talking about the unit of analysis being an  
20 event, an episode, a patient year or a population  
21 year, you know, you could try and really tie --  
22 we chose these different columns as, you know,

1 four examples of different units of analysis or  
2 different, you know, stakes or attribution  
3 models, measures, purposes.

4 I think when it can get confusing is  
5 if we choose different columns, like this column  
6 is an example of a quality measure. This column  
7 is an example of a PCP attribution. This column  
8 is an example of when we're only reporting, we're  
9 not actually doing pay for performance. I think  
10 it becomes a little more jumbled if you do that.

11 So my recommendation would be pick one  
12 of your dimensions of your taxonomy, and try to  
13 sort of stratify across them to give a sense of  
14 the breadth of the tree.

15 DR. AMIN: Do you have a recommendation  
16 of what that -- I mean you listed -- you listed a  
17 few of them but do you have -- I mean --

18 MEMBER POPE: I think either the -- to  
19 me the unit of analysis and the unit receiving  
20 the attribution those are going to end up being  
21 somewhat related, right? But if it's an acute  
22 event versus an episode, versus a patient year,

1       versus a population year, right, you're going to  
2       again -- similarly you're going to attribute  
3       those to things like a surgeon, a hospital, a PCP  
4       or an ACO. Right? You could go either one of  
5       those directions and I think you'd have a pretty  
6       good sense of the breadth of considerations.

7               CHAIR MEHROTRA: Ira.

8               MEMBER MOSCOVICE: Yeah, I guess I  
9       would resonate with what Laurie said earlier. I  
10      think what's on the top of each of these columns  
11      are different kinds of patients where one would  
12      be an acute care episode, and that could be in a  
13      bundled payment. Another could be the  
14      chronically ill patient. And the third would be  
15      the thorny one, population based, whether it's  
16      smoking, you can call it whatever you want.  
17      That's what should be driving the columns I think  
18      rather than the structures.

19              Then you can choose how this is going  
20      to play out in an ACO or how this is going to  
21      play out in whatever structure. But --

22              CHAIR MEHROTRA: Ira, I hear the point.

1 And I wonder whether there would be -- you know,  
2 as we have these little boxes we might have there  
3 was Ms. Jones who had this thing, and so when we  
4 talk about our logic we might refer back to a  
5 concrete case. But I do worry about making -- at  
6 least my own thought is because at the end of the  
7 day who's going to use this? Is it a interactive  
8 or is it a PDF? It's someone who's going to have  
9 I'm developing an ACO program or I'm developing  
10 the new outcome measure for SNF readmission.

11 And I think starting where the  
12 audience is, as opposed to the audience is not  
13 where a patient doing this. That's at least --  
14 or maybe I misheard you a little bit about that,  
15 but that's at least -- that's why I thought the  
16 logic going through it from a use case, if we're  
17 okay using that term still.

18 MEMBER MOSCOVICE: Yeah, I understand  
19 where you're going from but I don't think they  
20 preclude each other. But I think the comment  
21 that was made before, which is this can't be just  
22 provider driven I think is really important.

1           In the end, you're right, the users  
2       may well be certain types of providers. But I  
3       think what drives this -- and to me that means  
4       what drives the columns are how are different  
5       kinds of patients being attributed, rather than  
6       what organizations are taking -- starting with  
7       the organizational level.

8           CHAIR MEHROTRA: What if we were to do  
9       a way to address what I think is an important  
10      point, and I'm trying to make this feasible and  
11      not take on too much. But what I'm envisioning  
12      in the report is we have four case studies, use  
13      cases or whatever else we want to call it, we'll  
14      decide what those are. And we'll describe those  
15      in a sidebar explaining a little bit of the  
16      context so someone who's not familiar can  
17      understand it.

18           But we also have potentially a couple  
19      of sidebars of patients who've received a hip  
20      replacement, smoke, went to a SNF. And then when  
21      we discuss, for example, the accountable unit we  
22      -- beyond just going in generalities we could

1 say, hey, you know, Sally would have been  
2 attributed to the SNF but, you know, we gave you  
3 the example of Bill because Bill adds a nuance  
4 and, you know, an issue of it gets a little  
5 confusing because he also had a hip -- you know,  
6 I mean we can think about that.

7 But the idea would be is that if we  
8 provided those cases, it may make it even more  
9 concrete as we discuss these different criteria  
10 that we're going through. Isn't that -- do you  
11 think that would help or does that address your  
12 comment?

13 MEMBER MOSCOVICE: I think we're not  
14 that far apart. But I would go where Brandon was  
15 before which is we want to keep this as simple as  
16 possible but yet we want to cover a broad range  
17 of issues. And that -- where that -- those two  
18 spaces interact is sort of -- sort of the key I  
19 think.

20 CHAIR MEHROTRA: Quick time check just  
21 before I forget. So I think we'll have -- I'd  
22 love to discuss this for about ten more minutes

1 or so and then I think lunch.

2 MS. O'ROURKE: Lunch is going to be  
3 ready in about ten, if you want.

4 CHAIR MEHROTRA: Okay. So we'll talk  
5 for ten minutes about this and then we'll have  
6 lunch. And then I think we'll go back to the  
7 principles after that.

8 So let me -- Danielle.

9 MEMBER LLOYD: Of course I'm headed  
10 back to your specific question and the specifics.

11 So just as examples, if you decide to  
12 do it, because I'm struggling with how to do it  
13 from the patient perspective. It's almost you go  
14 patient to the payer, payer to the patient,  
15 either way I think you're discussing the same  
16 thing. You just need to make sure there is a  
17 vignette about the patient somewhere in there.

18 But if you wanted to sort of mix  
19 things up you could have a Medicare Track 3 ACO,  
20 because that has some distinctions in terms of  
21 risk and perspective and such, depending on  
22 what's in that, you could have a Medicaid bundle

1       like Arkansas or Tennessee or one of those,  
2       whichever you guys have in your paper, and then  
3       you could have a private payer tiering system or  
4       something like that.

5               And then it would sort of be different  
6       payers and so -- but it's still concepts that  
7       would apply to you guys. And it would draw  
8       different distinctions between the three.

9               But you could use -- instead of us  
10       making up these answers, you could just take  
11       three of the ones that you've already put in Dr.  
12       Ryan's paper and sidebar those and say let's call  
13       out three examples that we looked at and evaluate  
14       them against our criteria.

15               CHAIR MEHROTRA: Interesting. That's  
16       good.

17               So other -- so, Laurie, comments on  
18       any of those?

19               MEMBER RADWIN: Yeah. Just a remark on  
20       the dialog between you and Ira. And that is that  
21       people don't -- clinicians, providers don't set  
22       up structures and then say how am I going to



1       populate the structure with patients so that I  
2       can apply the attribution rule. You're taking  
3       care of a bunch of patients. And you're choosing  
4       the structure and then figuring out what  
5       attribution rule makes sense.

6                You know, so if I'm running a well  
7       woman clinic, you know, those are what my  
8       patients look like. Sometimes they have to go to  
9       the hospital. Sometimes they go to specialty  
10      care for an OB. But I've already populated my  
11      structure with patients.

12              And the question becomes the column  
13      headers, which type of structure and attribution  
14      rules make sense for me. You know, when you work  
15      the other way with let's talk about ACOs, you're  
16      applying ACOs to a group of people that you're  
17      taking care of, right? And so that tension, you  
18      know, it's impossible to ignore the patients when  
19      you designate structure and attribution rules  
20      because the patients are already populating your  
21      structure.

22              And that's why, you know, I would

1 advocate very strongly for having the case  
2 studies be about the typical kind of patients  
3 that muck you up, like the guy in case 2, or you  
4 know, like the person who disappears and doesn't  
5 come back for chronic care.

6 And so that was the point of having a  
7 prototypical patient populate, you know, the rows  
8 or not just be a sidebar.

9 CHAIR MEHROTRA: I hear a lot of  
10 people, this idea resonates with them. So I want  
11 to take that and see how we can incorporate that.  
12 And I don't want to be anti this approach because  
13 I do think it has a lot of merit, but I -- one of  
14 the things I'm also thinking about, which is that  
15 to really illustrate this you almost need a  
16 couple cases for each one. You know, you want  
17 your classic person who has a joint replacement,  
18 and then the person who has 20 comorbidities, and  
19 then the person who disappears for care.

20 And so maybe I'm being too reactionary  
21 but I'm trying to think of how can we really  
22 illustrate some of the nuances of attribution.

1       So I think the point's well taken. And then I'm  
2       just trying to think through how it would  
3       actually look like.

4               MEMBER RADWIN: I mean just to respond,  
5       I mean there's some pretty high level  
6       characteristics that patients have. And there's  
7       also the problems for -- there are the problem,  
8       you know, patients that are just plain hard to  
9       take care of, hard to pay for, hard to attach to  
10      a clinician. And I think, you know, your worst  
11      nightmares should be the case studies because  
12      then it would help.

13             CHAIR MEHROTRA: But I mean we do also  
14      want to be careful. We don't want the uncommon  
15      or the exception to undermine something right.  
16      Because if 90 percent are typical and ten percent  
17      are atypical, we don't want the case to only  
18      focus on the atypical. So that would be  
19      important.

20             So let me -- I'm talking too much, so  
21      Srinivas and then Helen.

22             MEMBER SRIDHARA: Sorry. I just wanted

1 to comment again on this patient organization  
2 sort of thing. And I think we want to use case  
3 scenarios to help people get a sense or  
4 understand. But I would argue that the notion of  
5 attribution performance measurement payment is a  
6 sort of population statistics idea. It's not an  
7 individual patient care idea, if you will, if you  
8 were to take that approach.

9 So I think people are going to find  
10 exceptions based on individual scenarios that  
11 don't work with the attribution model. So I'd go  
12 back to the notion that I think Mike mentioned  
13 some time ago which was there is error in this  
14 process and things are going to fall outside of  
15 it. And I think -- that's why I think if you  
16 think of who is trying to do this, it is usually  
17 a payer or an organization like an ACO, or a  
18 provider group, or someone else who's trying to  
19 do this activity. And they are looking across a  
20 broad spectrum of patients who are, you know, who  
21 have varying ranges of complexity and everything  
22 else.

1                   And so I think our guidance is  
2                   probably to the people trying to implement the  
3                   attribution and probably not to the doc who is  
4                   doing the services, though they probably need to  
5                   understand eventually how their behavior falls  
6                   into attribution models and how they get paid.  
7                   And I think we use specific case scenarios to  
8                   help a doc or anyone else sort of be able to  
9                   understand how it might fall into a logic as a  
10                  whole, but agree that we're focusing on the 80  
11                  percent and not the 20 percent and think of it  
12                  that way. I think we're trying to provide a  
13                  framework.

14                  CHAIR MEHROTRA: That's a good point.  
15                  Helen.

16                  DR. BURSTIN: Yeah, this is a great  
17                  discussion. I'm not sure it's an either/or. And  
18                  I guess I'm in Ira's camp and the other camp. I  
19                  actually think what Ira's proposing is being less  
20                  focused on the specific programs and being more  
21                  patient centered.

22                  And, you know, as employers look at

1 this, as patients look at this, there has to be  
2 something that logically makes sense. So I don't  
3 see it as an either/or, maybe it's that elusive  
4 third dimension you can't put on this chart, or  
5 maybe it is a way to just then describe this in  
6 ways that is more relatable. This is what happens  
7 to patients with acute illness. Not to get into  
8 the exceptions or the 20 percent that doesn't  
9 fit, but literally illustrate an acute patient  
10 going through a process, a patient with multiple  
11 chronic conditions going through a process. I  
12 think that's an -- or even a patient who goes in  
13 and out of settings of care. Maybe just a couple  
14 as illustrative examples.

15 And then, interestingly, see how well  
16 they tie or don't tie to the ways we're looking  
17 at it currently. I think it's good stuff to  
18 explore. I don't think you're going to fix it  
19 today but I think it's an intriguing idea.

20 CHAIR MEHROTRA: A lot of people have  
21 cards up. I want to make sure if -- I have  
22 Elizabeth and then Jenny I think are the people.

1 And, Elizabeth -- oh yes, so go ahead.

2 MEMBER DRYE: Since I'm sitting between  
3 Brandon and Ira, I actually think they're kind of  
4 rounding out, I mean your thing -- anyway, I was  
5 having a side conversation because I like -- I  
6 really like this idea of an event, acute event  
7 and episode, a patient year and a population  
8 year. And you could just make it a little more  
9 concrete.

10 This is still not down to the  
11 individual patient level but you could -- the  
12 generic could be something like an acute illness  
13 or admission, say for appendicitis or whatever, a  
14 heart attack. An episode would be like treatment  
15 of low back pain or treatment of chronic knee  
16 pain.

17 A patient year would -- you could make  
18 it for all ambulatory patients with multiple  
19 chronic conditions or whatever. You could choose  
20 your -- the generic would be, you know, a patient  
21 year. So you're looking at quality and cost.

22 And then the final population year

1 would be, you know, smoking cessation programs or  
2 whatever effort. And that would be quality and  
3 cost. And there you could figure out where you  
4 attribute it. Because I think we want one to keep  
5 on both quality and cost. And we want to be --  
6 this is one area where we basically want to be  
7 generic enough. Then you could have specific  
8 patients.

9 And the other thing I wanted to say  
10 was you could for those extreme cases -- and it's  
11 already on Danielle's chart -- think about either  
12 adjustments or exclusions when you got into the  
13 second level of, you know, here's how you would  
14 handle some of the problematic pieces that  
15 undermine fairness potentially.

16 MEMBER BEAM: Yes. And I think I was  
17 just, if I was hearing Helen correctly and  
18 talking about Ira's model, I almost see, like I  
19 said, the model, when you're thinking about  
20 implementing the model from a system perspective,  
21 and again whether you're providers or groups or  
22 whatever, you're implementing that to a large



1 body of patients.

2 But then Ira's is where I see is  
3 almost setting up with those particular and  
4 typical patient, like I said, the healthy, the  
5 chronically ill, the one that's gone to the ER,  
6 the one that's inpatient. And those are almost  
7 the things you want to go back and look at in  
8 your model to say how do they fall out in this  
9 model? So it's almost like a cross-section, like  
10 cross-sectional view of the model itself. You're  
11 going to come at it from this angle and from that  
12 angle, and then does it make sense.

13 I don't know, I think that's what  
14 Helen was saying, too. I'm not for sure but  
15 that's just it.

16 DR. RYAN: Comment because, okay, I  
17 really agree with Jenny. And I think that the  
18 problem is if we do, if the columns are based on  
19 kind of clinical circumstances is that some of  
20 the attribution models, you know, cover these  
21 different, apply to these different clinical  
22 circumstances. Like ACOs will apply to all these

1 things.

2 And presumably, unless we're talking  
3 about having multiple attribution approaches  
4 within ACO models, which I don't think we're  
5 talking about, then it does seem like we should  
6 -- the central organization should be based on  
7 that application, like the program application.  
8 But we should bring out the detail of how  
9 specific clinical events or patients, whatever,  
10 are captured within that, that programmatic  
11 context is how I see it.

12 CHAIR MEHROTRA: So let me wrap up  
13 here.

14 So first I thought we could wrap up  
15 some of the -- kind of summarize what I'm hearing  
16 right now. But before I do that, I know there  
17 are a couple people who haven't had a chance to  
18 weigh in. Jen, on the phone or others?

19 MEMBER PERLOFF: Oh, again this is I  
20 really appreciate the struggle of trying to get  
21 the grid correct. And anyway, I emailed in some  
22 comments on validation that might be interesting.

1 And I just wanted to highlight the patient  
2 perspective is a really interesting dimension to  
3 this.

4 When we talked about validation in  
5 terms of, you know, can the patient name their  
6 primary care provider, but you could think about  
7 this in a more extended way that providers have  
8 an obligation or a commitment to inform patients  
9 that they're in an ACO or what model or program  
10 they're in. And that may be another way to  
11 validate is to find out the extent to which  
12 patients understand, you know, the assignments  
13 they've been put into.

14 So I just wanted to throw that into  
15 the mix. It's a little bit in left field, but --

16 CHAIR MEHROTRA: No, not in left field  
17 at all.

18 MEMBER PERLOFF: All right, thank you.

19 CHAIR MEHROTRA: So, all right, well  
20 let me summarize quickly.

21 So it sounds like from where we were  
22 this morning. We had yesterday and through this

1 morning we had a desire to try to make this more  
2 concrete. And it sounds like the framework that  
3 we're discussing here, people are generally  
4 enthusiastic about it.

5 What we need to do is, building off  
6 Brandon's comments and Elizabeth's comments and  
7 others, about what are those case studies to try  
8 to -- huge landscape, which are the ones that we  
9 think are most illustrative, and building off  
10 also Ari's comments that maybe these aren't the  
11 right ones.

12 And we'll have some conversations with  
13 Dan, Sophia and others. We'll maybe put out  
14 after some discussion maybe in the next couple  
15 weeks we might distribute here are the four that  
16 we accumulate.

17 And then also building on the comments  
18 here of what are the criteria, we can maybe put  
19 those out at the same time as here's  
20 consolidating all these comments and then maybe  
21 have the group react to that and say, oh, I think  
22 this works; I don't; and tweet. And then maybe

1 for our August meeting we can then try to put  
2 those in together in terms of actually fleshing  
3 those out.

4 So does that seem to summarize where  
5 we are?

6 DR. AMIN: Absolutely, Ateev.

7 Just on that last point around the  
8 criteria, it seems, just to be a little bit more  
9 nuanced, what I'm here is that there is this sort  
10 of first order of criteria which we'll try to  
11 develop and sort of summarize. Some of the  
12 second area of criteria, second order criteria is  
13 in Andy's paper.

14 And then there's also this what are  
15 the elements of the empirical analysis that we'll  
16 try to bring together and maybe test with the  
17 group in the next several weeks, and we'll have a  
18 discussion about that in August as well.

19 CHAIR MEHROTRA: Right. And then also  
20 I don't want to use the thread of the patient's  
21 voice and trying to see how we might, as Helen  
22 articulated, not either/or but how we might try

1 to play that out.

2 And so I think my own reaction is I'm  
3 enthusiastic about the idea, but I want to see an  
4 example to see if it kind of works on the page or  
5 in a video.

6 So let me stop here. So we're going  
7 to have lunch for how long?

8 MS. O'ROURKE: Do you want to give them  
9 30 minutes, or do you want to do a working lunch?

10 CHAIR MEHROTRA: I think people would  
11 -- I'm always famished from actually talking. So  
12 how about a 30-minute break; would that be okay?  
13 I don't know. Sorry. Okay.

14 MS. O'ROURKE: Should we do the public  
15 comment first before we break?

16 CHAIR MEHROTRA: Oh yes. I apologize.  
17 How do I do that?

18 MS. O'ROURKE: Are there any public  
19 comments in the room?

20 OPERATOR: To ask a public comment  
21 please press star one.

22 CHAIR MEHROTRA: Come one. One public

1 comment.

2 OPERATOR: And we have no public  
3 comment.

4 CHAIR MEHROTRA: All right. Darn.

5 So 30 minutes break. We'll come back  
6 at 12:45. And for the rest of our time together  
7 we'll be going back to the principles and make  
8 sure we hammer those out and the language and so  
9 forth. So we'll talk about it.

10 (Whereupon, the above-entitled matter  
11 went off the record at 12:14 p.m. and resumed at  
12 12:54 p.m.)

13 CHAIR MEHROTRA: All right. We are  
14 all gathered. So the key thing is we want public  
15 comment, so I have put the gauntlet down for our  
16 folks to see if we will have any public comment  
17 during our time period here. So we'll see.

18 So in the last block we have together,  
19 you know, I feel like overall we have made great  
20 progress in terms of moving forward and a lot of,  
21 you know, really great input here.

22 I think where we want to end today is

1        what is going to go out to the public and get  
2        input, which are these draft principles and then  
3        what I reviewed earlier. My thought is -- my own  
4        inclination as I reflect upon the conversation  
5        today and sort of thinking what this report would  
6        look like, my thought is that some of these  
7        should potentially be removed as a principle and  
8        be more as a recommendation.

9                I know I was struggling with that  
10       little distinction there, but a principle is like  
11       a sort of guiding idea of what we want, and then  
12       a recommendation is -- maybe I'll just pick on  
13       Elizabeth. Like, Elizabeth, next time you have a  
14       measure, here is what we think you should do, and  
15       that is sort of part of that  
16       recommendation/checklist kind of idea.

17               So that is at least one thought I had,  
18       but maybe we can just kind of go one by one  
19       through these and get people's reaction about  
20       drop it, change the language, et cetera.

21               So the first one is the goal -- a goal  
22       of attribution is to drive the system towards



1 shared accountability and advance the goals of  
2 the National Quality Strategy. I am going to  
3 start with the first clarification, which I  
4 should have asked, what is the National Quality  
5 Strategy like? Just to make sure like -- you  
6 know, like what element of this is on there or --  
7 Kim, as the author of the National Quality  
8 Strategy, give us a sense of --

9 (Laughter.)

10 CHAIR MEHROTRA: It is one of those  
11 things, you laughed, so --

12 (Laughter.)

13 CHAIR MEHROTRA: -- what you have  
14 chosen. I know, it's a terrible thing.

15 MS. IBARRA: Well, I will start. I am  
16 not the author of the National Quality Strategy,  
17 for the record. So this is in response to some  
18 early -- early committee discussions that we have  
19 had around capturing the importance of  
20 attribution and bringing in the Triple Aim.

21 And so the National Quality Strategy  
22 builds on the Triple Aim, and it is better care,

1 healthier people, and affordable care. And so it  
2 just tries to take it a little bit further. It  
3 is work that we are using at NQF, we are  
4 supporting at NQF. It is at CMS, and it tries to  
5 encompass not only the Triple Aim but kind of  
6 bring it a little bit further down the road.

7 So does that help?

8 CHAIR MEHROTRA: That does help me,  
9 yes.

10 Reactions from the group for this  
11 first one? Changes you would make? Go ahead,  
12 Michael.

13 MEMBER BARR: Sorry to be picky, but  
14 "the system," do we want to be a little bit more  
15 specific or -- that could be interpreted very  
16 broadly or narrowly or -- it's just a generic  
17 word, "the system." Some people might even say  
18 we don't have a system.

19 CHAIR MEHROTRA: So I think that's a  
20 really good point. I agree with Taroon that just  
21 adding "healthcare" would help a little bit, but  
22 I don't think it fully captures what you're

1 looking for, Michael. Do you have any proposed  
2 language there?

3 MEMBER BARR: I mean, in theory, you  
4 could handle it in a series of definitions  
5 potentially. I think "healthcare" helps, but  
6 then I think there has to be some sort of  
7 expanded language within the document that  
8 references everything that you might be including  
9 at the different levels, practices, you know,  
10 clinically integrated networks, and so on,  
11 whatever the target of the measurement might be  
12 or the attribution might be.

13 CHAIR MEHROTRA: Other thoughts? One  
14 thought I had was basically the goal of  
15 attribution, is there also -- we have talked  
16 about this aspirational aspect of attribution,  
17 which is the shared responsibility. But at its  
18 heart, should we also add the point that  
19 attribution is to identify who the responsible  
20 provider is, so it would be two goals? Or is  
21 that already taken for granted and that's not  
22 necessary, or that's -- do you disagree? Go

1 ahead, Michael.

2 MEMBER BARR: That was the other  
3 question I had was I -- we all talked about  
4 shared accountability. But in the context of a  
5 principle, should we leave it at accountability?  
6 Because that could be shared or not shared. And  
7 to be driving towards accountability -- shared  
8 accountability may not work in all circumstances.  
9 So if you make it a principle, that elevates it  
10 to across everything.

11 I mean, there are some cases I think  
12 people made where there is one person who is  
13 accountable, and so sharing doesn't apply to all  
14 circumstances, and principle should apply across  
15 the board.

16 CHAIR MEHROTRA: I didn't see when the  
17 cards came up, so maybe Ari first.

18 MEMBER HOUSER: Just to get to the  
19 point you had said about whether it goes without  
20 saying, too, that attribution is to identify the  
21 responsible party, I think that's not quite  
22 right. It's not "the." It could be "a"

1 responsible party, and I might even say a  
2 potentially responsible party, because you could  
3 have multiple parties and they may or may not be  
4 responsible. But there could theoretically --

5 CHAIR MEHROTRA: I hear you. That  
6 sounds sort of like potentially responsible.

7 (Laughter.)

8 MEMBER HOUSER: I don't know.

9 MEMBER BEAM: And that's the same. I  
10 was going to even say you're really identifying  
11 relationships. That's what you're -- you're  
12 identifying the relationships in the care  
13 delivery system, so that it can facilitate, you  
14 know, but those relationships are --

15 CHAIR MEHROTRA: Right. But, you  
16 know, just to push on that, so, you know, if we  
17 look in the claims pattern and we're looking at  
18 PCP, you know, ENM visits, and we see that Ms.  
19 Jones had a visit with the orthopedic surgeon,  
20 and there's an ACO thing, they have a  
21 relationship, but what we're really trying to do,  
22 the reason we focus on PCPs in that context is we

1 think that PCP has that responsibility or care  
2 coordination or overseen aspect.

3 For example, Keith in the ED, not --  
4 you know, you're not thinking, oh, I'm taking  
5 care of Mrs. Jones, all her care. You're  
6 thinking of -- so that is the reason I didn't --  
7 but they did have a relationship, because they  
8 had an encounter. I don't know. Just pushing on  
9 that a little.

10 CHAIR MEHROTRA: Go ahead, Ira.

11 MEMBER MOSCOVICE: I thought this was  
12 going to be easy. We're never going to get  
13 through these.

14 CHAIR MEHROTRA: I know. We've got to  
15 like hurry up.

16 (Laughter.)

17 MEMBER MOSCOVICE: If we're going to  
18 deal with wordsmithing, we're not -- but it's not  
19 -- the healthcare system doesn't fit in there.  
20 It means nothing to say we're driving the  
21 healthcare system towards accountability. And we  
22 don't want to use the word "providers," and I

1 don't know what the right words are, but I think  
2 we need to get a little bit more specific.

3 And what we're really trying to do is  
4 to clarify, define, call it what you want, but it  
5 -- I just wish we would use a different term than  
6 "healthcare system," which is sort of a generic  
7 Pabulum.

8 CHAIR MEHROTRA: And then, do you  
9 think that if we said "clinicians," or what would  
10 be -- I hear your point, but then I'm like, oh, I  
11 don't know. Oh, Nate has got an idea.

12 MEMBER SPELL: I was going to suggest  
13 that we just say "to drive accountability and  
14 advance the goals of the National Quality  
15 Strategy," and leave it at that.

16 CHAIR MEHROTRA: I like that. Others  
17 agree? Jenny, did that -- okay. Oh, Jen, go  
18 ahead.

19 MEMBER NOWAK: I wanted to support  
20 the concept that attribution is identifying  
21 relationships, because it depends on how you use  
22 attribution. You may be using it to identify

1       accountability, but it may be used in measurement  
2       to identify some other aspect of healthcare. So  
3       in an ACO situation, it is to identify  
4       accountability.

5               MEMBER BEAM: And I think that was my  
6       -- I wrote this down. I was saying earlier --  
7       and I think this is still something we are  
8       keeping with as -- we said earlier that  
9       attribution was our -- accountability -- one  
10      equals one, but one does not equal the other. So  
11      are we contradicting that by the statement?  
12      Because we said accountability always equals  
13      attribution, but attribution does not always  
14      equal accountability. That was an earlier  
15      statement we had made, and we wrote that up.

16             So if we say it like this, I feel like  
17      we're almost contradicting. So that's where the  
18      relationships come into play.

19             MEMBER POPE: Yes. I don't read it  
20      like that. I read it as accountability is going  
21      to be -- I don't think anyone would debate that  
22      accountability is going to be necessary at some -



1 - to some extent in some places to achieve the  
2 goals of the National Quality Strategy.

3 So I think we're saying attribution is  
4 to do that, and to more broadly advance the goals  
5 of the National -- it's not necessary that  
6 someone being accountable for every single  
7 outcome is going to be necessary to achieve a  
8 strategy. It is sort of this and this, not this  
9 or this, if you -- if I can start using arm  
10 gestures.

11 CHAIR MEHROTRA: I think some people  
12 have their mics on. I think, Ira, if --  
13 Danielle?

14 MEMBER LLOYD: I guess because this is  
15 -- I recognize that what you're saying, Jenny,  
16 doesn't go both ways, right? But I think we are  
17 in a goal statement, right? So I think part of  
18 the goal that I heard out of those three groups  
19 is to use the attribution to drive providers  
20 toward accountability for the National Quality  
21 Strategy goals, right?

22 So, ultimately, attribution is to a

1 provider. So I don't think we can get around  
2 that. And you can't -- I don't think we can just  
3 put in health system, right, because it's too  
4 amorphous. The attribution is linking the  
5 patient and the provider, and part of the point  
6 of this is we want to use it to try to get more  
7 people to take accountability.

8 CHAIR MEHROTRA: So we are measuring  
9 relationships but driving towards accountability?

10 MEMBER LLOYD: Yes. So, I mean, a  
11 goal of attribution is to drive providers toward  
12 accountability for the goals of the National  
13 Quality Strategy, right? Is that -- you're  
14 trying to tag people, so that they have the  
15 accountability?

16 CHAIR MEHROTRA: Okay. Well, I'm --  
17 these are great. I'm also -- I think Ira's point  
18 is also well taken, which is we do have a lot  
19 more. So why don't we keep on going and iterate  
20 here a little bit, because otherwise we'll be on  
21 number one until 2:30 here.

22 So the second one here, if that's okay

1       -- I don't want to cut off conversation too  
2       early, but attribution is a central part of  
3       measure specification and policy and program  
4       design. Measures and programs should be tested  
5       with more than one attribution approach to ensure  
6       accuracy and fairness.

7               Provider and patient input on  
8       attribution of approaches may help to obtain face  
9       validity for selected approaches, and we should  
10      consider both alignment of the attributed and  
11      measure populations as well as consider alignment  
12      of purpose of attribution, attribution approach,  
13      and measure concept.

14              So I think the first point I heard,  
15      which I think is a very valid one, which is, what  
16      does number 2B mean? And I think I -- as I said  
17      it, I wasn't sure exactly either, so maybe we  
18      could kind of -- my memory is what we are trying  
19      to do is address the ideas that were presented  
20      earlier yesterday, which was like you've got your  
21      cost measure, you know, your population by which  
22      you are -- I think -- let me see if I have this

1 right.

2 You are -- let's say you're measuring  
3 cost and quality. On one measure you have one  
4 population; on another metric you have another  
5 population. To the degree that we can align the  
6 two, that would be correct. Is that what this is  
7 trying to capture? Oh, Erin, you're going to say  
8 -- you didn't put your tag up.

9 (Laughter.)

10 CHAIR MEHROTRA: Just joking. Go  
11 ahead, Erin.

12 MS. O'ROURKE: Yes. We were trying to  
13 get to, Danielle, you made the point a little  
14 more in real-world examples yesterday. So we  
15 were trying to take that up to the principle  
16 level about aligning the people assessed in the  
17 measure as well as the attributed in a various  
18 program, if you will.

19 So it seems like we did not get that  
20 language right, so, Danielle, if you wouldn't  
21 mind reiterating your position.

22 MEMBER LLOYD: I was going to say I

1 didn't know that was mine, so I think that means  
2 it didn't work. I think you are trying to align  
3 the measurement -- well, we are -- I'm not going  
4 to be able to write it right now. You know what  
5 I mean? We're going to have to wordsmith that  
6 later, but you're trying to align the measure --  
7 the population you're measuring, which is the  
8 attributed population -- with those for whom you  
9 have the accountability, right?

10           You don't want there to be a mismatch  
11 between who do you have accountability for and  
12 who you are measuring in the measure. That's  
13 ultimately -- as we have said, it's not always  
14 the same thing, right? So if you have a quality  
15 measure that's on 10 people, and you're applying  
16 it to a payment ramification that is on 100  
17 people, like that doesn't work. You want the  
18 same people who -- the 100 people you have  
19 payment responsibility for are the 100 people who  
20 are in your quality measure. You want those to  
21 be the same.

22           CHAIR MEHROTRA: And so what I'm

1 hearing from you is in that -- that's a case of  
2 payment and quality. It could be cost and  
3 quality or two quality metrics, but when you have  
4 a program that --

5 MEMBER LLOYD: It could be patient  
6 experience also.

7 CHAIR MEHROTRA: -- combines the  
8 two --

9 MEMBER LLOYD: It could be patient  
10 experience. It is whatever -- whatever is  
11 relevant to the program, the attribution should  
12 be the same across them. You pick one method per  
13 program, and that's it.

14 CHAIR MEHROTRA: Okay.

15 MEMBER LLOYD: But I think the piece  
16 of this that is troubling me, I continue to worry  
17 about the testing, you must test piece. Can we  
18 say novel models need to be -- if you have a  
19 novel model, it needs to be tested, because to  
20 the point of driving up costs, it might be that  
21 some model ends up being tested ad nauseam.  
22 Everybody doesn't have to test it.

1           If you pick up something that is  
2           already tested, that should be fine. You  
3           shouldn't have to test just to test, but only if  
4           you are taking a new approach, I think.

5           CHAIR MEHROTRA: This is helpful; I  
6           think we can continue to refine this. I did hear  
7           something on -- and just because it was hard on  
8           the phone -- Jen, did you say something on the  
9           phone? I heard something.

10          MEMBER PERLOFF: Yes. I just want --  
11          yes, I'm sorry. I just wanted to jump in that  
12          that's an excellent criteria or goal, but a lot  
13          of work fails to meet that right now. And I  
14          think MIPS might not even meet it in its first  
15          iteration because, you know, attribution and  
16          quality measures are not aligned at this point.

17          So I just wanted to point out that we  
18          might be setting a bar that for a long time  
19          people can't meet.

20          CHAIR MEHROTRA: Would it be because  
21          we did -- the part of the conversation yesterday  
22          was really trying to say we're trying to see

1 where we want to push attribution in the future.  
2 Could we frame this to both capture reality but  
3 also be aspirational, to say in the ideal this is  
4 what we want, and so there were -- at least, you  
5 know, acknowledging what you're saying right now,  
6 Jen, but also to say in the ideal world we would  
7 have that.

8 MEMBER LLOYD: But that's why I  
9 started with saying these are goals. I don't  
10 want to hamstring myself on goals as to what we  
11 can or can't do today, and so it is a goal that  
12 it drives accountability. It is a goal that  
13 there is matching. It doesn't have to be in  
14 every scenario you are only going to approve the  
15 things that meet -- these are not the criteria;  
16 they're the goals.

17 MEMBER RADWIN: Could it be something  
18 like as new measures are developed, or as new  
19 models are developed, so that you become that  
20 cutting edge instead of having to carry the  
21 burden of history on your back to get everything  
22 right again?



1 CHAIR MEHROTRA: That's a good point.  
2 But some sort of language in that I think makes a  
3 lot of sense.

4 So let me see, Troy, Ari, and Srinivas  
5 are next. So, Troy?

6 MEMBER FIESINGER: So I'll give you an  
7 alternate take. I agree with the point and the  
8 goal. To me, thinking it is somewhat on the  
9 ground level, I would like attribution to be  
10 accurate, equitable, and fair, and we can  
11 wordsmith the nuances, the terminology. But I  
12 want to feel like it's right. I want to feel  
13 like I'm being treated fairly. I want to feel  
14 like the allocation of responsibility is  
15 equitable and balanced.

16 So when I think of aligning  
17 populations, different measure types, processes,  
18 that is the lens that I think through. Does it  
19 feel -- I may not love it, but it's okay.

20 CHAIR MEHROTRA: Reactions to that, as  
21 well as others? Let me go with Ari next.

22 MEMBER HOUSER: So I wanted to speak

1 up in terms of keeping that you should test more  
2 than one attribution approach in the goal. And I  
3 -- it doesn't say that you -- every time you want  
4 to create a measure, you have to test multiple  
5 attribution approaches and then pick the one that  
6 is best in the testing.

7           You may have, for other reasons, an  
8 attribution approach in mind, but you still need  
9 to test to make sure that the approach that you  
10 want to use isn't bad. You know, there can be  
11 lots of good approaches that are not exactly the  
12 same, and so you can test to see whether the  
13 approach that you want to use, because it aligns  
14 with some other -- with some other purposes, is  
15 valid here, and give you some evidence that that  
16 is the decent way to do it.

17           You don't have to choose the result of  
18 your testing, but you should still test. Does  
19 that make sense?

20           CHAIR MEHROTRA: Right. So you are  
21 really pushing to keep that as really a principle  
22 in terms of what we're --

1                   MEMBER HOUSER: Yes. I mean,  
2 otherwise, I worry if you can -- again, just  
3 because someone else has done it doesn't mean  
4 that it was good when they did it. So --

5                   CHAIR MEHROTRA: Okay. We'll keep --  
6 Srinivas?

7                   MEMBER SRIDHARA: So a comment on the  
8 test, and I think that we may be getting tripped  
9 up over the word "test." At least that's how I  
10 am seeing it right now, and I think the way I  
11 heard Danielle describe it, that to me sounds  
12 like a research question or an empirical analysis  
13 of an approach and whether it is good or bad, as  
14 opposed to how I think about it is more -- it's  
15 more like a sensitivity analysis.

16                   Like if I did it this way, or a what-  
17 if sort of analysis, and I think that's really  
18 what we're after is try out a couple of different  
19 approaches and figure out how that impacts the --  
20 you know, sort of the question you are asking and  
21 how that might inform the answer. So that's --  
22 so I think, again, some wordsmithing on that, but

1 I think that's what we're trying to communicate.

2 And, two, in terms of the, you know,  
3 sort of ABC or, you know, if we are worried about  
4 this alignment question, and it's not currently  
5 possible, to me some of this is like, what's in  
6 two is our either principle or goal, and maybe  
7 these are recommendations, you know, to align  
8 with that particular principle.

9 So maybe not all of this needs to be  
10 a principle as opposed to a recommendation,  
11 especially for things that are aspirational.

12 DR. RYAN: On the tested part, maybe  
13 we could say evaluated and compared?

14 MEMBER SRIDHARA: Sure.

15 DR. RYAN: Because I was thinking the  
16 same thing. Testing seems to imply like a  
17 certain -- like a regimented process that has  
18 already been specified. And it seems like we are  
19 not quite there yet.

20 CHAIR MEHROTRA: Done. Michael, you  
21 put your card down.

22 MEMBER BARR: I took it down because

1       Srinivas -- I had a question on 2B. I'm not sure  
2       my understanding is the same as the prevailing  
3       one. I was thinking about the overlapping of the  
4       denominators of the population that meets a  
5       measure and how -- what percentage of those you  
6       can actually attribute. So that's how I read  
7       that.

8               CHAIR MEHROTRA: Oh, okay. And I also  
9       thought that was almost a criteria that would go  
10      into the recommendation. So that -- so I think,  
11      clearly, we need to clarify that. Do you think  
12      that that should be a principle?

13             MEMBER BARR: I think it should be the  
14      aspirational goal for -- as many of the folks who  
15      meet the measure definition. Right?

16             CHAIR MEHROTRA: Well, I was thinking  
17      about -- the health partners folks made the point  
18      in theirs about -- in their report where they  
19      were talking about how many people were  
20      attributed, and they made this point that -- but  
21      the goal is not to get to 100 percent, because  
22      they felt that this might be going a little bit

1 to what Andy was saying, which was, if you have a  
2 measure -- an attribution approach that  
3 attributes everybody, then you probably have  
4 something that is a little bit too sensitive and,  
5 therefore, is adding noise.

6 So that's why I didn't -- that's the  
7 only part that gave me pause. Well, five percent  
8 ain't going to cut it for me, but what should  
9 that right number be?

10 MEMBER BARR: So maybe that's what we  
11 need to come up with, so the parameters -- they  
12 need the metric to judge the adequacy of the  
13 model. I think that was a comment we made during  
14 the earlier conversation. I haven't heard  
15 anybody suggest it, so I'll go ahead and suggest  
16 that we put something along those lines in  
17 number 2.

18 CHAIR MEHROTRA: Okay. Do you want to  
19 play with this?

20 Let me -- Jenny, Brandon, and  
21 Elizabeth are next.

22 MEMBER BEAM: And I just have a

1 comment on the -- aligning the population you're  
2 measuring with those for whom you have  
3 accountability. And I guess I'm still -- because  
4 I can think of a couple of cases like where you  
5 may not want to do that, and you don't want them  
6 to be aligned, and one is.

7 You know, again, you have a panel of  
8 patients. You know you are accountable for a  
9 period, and that maybe is based on retrospective.  
10 But then, also, there are times that people say,  
11 "But you're likely to be -- these will show up on  
12 your panel next year," and so you want to know  
13 ahead of time who those people are likely to be,  
14 because you have a claim that has been triggered,  
15 or two.

16 So they may not always be aligned, but  
17 as a provider I would want to know that I'm  
18 likely that these patients are liable to end up  
19 on my panel next year, so I can go ahead and  
20 start managing their care and talk to the patient  
21 and say, you know, "Am I your primary care  
22 provider? Are you seeing someone else? What's"

1 -- you know, so to try to establish that  
2 relationship.

3 And also, you know, thinking about  
4 where you may have a panel for -- and I know  
5 Danielle's example was a payment. So it was  
6 saying, you know, for the patients that you are  
7 going to be paid for, but then also there is a  
8 larger -- if I'm a provider and I've got a larger  
9 panel that I'm responsible for, maybe from a  
10 population health perspective I'm only going to  
11 get paid for these, because we talked before  
12 about in a payment model you only pay -- want to  
13 pay for one patient on one physician panel, but  
14 yet there are -- sometimes multiple providers are  
15 involved in the care.

16 So if I know that I'm partially  
17 responsible for your care, I may not be getting  
18 paid for you, but I still want to make sure that  
19 you've had your whatever, your colonoscopy or  
20 whatever screenings that you need, so there's two  
21 different things. One is payment, and one is who  
22 am I trying to influence their care and their



1 outcomes.

2 CHAIR MEHROTRA: That's a great  
3 example. So I think this really builds on what  
4 Danielle was saying, that -- do you think it's --  
5 so, first, add this as a point. There are  
6 clearly examples out there right now, just take  
7 myself in your patient panel, where you are not  
8 responsible -- you are not being paid for my  
9 care, but you're responsible for my quality.

10 And what Danielle was I think  
11 articulating -- tell me if I have paraphrased  
12 this right -- which is that in the ideal world,  
13 the two of those are aligned and that should be  
14 an aspirational goal or a principle of  
15 attribution to whatever degree.

16 And so I guess, do you think -- am I  
17 hearing you say that that's not the reality right  
18 now and that's okay, or do you think that should  
19 be where we're trying to go?

20 MEMBER BEAM: I don't think patient  
21 behavior and care-seeking patterns are going to  
22 allow that. I live an hour away from where I

1 work. I see two providers; I'm not going to see  
2 one ever. So, you know, you're ending up in  
3 situations where that people don't always -- they  
4 are not always loyal to one given PCP. So unless  
5 you are willing to take away patient choice, I  
6 don't know how we can do that.

7 MEMBER LLOYD: I think this -- I think  
8 the problem is that this is sort of how we ended  
9 up circling yesterday and why we ended up with  
10 the four case studies is I think to some extent  
11 it fits certain case studies better than it fits  
12 others. But I think ultimately what Troy said is  
13 the crux of it, is you want -- the providers want  
14 to believe that there is some fairness involved  
15 here, and that you're -- the measure for which  
16 you are measured -- the population for which you  
17 are measured in terms of quality is not entirely  
18 different from the population for which you are  
19 measured for payment, right?

20 That there is some alignment between  
21 the two, that there is some idea that if you are  
22 going to take a quality measure score and apply

1       it -- direct that the two -- when the two are  
2       used together, when the quality score reduces or  
3       increases your payment, that they have something  
4       to do with each other.

5               MEMBER BEAM:   And I think that works  
6       when you have a panel that you are entirely  
7       getting paid for.

8               MEMBER LLOYD:   When one is applied for  
9       the other, together.

10              MEMBER BEAM:   But for markets where  
11       payment models and incentive models are not  
12       implemented on a large scale -- so I can give you  
13       an example of providers, provider groups, maybe  
14       where only 10 percent of their patients they are  
15       getting paid on.   So do we just say that -- don't  
16       worry about the other 90 percent?   You don't have  
17       to worry about their quality, because you're not  
18       getting paid for them.

19              MEMBER LLOYD:   So let me take one more  
20       stab, because I don't think I made it clear here.

21              MEMBER BEAM:   Sure.   Okay.

22              MEMBER LLOYD:   It's not to say you're

1 not responsible for the quality. It's not to say  
2 that you're not getting paid for them. But if  
3 you take a measure and say on this shared savings  
4 check, you're going to have your shared savings  
5 check reduced by 10 percentage points because you  
6 had a fault on the following quality, that is  
7 when they need to be together.

8           You're still getting paid your fee for  
9 service for all of the patients. You're still,  
10 you know, going to be -- you know, you're still  
11 responsible for their quality. But when the  
12 quality measure actually affects that particular  
13 shared savings check, or that bundled payment, or  
14 that, you know, whatever, that they are at least  
15 reasonably the same populations. That doesn't  
16 have to be perfect, but that there -- I mean, I  
17 think the part of it is it doesn't have to match;  
18 it just has to be aligned.

19           MEMBER BEAM: And I think we just need  
20 to -- and maybe that's in the paper to be  
21 addressed, as far as the audience and who is  
22 developing, because if you're developing a

1       measure, I agree. But, again, when you're  
2       dealing with multiple measures, multiple  
3       programs, you've got physician groups or you've  
4       got collaboratives or other third party entities  
5       trying to roll multiple programs and panels  
6       together, so that providers don't have -- I have  
7       -- here is my Medicare shared savings patients,  
8       here is my these patients, here is my Aetna  
9       patients, here is my -- that doesn't work for  
10      providers. You know, they want one consolidated  
11      panel to work from, you know, regardless of who  
12      the payer is. So I just --

13               CHAIR MEHROTRA: So let me make two  
14      proposals. First, I want to put on the table if  
15      you would consider that that was something that I  
16      realize did get lost, which was that in the  
17      ideal, if you have four different ACO programs,  
18      you would have four -- one attribution rule.

19               And so I think the consider -- in the  
20      ideal -- and I don't know what the right term is,  
21      but in the ideal there should be -- for similar  
22      programs there should be alignment of the

1 attribution rules. And maybe that's C or item D  
2 or whatever, but I think that might be an  
3 interesting idea.

4 And then, specifically about the  
5 alignment of those where you have financial and  
6 quality accountability, I would love for others  
7 to weigh in as they go with comments, because I  
8 hear both sides of this and I'm trying to decide  
9 what is the right language to use.

10 And so let me -- but I also want to  
11 keep on going, too. So maybe, Brandon, if you  
12 want to weigh in on this.

13 MEMBER POPE: Yes. I guess I favor  
14 keeping this list of principles somewhat short  
15 and not starting to go A, B, C, D, and then I,  
16 double, I, triple I. So I actually favor this  
17 concept you all are talking about being a  
18 normative principle that could be applied.

19 I phrase it simply as, look, when  
20 you're considering a program, does the  
21 attribution align with other existing  
22 attributions, both quality and cost, that are

1 being imposed on the entity, right? So, in other  
2 words, and here we said align the population,  
3 right? It's not population as much as I'm  
4 thinking in this context the attribution, right?  
5 So, in other words, for readmission are we  
6 attributing to the attending provider, but for  
7 mortality are we attributing to the discharging  
8 provider? Or, you know, it's -- there's  
9 attribution differences that are not just  
10 population differences.

11 So I guess that's my thought. I like  
12 number 2, that, you know, a principle is that  
13 this is an important part of the program design.  
14 You've got to evaluate it. You can't just sort  
15 of go willy-nilly. And that we maybe would have  
16 a list of these normative principles being a  
17 separate list, because otherwise I think it will  
18 sort of just become a little big.

19 CHAIR MEHROTRA: So I hear you, and I  
20 am a little worried about A, B, C, D, and all the  
21 way to I. Are you -- but just to be very  
22 concrete, are you saying take the A, B, C, D, and

1 move them out for now?

2 MEMBER POPE: I am. I think -- I am  
3 looking at these. I think these are all good --  
4 like I think Elizabeth had the suggestion of a  
5 list of normative tests that could be like --  
6 this could be further elaborated on in a  
7 different list, right? So, for example, these  
8 are some of the considerations you might want to  
9 explicitly address. Have you considered both the  
10 patient and the provider's perspective? Have you  
11 considered what other attributions are being cast  
12 upon this provider or this hospital? Have you  
13 considered, you know, if you can actually  
14 implement this for the data they have available  
15 to them? Things like that. And that would be a  
16 normative list, but maybe not a principle. I  
17 don't --

18 CHAIR MEHROTRA: That is a fair point.  
19 I'm going to vote for not removing these concepts  
20 entirely but removing them from the principles  
21 here. Those -- so I'm seeing some shaking heads  
22 up and down. Are there those who disagree with



1       that idea? So maybe if you can move those, that  
2       would be awesome.

3               So let me -- I'm also conscious of the  
4       time, so maybe we can have Dan, Keith, and Bharat  
5       speak about these -- this -- number 2, and then  
6       we could then maybe go to the next one?

7               MEMBER SUTARIYA: If you don't mind,  
8       since I've got to run, I'll just make a very  
9       quick comment. I'm in favor of keeping this  
10      short as well. But at the same time, there is  
11      probably a right balance to strike somewhere. It  
12      can't just be five bullet points.

13              Second, I think the other concept I  
14      want to make sure the committee keeps in mind is  
15      the concept of aggregation. Andy put in his  
16      paper the definition of aggregation, and most all  
17      attribution models are applied at the aggregation  
18      level when it comes to CMS payment, meaning at  
19      the risk-taking entity level.

20              So that affords this level of  
21      forgiveness from getting an individual  
22      attribution perhaps slightly wrong, but at the

1 same time we also need to think about most  
2 federal programs today are paid based on an  
3 aggregated attribution and not based on an  
4 individual, one single physician provider.

5 CHAIR MEHROTRA: If you don't mind, we  
6 can just build on that point a little bit,  
7 because that's really -- it was in number 7  
8 before. It was -- that was, to drive the system  
9 forward, it is necessary to challenge current  
10 norms of attribution, including desire to  
11 identify a single clinician or provider. And I  
12 think that was trying to address this issue, both  
13 do you assign it to multiple people as well as do  
14 you assign it to a single physician or other  
15 entity? And is that a principle or -- I don't  
16 know.

17 I'm curious what people's reaction is  
18 because I was struggling with number 7, to be  
19 honest with you. Like I get the idea, I like the  
20 idea, but I don't know if it's a principle  
21 because in some cases, as somebody said, it  
22 sometimes does make sense to go to an individual

1 doc.

2 Well, so I did a bad thing here, so I  
3 should -- didn't go in the order. So maybe I'll  
4 stick with the order, and if you could comment on  
5 something else as well as that point, that would  
6 be great. I don't know if that's too much.  
7 Everybody is putting their cards down now.

8 Elizabeth? I don't know. Were you  
9 going to comment on that point or any other  
10 point?

11 MEMBER DRYE: I think you just spied  
12 something I would -- a lack of -- something I  
13 wasn't clear about. When we were talking before  
14 about not an individual provider, I literally was  
15 thinking about an individual like doctor or  
16 nurse, not about, you know, an individual ACO or  
17 an individual hospital.

18 So I think that we were thinking this  
19 is a team sport, and also, I mean, as a measure  
20 developer and doing outcomes, I am always  
21 thinking there is just no technical way to  
22 evaluate individual providers almost ever unless

1 it's like, you know, a cataract surgeon who does  
2 hundreds and hundreds and hundreds of cases.

3 So I didn't know, though, is that  
4 something we are trying to say? Like because  
5 delivering care is a team sport or because we're  
6 worried about technical issues, or is it -- am I  
7 just interpreting that wrong?

8 CHAIR MEHROTRA: So, yes, let me -- I  
9 might have made a mistake by skipping ahead, but  
10 let me explain -- at least what I heard yesterday  
11 from Troy and others was, should there be a  
12 principle that the idea of attributing care to an  
13 individual clinician is generally not a good  
14 idea, and should that be almost a principle that  
15 should be put out there?

16 And we saw so many rules put in that  
17 -- so many attribution models currently do do  
18 that. And so the question at hand is: is that a  
19 principle we should put out there or not? Maybe  
20 that's where -- I don't know if that's where  
21 Bharat was heading, but that's one thing I heard  
22 from his comment. So that's why I brought it up.

1                   Let's see --

2                   MEMBER LLOYD: Can I actually just  
3                   make a technical comment on that? There is one  
4                   thing about the paper that I think was a little  
5                   bit confusing. So it's my understanding, for  
6                   instance, in the Medicare Shared Savings Program  
7                   you are not actually attributing to an individual  
8                   physician. You are actually attributing to the  
9                   tax ID number. You have to start with looking  
10                  at, did they have at least one physician ENM  
11                  visit?

12                 But at the end of the day, you take  
13                 the PA, NP, CNS, various -- et cetera, and it is  
14                 still at the TIN level. And I actually thought  
15                 that was a little bit confusing and misleading in  
16                 the paper, that it's not a doc exactly, for at  
17                 least that model. Some of them do, and maybe  
18                 quality improvement, et cetera, but I think -- I  
19                 found that confusing in the paper, and that might  
20                 have contributed to leading us astray on that  
21                 individual --

22                 CHAIR MEHROTRA: So, first, it's a

1 good point. The tax ID is -- as we I think  
2 discussed yesterday -- is a very difficult thing  
3 to use because it can represent so many things  
4 from an individual physician all the way to a  
5 very, very large physician group under -- all  
6 under one tax ID.

7 I think, given we are at the principle  
8 and aspirational role goal here, I think why was  
9 tax ID used, because the tax ID is available, and  
10 that's the only thing -- you know, you can't go  
11 more granular often, though with NPIs you can  
12 start to do so.

13 But I guess the question is, going  
14 back to the point, maybe people -- I have an  
15 order here, but maybe just to finish up this  
16 point -- is it a good principle to have that idea  
17 of we should not be attributing to a single  
18 clinician?

19 And I don't know, Troy, did you have  
20 a comment on that specifically? I'll --

21 MEMBER FIESINGER: Yes. I'll address  
22 that. So I'm trying to think of like a buzz word

1 or phrase. So when I think of accurate,  
2 equitable, and fair, that's what I want it to be.  
3 As I wrestled with this this morning, I was  
4 thinking about earlier when I was on a walk, can  
5 we -- to me, there is a way to separate  
6 attribution, meaning what bucket does each  
7 patient go in?

8 A population of 5,000 or 10,000, this  
9 ACO versus accountability, like -- or the Scott &  
10 White Baylor, you're talking about for audit  
11 purposes we might want to know very specifically  
12 who goes where, who does what. But for  
13 attribution, you may just know that it's Baylor  
14 Scott & White ACO.

15 And I don't think I can specifically  
16 say we should never attribute to single  
17 clinicians. There might be times when that's  
18 necessary, but in the big picture attribution  
19 really -- what group of people and team is  
20 responsible for it, and that team can decide  
21 internally through governance policies, et  
22 cetera, how to handle what part of the process is

1 -- needs to be dealt with, what team members'  
2 actions or inactions need to be modified or  
3 changed. So, to me, I would like to separate  
4 them, but I don't know if I can exactly say it  
5 should never ever be attributed to one person.  
6 That might be necessary in terms of assigning a  
7 patient to a bucket, but totally different is how  
8 we use that information to improve health care.

9 CHAIR MEHROTRA: So if I was to write  
10 the principle, "In general, we believe that it is  
11 better to attribute to a team of provider -- not  
12 to attribute to a single clinician," is generally  
13 the right way to go, is that -- I mean, so I'm  
14 not -- we're not saying absolute.

15 MEMBER FIESINGER: Yes. I would be  
16 okay with that.

17 CHAIR MEHROTRA: Others on that? So  
18 are you -- I know I'm going a little bit out of  
19 order here. Sorry. Go ahead.

20 MEMBER HOUSER: I was going to say  
21 that I think the issue is not attribution to a  
22 single physician, but holding a single physician,



1 or even a group of physicians, accountable for  
2 activity that is outside of their levels of  
3 control to bring in another terminology from  
4 yesterday.

5 That the problem is not with  
6 attribution to an individual physician, which  
7 could be desirable in the case of quality  
8 improvement, or it could be a necessary step in  
9 terms of holding that physician's ACO  
10 accountable.

11 It could be -- attribution to the ACO  
12 may go through the physician as a mechanism to  
13 get there. And that's not -- that is probably  
14 not problematic. What is potentially problematic  
15 is holding individual physicians accountable for  
16 the entirety of that attributed patient over  
17 which they may have only a small level of  
18 control.

19 CHAIR MEHROTRA: Others want to weigh  
20 in? Okay.

21 MS. O'ROURKE: So Ira has been wanting  
22 to weigh in on this point.

1 CHAIR MEHROTRA: Okay. So Ira, and  
2 then Brandon maybe?

3 MEMBER MOSCOVICE: Just two things.  
4 When we use the words "it is necessary," it  
5 sounds to me like it's a recommendation rather  
6 than a principle. Most of the other statements  
7 were more normative statements. "Necessary"  
8 sounds like it's a requirement; it's something we  
9 are really recommending.

10 But the other part is, given the last  
11 conversation, once again, I think we may have our  
12 urban values influencing ourselves. It depends  
13 on the supplier providers, by the way, and it may  
14 well be in a smaller, underserved rural area  
15 where there is not a lot of bypass, maybe it is  
16 okay to attribute --

17 CHAIR MEHROTRA: To an individual?

18 Brandon, do you want to --

19 MEMBER POPE: I would say at a high  
20 level I'm actually in favor of attributing at the  
21 most granular -- yes, the most granular level  
22 possible when we have sufficient sample sizes,

1 reliable measures, and data to support it.

2           So if we were to -- I would not, in  
3 general, be in favor of saying a principle is we  
4 don't want to attribute to the physician level  
5 sort of higher -- I am more of that I actually  
6 want to do that. In a lot of cases, it's not  
7 possible.

8           CHAIR MEHROTRA: So why don't we just  
9 summarize this. It sounds like there is little  
10 enthusiasm for this idea, so I'm going to propose  
11 cutting number 7 fully and moving that to when we  
12 talk about the recommendations and we go through  
13 that checklist that, you know, this is something  
14 you should think about, building on Brandon's  
15 point is, is that when you are doing this  
16 attribution rule, don't always go to the  
17 individual physician level, especially when you  
18 have sample size issues, et cetera, or it might  
19 even make more sense to do it at the group level.

20           But that would be more a thing you  
21 should think about as opposed to this is some  
22 sort of principle. Does anyone disagree with

1       that idea? So, Jenny, do you want to --

2               MEMBER BEAM: Not necessarily  
3       disagreement, but, you know, a lot of times  
4       provider groups want to know at the physician  
5       level because when they are taking -- when you  
6       have a large physician group and they have to  
7       distribute the payment to their physicians, they  
8       want to know -- you have 100 patients, you only  
9       have 10. You're going to get more of the money  
10      when they distribute.

11              So I still think the attribution is  
12      fine to occur at that level, at that group level,  
13      but to have the more -- the reporting and saying  
14      you are the most likely responsible, or you are  
15      responsible for the majority of care within your  
16      group. So however you want to --

17              CHAIR MEHROTRA: Okay. Thank you.

18              Bob, were you saying --

19              MR. MULDOON: Can I say something  
20      about the --

21              CHAIR MEHROTRA: Oh, go ahead, Daniel.

22              MR. MULDOON: -- in response to Jenny

1 and say I think that's something, though, that we  
2 could do by, you know, really, the consideration  
3 is find the level at which you sort of can  
4 balance the accuracy, equity, and the fairness of  
5 your attribution.

6 But in terms of figuring out which  
7 providers -- and by "providers" now I'm meaning  
8 individual clinicians are sort of touching the  
9 patient and furnishing services, seeing them.  
10 That sort of also seems like it could come into  
11 types of data that -- like CMS or other payers  
12 provide in terms of providing whatever level we  
13 do attribute a beneficiary or a patient to, that  
14 that then allows for sort of a more granular  
15 distribution of any potential payments that are  
16 tied to those -- the quality measures or as part  
17 of the payment model that we are attributing a  
18 beneficiary to.

19 I think sort of it's a balance between  
20 what is the right level of attribution, but then  
21 still making it available for the entity to which  
22 you are doing the attribution to figure out which

1 providers within the entity are sort of  
2 responsible for the majority of the care the  
3 beneficiary is receiving.

4 MEMBER BEAM: Right. And as far as,  
5 you know, even looking at -- I would say  
6 individual physicians within a group, they don't  
7 always have the control to change certain things,  
8 whether -- especially if you are talking cost,  
9 because it's a lot of times purchasing and  
10 contracts are negotiated at a group level.

11 So when you are attributing to the  
12 physician instead of the group, you know, it's  
13 not always -- I guess it goes back to that locus  
14 of control, you know, issue. So I just thought  
15 that as well. I don't know.

16 CHAIR MEHROTRA: Right. These are  
17 things we should be thinking about.

18 Bob, you got cut off, so I just wanted  
19 to --

20 MEMBER KROPP: Yes. I'm in favor of  
21 keeping it as a principle for a couple of  
22 reasons. The first is that I think there is a

1 strong tendency to go to the individual provider  
2 too quickly, and most -- and a lot of the  
3 injustices I have seen in the name of attribution  
4 have occurred in this domain.

5 So I would suggest keeping it as a  
6 principle because I think it deserves that kind  
7 of attention. And I would suggest perhaps to  
8 make it more acceptable, that the language might  
9 say, "To drive the system forward, it is  
10 necessary to" -- oops, where am I? Yes. "It is  
11 necessary to change current -- current" -- this  
12 is all messed up now. "Current norms of  
13 attributions, including a desire to always  
14 identify only a single clinician." And does that  
15 -- you know, does that -- do those clarifying  
16 adverbs help?

17 DR. RYAN: It would be a tendency.

18 MEMBER KROPP: A tendency. Okay.

19 CHAIR MEHROTRA: I don't think I have  
20 a good finger on the pulse of what the -- where  
21 the group is. So maybe I could even have like a  
22 vote here a little bit. So, Bob, what you're

1 saying makes a lot of sense to me. It's  
2 consistent with others. On the other hand, I  
3 hear the voice of maybe this isn't a principle  
4 that we want to articulate, so I'm kind of on the  
5 fence.

6 So maybe I could put it back to you,  
7 that recognizing the language is not perfect here  
8 but just -- I think Bob articulated well the idea  
9 that he is putting out there and that others have  
10 articulated, who thinks this should be a  
11 principle? If you would just raise your hand.  
12 Well, that was not helpful. We are split.

13 So go ahead, Srinivas.

14 MEMBER SRIDHARA: So I think what --  
15 again, so, to me, this comes back to what you are  
16 trying to do. Again, and sort of, if you take  
17 the look at an ACO, the comment was made that  
18 they and, say, CMS are attributing to the level  
19 of an ACO, and that's appropriate because that's  
20 the level of accountability.

21 But the ACO, in reacting to that,  
22 wants to attribute to the single clinician level



1 when they build their network. So I think it's  
2 dependent on what you're trying to do that  
3 informs what you do here. And so I actually  
4 would say I think Troy's comment before, or  
5 otherwise, that this is really about not saying -  
6 - think about this notion of locus of control or,  
7 you know, and the notion of equity and fairness,  
8 and maybe we need to package a principle around  
9 that that says you should be considering who has  
10 the ability to change whatever it is that you're  
11 trying to change, tied back to your goal. I  
12 mean, this is not certainly the wording that you  
13 should use, but, you know, I think that's the  
14 principle we are after.

15 And what the recommendation will come  
16 that follows that is going to center around  
17 certain scenarios where you would attribute to a  
18 group versus an individual, and how that is fair  
19 or not fair. But the principle rises to a higher  
20 level for me.

21 CHAIR MEHROTRA: So what about this --  
22 yes, I'm going to throw a proposal out, which is

1        number 3 here is about transparency about the  
2        goals. It was also articulated the idea here is  
3        that you want to -- when you are transparent  
4        about the goals, you try to figure out who is  
5        going to act upon those goals. And we went back  
6        -- I at least keep on coming back to that  
7        hospital versus ACO in the smoking example. And  
8        maybe that kind of captures what you are saying,  
9        Srinivas, which is that as, you know, we have, A,  
10       B, C, D for two, maybe there is an A, B, C, D  
11       here that captures what Bob is saying, which is  
12       when you're transparent about the goals, and you  
13       know exactly what you're aiming for, part of that  
14       process is don't always go to what is easy for  
15       you, which is the individual clinician.

16                Similarly, and then also think about  
17       the locus of control, who is most likely going to  
18       act, react? Given your goals, who is the level  
19       of the organization that has the resources and  
20       wherewithal to actually act upon this and improve  
21       whatever the goal is? That was very  
22       inarticulate, but sort of -- does that sort of

1 get to where you are thinking?

2 MEMBER SRIDHARA: Yes. I think so.

3 CHAIR MEHROTRA: So, others? So I  
4 have cut off Keith for like ever, so, Keith, do  
5 you want to weigh in here?

6 MEMBER KOCHER: Sure. So I think part  
7 of the challenge here is we have sort of been  
8 muddying the waters because we don't -- we  
9 haven't really coalesced around a principle  
10 around how we assess measurement yet, sort of  
11 back up, but sort of when we were on point 2.  
12 And I think we are probably all on the same page  
13 about it. It is just getting the language right.  
14 So I want to toss out sort of some language to  
15 consider.

16 I wonder if we start with something  
17 like there is no gold standard for determining  
18 methodology for attribution. Therefore, when  
19 assessing any one methodology, it's important to  
20 understand the goals of the methodology or the  
21 attribution and balance that with things like  
22 equity, fairness, those other considerations.

1           I don't think we've -- I think it is  
2   important to settle the fact that there is no  
3   gold standard out there to rely on, and making  
4   sure that we state that up front before we start  
5   diving into how we do methodology. And I think  
6   even -- you know, we haven't even gotten beyond  
7   whatever -- a few of these, but like six point --  
8   you know, principle 6 I think is probably  
9   something that has fallen by the wayside, that  
10   basically we are also beginning to address  
11   already in these conversations, and we could  
12   probably even almost take that off the table, I  
13   feel like.

14           CHAIR MEHROTRA: So I think your -- so  
15   if I could unpackage some of the things, I think  
16   first you said is it would be useful just to  
17   emphasize there is no gold standard right now for  
18   attribution. I also might add a caveat, which is  
19   that also the attribution rules or method will  
20   likely be different for different purposes.  
21   There is no one single rule that is going to be  
22   out there.

1                   And so I think both of those I am 110  
2           percent with you, and then I'm -- then, just to  
3           think out loud, now I'm trying to think, is that  
4           a principle, or is that an explanation, as we  
5           described that?

6                   So let me go to a couple of others to  
7           weigh in on that point as well as others.  
8           Elizabeth, I think you were next.

9                   MEMBER DRYE: Well, first of all, this  
10          conversation really turned me around on the one  
11          provider thing. I think sometimes it's okay,  
12          sometimes it's not, and that's either, you know,  
13          locus of control goal-related, but, you know, it  
14          also has to be technically possible. And I don't  
15          think those might -- they may not end up in the  
16          same principle. So, anyway, that was super  
17          helpful to hear that, because I am -- I have  
18          always been biased against one, but I don't think  
19          that's right.

20                   But I just wanted to let you know what  
21          I'm doing, which hopefully it will be helpful, is  
22          I am just taking the normative criteria we talked

1 about earlier, and the things that are kind of  
2 coming out of the principle level and -- might be  
3 the rows of that table that you would just -- you  
4 know, is the goal of attribution clearly  
5 articulated? Does the goal reflect patient  
6 input? Is the level aligned with -- of  
7 attribution aligned with the goal?

8 I am just putting some of those sub-  
9 bullets in my thing here, so we can keep track of  
10 them, because some of them fall under those more  
11 technical decisions. And then I will just send  
12 it to you guys. So while you are shortening  
13 this, I am just trying to -- because I think  
14 there is a tension between the principles,  
15 because if you really want to keep these short  
16 and very high level, they are not going to be the  
17 normative criteria that we can -- people can go  
18 through, boom, boom, boom, boom for their, you  
19 know, ACO level or whatever, their chronic  
20 disease management patient, their acute  
21 management.

22 So I'm just going to stay quiet and

1 keep typing.

2 CHAIR MEHROTRA: So, let's see, I have  
3 Ira, Danielle, Brandon, Ari, and Troy. Yes?

4 MEMBER LLOYD: So I think we kind of  
5 led Elizabeth astray in that comment of the group  
6 to the one thing, because I think really what we  
7 were trying to convey yesterday. If you  
8 remember, in our report out my example was, you  
9 know, if the Alc is not done, and they saw a  
10 cardiologist, endocrinologist, and a primary  
11 care, they all should be responsible for the fact  
12 that that wasn't done.

13 You start with this overtagging notion  
14 of providing attribution to multiple, multiple --  
15 to try to -- because we are still in this, you  
16 know, dispersed state where there is not sort of  
17 everybody grouped up into ACOs or whatever, you  
18 start with the overtagging, and then you narrow  
19 down into an accountable unit that -- you know,  
20 so instead of tagging medical group 1 that had  
21 the endocrinologist, medical group 2 that had the  
22 cardiologist, medical group 3 that had the

1 primary care, right, they could be three  
2 different groups, and you're overtagging them.

3 And at some point, one group is going  
4 to be responsible because they will have taken on  
5 the accountability step, and they will say this  
6 patient is mine, and they are working with all of  
7 the others.

8 I think that was what we were trying  
9 to say yesterday. It's not necessarily a  
10 physician. It could be a physician, but the  
11 point is at some point there will be an  
12 accountable unit, not just we're going to overtag  
13 everybody. Is that at all clear?

14 MEMBER DRYE: Yes. I mean, I think --  
15 I guess what I'm realizing is I don't totally  
16 agree with that. I think we are all seeing that  
17 sentence about a single physician a little bit  
18 differently, and I'll give an example.

19 So, for example, I was part of a team  
20 consulting to Blue Cross/Blue Shield in Hawaii  
21 where they were moving to a per member per month  
22 through their primary care providers, and they



1 wanted to -- they have gone to attributing or  
2 they're piloting attributing, you know,  
3 hemoglobin A1c to the primary care provider.

4 And I actually think that's  
5 aspirational, right? It's like you're in charge  
6 of making sure this person gets their hemoglobin  
7 A1c. And maybe the person is really being cared  
8 for by a specialist, so they are piloting it, and  
9 all those things are going to come up.

10 But I just -- so I feel like in that  
11 context that might be okay, if they have enough  
12 patients and technically we can manage -- you  
13 know, we can measure their -- what's their  
14 hemoglobin A1c, you know, average or whatever on  
15 their patients, and how many people are getting  
16 it, what proportion.

17 So I actually feel myself conflicted.  
18 In the end, for me it's, is it aligned with the  
19 goal? And I think in that context you're saying  
20 you may not be so pushy. You know, you may be  
21 like let's start by allocating across or by  
22 holding everybody. Let's try to drive towards

1 single accountability, but I'm kind of more -- as  
2 you guys know, I'm more aspirational on these  
3 things. I'm like, okay, just set up the primary  
4 care. If you want the primary care doctor to be  
5 responsible, let's just give that person or his  
6 or her practice 100 percent responsibility. That  
7 is a piece.

8 The other piece is technical. Can we  
9 technically do it? And that's something you can  
10 test, so that's --

11 MEMBER LLOYD: It's almost like, you  
12 know, if you're starting in a MIPS world but  
13 you're going to an advanced APM world at some  
14 point, right? If you've got this disarray, you  
15 know, then just do the weighting concept across  
16 many. But eventually you want an accountable  
17 unit.

18 But I don't know that that needs to be  
19 a goal. I think this can be discussed later in  
20 the document. So I'm changing my vote.

21 MEMBER PERLOFF: This is Jen from the  
22 phone. Can I jump in at some point?

1 CHAIR MEHROTRA: Sure, Jen. Go ahead.  
2 It's hard for you to put your tag up, so why  
3 don't you just go ahead.

4 MEMBER PERLOFF: This is a great  
5 discussion. I just want to point out one error  
6 that we haven't talked about. One of the  
7 problems -- we talked about the small sample  
8 size. When you drill down to the provider, a  
9 single provider might only touch 10 patients.

10 But the concern I have is sometimes  
11 when we do that, we attribute the effect of the  
12 group, the delivery system, variation, you know,  
13 is all around the provider to that provider. We  
14 can't always tease apart what that provider's  
15 unique contribution is. But in single  
16 attribution, we kind of nail it all on that one  
17 person.

18 And I know we have been talking about  
19 these ideas, but it's that bias that worries me  
20 about the single attribution. That's the crime  
21 we have committed against, you know, providers.  
22 So, anyway, I just -- this is a fascinating

1 debate. So, thanks.

2 CHAIR MEHROTRA: Thank you, Jen.

3 Let me go with Ari, Troy, and Mike,  
4 and then we will -- I do think we should probably  
5 move on to the other principles here, just to  
6 make sure we don't drop -- miss those completely.

7 MEMBER HOUSER: So I just recognize  
8 that we are in about the place where I wanted to  
9 make a comment back in the first session, and  
10 then we tabled it. And that is, in this point 3  
11 where it -- and Troy had mentioned something  
12 about the idea of that -- gaming the attribution  
13 rules, either intentionally or unintentionally.

14 And it was suggested that that could  
15 fall sort of into three unintended consequences.  
16 And I don't like the use of unintended  
17 consequences here. I would probably say "in  
18 consideration of the consequences that might  
19 arise." And if they're foreseeable, I don't  
20 think they're unintended. They may be unwanted  
21 but unavoidable, but not unintended if you're  
22 declaring them up front.

1 CHAIR MEHROTRA: But you think about  
2 -- I think the unintended consequences was trying  
3 to be polite about gaming. So do you -- would it  
4 be better just to be clear-cut and say "and  
5 consideration of potential gaming that might  
6 arise"?

7 MEMBER HOUSER: Well, I want to  
8 separate gaming from other consequences, because  
9 there are consequences that result from the fact  
10 that you are -- when you attribute to a single  
11 physician or a couple of physicians, you are  
12 grossly oversimplifying what is actually going  
13 on, and there is consequences that result from  
14 that simplification. And that is really I would  
15 call more like a measure imperfection type  
16 consequence.

17 And then there is susceptibility to  
18 gaming, which is another type of consequence that  
19 is -- and I -- I'm not sure they should be mixed,  
20 and certainly they should -- they shouldn't be --  
21 they both are important, and we shouldn't have  
22 language that suggests one to the exclusion of

1 the other.

2 CHAIR MEHROTRA: Yes. So my quick  
3 reaction was is that I had seen the transparency  
4 about the goals as being the -- what we hope will  
5 happen or what we think is going to happen, and  
6 then just make sure that you think about the  
7 things that you -- like make sure you put your  
8 evil hat on and say, "What would you do in terms  
9 of response?" But that's at least what I --  
10 where I was thinking, but I do think that the  
11 unintended consequences -- maybe that choice of  
12 language is a poor one, and I appreciate that  
13 point.

14 So let me go to Troy and then Mike and  
15 then Brandon.

16 MEMBER FIESINGER: I just want to make  
17 a couple of points. I'll take back my comment  
18 that I'm okay with attributing the teams, because  
19 I think I'm like Elizabeth; there's a lot of  
20 different options and possibilities we have to  
21 think about.

22 In terms of the comments, there is no

1 gold standard, et cetera. Why don't we call it a  
2 preamble? Not to be too much of a history buff,  
3 but they put the preamble to the Constitution for  
4 a reason. Here is the basic stuff we want to put  
5 out there that we think is important. And then  
6 we go through all these rules. I think that  
7 would be a nice place to say there is no gold  
8 standard, there is no road map, there is not a  
9 lot of research or data, all these issues we are  
10 covering, and we can wordsmith it.

11 In terms of the consequences of --

12 CHAIR MEHROTRA: This is in the Bill  
13 of Rights.

14 (Laughter.)

15 We're aspirational here. We're going  
16 change this from principles to --

17 MEMBER FIESINGER: I was a history  
18 major, so it all comes back to that.

19 CHAIR MEHROTRA: -- bill of  
20 attribution rights.

21 MEMBER FIESINGER: I mean, they locked  
22 200 people in a room and let them argue for a

1 year. The notes are actually very revealing --  
2 three kings, one president, whatever. They  
3 finally came up with a document that worked  
4 pretty well. We're going through a similar kind  
5 of process while trying to get to the same place.  
6 So preamble might be a home for these principles  
7 we agree on, but I won't call them principles.

8 In terms of the consequences, I think  
9 we have to balance getting at what we're talking  
10 about with being sensitive and diplomatic. When  
11 I have -- like we had to create legislation in  
12 our state for supervision of mid-level providers,  
13 is it supervision, is it regulation, so on and so  
14 forth. You don't want to put words in the law  
15 that you wish you hadn't put in.

16 So I'm okay with "consequences,"  
17 knowing that I'm going to mean manipulation,  
18 gaming, and unintended consequences. And, to me,  
19 a great unintended consequence would be when ACOG  
20 set up new rules about vaginal birth after C-  
21 section criteria, I did OB as a family doc for 15  
22 years, what happened is, once you had to have a



1 C-section-capable OB/GYN or a family doctor in  
2 house, VBAC rates went to nothing.

3 And timed antibiotic in the ER,  
4 similar issue. I remember in the ER I was in  
5 them saying, you know, that wasn't a great  
6 quality measure to say timed antibiotics, because  
7 we pushed inappropriate antibiotic use. We  
8 didn't realize that would happen. So those are  
9 two good examples of they didn't want those  
10 things to occur, but they did.

11 But if we say gaming, and we say  
12 manipulation, even though I'm thinking that, I'm  
13 not sure I want to read that on the NQF website,  
14 so we need to be a little diplomatic.

15 CHAIR MEHROTRA: And we also recognize  
16 that we will have language under each of these  
17 principles that kind of explains and provides  
18 context. So let me keep on going with Mike and  
19 then Brandon and then I'll move on, if that's  
20 okay with folks.

21 MEMBER SAMUHEL: I just want to come  
22 back to this notion that attribution is not an

1 exact science, that there is error in  
2 attribution, and there are several sources of  
3 error. And I don't think we've got a principle  
4 that really covers that. It feels like it's  
5 connected with not having the gold standard in  
6 fairness, and so on.

7 I might be getting a little bit ahead  
8 of myself. What we're talking about in terms of  
9 error may come out as we work through some of  
10 these case studies or whatever we're calling  
11 them. But I do think it's important in some  
12 solutions down the road, instead of like  
13 percentages of payments and, you know, you get  
14 three percent, you get six percent, is a banding,  
15 you know, this group will all get five percent in  
16 terms of payment. But I think it is an issue  
17 that is going to come up, and we need to address  
18 it.

19 CHAIR MEHROTRA: I think that's a good  
20 point, and it might also come up with number 4  
21 when we turn to it in a second. So --

22 MEMBER SAMUHEL: Yes. I looked at

1 number 4, but I think 4 is really talking about  
2 quality measures, the impact of the attribution  
3 on quality measures, if I'm reading it right. So  
4 it doesn't quite fit with what I'm talking about.

5 CHAIR MEHROTRA: Yes. I know that's  
6 a good point.

7 Let me -- Mike? I'm sorry, Brandon?

8 MEMBER POPE: I would agree with both  
9 Ari and Troy on -- I like the language shift away  
10 from unintended consequences to something more  
11 about, you know, the direct and indirect impacts  
12 taking into, you know, effect how people will  
13 change their behavior according to the sort of  
14 mechanisms you'd put in place.

15 I also like Troy's idea. I think we  
16 have hit on this a lot, that maybe it is both  
17 appropriate in the preamble and the afterword to,  
18 you know, express our humility in this matter,  
19 that it's difficult and, you know, but I was just  
20 going to say, with regards to the overtagging, I  
21 don't see this being a huge issue in the near  
22 future that we've -- you know, we've decided that

1 we need to hold accountable, you know, both the  
2 PCP and the endocrinologist and the hospitalist  
3 and the diabetes educator and the care manager  
4 all for the A1c test.

5 And this has become sort of a tragedy  
6 of the commons A1c test situation where, look, I  
7 thought you guys were going to take care of it.  
8 I don't really see that being a near-term  
9 problem, so I just wanted to -- you know, I think  
10 we've talked about that a little bit, but I think  
11 we're more on the other side where we're trying  
12 to figure out what are the appropriate ways to  
13 hold somebody accountable for these things?

14 CHAIR MEHROTRA: So let me move on, if  
15 that's okay with you, just because I do -- we  
16 only have about half an hour left. We have a  
17 number of other principles here. And as I look  
18 at -- I'm just going to vote, just in -- to give  
19 you my own thoughts on number 4. I'm the one who  
20 I think pushed for this, which is basically, if I  
21 could simplify with two words. It was  
22 attribution matters.

1                   And I am wondering whether that is not  
2 really a principle. It is more of a -- to use  
3 Troy's language, a preamble kind of point. So  
4 I'm going to argue that that moves away from a  
5 principle and moves to more just trying to say,  
6 why the heck are we spending all this time  
7 working on this issue?

8                   That's my vote. Do -- I see some  
9 shaking heads yes. Is there anyone who disagrees  
10 with that idea? Okay. Well, that was easy.

11                  All right. Well, let's move on.  
12 Number 5 is attribution rules are not static and  
13 likely will evolve over time with increased data  
14 availability, and as the health system changes,  
15 maybe as the -- belongs there, good principle,  
16 bad principle? Elizabeth?

17                  MEMBER DRYE: I would just revise it  
18 to say "as the goals of health" -- I don't want  
19 to use the word "reform," but as our goals for  
20 our health system evolve, because --

21                  DR. RYAN: That should say "should."  
22 If that's the idea, it should evolve over time.

1 I mean, otherwise, with the "will evolve over  
2 time," it sounds like maybe it's the preamble  
3 statement.

4 CHAIR MEHROTRA: No. I think that's  
5 a good point. We are trying to say what we  
6 think.

7 Go ahead, Charles.

8 MEMBER HAWLEY: This is just I think  
9 restating that there is no gold standard, so I  
10 don't know if they can be lumped together or --

11 CHAIR MEHROTRA: To put like almost a  
12 clause underneath it as we have done for some of  
13 the other ones, given that there is no gold  
14 standard, so as data availability becomes --  
15 better data becomes available, you want another  
16 rule that captures that. Do you think that is --  
17 did I capture what you were saying?

18 MEMBER HAWLEY: Yes. I mean, yes, I  
19 guess so. I guess the point of saying that there  
20 is no gold standard is -- you know, that there is  
21 no one way of doing it, this is basically saying  
22 not only is there no one way to doing it, but

1       there is -- these several ways are likely to  
2       change. I feel like those are kind of the same  
3       point, which is, yes, just that there is no one  
4       way of doing it.

5                   CHAIR MEHROTRA: So I agree with that  
6       idea. I wouldn't put -- I'm just going to put my  
7       own personal thought that that -- the point you  
8       just made goes right underneath the principle but  
9       isn't part of the principle itself. Or maybe I  
10      misunderstood you. You could add the caveat,  
11      "Given there is no gold standard, attribution  
12      rules should evolve over time." Is that -- or  
13      which one of the two did you favor?

14                  MEMBER HAWLEY: Yes. I think that --  
15      I think that would -- I just kind of think --

16                  CHAIR MEHROTRA: Love this real-time  
17      -- it is also intimidating, by the way. It can  
18      be. It's like, I didn't say that. Did I say  
19      that?

20                  (Laughter.)

21                  MEMBER HAWLEY: I just feel like they  
22      could be combined. I guess that's -- you know, I

1 don't know that it needs to stand -- I don't  
2 think that either one needs to stand alone, the  
3 gold standard -- I think they're related I guess.  
4 I'm not exactly sure how to capture that, but --

5 CHAIR MEHROTRA: Oh, go ahead, Jen.  
6 Sorry. You always have --

7 MEMBER PERLOFF: I'm so sorry. Is the  
8 principle that you should revisit or reconsider  
9 your attribution methodology on a regular basis?  
10 I'm not sure I understand the necessity to change  
11 if you nailed it, but we're saying that the  
12 dynamic is data is becoming available -- is the  
13 principle that you should always be aware of, you  
14 know, testing and abating your approach rather  
15 than being prescriptive that you shall change  
16 over time?

17 CHAIR MEHROTRA: That's a good point.  
18 So it's given there is no gold standard, and data  
19 systems and health systems are evolving over  
20 time, one should revisit your attribution rule  
21 over time.

22 MEMBER PERLOFF: Every six months.



1           MEMBER HAWLEY: So I think maybe that  
2       kind of highlights that maybe this isn't so much  
3       a principle as something that should go into  
4       whatever the preamble might be, because we are  
5       not necessarily prescribing that it should  
6       change. We are just sort of acknowledging that  
7       given the fact that there is not a single way of  
8       doing this at this time, that it is likely to  
9       change. That seems more of a preamble.  
10      Interesting conversation.

11           CHAIR MEHROTRA: Nate, you had your  
12      card up. Reaction to that or --

13           MEMBER SPELL: Yes. I think our  
14      original -- to respond to Elizabeth, our original  
15      intent with the word "health system changes" was  
16      the acknowledgment that it is structural change  
17      that is really happening toward more team-based  
18      and, you know, integrated networks and those  
19      sorts of things.

20                   But to state that -- because it does  
21      kind of state the obvious. I do like the idea  
22      that maybe if we're putting it out there as a

1 principle, the principle is that attribution  
2 models will, by necessity, need to be reevaluated  
3 periodically because there are changes in the  
4 health system.

5 CHAIR MEHROTRA: I like the change in  
6 language there. Would you guys agree with that?  
7 So let me just make sure -- if Kim, in her  
8 amazing writing, can try to capture that again  
9 from what you heard from Nate. Any disagreements  
10 to that in principle, or does anyone feel like it  
11 should be struck?

12 So why don't you -- if you can try to  
13 capture that, why don't we keep on going here,  
14 because I think number 6 is going to garner some  
15 significant debate here. "Provider and patient  
16 self-selection of the responsible provider may be  
17 preferable to only use of claims-based  
18 attribution algorithms."

19 So I think in response to some of --  
20 we had some nice debate about this issue about --  
21 or examples of when patient providers' self-  
22 selection can be wrong, or auto assignment of a

1 PCP can be wrong, I think that's why the word  
2 "may be" -- it just has the word "may" there.  
3 But is that not far enough, and should this be --  
4 to respond to question of "strike this," should  
5 it be struck? Go ahead, Jenny.

6 MEMBER BEAM: I was just going to say,  
7 because if it is a "may," then it's probably not  
8 a principle would be my --

9 MEMBER MOSCOVICE: Principles don't  
10 have the word "maybe."

11 (Laughter.)

12 CHAIR MEHROTRA: All right. So, on  
13 that note, maybe we will take a vote here.  
14 Should this be -- all in favor of striking this?  
15 Oh, I'm sorry. I don't know why I looked at you.  
16 I'm sorry, Laurel. My apologies. I'm getting --  
17 I'm having a hard time here. I'm missing Carol.

18 MEMBER RADWIN: Before we throw the  
19 baby out with the bath water, are we trying to  
20 say something about claim-based attribution  
21 algorithms that can be stated alone as a  
22 principle without the prelude there of "provider

1 and patient may be." Is there something in  
2 principle -- and it's a real question. I'm not  
3 advocating either way that we want to say about  
4 claim-based attribution systems. I think they're  
5 weaker, they're less desirable, they're often  
6 flawed. I mean, is there something we want to  
7 say or not?

8 CHAIR MEHROTRA: So I guess if we were  
9 to go back to -- that's an interesting point, so  
10 let me reframe that slightly. So let's not take  
11 the reality of our crazy HMO assignment of a PCP,  
12 and let's say every day -- I'm taking it to the  
13 extreme -- I have checked in with our patients  
14 and said, "Who is your provider today?" And we  
15 have that every single day, and that was the --  
16 and we used that -- I think that would be  
17 preferable to what we are currently doing maybe  
18 in terms of claims-based or no. Maybe not.

19 MEMBER HOUSER: It's hard to say that  
20 I think.

21 CHAIR MEHROTRA: So I guess my -- just  
22 to emphasize the point, I think what I'm trying

1 to raise is that is our concern about this  
2 particular principle because of the current self-  
3 selection and the biases in that? Or is it that  
4 principally we just don't agree with the general  
5 principle? So sorry for --

6 MEMBER HOUSER: I mean, the question  
7 whether it's better is, how do you define  
8 "better"? Is it more accurate for the people to  
9 whom it is applied? Probably. Is it -- but it  
10 may be worse in that it now creates inconsistency  
11 in the way that it -- that this is defined across  
12 your population. Is that, in aggregate, better  
13 or worse? I don't know. But that kind of  
14 suggests that this goes into the things-you-  
15 should-consider menu and not the principles menu.

16 MR. MULDOON: And it seems like maybe  
17 it's -- have you considered all of your available  
18 data sources that you could potentially use, and  
19 which combination of those best furthers the  
20 ultimate goal of why you're performing this  
21 attribution.

22 CHAIR MEHROTRA: Right. So it sounds

1       like there is -- first, built on the Ira "maybe,"  
2       as well as just generally. So this sounds like  
3       this should be removed and down lower.

4               Srinivas?

5               MEMBER SRIDHARA: I just want to make  
6       one -- I actually -- I think what we -- that  
7       particular comment, you know, yes, probably is a  
8       recommendation. But I think along the lines of  
9       what -- actually what Dan was saying, I think  
10      there are several things here what -- including  
11      our level of -- do you attribute to the provider  
12      level or not?

13              All of these I think our principle, if  
14      you will, is that the available data and data  
15      quality are fundamental to deciding an  
16      attribution approach, or some wording like that.  
17      And I think because that's a theme that is going  
18      to come across like everything that we say is  
19      that, you know, you may have some ideals, but  
20      you're not able to do it today, and that sort of  
21      is what you were asking.

22              If I could ask someone every day,

1 would that be better? But maybe once EHRs and  
2 HIEs proliferate and you have better information,  
3 maybe that's another source. Maybe, you know,  
4 CAHPS has better sampling in, you know, certain  
5 places. Or, you know, I don't know. There are  
6 so many places where you could do things like  
7 this that you -- if your people are doing  
8 attribution.

9 So I would go for something like that,  
10 and then in the recommendations --

11 CHAIR MEHROTRA: Do you think that  
12 would go under number 3 where we were talking  
13 about when you think about from a conceptual  
14 perspective how you choose your attribution rule,  
15 or is that a separate principle? I agree with  
16 the idea fully, and I'm just trying to understand  
17 whether -- where it's --

18 MEMBER SRIDHARA: I think it is  
19 actually different than the goal, because you  
20 have a goal and then you have what are -- you  
21 know, I think the data quality and data  
22 availability is a fundamental problem, and I

1 think -- because when you think about later  
2 recommendations and perhaps even sort of, how  
3 does this committee look to the future and maybe  
4 make recommendations that aren't just attribution  
5 recommendations but sort of highlight the need  
6 for better quality data, and more availability of  
7 data broadly, that becomes something that we  
8 probably need to talk about in this, whether it's  
9 a preamble type of thing or a recommendation,  
10 that it's a fundamental problem. And so I think  
11 we can say something about that in a principle  
12 standing alone.

13 CHAIR MEHROTRA: Let me -- I have cut  
14 off a couple of people for a while, so let me  
15 just come back to them. Troy, and then Bob.

16 MEMBER FIESINGER: If I can comment  
17 directly on that. I'm okay with moving the  
18 specific language about patient designation and  
19 provider designation, claims data, but I want to  
20 give up on the principle because to me what  
21 matters is accuracy. We have already talked  
22 about how we can't be 100 percent accurate, and



1       that may be bad. But the principle I want is  
2       every attribution measure should have mechanisms  
3       by which it can be corrected.

4                You know, Jennifer told me all the  
5       work that goes into Blue Cross/Blue Shield's  
6       efforts to assign patients. Jenny has talked  
7       about this, too. If I perceive it as inaccurate,  
8       I need a mechanism and a way to adjudicate that,  
9       and I think that is going to -- to me, that needs  
10      to be enshrined in attribution measures going  
11      forward.

12               My memory of who my patients are isn't  
13      perfect. Their thought about who their doctor is  
14      isn't perfect. But claims data also has multiple  
15      problems we are probably already -- we are all  
16      painfully familiar with, yet we use it because  
17      it's available.

18               So the principle of accuracy I want to  
19      keep in here somewhere, even if we move  
20      mechanisms or tactics down.

21               CHAIR MEHROTRA: So I hear -- that's  
22      a great point, which is this -- how to address

1 the accuracy. And so to push the point, this is  
2 very similar to what I was thinking with in --  
3 also saying that I'm with you, but is that a  
4 principle? And so just to make sure you're  
5 proposing that there should be -- I won't use the  
6 right words, but there should be some mechanism  
7 by which people can address perceived  
8 misattribution.

9 MEMBER FIESINGER: Yes. Like in the  
10 Next Generation ACO model, the patient can  
11 voluntarily attribute. So if someone is seeing  
12 me, and is a Medicare or fee for service patient,  
13 they could join the Next Generation ACO under me,  
14 even if they weren't originally attributed on  
15 their prospective model. I like that. That is  
16 just one example, but, you know, anyway --

17 MEMBER DRYE: May I just --

18 CHAIR MEHROTRA: Go ahead, Elizabeth.

19 MEMBER DRYE: I just want to suggest  
20 a way to solving that, because I'm putting back  
21 on my working in the executive branch and the  
22 Congress, the sort of policy-writing hat. That

1 goes pretty far. I mean, that's very  
2 prescriptive, so I think it's too prescriptive  
3 for principle.

4 But you could say something like  
5 opportunities, you know, or opportunities to  
6 review and correct attribution contribute to  
7 fairness, or something, contribute to greater  
8 fairness. As opposed to saying everybody has to  
9 do this, you could say something more general  
10 like, if you build that in, it contributes to  
11 greater fairness. Even that I am little -- I  
12 feel like it's a little granular for a principle,  
13 but it backs off of the requirement and gets --  
14 hopefully it supports your point.

15 MEMBER FIESINGER: I guess to clarify,  
16 if accuracy is in there as a principle, I'm okay  
17 with everything else being somewhere farther  
18 down, so I don't mean to put the Next Gen ACO  
19 example in the principles at all. It's more  
20 let's be accurate. Later, okay, here's all the  
21 different ways we can make sure things are  
22 accurate.

1 CHAIR MEHROTRA: So what if we -- I'm  
2 going to propose combining a couple of things  
3 here. So what if we -- you see this 5A? What if  
4 it was, given that there is no gold standard and  
5 data systems and health systems -- well, are  
6 evolving over time, one should revisit your  
7 attribution rule and allow mechanisms for -- to  
8 consider mechanisms for misattribution?

9 So it sort of captures I think what  
10 Charles was saying. There is no gold standard  
11 here, so we need to be thinking about changing  
12 things over time, or so forth. Does that help,  
13 or is it --

14 MEMBER FIESINGER: That's pretty close

15 MEMBER BEAM: Or does that belong with  
16 transparency? Because if I'm being transparent,  
17 you know who is on your panel, and then I have to  
18 allow you a way to address what is on their  
19 panel.

20 CHAIR MEHROTRA: Okay.

21 MEMBER BEAM: I don't know. Just --

22 CHAIR MEHROTRA: Bob, you had

1 something you wanted to show that, or would that  
2 be -- I would be happy to look at that for a  
3 second. Is that something you could -- Bob, you  
4 shared a little bit of these RACI --

5 MEMBER KROPP: Yes. It's late in the  
6 day to introduce another concept, but I'd like --  
7 I sent you that just to consider after the  
8 meeting and after an adult beverage or two.

9 CHAIR MEHROTRA: RACI --

10 (Laughter.)

11 CHAIR MEHROTRA: Do you want to walk  
12 us through --

13 MEMBER KROPP: We are struggling with  
14 the concept of who really is -- attribution, I am  
15 sensing from the group, is a process by which we  
16 determine who is accountable, and we have taken  
17 that to mean who is ultimately responsible for  
18 getting something done. And then, further, who  
19 might contribute to that activity and who might  
20 get paid for it. And I just -- I have given  
21 Ateev some additional terms to consider that  
22 might help us distinguish between these groups.

1                   MEMBER KROPP: Yes. What is the  
2 context behind this? Like where does the RACI  
3 thing come from?

4                   CHAIR MEHROTRA: Oh. Well, there it  
5 is. I didn't mean for it to come out.

6                   (Laughter.)

7                   CHAIR MEHROTRA: This is a business  
8 model that large organizations use to allocate  
9 work.

10                  MEMBER KROPP: I see.

11                  CHAIR MEHROTRA: So in large -- in  
12 project management, this is something that is  
13 routinely done to identify who is on first, and  
14 it overlaps with some of the concepts that we  
15 have been talking about the last two days. It is  
16 also --

17                  MEMBER KROPP: I don't know whether --

18                  CHAIR MEHROTRA: -- like what I was  
19 thinking with Danielle, or somebody made the  
20 whole point about the hemoglobin A1c, and all of  
21 these different people.

22                  MEMBER KROPP: Correct.

1 CHAIR MEHROTRA: Who is in charge of  
2 getting the hemoglobin Alc to less than 7-1/2,  
3 but then who should be consulted, who should be -  
4 -

5 MEMBER KROPP: Yes.

6 CHAIR MEHROTRA: That's interesting.  
7 I'm -- I appreciate you bringing this up, but I'm  
8 still not sure how to incorporate it.

9 MEMBER KROPP: No, no. And I -- and  
10 that's why I was trying to sort of not have it  
11 come out publicly, because --

12 (Laughter.)

13 CHAIR MEHROTRA: No. I appreciate it.  
14 I think it's good to bring this up.

15 MEMBER KROPP: No, it's late -- it's  
16 late in the day, and I think it's a concept that  
17 is best, as I suggested, after a meeting and  
18 adult beverage, you know, see if this helps  
19 inform the discussion between now and next time.

20 CHAIR MEHROTRA: So we'll make sure  
21 this is after dinner -- on the August dinners  
22 that we have red wine any other adult beverage

1       that is --

2                   MEMBER KROPP:   But thank you both for  
3       bringing it forward.

4                   CHAIR MEHROTRA:   All right.   So let me  
5       do a time check.   We've got 15 minutes.   We have,  
6       how many, five minutes?

7                   DR. AMIN:   Yes, five minutes because  
8       we need to wrap up and talk about next steps.   So  
9       if we can --

10                  CHAIR MEHROTRA:   Okay.   So, Charles,  
11       why don't I have you weigh in and then I'd love  
12       to -- and then I'll probably propose some changes  
13       here to sort of get closer to final here.

14                  MEMBER HAWLEY:   Okay.   I'll just say  
15       quickly that the one -- the one concept that I  
16       think should be captured when talking about self-  
17       selection is consistency -- and this came up  
18       yesterday -- and understanding that the method  
19       may change over time is one thing, but in any  
20       given moment being consistent is important;  
21       otherwise, I think what you have measured is not  
22       necessarily comparable.



1           So if you're going to have provider  
2     and patient self-selection, everyone needs to  
3     have self-selection. Or if you are going to rely  
4     on claims data, you should rely on claims data.  
5     But I'm not sure that a mix-and-match approach is  
6     consistent, and I think that that's problematic  
7     or at least potentially problematic. So --

8           CHAIR MEHROTRA: Something that Ari  
9     brought up -- and I wasn't sure if I -- I can  
10    kind of see -- I'll say that, in general, we have  
11    this idea what we're trying to capture, and you  
12    try to use all the data, available sources, to do  
13    it. And, in some cases, you have that patient  
14    self-selection; in other cases you have to do  
15    something else and fill in the gaps. And we -- I  
16    feel like we do that in policy interventions all  
17    the time.

18           But why don't -- but I take your point  
19    also. I see why you could have -- want to have a  
20    consistent approach across all. So given the  
21    time here, I feel like this -- it sounds like  
22    we're going in circles a little bit, but I do

1 think, to build on the example of locking people  
2 in for 100 days and trying to get the declaration  
3 of -- we are only locking you in until 2:30, and  
4 -- but it's something slightly less important,  
5 but I think this kind of wordsmithing has been  
6 helpful.

7 I am going to expect that, based on  
8 these caveats, you can adjust some of this  
9 language. Let me make a couple of points that I  
10 think I heard. I think we decided to get rid of  
11 six fully. And all who disagree, okay. And  
12 then, if you go back up, six was the self-  
13 selection thing that we thought that was a  
14 principle.

15 Oh, no. I'm just joking with you,  
16 Danielle. Please weigh in.

17 MEMBER LLOYD: So I think the reason  
18 I'm struggling with losing it from the principles  
19 is because fundamentally, from my perspective,  
20 and I think others, including the health care  
21 transformation task force, and I think even some  
22 of the land papers, is that to me attribution is

1 a proxy, right? What is the true answer is, what  
2 is the compact between the patient and the  
3 provider, right?

4 So we are trying to capture that in an  
5 automated fashion by harnessing data and -- but  
6 it is a secondary process. The ideal first  
7 process is to actually identify it between those  
8 two parties who essentially entered into that  
9 agreement with each other. And that's why I  
10 think it needs to stay as -- at some point at a  
11 principle level.

12 CHAIR MEHROTRA: Jenny, can I have you  
13 -- do you mind weighing in? Because you have  
14 articulated the --

15 MEMBER BEAM: Right. I just -- you  
16 know, looking at the data and what I have seen,  
17 you know, the patients don't always -- again, who  
18 is your patient? Dr. Smith. Well, which Dr.  
19 Smith? Because you're in a large city, so  
20 there's five Dr. Smiths. Oh, I don't know, you  
21 know. Or even if you get to Tom Smith, you know,  
22 then you go, well, is it Jr. or Sr.? Oh, I don't

1 know, who's 40 or 50.

2 So then people are not accurately  
3 really selecting. The data often shows that  
4 whoever the patient selects really is not who  
5 they are seeking for care. Or I have said I am  
6 going to come see you, but, then again, I go see  
7 -- you're on vacation. I go see someone else in  
8 your group, and I really like them better and I  
9 stay with them.

10 So what the data has actually shown is  
11 that oftentimes there is not good overlap. So,  
12 again, I would hate to replace actual data, where  
13 we know a patient is seeing a provider, with a  
14 less accurate measure. I think in the ideal  
15 world, if you could capture that, and it would be  
16 accurate, I don't think anybody would argue. But  
17 I just don't think it's clean today.

18 MEMBER LLOYD: Yes. We've got to go,  
19 but I think part of it is also there are other  
20 mechanisms that people are starting to test to  
21 get around this.

22 In fact, we were just talking about

1 putting it in something like the current -- you  
2 know, the Medicare beneficiary survey is if you -  
3 - if you put in, you know, here is three people  
4 you commonly see, who do you believe is the  
5 person that is ultimately responsible for your --  
6 so you are not just having them fill out a blank  
7 form where the 85-year-old blind diabetic was  
8 like, what was his name?

9 You know, like there can be  
10 combinations of these things, but ultimately part  
11 of the goal here is to make sure that we have a  
12 new day and age where people are making an overt  
13 decision. So it is on the aspirational side, not  
14 the in today's -- is it --

15 MEMBER POPE: Ateev, I think part of  
16 the reason we started to strike it was, you know,  
17 we had this language from May, and so I think  
18 everybody agrees we -- you know, we can't leave  
19 it as a principle where we say you may do this or  
20 that.

21 I really favor, you know, having some  
22 discussion around that in the section where we

1 talk about as new data sources become available,  
2 and ways of more discretely and concretely  
3 capturing that relationship come onto the scene,  
4 you can incorporate that, the reality is those  
5 things don't exist today. So I don't know how --  
6 you know, how useful that is in some sense.

7 CHAIR MEHROTRA: So what if we were to  
8 say basically attribution rules or attribution  
9 methods have often been equated with claims-based  
10 mechanisms. And given what we are trying to  
11 capture here, we recognize that attribution can  
12 come from many other sources, including self-  
13 selection, EHR data, et cetera. But that would  
14 not be a principle, but that would, rather, be in  
15 the language we describe and is really an  
16 important part of this document.

17 MEMBER BEAM: I would just say that  
18 many other sources are not available, and EHR is  
19 not available today. I mean --

20 CHAIR MEHROTRA: No, no, no. I'm  
21 saying that, as time evolves, these --

22 MEMBER BEAM: Yes.

1 CHAIR MEHROTRA: Exactly.

2 MEMBER BEAM: Yes.

3 CHAIR MEHROTRA: Okay. So very  
4 conscious of time, and so I am going to just  
5 quickly -- we never really addressed six, seven,  
6 and eight. So what I would like to do is propose  
7 just having some quick votes, just to get a sense  
8 for the NQF staff to do -- what to do with these,  
9 and then I think there should be -- I think there  
10 is a necessary next step, which is to clean up  
11 the language, for us to reflect a little bit, and  
12 then to have us have another opportunity to weigh  
13 in on these principles. Does that make sense?  
14 In the future.

15 So let me just get a sense of --  
16 number 6 I thought was a great idea, but I wasn't  
17 sure that it was a debate about principle.  
18 Available data and data quality are fundamental  
19 to deciding on attribution approach. There's a  
20 thought that should be a principle.

21 We have about four or so but -- okay,  
22 a little bit more than half, maybe two-thirds.

1 To drive the system forward, it's necessary to  
2 challenge current norms of attribution, including  
3 a tendency to identify a single -- only identify  
4 a single clinician or provider. Who thought that  
5 was a good principle? Okay. Maybe a little bit  
6 less support for that idea, though there are  
7 certainly key -- those who agree think it is --

8 (Simultaneous speaking.)

9 CHAIR MEHROTRA: Okay.

10 MEMBER FIESINGER: I like the concept,  
11 but the wording doesn't quite say what in my head  
12 I'm trying to articulate.

13 CHAIR MEHROTRA: Okay. But that's  
14 exactly what kind of feedback we needed.

15 And, lastly, simplicity and  
16 consistency of attribution rules are the ideal  
17 state. However, flexibility is necessary to  
18 align the attribution method and the use case.

19 (Laughter.)

20 CHAIR MEHROTRA: And you should love  
21 your mother and baseball.

22 (Laughter.)



1                   MEMBER BARR:       Shouldn't that be in  
2     the preamble?

3                   CHAIR MEHROTRA:   So those who thought  
4     this was something really critical -- important  
5     for us to put as a principle? I'd just remind  
6     you, put your mic on.

7                   MEMBER KROPP:     I'm sorry. Two days  
8     and I'm challenged with technology. Sad.

9                   I think it needs to stay as a  
10    principle, because this is where a lot of  
11    providers will just immediately reject  
12    attribution out of hand. So I think that some  
13    acknowledgment up front that this is -- that  
14    simplicity and consistency is what we're looking  
15    for. Troy said it several times.

16                  However, the system is complex, and  
17    the rules need to reflect the complexity of the  
18    system in order to ensure fairness and equity and  
19    things like that. So I think it is a principle.

20                  CHAIR MEHROTRA:   Right. So that's  
21    helpful. I know we haven't come to full  
22    conclusion. Let me -- Jen, you had -- you

1 just --

2 MEMBER NOWAK: Just a real quick  
3 statement. We use attribution rules, attribution  
4 method, attribution model, attribution  
5 algorithms. There is logic. I think we just  
6 need to land on something. There is rules, and  
7 then there is the logic and algorithm around  
8 those rules. That's --

9 CHAIR MEHROTRA: So I think we'll --

10 MEMBER NOWAK: It's consistent in our  
11 wording.

12 CHAIR MEHROTRA: That's a very fair  
13 point. I think attribution model, based on Dr.  
14 Ryan's recommendation, is what we -- at least  
15 where I am. You good with that?

16 All right. So I'm going to now turn  
17 it over to the capable NQF staff to wrap up.

18 DR. AMIN: I have some wrap up  
19 elements, but, Donna, do you have some that you  
20 want to walk through as well?

21 MS. HERRING: Just quickly. Operator,  
22 could you open the line for public comment?

1 OPERATOR: Thank you. At this time,  
2 if you would like to make a comment, please press  
3 star, then the number one on your telephone  
4 keypad. We'll pause for just a moment.

5 And there are no public comments at  
6 this time.

7 MS. HERRING: Okay. So I'm just going  
8 to go over some next steps for the project. So  
9 next we will be posting the summary of this  
10 meeting to our project page. That will happen  
11 next week. The authors will continue to refine  
12 the paper based on the discussion that we have  
13 had today and yesterday.

14 Our next meeting is in person at NQF  
15 in this same room again in August, and we will  
16 discuss the public comments that have occurred on  
17 the paper, and we will refine the principles and  
18 make recommendations.

19 And then, on the next slide, we will  
20 just quickly review where we have been and where  
21 we are going. So, as you can see, we did convene  
22 the committee and the commission's authors. We

1 had a web meeting to review the environment scan  
2 outline. The authors conducted their  
3 environmental scan, drafted the commission paper,  
4 and here we are today at our in-person meeting  
5 number one.

6 So next we will post the report for  
7 public comment, and then we will have our second  
8 in-person meeting before drafting the report, and  
9 then having our final report.

10 That's all I have.

11 DR. AMIN: So, Donna, a few things for  
12 the committee. There is a number of elements of  
13 pre-work that is going to really be helpful in  
14 order to get our August meeting to where we want  
15 it to be. We really want to start looking at  
16 this -- at the criteria, the second order  
17 criteria as we referred to.

18 Sorry. Let me just look at my notes  
19 here. The criteria, the second order criteria,  
20 and the elements that we want to -- as part of  
21 the checklist.

22 So I know, Elizabeth, you mentioned

1       that there are some things that you are working  
2       on, so it would be helpful if others would send  
3       it along. We are going to -- we are sort of  
4       going to ask a few of you to work on sort of  
5       small groups with us, so we'll be reaching out to  
6       you individually to help us sort of refine the  
7       various criteria.

8               And then, as we identify the use cases  
9       from the input from CMS, and then others in the  
10      room, we are going to ask -- again, convene a  
11      small workgroup of this group to help, you know,  
12      put together kind of what we did between day one  
13      and day two here, just run those case studies  
14      through the criteria and have that as a starting  
15      point for our discussion in August, so that we  
16      are sort of working, you know, from a more robust  
17      product and to keep the work going in the interim  
18      period.

19             So please look out for that. We're  
20      just going to sort of reach out to folks that  
21      have been really actively participating in those  
22      elements. I'm sure you guys know who you are.

1 And then we'll convene a small call to do that.

2 Now, the other question is that,  
3 clearly, what we're going to public comment on  
4 is, in addition to Andy's paper, is going to be  
5 these principles. You know, we still need some  
6 refinement, clearly, in terms of where we are.  
7 There are two different ways that we have done  
8 this in the past. The first is to -- you know,  
9 staff will take the list and sort of pass it  
10 around, ask for track changes, and have that all  
11 sent back to us, and we'll do the second set of  
12 iteration.

13 The other option is that we do have a  
14 call that is currently on the books, next  
15 Tuesday, which would be another opportunity for  
16 us to refine it, send it back to you, and for you  
17 all to jump on a call and talk it out. We can do  
18 either approach, and so I think I'm actually  
19 asking for recommendations about how we want to  
20 do it. Ashlie?

21 MS. WILBON: Yes. If we could vote,  
22 I'm -- we could go either way, but I think I'm

1 with Ateev on this. I think it's helpful to have  
2 people talk, because my sense is that track  
3 changes will get conflicting recommendations, and  
4 then staff is left to try to reconcile those,  
5 which may or may not be -- you know, we can only  
6 go back and forth so many times before we have to  
7 put things out for comment.

8 So I think my leaning would probably  
9 be towards the call, just so we have an  
10 opportunity to verbally hash it out and kind of  
11 either get strawman vote on the phone or whatever  
12 about which way to go, so that we are not left to  
13 reconcile conflicting recommendations.

14 But I did also want to put -- put that  
15 out to the group. If we could just see a show of  
16 hands of people who are willing to hop on a call  
17 on Tuesday. We would take another stab at what  
18 we were left with today, try clean it up again,  
19 send it out to you guys, and then use the call to  
20 just make sure we get the final okay before it  
21 goes out for comment, or just kind of get the  
22 temperature of where you guys -- you know, if

1       that's -- just let us know what you're thinking  
2       based on where we left off today, and that plan  
3       of us going back and doing some editing and then  
4       what's the step after that in terms of committee  
5       checkoff.

6               CHAIR MEHROTRA:   So maybe we'll just  
7       have a vote?

8               MS. WILBON:   Yes.

9               CHAIR MEHROTRA:   So those in favor of  
10       having a phone call next Tuesday?

11              (Simultaneous speaking.)

12              MEMBER SRIDHARA:   I just have a  
13       question about that.   Is it -- how realistic is  
14       it that from now 'til Tuesday, given you have all  
15       been here for two full days, and so has everyone  
16       else, and a number of other things you have  
17       probably left behind for the two days, how much  
18       further will this move forward before our Tuesday  
19       call if you have to get something back to us in  
20       like a day or something, two days, for us to have  
21       time to review?

22              I mean, I think a call, good idea.



1 I'm asking a "when" question, of actually having  
2 time to process this, and especially if you  
3 wanted to reach out to anyone else or do whatever  
4 else to sort of refine -- there are some pretty,  
5 you know, substantial questions or elements left  
6 open right now. And so if you want the most out  
7 of that feedback, is it better to push it out a  
8 little bit and have time to do that?

9 CHAIR MEHROTRA: When do you have to  
10 send this out for public comment?

11 MEMBER SRIDHARA: Yes, right. I don't  
12 know what the logistics are, but, yes.

13 MS. HERRING: Yes. So the report goes  
14 out for public comment in mid-July, July 15th.  
15 We had the June 21st meeting on everyone's books  
16 as follow-on from this meeting. That's why it  
17 held. We have an option of finding -- the  
18 challenge is is that we want everyone to  
19 participate in the discussion, and so that's why  
20 we send the dates out so far in advance.

21 So I think it's an open question, but  
22 logistically whether or not that's possible at

1       this time is potentially going to be the monkey  
2       wrench in there.

3               CHAIR MEHROTRA:   Srinivas, I was going  
4       to say that, given those issues, and this is  
5       fresh in our minds, and so forth, and the  
6       capabilities of this NQF staff and how quickly  
7       they move, that we keep with the next Tuesday  
8       call, just because I think we will be all fresh  
9       with it and we will be thinking about it, because  
10      I think in two or three weeks we might be like,  
11      what is attribution?   And so --

12               (Laughter.)

13              CHAIR MEHROTRA:   So if that's -- so  
14      recognizing it may not be perfect timing, but  
15      just the logistics.   That seems reasonable.

16              MS. WILBON:   So it sounds like the  
17      consensus is that we're going to use the call on  
18      Tuesday.   Okay.   So we will be sending something  
19      out to you guys -- today is Wednesday -- by the  
20      end of the week maybe.   We'll have it to you guys  
21      by the end of the week, so you have the weekend  
22      plus Monday and the call will be on Tuesday.

1 CHAIR MEHROTRA: It's only half a page  
2 or so, so --

3 MS. WILBON: Yes. It's not -- yes, we  
4 can call that out. So does that sound like a  
5 plan? Okay. Good.

6 CHAIR MEHROTRA: Is that it?

7 DR. AMIN: All right. So, in summary,  
8 we will send this out, and then there is going to  
9 be small workgroups on the criteria, and the case  
10 studies, and then that will feed our discussion  
11 for next time. And, again, just for everyone's  
12 sort of orientation, the real content for next  
13 meeting is to then take these case studies and  
14 look at the criteria, work it through, and then  
15 really extract sort of the logic that we have  
16 talked about in terms of, you know, the logic  
17 that we've talked about. I'm not even going to  
18 try to summarize what that is.

19 And, you know, and then we will use  
20 that as -- and then take that and apply it to  
21 what we -- the NQF process, meaning the consensus  
22 development process for measure endorsement and

1       measure selection and make specific  
2       recommendations on how that affects our internal  
3       processes, and then that will basically be the  
4       structure of the second meeting that we have in  
5       October.

6               So thank you all for your time and  
7       your mental energy that you have all contributed  
8       to this over the last two days. Ateev, for your  
9       excellent leadership of the team. And it has  
10      been a great two days.

11             Are there any additional questions  
12      about what we are trying to get done, where we  
13      are in the process? Any questions from the  
14      group?

15             All right. Thank you all. Thank you  
16      very much.

17             (Whereupon, the above-entitled matter  
18      went off the record at 2:35 p.m.)  
19  
20  
21  
22

<b>A</b>	
<b>a.m</b> 1:9 4:2 103:9,10	96:18 97:1 100:9
<b>A1c</b> 231:9 233:3,7,14	108:9 110:3,15 111:4
244:4,6 262:20 263:2	113:13,17 117:12
<b>AARP</b> 1:15	118:20,21 119:2,4
<b>abating</b> 248:14	121:20 122:3,8
<b>ABC</b> 196:3	138:11 141:10 151:6
<b>ability</b> 45:5 225:10	151:8 155:4,20 156:9
<b>able</b> 11:17 16:13,18	159:19 164:17 170:4
19:21 45:2 78:18	171:9 181:20 184:3
128:18 131:19 165:8	205:17 211:16 215:9
189:4 254:20	215:14 217:9,11
<b>above-entitled</b> 103:8	224:17,19,21 226:7
175:10 284:17	230:19 258:10,13
<b>absolute</b> 216:14	259:18
<b>absolutely</b> 18:8 83:6,11	<b>ACOG</b> 240:19
120:15 173:6	<b>ACOs</b> 47:10 57:9 58:1
<b>acceptable</b> 223:8	77:1 106:6 161:15,16
<b>access</b> 141:7 142:1	169:22 231:17
<b>accomplish</b> 77:19	<b>act</b> 139:22 140:11,17,19
<b>accountability</b> 23:19	226:5,18,20
24:1 27:18 30:2 34:3	<b>actions</b> 216:2
34:6 35:18 36:12	<b>active</b> 4:19
38:16 45:2 47:17 49:2	<b>actively</b> 4:22 6:14
49:15 53:7,14 54:11	277:21
54:16,19 55:3 69:2	<b>activity</b> 121:8 122:13
177:1 180:4,5,7,8	164:19 217:2 261:19
182:21 183:13 184:1	<b>actor</b> 32:3
184:4,9,12,14,20,22	<b>actual</b> 118:7 268:12
185:20 186:7,9,12,15	<b>acute</b> 154:21 155:12
189:9,11 192:12	166:7,9 167:6,12
199:3 206:6 215:9	230:20
224:20 232:5 234:1	<b>ad</b> 190:21
<b>accountable</b> 1:17	<b>add</b> 9:7 12:10 13:12
110:11 113:6,8 124:9	16:1,15,19 28:8 73:2
129:3 157:21 180:13	118:2 128:6 179:18
185:6 199:8 217:1,10	201:5 228:18 247:10
217:15 231:19 232:12	<b>added</b> 107:2
234:16 244:1,13	<b>adding</b> 31:6 178:21
261:16	198:5
<b>accumulate</b> 172:16	<b>addition</b> 131:18 278:4
<b>accuracy</b> 24:9 114:15	<b>additional</b> 11:16,18,19
187:6 221:4 256:21	38:6,9 261:21 284:11
257:18 258:1 259:16	<b>address</b> 129:22 143:8
<b>accurate</b> 62:7,16	157:9 158:11 187:19
193:10 215:1 253:8	208:9 210:12 214:21
256:22 259:20,22	228:10 242:17 257:22
268:14,16	258:7 260:18
<b>accurately</b> 268:2	<b>addressed</b> 204:21
<b>achieve</b> 45:6 152:12	271:5
185:1,7	<b>addressing</b> 148:8
<b>acknowledging</b> 192:5	<b>adds</b> 31:1 158:3
249:6	<b>adequacy</b> 198:12
<b>acknowledgment</b>	<b>Adjourn</b> 3:20
249:16 273:13	<b>adjudicate</b> 257:8
<b>ACO</b> 31:18,19 44:11	<b>adjust</b> 266:8
47:18,19 62:5 68:6	<b>adjustments</b> 168:12
69:4,9 75:2 84:4 87:1	<b>admission</b> 167:13
	<b>adult</b> 261:8 263:18,22
	<b>advance</b> 16:3 23:19
	62:12 177:1 183:14
	185:4 281:20
	<b>advanced</b> 234:13
	<b>advantages</b> 41:19
	101:8 120:12
	<b>adverbs</b> 223:16
	<b>Advisor</b> 2:13
	<b>Advisory</b> 2:5
	<b>advocate</b> 162:1
	<b>advocating</b> 252:3
	<b>Aetna</b> 1:17 60:2 205:8
	<b>affect</b> 44:7 45:5 98:9
	128:3
	<b>affordable</b> 178:1
	<b>affords</b> 209:20
	<b>afield</b> 23:2 134:11
	<b>afterword</b> 243:17
	<b>age</b> 269:12
	<b>aggregate</b> 253:12
	<b>aggregated</b> 210:3
	<b>aggregation</b> 209:15,16
	209:17
	<b>ago</b> 65:5 91:14 94:13
	105:16 148:2 164:13
	<b>agree</b> 43:14 49:11 77:9
	87:10 91:17 94:18
	101:21 120:1 122:1
	130:8 137:5 139:2
	165:10 169:17 178:20
	183:17 193:7 205:1
	232:16 240:7 243:8
	247:5 250:6 253:4
	255:15 272:7
	<b>agreeing</b> 129:22 130:4
	<b>agreement</b> 267:9
	<b>agrees</b> 269:18
	<b>AHA</b> 137:12
	<b>ahead</b> 9:18 19:19 27:14
	33:4 103:11,12
	148:11 167:1 178:11
	180:1 182:10 183:18
	188:11 198:15 199:13
	199:19 212:9 216:19
	220:21 224:13 235:1
	235:3 242:7 246:7
	248:5 251:5 258:18
	<b>AHRQ</b> 20:19
	<b>Aim</b> 177:20,22 178:5
	<b>aiming</b> 226:13
	<b>ain't</b> 198:8
	<b>air</b> 6:13
	<b>algorithm</b> 40:6,14,22
	44:16 46:7 64:20 68:1
	68:5 99:10 100:14
	274:7
	<b>algorithms</b> 25:20 63:8
	68:10 100:9 102:1
	146:10 250:18 251:21
	274:5
	<b>align</b> 26:11 78:11 79:1
	79:9 188:5 189:2,6
	196:7 206:21 207:2
	272:18
	<b>aligned</b> 79:14 191:16
	199:6,16 201:13
	204:18 230:6,7
	233:18
	<b>aligning</b> 188:16 193:16
	199:1
	<b>alignment</b> 24:14,18
	110:22 187:10,11
	196:4 202:20 205:22
	206:5
	<b>aligns</b> 194:13
	<b>all's</b> 125:11
	<b>Allen</b> 2:2
	<b>allocate</b> 262:8
	<b>allocating</b> 233:21
	<b>allocation</b> 193:14
	<b>allow</b> 91:21 201:22
	260:7,18
	<b>allows</b> 221:14
	<b>alternate</b> 193:7
	<b>Alternately</b> 85:16
	<b>alternative</b> 69:8 83:19
	109:14 128:10 138:20
	144:6,14 145:18
	<b>amazing</b> 250:8
	<b>ambulatory</b> 167:18
	<b>American</b> 92:3,4
	<b>AMIN</b> 2:13 4:3 12:10
	14:7 18:8 81:5 87:10
	148:10,12,14 154:15
	173:6 264:7 274:18
	276:11 283:7
	<b>amorphous</b> 186:4
	<b>amount</b> 65:8 73:21
	90:15
	<b>analyses</b> 57:22
	<b>analysis</b> 43:2 62:7
	76:11 86:16 106:5
	126:10 149:3 150:12
	150:17 152:5 153:19
	154:1,19 173:15
	195:12,15,17
	<b>Analyst</b> 2:8
	<b>analytic</b> 92:17
	<b>analyze</b> 102:13
	<b>ancillary</b> 80:7,20
	<b>and/or</b> 99:2
	<b>Andrew</b> 2:16 3:7,10
	<b>Andy</b> 5:10,21 7:1 11:16
	21:12,22 23:12 27:12
	33:3,15 50:10 51:7
	52:2 69:12 71:8 89:12

89:19 90:20 95:18  
 142:19 198:1 209:15  
**Andy's** 9:1 33:3 34:16  
 51:1 62:20 74:7  
 148:21 173:13 278:4  
**anecdotal** 68:20 82:13  
**Angeles** 132:19  
**angle** 169:11,12  
**answer** 59:6 72:19,21  
 78:19 83:15 94:6 98:5  
 195:21 267:1  
**answers** 160:10  
**anti** 162:12  
**antibiotic** 241:3,7  
**antibiotics** 241:6  
**anticipate** 10:15  
**anybody** 114:7 135:9  
 198:15 268:16  
**anyway** 64:11 94:18  
 140:15 167:4 170:21  
 229:16 235:22 258:16  
**anyways** 83:2,16  
**apart** 158:14 235:14  
**APM** 234:13  
**apologies** 60:18 61:7  
 128:14 251:16  
**apologize** 5:8 61:6  
 100:7 127:9 174:16  
**app** 141:16,21  
**appeal** 89:15  
**appear** 99:18  
**appendicitis** 167:13  
**appendix** 7:14 57:2  
**applaud** 125:11  
**applicable** 119:4 150:7  
**application** 63:20 92:17  
 97:9 98:16 118:15  
 170:7,7  
**applications** 12:19  
 57:22  
**applied** 43:7 69:18  
 203:8 206:18 209:17  
 253:9  
**apply** 20:2 36:19 45:10  
 74:2 96:14 128:21  
 146:9 160:7 161:2  
 169:21,22 180:13,14  
 202:22 283:20  
**applying** 37:2 63:16  
 161:16 189:15  
**appreciate** 103:1  
 106:21 125:8 128:18  
 152:17 170:20 238:12  
 263:7,13  
**approach** 5:17 12:16,21  
 13:1,6,16 14:12 24:9  
 24:19 26:19 40:3 41:6  
 44:14 50:3 84:5 86:16

91:22 92:17 93:2  
 94:14 95:13 97:13,19  
 121:15 124:19 139:3  
 141:1 162:12 164:8  
 187:5,12 191:4 194:2  
 194:8,9,13 195:13  
 198:2 248:14 254:16  
 265:5,20 271:19  
 278:18  
**approaches** 1:3 3:6,9  
 11:20 20:1 37:6 38:6  
 38:9 41:4,10,22 42:2  
 43:4,19 44:7 49:5  
 52:15 53:2 61:1 64:1  
 73:10 87:17 97:20  
 127:22 144:14 145:18  
 170:3 187:8,9 194:5  
 194:11 195:19  
**appropriate** 17:6 79:4  
 92:14,16 224:19  
 243:17 244:12  
**appropriateness** 107:8  
**approve** 192:14  
**area** 2:3 22:13 65:9  
 133:2 168:6 173:12  
 218:14  
**areas** 30:3  
**argue** 164:4 239:22  
 245:4 268:16  
**arguing** 143:12  
**Ari** 1:15 34:17 85:5  
 124:5 132:5 180:17  
 193:4,21 231:3 236:3  
 243:9 265:8  
**Ari's** 172:10  
**Ariel** 37:14  
**Arkansas** 160:1  
**arm** 185:9  
**arrayed** 33:6  
**arraying** 33:11  
**articles** 37:20 38:1,3,3  
 38:4,4,13  
**articulate** 25:9 137:18  
 140:8 143:10 224:4  
 272:12  
**articulated** 25:6 137:21  
 138:7 139:1,8 173:22  
 224:8,10 226:2 230:5  
 267:14  
**articulating** 151:4  
 152:14 201:11  
**artificial** 68:8  
**Ashlie** 2:10 5:8 28:13  
 278:20  
**asked** 57:18 61:18  
 177:4  
**asking** 19:5 57:21  
 78:17 153:10 195:20

254:21 278:19 281:1  
**aspect** 36:10 80:10  
 85:2 179:16 182:2  
 184:2  
**aspects** 33:12 109:11  
 126:22  
**aspiration** 27:21 126:13  
**aspirational** 22:14  
 55:19 102:15 179:16  
 192:3 196:11 197:14  
 201:14 214:8 233:5  
 234:2 239:15 269:13  
**assess** 21:14 78:14  
 138:5 227:10  
**assessed** 188:16  
**assessing** 227:19  
**assessment** 92:17  
**assign** 46:8 83:4 85:17  
 106:15 210:13,14  
 257:6  
**assignment** 83:9  
**assigned** 85:14,15  
 100:14  
**assigning** 26:7 152:2  
 216:6  
**assignment** 83:12  
 250:22 252:11  
**assignments** 171:12  
**associated** 35:20  
**Association** 1:20 92:4  
**assume** 32:2 75:16  
**assumed** 60:7  
**assumption** 77:5,12  
**assumptions** 41:3  
**Assurance** 1:12  
**astray** 213:20 231:5  
**Ateev** 1:9,11 3:3 5:5  
 52:15 56:16 70:17  
 173:6 261:21 269:15  
 279:1 284:8  
**Ateev's** 45:8  
**Atrius** 99:22  
**attach** 163:9  
**attack** 129:7 167:14  
**attempt** 32:4  
**attending** 29:16 151:17  
 152:6,7 207:6  
**attention** 49:17 223:7  
**attestation** 114:21  
**attributable** 118:10  
**attribute** 25:9 31:20  
 40:7 42:6 51:21 63:13  
 69:22 70:6 87:1  
 106:14 112:21 119:1  
 129:4,10 131:14  
 132:21 140:6,16  
 151:15,20 152:4,6,7  
 155:2 168:4 197:6

215:16 216:11,12  
 218:16 219:4 221:13  
 224:22 225:17 235:11  
 237:10 254:11 258:11  
**attributed** 24:15 39:1  
 42:4 44:14,17,21  
 45:13 46:10,13,21  
 47:18 72:8 82:3 129:6  
 130:3 139:19 145:7  
 145:13,14 151:9  
 157:5 158:2 187:10  
 188:17 189:8 197:20  
 216:5 217:16 258:14  
**attributes** 72:9 75:4  
 86:21 92:6 198:3  
**attributing** 51:9,13,13  
 73:5 81:18,19 140:18  
 151:6,7 207:6,7  
 212:12 213:7,8  
 214:17 218:20 221:17  
 222:11 224:18 233:1  
 233:2 238:18  
**attribution** 1:3 3:6,9,14  
 4:4,7,20,22 7:13 8:19  
 8:22 11:7,8,11 12:21  
 14:6 23:1,4,17,22  
 24:5,9,13,17,19,19  
 25:2,5,11,18,19 26:6  
 26:10,12,14,19 28:5  
 30:1 31:7 33:5 35:12  
 35:17 36:4,17,22 37:4  
 37:5,11 38:1,6,14,20  
 39:4,6,7,10,14,15,21  
 40:22 41:6,8,16,17,20  
 41:22 42:1,10,14  
 43:19,20 44:1,2,7,16  
 44:22 45:3,4,17 46:16  
 46:17,20,22 47:4,8,15  
 48:6,12,16 49:6,10,20  
 50:3 51:20 52:12,13  
 55:18 56:2,19,20  
 62:14 63:1 65:21 66:3  
 68:5 69:14 70:14,22  
 71:7 72:15 73:10,12  
 74:11 80:2,11 82:5  
 84:9,12 85:12,22 86:4  
 86:9,12 87:12,13  
 90:16 91:22 94:15  
 95:10 97:4,9,12 98:8  
 98:18 99:2 100:2  
 108:10,11 110:14  
 111:20 112:3 113:10  
 113:13,21 115:6  
 117:17 121:14 122:9  
 126:5,8,11 127:11,18  
 129:17 138:10,20  
 143:13,17 144:3,7,13  
 145:4,18 146:10,19

147:11 150:17 154:2  
 154:7,20 161:2,5,13  
 161:19 162:22 164:5  
 164:11 165:3,6  
 169:20 170:3 176:22  
 177:20 179:12,15,16  
 179:19 180:20 183:20  
 183:22 184:9,13,13  
 185:3,19,22 186:4,11  
 187:2,5,8,12,12  
 190:11 191:15 192:1  
 193:9 194:2,5,8 198:2  
 201:15 205:18 206:1  
 206:21 207:4,9  
 209:17,22 210:3,10  
 212:17 215:6,13,18  
 216:21 217:6,11  
 219:16 220:11 221:5  
 221:20,22 223:3  
 227:18,21 228:18,19  
 230:4,7 231:14  
 235:16,20 236:12  
 239:20 241:22 242:2  
 243:2 244:22 245:12  
 247:11 248:9,20  
 250:1,18 251:20  
 252:4 253:21 254:16  
 255:8,14 256:4 257:2  
 257:10 259:6 260:7  
 261:14 266:22 270:8  
 270:8,11 271:19  
 272:2,16,18 273:12  
 274:3,3,4,4,13 282:11  
**attributions** 39:2 46:5  
 80:1 110:10 141:11  
 206:22 208:11 223:13  
**atypical** 163:17,18  
**audience** 98:6 104:6  
 120:22 149:7 152:21  
 156:12,12 204:21  
**audit** 215:10  
**August** 7:20 14:17 72:4  
 148:19 173:1,18  
 263:21 275:15 276:14  
 277:15  
**author** 5:9 67:10 177:7  
 177:16  
**authors** 275:11,22  
 276:2  
**auto** 250:22  
**automated** 267:5  
**availability** 245:14  
 246:14 255:22 256:6  
**available** 67:21 88:9,11  
 88:15 208:14 214:9  
 221:21 246:15 248:12  
 253:17 254:14 257:17  
 265:12 270:1,18,19

271:18  
**average** 233:14  
**avoid** 63:10  
**avoiding** 30:20  
**aware** 136:21 248:13  
**awesome** 209:2  
**awhile** 91:14 94:22  
**awkward** 107:16

---

**B**

---

**B** 206:15 207:20,22  
 226:10,10  
**baby** 251:19  
**back** 18:2 23:12 27:1  
 28:11 34:18 51:5,9,12  
 59:13 73:11 78:9  
 83:19 88:12 91:14  
 100:11 103:3,7  
 104:11 106:22 114:8  
 121:5,18 125:6  
 128:17 131:11 139:16  
 147:22 156:4 159:6  
 159:10 162:5 164:12  
 167:15 169:7 175:5,7  
 192:21 214:14 222:13  
 224:6,15 225:11  
 226:5,6 227:11 236:9  
 238:17 239:18 241:22  
 252:9 256:15 258:20  
 266:12 278:11,16  
 279:6 280:3,19  
**background** 35:15  
 62:22  
**backs** 259:13  
**bad** 35:21 77:7 85:14  
 88:5 101:2 194:10  
 195:13 211:2 245:16  
 257:1  
**baked** 108:5  
**balance** 63:22 151:15  
 209:11 221:4,19  
 227:21 240:9  
**balanced** 193:15  
**ball** 129:5  
**banding** 242:14  
**bar** 191:18  
**BARR** 1:11 130:8  
 178:13 179:3 180:2  
 196:22 197:13 198:10  
 273:1  
**base** 101:18  
**baseball** 272:21  
**based** 13:8 22:4 38:20  
 39:15,16 46:8 49:15  
 67:4 69:2 82:11 86:1  
 100:14 113:4 115:6  
 121:15 139:6,20  
 143:2 152:11 155:15

164:10 169:18 170:6  
 199:9 210:2,3 266:7  
 274:13 275:12 280:2  
**basic** 36:16 145:15  
 239:4  
**basically** 6:16 14:17  
 40:18 92:7 109:13  
 118:12 139:4 168:6  
 179:14 228:10 244:20  
 246:21 270:8 284:3  
**basis** 13:22,22 81:19  
 82:6 248:9  
**bath** 251:19  
**Baylor** 1:22 215:10,13  
**BEAM** 1:12 51:7 87:22  
 168:16 181:9 184:5  
 198:22 201:20 203:5  
 203:10,21 204:19  
 220:2 222:4 251:6  
 260:15,21 267:15  
 270:17,22 271:2  
**bearing** 111:4  
**becoming** 248:12  
**began** 129:2  
**beginning** 79:22 80:6  
 124:4 125:3 228:10  
**behavior** 70:8 96:2,3,3  
 96:17,19 165:5  
 201:21 243:13  
**behaviors** 22:13  
**believe** 127:5 202:14  
 216:10 269:4  
**belong** 260:15  
**belongs** 245:15  
**benchmark** 31:21  
**Bend** 1:14  
**beneath** 124:10  
**beneficiaries** 62:12  
 112:12 138:12  
**beneficiary** 112:5  
 114:21 151:9 221:13  
 221:18 222:3 269:2  
**beneficiary's** 151:7,11  
**benefits** 117:4  
**bennies** 137:15  
**best** 15:21 16:11 39:15  
 71:7,11 97:14 153:14  
 194:6 253:19 263:17  
**bet** 123:6  
**better** 6:19,21 50:5 54:4  
 72:2 101:20 146:22  
 177:22 202:11 216:11  
 237:4 246:15 253:7,8  
 253:12 255:1,2,4  
 256:6 268:8 281:7  
**beverage** 261:8 263:18  
 263:22  
**beyond** 40:19 53:6

75:10 94:3 157:22  
 228:6  
**Bharat** 2:5 66:16 71:15  
 76:21 77:20 209:4  
 212:21  
**Bharat's** 74:20  
**bias** 82:17 99:15 235:19  
**biased** 229:18  
**biases** 253:3  
**big** 8:3 25:11 32:14  
 83:7 86:4 96:9 153:14  
 153:15 207:18 215:18  
**bill** 80:4 158:3,3 239:12  
 239:19  
**bins** 153:4  
**birth** 141:17 240:20  
**bit** 17:7 19:20 28:4  
 29:21 35:12 37:9  
 42:12 53:16 57:11  
 71:20,20,21 86:3,8  
 87:19 89:20 93:1,16  
 100:15 104:1,5 108:1  
 109:18 121:5 126:2  
 129:13 135:20 149:3  
 156:14 157:15 171:15  
 173:8 178:2,6,14,21  
 183:2 186:20 197:22  
 198:4 210:6 213:5,15  
 216:18 223:22 232:17  
 242:7 244:10 261:4  
 265:22 271:11,22  
 272:5 281:8  
**blank** 269:6  
**blend** 21:19  
**blind** 269:7  
**blinded** 56:18  
**block** 175:18  
**Blue** 1:19,19 69:9,9  
 232:20 257:5  
**Blueprint** 92:11  
**board** 2:5 25:16 80:16  
 180:15  
**Bob** 28:22 29:2 32:17  
 60:8 220:18 222:18  
 223:22 224:8 226:11  
 256:15 260:22 261:3  
**body** 169:1  
**bogus** 71:21  
**boils** 41:9  
**book** 133:20  
**books** 278:14 281:15  
**boom** 230:18,18,18,18  
**Booz** 2:2  
**born** 132:18  
**Boston** 2:1  
**bottom** 38:11  
**bounds** 64:8  
**box** 110:5

**boxes** 113:3 117:18  
124:1 156:2  
**boy** 147:21  
**Brahmajee** 37:15  
**branch** 258:21  
**branching** 130:13  
**Brandeis** 1:21 4:16  
11:9  
**Brandon** 1:22 27:14  
28:9 81:15 88:1  
125:10 130:11 139:2  
153:8 158:14 167:3  
198:20 206:11 218:2  
218:18 231:3 238:15  
241:19 243:7  
**Brandon's** 172:6  
219:14  
**bravery** 125:12  
**breadth** 151:1 154:14  
155:6  
**break** 81:12 95:2 102:6  
103:2 174:12,15  
175:5  
**breaking** 81:5  
**breaks** 103:17  
**breathe** 141:12  
**brief** 10:16  
**bring** 37:9 38:5,9  
101:14 128:16 136:20  
170:8 173:16 178:6  
217:3 263:14  
**bringing** 106:22 177:20  
263:7 264:3  
**broad** 29:13 37:3 57:4  
158:16 164:20  
**broader** 8:13  
**broadest** 150:4  
**broadly** 31:1 150:7  
178:16 185:4 256:7  
**brought** 40:21 54:9  
78:12 129:13 212:22  
265:9  
**Bs** 20:15  
**bucket** 215:6 216:7  
**buckets** 51:17 87:4  
**buff** 239:2  
**build** 7:4 8:1 15:9 16:4  
79:4 101:13 130:17  
210:6 225:1 259:10  
266:1  
**builder** 147:12  
**building** 130:11 139:13  
172:5,9,17 219:14  
**builds** 9:13 24:21 55:16  
177:22 201:3  
**built** 254:1  
**bullet** 209:12  
**bullets** 230:9

**bunch** 121:2 141:9  
161:3  
**bundle** 66:1 68:13  
112:17 117:13,16  
123:9 151:13 159:22  
**bundled** 155:13 204:13  
**burden** 192:21  
**burning** 27:13  
**BURSTIN** 2:7 18:14,17  
19:2 20:8,16,22 22:22  
83:4,7 101:4,21  
131:16 165:16  
**business** 142:5 262:7  
**busy** 15:14  
**buzz** 214:22  
**bypass** 218:15

### C

**C** 206:1,15 207:20,22  
226:10,10  
**C-** 240:20  
**C-1** 115:17  
**C-section-capable**  
241:1  
**caboodle** 133:13  
**CAHPS** 255:4  
**calculation** 31:22  
**California** 132:17  
**call** 16:7,12 26:18 28:20  
31:8 40:20 49:12 96:1  
99:3 155:16 157:13  
160:12 183:4 237:15  
239:1 240:7 278:1,14  
278:17 279:9,16,19  
280:10,19,22 282:8  
282:17,22 283:4  
**calling** 126:8 242:10  
**camp** 165:18,18  
**candidate** 147:13 149:1  
**candidates** 147:20  
**capabilities** 282:6  
**capable** 274:17  
**capacity** 101:12  
**capture** 11:15,17 99:14  
102:1 117:17 118:9  
188:7 192:2 246:17  
248:4 250:8,13  
265:11 267:4 268:15  
270:11  
**captured** 11:20,22  
27:16 170:10 264:16  
**captures** 138:22 178:22  
226:8,11 246:16  
260:9  
**capturing** 6:14 136:3  
177:19 270:3  
**card** 32:17 91:8,10  
196:21 249:12

**cardinal** 33:12  
**cardiologist** 231:10,22  
**Cardiology** 92:5  
**cards** 147:6 166:21  
180:17 211:7  
**care** 1:17 4:18 27:4  
35:21 36:10 37:3 39:8  
46:18 47:20 48:2,5,14  
48:19 49:14 55:6,7  
78:12,13 109:8 110:9  
110:10,11,12,14  
113:8 115:18,19,20  
128:5,7 129:2,3,5,7  
129:10 138:5 145:8  
151:7,11,17 155:12  
161:3,10,17 162:5,19  
163:9 164:7 166:13  
171:6 177:22 178:1  
181:12 182:1,5,5  
199:20,21 200:15,17  
200:22 201:9 212:5  
212:12 216:8 220:15  
222:2 231:11 232:1  
232:22 233:3 234:4,4  
244:3,7 266:20 268:5  
**care-seeking** 201:21  
**care/money/patients**  
72:8  
**cared** 233:7  
**careful** 32:11 76:22  
132:12 163:14  
**Carol** 100:20 251:17  
**carry** 192:20  
**case** 26:12 29:20 55:19  
78:11 107:8 109:4,6  
109:22 110:6 116:16  
116:22 118:4 124:2  
127:17 129:1 130:17  
132:11,13,14 135:11  
136:15 138:6 149:21  
150:15 156:5,16  
157:12 162:1,3  
163:11,17 164:2  
165:7 172:7 190:1  
202:10,11 217:7  
242:10 272:18 277:13  
283:9,13  
**cases** 13:2 26:2 42:16  
42:17 47:9 77:17 78:3  
78:15 79:1,10,14  
107:14 108:22 109:7  
112:13 121:13 126:17  
128:21 133:5 149:10  
150:4,22 152:19  
157:13 158:8 162:16  
168:10 180:11 199:4  
210:21 212:2 219:6  
265:13,14 277:8

**cast** 208:11  
**catalog** 12:2  
**cataract** 212:1  
**catch** 30:12  
**categories** 80:19 110:7  
**categorization** 21:15  
**categorize** 128:18  
**caveat** 97:11 228:18  
247:10  
**caveats** 82:16 266:8  
**cells** 118:12,19 120:3  
**center** 1:13 2:14,15  
225:16  
**centered** 165:21  
**central** 47:3,3 170:6  
187:2  
**Cerner** 2:5  
**certain** 46:12,19 59:14  
61:14 78:14,15 79:9  
79:13 88:6 99:1,14  
112:9 140:20 157:2  
196:17 202:11 222:7  
225:17 255:4  
**certainly** 15:9,19 16:11  
21:8 35:1,4 53:1  
60:20 131:22 143:22  
152:18 225:12 237:20  
272:7  
**cessation** 119:6 122:4  
139:18 168:1  
**cetera** 23:3 110:8  
116:14 128:6 142:1  
142:11 176:20 213:13  
213:18 215:22 219:18  
239:1 270:13  
**Chair** 1:9,11 4:12 5:2  
8:16,21 9:5,15,17  
10:17,19 12:4,9 14:19  
15:11,16 17:2 18:3  
19:9 20:4,9,12 22:8  
23:6 28:8,21 29:3,18  
30:18 31:11 32:10  
33:13 34:11 39:17  
40:8 41:1 50:10 51:4  
52:19 53:19 54:5  
55:15 57:19 58:12,16  
58:20 59:9,12,18,21  
62:18 64:13 65:17  
66:13,16 69:12 71:8  
73:14 75:6 76:1,9,20  
78:6 79:15 80:15,22  
81:6,9 82:15 85:3  
87:21 89:10 90:13  
91:3,12 93:4 94:20  
98:12 100:5 101:15  
101:22 102:21 103:6  
103:15 105:6 106:10  
106:21 107:15 110:2



- 116:17 119:15 120:17  
122:16 123:1,13  
125:2 127:1 128:12  
130:5 131:10 132:2  
134:7 137:3 139:9  
140:21 142:16 144:20  
146:15 148:1,11,13  
152:16 155:7,22  
157:8 158:20 159:4  
160:15 162:9 163:13  
165:14 166:20 170:12  
171:16,19 173:19  
174:10,16,22 175:4  
175:13 177:10,13  
178:8,19 179:13  
180:16 181:5,15  
182:10,14 183:8,16  
185:11 186:8,16  
188:10 189:22 190:7  
190:14 191:5,20  
193:1,20 194:20  
195:5 196:20 197:8  
197:16 198:18 201:2  
205:13 207:19 208:18  
210:5 212:8 213:22  
216:9,17 217:19  
218:1,17 219:8  
220:17,21 222:16  
223:19 225:21 227:3  
228:14 231:2 235:1  
236:2 237:1 238:2  
239:12,19 241:15  
242:19 243:5 244:14  
246:4,11 247:5,16  
248:5,17 249:11  
250:5 251:12 252:8  
252:21 253:22 255:11  
256:13 257:21 258:18  
260:1,20,22 261:9,11  
262:4,7,11,18 263:1,6  
263:13,20 264:4,10  
265:8 267:12 270:7  
270:20 271:1,3 272:9  
272:13,20 273:3,20  
274:9,12 280:6,9  
281:9 282:3,13 283:1  
283:6  
**challenge** 26:5 33:22  
106:15 210:9 227:7  
272:2 281:18  
**challenged** 273:8  
**challenges** 68:19 98:20  
119:19 131:1 146:13  
**challenging** 84:20  
106:13 125:18 146:4  
**chambers** 142:5  
**CHAN** 2:14  
**chance** 5:13 18:1  
170:17  
**change** 54:14 63:17  
70:7 84:17,17 96:15  
96:16,17 104:18  
140:5 145:9 176:20  
222:7 223:11 225:10  
225:11 239:16 243:13  
247:2 248:10,15  
249:6,9,16 250:5  
264:19  
**changed** 216:3  
**changes** 25:17 178:11  
245:14 249:15 250:3  
264:12 278:10 279:3  
**changing** 148:5 234:20  
260:11  
**chapter** 133:21  
**characteristics** 86:19  
124:14 153:16 163:6  
**characterize** 126:16  
**charge** 69:22 233:5  
263:1  
**Charles** 1:15 246:7  
260:10 264:10  
**chart** 166:4 168:11  
**check** 81:2 158:20  
204:4,5,13 264:5  
**checked** 252:13  
**checklist** 135:2,6,8,11  
135:21 219:13 276:21  
**checklists** 136:22  
**checkoff** 280:5  
**cherry** 31:9  
**Chief** 2:7  
**choice** 62:14 109:3  
113:22 120:4 136:14  
136:18 141:20 202:5  
238:11  
**choices** 117:1 130:18  
131:2  
**choose** 83:2 90:21  
102:11 119:3,21  
121:16 122:12 134:9  
141:16 153:11,15  
154:5 155:19 167:19  
194:17 255:14  
**choosing** 82:19 94:8  
161:3  
**chose** 25:2 118:10  
153:22  
**chosen** 177:14  
**chronic** 128:4 162:5  
166:11 167:15,19  
230:19  
**chronically** 155:14  
169:5  
**circles** 265:22  
**circling** 202:9  
**circulated** 45:9  
**circumstances** 36:19  
38:22 39:1 44:4 48:18  
169:19,22 180:8,14  
**cite** 120:13  
**cited** 38:4 59:2  
**citing** 38:3  
**city** 267:19  
**CJR** 121:19  
**CJR-type** 122:6  
**claim** 199:14  
**claim-based** 251:20  
252:4  
**claims** 62:7 82:11 88:9  
181:17 256:19 257:14  
265:4,4  
**claims-based** 25:21  
41:6 250:17 252:18  
270:9  
**clarification** 177:3  
**clarify** 8:17 12:4 57:20  
183:4 197:11 259:15  
**clarifying** 30:10 223:15  
**clarity** 136:15  
**classic** 162:17  
**classification** 87:17  
**classified** 75:12  
**classify** 108:6  
**clause** 246:12  
**clean** 268:17 271:10  
279:18  
**clear** 14:19 22:2 28:5  
30:21 32:22 36:15  
84:10 92:14 152:13  
203:20 211:13 232:13  
**clear-cut** 65:8,11 237:4  
**clearly** 36:11 98:4  
137:21 138:6,13,14  
139:1,8 197:11 201:6  
230:4 278:3,6  
**client** 68:11  
**clients** 68:4  
**clinic** 96:19 161:7  
**clinical** 2:14 11:8 38:22  
127:17 169:19,21  
170:9  
**clinically** 179:10  
**clinician** 26:7 30:21  
96:2 163:10 210:11  
212:13 214:18 216:12  
223:14 224:22 226:15  
272:4  
**clinicians** 160:21 183:9  
215:17 221:8  
**close** 54:2 260:14  
**closer** 264:13  
**cluster** 43:2 75:15  
76:11 86:15 102:12  
102:14  
**clustering** 120:9  
**clusters** 43:6 77:11  
**CMMI** 131:20  
**CMS** 11:10 13:3 45:20  
150:5,8 152:19 178:4  
209:18 221:11 224:18  
277:9  
**CMS'** 92:11  
**CNS** 213:13  
**coalesced** 43:3 227:9  
**codes** 115:19,20 118:5  
118:7  
**cohesion** 61:14  
**collaboratives** 205:4  
**colleague** 11:8 54:9  
**collect** 90:19  
**collected** 59:2  
**collection** 19:18 118:21  
**collective** 113:11  
**collectively** 113:12  
**College** 92:4  
**colonoscopy** 200:19  
**column** 112:15 115:20  
119:19 137:14 138:1  
138:2 154:5,6,7  
161:12  
**columns** 111:3 133:16  
136:18 149:8 153:11  
153:22 154:5 155:10  
155:17 157:4 169:18  
**combination** 38:19  
40:4 58:20 76:6 118:8  
121:13,16 123:8  
253:19  
**combinations** 75:20  
79:7,14 269:10  
**combine** 64:7  
**combined** 247:22  
**combines** 190:7  
**combining** 260:2  
**come** 6:7,17 7:18 8:9  
23:12 25:16 34:18  
59:13 67:4 70:14 74:4  
74:10 75:20 90:8,12  
96:6 103:3 147:19  
162:5 169:11 174:22  
175:5 184:18 198:11  
221:10 225:15 233:9  
241:21 242:9,17,20  
254:18 256:15 262:3  
262:5 263:11 268:6  
270:3,12 273:21  
**comes** 36:4 76:11  
209:18 224:15 239:18  
**comfortable** 13:8 14:10  
146:5  
**coming** 22:7 51:9 54:8

65:6 80:16 81:4 96:22  
 98:22 226:6 230:2  
**comment** 3:12 6:7 7:19  
 8:2,18 9:4,8,10 10:5  
 15:4 16:17,17 43:11  
 66:17 71:16 73:19  
 74:6 79:16 81:3 83:17  
 84:7,22 91:14 95:1  
 96:21 104:14 105:14  
 131:11 136:8 156:20  
 158:12 164:1 169:16  
 174:15,20 175:1,3,15  
 175:16 195:7 198:13  
 199:1 209:9 211:4,9  
 212:22 213:3 214:20  
 224:17 225:4 231:5  
 236:9 238:17 254:7  
 256:16 274:22 275:2  
 276:7 278:3 279:7,21  
 281:10,14  
**commentary** 79:1  
**comments** 16:1,6,18,19  
 35:1 50:20 51:1 66:19  
 66:19 74:9,20,21  
 105:8,21 107:6,12  
 117:6 125:21 130:9  
 130:11 160:17 170:22  
 172:6,6,10,17,20  
 174:19 206:7 238:22  
 275:5,16  
**commerce** 142:5  
**commercial** 100:9  
**commission** 276:3  
**commission's** 275:22  
**commissioned** 5:9  
**commitment** 171:8  
**committed** 235:21  
**committee** 1:3,8,11  
 4:13 7:4 15:10,18  
 24:3 33:11 45:9 50:19  
 67:18 88:22 118:16  
 177:18 209:14 256:3  
 275:22 276:12 280:4  
**Committee's** 9:11  
 49:12  
**common** 42:6,15,22  
 43:6,18 46:12 76:6  
 78:22 79:1 146:6  
**commonalities** 57:7  
 100:2  
**commonality** 66:21  
**commonly** 269:4  
**commons** 244:6  
**communicate** 15:21  
 55:5 196:1  
**communicated** 142:14  
**community** 142:6  
**community-based**

83:22  
**comorbidities** 162:18  
**compact** 267:2  
**comparable** 264:22  
**compare** 93:21 94:5  
 96:12  
**compared** 41:16 42:2  
 196:13  
**comparing** 94:3 147:1  
 150:17  
**comparison** 146:18  
**compelling** 146:17  
 152:21  
**complain** 85:20  
**complained** 82:5  
**complaint** 81:22  
**complaints** 82:2,21  
 83:8  
**completed** 81:21  
**completely** 78:8 236:6  
**complex** 70:5 273:16  
**complexity** 8:12 164:21  
 273:17  
**complication** 111:20  
**complications** 111:19  
 114:8 133:9  
**components** 31:6  
**concept** 24:20 27:16  
 115:14 143:18 183:20  
 187:13 206:17 209:13  
 209:15 234:15 261:6  
 261:14 263:16 264:15  
 272:10  
**concepts** 160:6 208:19  
 262:14  
**conceptual** 255:13  
**conceptually** 43:22  
 87:7,18 124:7,21  
**concern** 11:2 81:18  
 142:18 235:10 253:1  
**concerns** 104:20  
**conclusion** 67:11 68:17  
 98:7 273:22  
**conclusions** 98:15  
**concrete** 12:18 17:7  
 19:12 40:9 93:13  
 104:5 116:20,21  
 120:22 123:18 125:7  
 149:7,9,13 150:21  
 156:5 158:9 167:9  
 172:2 207:22  
**concretely** 147:3 270:2  
**condense** 126:2  
**condensed** 40:17  
**conditions** 117:22  
 143:17 166:11 167:19  
**conducted** 276:2  
**confer** 150:2

**conference** 1:8 16:7  
**confidence** 19:22  
**confirm** 148:19  
**confirming** 57:13  
**conflict** 34:4  
**conflicted** 233:17  
**conflicting** 279:3,13  
**conflicts** 34:9  
**confusing** 154:4 158:5  
 213:5,15,19  
**confusion** 31:2 54:7  
**Congress** 258:22  
**connected** 242:5  
**conscious** 209:3 271:4  
**consciously** 32:4  
**consensus** 21:19 22:4  
 92:5 282:17 283:21  
**consequence** 237:16  
 237:18 240:19  
**consequences** 25:4  
 31:12,17 95:22  
 236:15,17,18 237:2,8  
 237:9,13 238:11  
 239:11 240:8,16,18  
 243:10  
**consider** 13:1 24:14,18  
 25:3,10 31:6 32:14  
 79:9 84:12 115:3  
 141:10 149:21 151:2  
 187:10,11 205:15,19  
 227:15 260:8 261:7  
 261:21  
**considerably** 43:21  
**consideration** 221:2  
 236:18 237:5  
**considerations** 13:20  
 14:3 62:13 79:3,13  
 105:22 106:3,8,20  
 107:13 121:16 122:12  
 123:9 155:6 208:8  
 227:22  
**considered** 25:21 36:18  
 208:9,11,13 253:17  
**considering** 48:6 135:5  
 206:20 225:9  
**consistency** 21:10  
 26:10 58:3 264:17  
 272:16 273:14  
**consistent** 13:7 33:19  
 35:13 70:16 137:11  
 138:21 224:2 264:20  
 265:6,20 274:10  
**consistently** 27:19  
**consolidate** 135:20  
**consolidated** 205:10  
**consolidating** 172:20  
**consolidation** 148:8  
**constant** 145:17

**Constitution** 239:3  
**construction** 54:1  
**consulted** 263:3  
**consulting** 232:20  
**consumption** 8:8,14  
**content** 283:12  
**CONTENTS** 3:1  
**context** 4:19 26:22 27:2  
 47:16 101:9 125:6  
 157:16 170:11 180:4  
 181:22 207:4 233:11  
 233:19 241:18 262:2  
**contextual** 71:3  
**continue** 81:11 190:16  
 191:6 275:11  
**continuous** 16:22  
**contract** 69:9  
**contracts** 131:21  
 222:10  
**contradicting** 184:11  
 184:17  
**contrast** 47:3  
**contribute** 259:6,7  
 261:19  
**contributed** 213:20  
 284:7  
**contributes** 259:10  
**contribution** 74:10 75:3  
 137:1 235:15  
**contributions** 4:5  
**control** 27:6 55:2,4 56:3  
 141:17 217:3,18  
 222:7,14 225:6  
 226:17 229:13  
**controversial** 146:3  
**controversy** 24:3 63:11  
**convene** 275:21 277:10  
 278:1  
**converge** 125:16  
**conversation** 17:4  
 26:17 27:11 34:14  
 55:17 66:7,20 78:9  
 81:11 105:10 107:17  
 130:12 131:17,22  
 139:20 142:17 167:5  
 176:4 187:1 191:21  
 198:14 218:11 229:10  
 249:10  
**conversations** 89:1  
 108:14 172:12 228:11  
**convey** 231:7  
**convinced** 73:20  
**coordination** 182:2  
**copied** 77:6  
**copies** 100:4  
**copy** 20:14  
**CORE** 1:13  
**Corporation** 2:5

**correct** 71:7 120:15  
170:21 188:6 259:6  
262:22  
**corrected** 257:3  
**correctly** 134:15 168:17  
**correlation** 146:18  
**cost** 48:20 49:21,22  
63:13,18 69:5,10,21  
127:15,17 167:21  
168:3,5 187:21 188:3  
190:2 206:22 222:8  
**costs** 115:15 190:20  
**count** 92:18  
**county** 25:8 112:9,11  
119:1 132:17,19  
139:18  
**couple** 6:17 10:13  
28:13 29:21 30:3  
33:21 57:16 71:19  
85:7 87:8 109:5 113:5  
113:6 115:5 118:13  
118:19 124:16 127:7  
129:2 153:18 157:18  
162:16 166:13 170:17  
172:14 195:18 199:4  
222:21 229:6 237:11  
238:17 256:14 260:2  
266:9  
**course** 15:13 20:8 55:2  
65:17 84:16 97:10  
159:9  
**cover** 158:16 169:20  
**covering** 239:10  
**covers** 242:4  
**cowboys** 74:13  
**CPA** 2:2  
**CPT** 118:5,7  
**crazy** 252:11  
**create** 19:20 31:17  
86:18 87:1 194:4  
240:11  
**created** 153:5  
**creates** 253:10  
**credibility** 56:16  
**creep** 89:19  
**crime** 235:20  
**criteria** 27:5,5 37:5  
42:13 50:4 72:5,18  
74:3 91:16,19,22 93:2  
93:18,21 94:2 102:10  
102:11 104:3 108:10  
122:20 127:14 135:2  
135:17 140:6 143:4,5  
144:5,11,15,19 147:5  
147:17 148:7,17,22  
150:12 158:9 160:14  
172:18 173:8,10,12  
173:12 191:12 192:15

197:9 229:22 230:17  
240:21 276:16,17,19  
276:19 277:7,14  
283:9,14  
**critical** 50:6 99:19  
141:7 273:4  
**Cross** 1:19 69:9  
**cross-section** 169:9  
**cross-sectional** 169:10  
**Cross/Blue** 232:20  
257:5  
**crucial** 42:19 45:13  
**crux** 202:13  
**curious** 119:11 143:8  
210:17  
**current** 11:12 12:2,12  
26:5 29:13 56:18  
104:17 210:9 223:11  
223:11,12 253:2  
269:1 272:2  
**currently** 37:12 38:7,15  
38:15 58:3 71:17  
166:17 196:4 212:17  
252:17 278:14  
**cut** 119:17 187:1 198:8  
222:18 227:4 256:13  
**cutoff** 40:11  
**cutting** 100:22 192:20  
219:11

## D

**D** 206:1,15 207:20,22  
226:10,10  
**D.C** 1:9  
**Dan** 2:15 13:11 14:18  
129:16 149:11 172:13  
209:4 254:9  
**dance** 131:13,16  
**Daniel** 220:21  
**Danielle** 1:18 17:8 56:5  
57:19 59:12,13 60:17  
77:22 101:1 110:2  
116:17 153:5 159:8  
185:13 188:13,20  
195:11 201:4,10  
231:3 262:19 266:16  
**Danielle's** 74:8 168:11  
200:5  
**dark** 124:1  
**Darn** 175:4  
**Dartmouth** 41:18  
**data** 25:16 43:1 67:20  
81:17 82:14 87:5,18  
92:18 100:16 115:6,9  
115:9,11 124:6,12  
126:6 133:21 134:3  
136:16 139:2 146:10  
208:14 219:1 221:11

239:9 245:13 246:14  
246:15 248:12,18  
253:18 254:14,14  
255:21,21 256:6,7,19  
257:14 260:5 265:4,4  
265:12 267:5,16  
268:3,10,12 270:1,13  
271:18,18  
**data-driven** 86:16  
**dates** 281:20  
**day** 3:2,2 4:4,7 7:10  
92:8 156:7 213:12  
252:12,15 254:22  
261:6 263:16 269:12  
277:12,13 280:20  
**days** 6:3,18 20:19 55:20  
56:1 262:15 266:2  
273:7 280:15,17,20  
284:8,10  
**deal** 25:11 95:14 105:10  
112:19 182:18  
**dealing** 84:5 131:9  
205:2  
**dealt** 216:1  
**debate** 184:21 236:1  
250:15,20 271:17  
**decade-long** 96:5  
**decent** 194:16  
**decide** 95:3,12 116:6  
157:14 159:11 206:8  
215:20  
**decided** 243:22 266:10  
**deciding** 42:17 254:15  
271:19  
**decision** 113:3 120:12  
269:13  
**decisions** 123:20  
230:11  
**declaration** 266:2  
**declaring** 236:22  
**decrease** 118:22  
126:19 148:6  
**deep** 3:5 14:16 45:16  
52:17  
**deeper** 90:7 107:13  
142:14  
**defer** 122:8  
**define** 52:11 66:5 101:6  
148:22 183:4 253:7  
**defined** 30:8,17 38:20  
41:4 48:21 91:17  
138:17 253:11  
**definitely** 10:3,6,10  
127:5  
**definition** 29:13 30:10  
92:14 197:15 209:16  
**definitions** 29:11 179:4  
**degree** 22:6 82:18

188:5 201:15  
**deliberations** 33:10  
**delighted** 131:21  
**deliver** 129:10  
**delivered** 84:16  
**delivering** 212:5  
**delivery** 27:4 181:13  
235:12  
**denominators** 127:13  
197:4  
**dense** 8:11  
**Department** 1:15  
**dependent** 225:2  
**depending** 109:3  
113:22 150:14 151:3  
152:1,8 159:21  
**depends** 71:3 101:5  
112:6 116:8 183:21  
218:12  
**derived** 63:20  
**describe** 38:14 55:13  
136:12 141:3 157:14  
166:5 195:11 270:15  
**described** 14:18 28:14  
102:17 121:7 136:22  
149:2 229:5  
**describing** 89:17  
**description** 64:10  
**deserve** 49:17  
**deserves** 223:6  
**design** 24:7 31:10 66:9  
68:1 187:4 207:13  
**designate** 161:19  
**designation** 256:18,19  
**designing** 14:5 147:12  
147:13  
**desirable** 37:6 217:7  
252:5  
**desire** 17:6,6 26:6  
172:1 210:10 223:13  
**detail** 15:8 53:12  
123:19 170:8  
**detailed** 13:7  
**details** 124:15,17 126:5  
**determination** 42:18  
116:11 138:19  
**determine** 261:16  
**determining** 3:9 227:17  
**develop** 87:6 102:9  
173:11  
**developed** 44:15  
192:18,19  
**developer** 211:20  
**developers** 7:22  
**developing** 4:22 11:6  
85:8 156:9,9 204:22  
204:22  
**development** 283:22

**devote** 125:19  
**diabetes** 55:2 244:3  
**diabetic** 54:20 55:4  
 269:7  
**diagram** 130:12  
**dialog** 160:20  
**differ** 111:20 150:18  
**difference** 39:19 73:12  
 96:13 98:17 122:5  
 133:2 151:22  
**differences** 86:5 111:1  
 111:14 115:10 207:9  
 207:10  
**different** 13:2 26:20  
 27:17 36:19 37:2  
 38:12,14,19 40:4,13  
 42:21 43:7 44:1,4  
 45:10,11 47:8 48:17  
 48:18 50:11,17 54:18  
 63:16,19,21 64:1  
 66:10,11 68:6 69:15  
 73:2,5,6,9 75:4 76:3  
 76:17 80:17 84:5,18  
 86:22 87:8 93:19,20  
 94:5 95:10 97:2,9,20  
 98:17 104:4 108:22  
 109:2,3 110:6 113:3  
 113:20 120:5 122:12  
 126:12,14 127:18,21  
 130:17 146:9,20  
 149:4 150:17 151:5  
 152:1,7 153:17,18,22  
 154:1,2,5 155:11  
 157:4 158:9 160:5,8  
 169:21,21 179:9  
 183:5 193:17 195:18  
 200:21 202:18 205:17  
 208:7 216:7 228:20  
 228:20 232:2 238:20  
 255:19 259:21 262:21  
 278:7  
**differentially** 37:2  
**differently** 76:2 96:8  
 140:8 232:18  
**difficult** 32:8 71:13  
 214:2 243:19  
**difficulties** 105:5  
**difficultly** 39:18  
**difficulty** 43:5  
**digested** 10:9  
**dimension** 49:13 66:6,9  
 166:4 171:2  
**dimensional** 125:13  
**dimensions** 36:22 37:1  
 38:21 154:12  
**dinner** 263:21  
**dinners** 263:21  
**diplomatic** 240:10

241:14  
**direct** 203:1 243:11  
**direction** 17:12 91:18  
 120:20 125:22 128:11  
**directions** 126:21  
 153:18 155:5  
**directly** 256:17  
**Director** 2:10,10  
**disadvantages** 120:12  
**disagree** 179:22 208:22  
 219:22 266:11  
**disagreement** 220:3  
**disagreements** 250:9  
**disagrees** 245:9  
**disappears** 162:4,19  
**disarray** 234:14  
**discerning** 53:9  
**discharging** 207:7  
**disclosure** 4:21 95:12  
**disclosures** 4:14  
**disconnect** 143:4,11  
**discourse** 149:17,18  
**discrete** 38:18  
**discretely** 270:2  
**discuss** 11:21 23:10  
 24:2 26:2 31:2 42:11  
 43:22 50:7 53:1 71:17  
 127:21 133:7 157:21  
 158:9,22 275:16  
**discussed** 8:5 12:15  
 17:7 55:19 108:4,18  
 109:16 145:16 148:5  
 214:2 234:19  
**discussing** 25:7 159:15  
 172:3  
**discussion** 4:7 6:13,20  
 7:3 9:12 12:11,12  
 18:10,15 23:21 35:3  
 35:16 43:13 50:8,20  
 68:20 94:15 149:22  
 165:17 172:14 173:18  
 235:5 263:19 269:22  
 275:12 277:15 281:19  
 283:10  
**discussions** 6:3,10 7:9  
 35:6 71:2 108:7  
 177:18  
**disease** 128:4 230:20  
**disentangle** 122:11  
**dispersed** 231:16  
**disquieted** 22:17  
**distill** 8:13  
**distinction** 75:10  
 176:10  
**distinctions** 159:20  
 160:8  
**distinguish** 261:22  
**distracted** 132:10

**distracts** 134:11  
**distribute** 172:15 220:7  
 220:10  
**distribution** 221:15  
**dive** 3:5 14:16 107:13  
 142:14  
**diving** 228:5  
**doc** 65:4 99:11,11  
 100:19 116:13 165:3  
 165:8 211:1 213:16  
 240:21  
**docs** 95:9 116:14  
**doctor** 55:6 70:1 84:17  
 211:15 234:4 241:1  
 257:13  
**doctors** 68:12 128:5  
**document** 142:1 179:7  
 234:20 240:3 270:16  
**documenting** 102:8  
**documents** 92:12  
**dodge** 71:4  
**doing** 4:19 5:11 10:1,7  
 11:9 28:12 36:13  
 51:20 76:16 89:4  
 101:8 108:11,11  
 113:9,13,14,17 116:9  
 120:18 137:9 140:19  
 146:13 150:11 154:9  
 156:13 165:4 211:20  
 219:15 221:22 229:21  
 246:21,22 247:4  
 249:8 252:17 255:7  
 280:3  
**domain** 223:4  
**Donna** 2:8 274:19  
 276:11  
**double** 206:16  
**doubt** 74:9  
**dovetail** 78:8  
**downstream** 55:12  
**Dr** 4:3 5:12 12:10 14:7  
 18:8,14,17 19:2 20:8  
 20:16,22 22:22 34:22  
 36:8 40:2,16 41:2  
 52:10,22 56:9 59:5  
 60:17 61:3,12,16  
 62:17 63:15 65:13  
 68:22 69:16 70:2,9,12  
 73:1 81:5 83:4,7  
 87:10 89:22 90:5  
 96:21 101:4,21  
 131:16 143:14 145:10  
 148:10,12,14 154:15  
 160:11 165:16 169:16  
 173:6 196:12,15  
 223:17 245:21 264:7  
 267:18,18,20 274:13  
 274:18 276:11 283:7

**draft** 3:16 5:6 6:1 15:22  
 17:21 19:19 30:7,15  
 33:2 176:2  
**drafted** 276:3  
**drafting** 276:8  
**draw** 22:14 98:2 160:7  
**drill** 131:3 235:8  
**drilling** 124:22  
**drive** 22:13 23:18 26:4  
 35:17 36:11 47:16  
 54:14 55:2 56:2 67:20  
 121:14 124:17 176:22  
 183:13 185:19 186:11  
 210:8 223:9 233:22  
 272:1  
**driven** 21:14 124:6  
 156:22  
**drives** 157:3,4 192:12  
**driving** 94:17 155:17  
 180:7 182:20 186:9  
 190:20  
**drop** 176:20 236:6  
**dropping** 129:4  
**DRYE** 1:13 9:19 10:4  
 33:21 91:9,13 94:9  
 137:4 140:7 167:2  
 211:11 229:9 232:14  
 245:17 258:17,19  
**dynamic** 248:12

---

**E**


---

**E&M** 118:5  
**E&Ms** 115:16,16  
**earlier** 54:9 71:15 79:17  
 106:1 155:9 176:3  
 184:6,8,14 187:20  
 198:14 215:4 230:1  
**early** 92:2 177:18,18  
 187:2  
**easier** 18:21 103:4  
 109:18 140:13  
**easily** 62:8 133:11  
**easy** 74:1 85:11 109:18  
 114:2 133:22 137:8  
 182:12 226:14 245:10  
**echo** 125:20  
**economic** 32:3  
**economist/health** 5:14  
**ED** 182:3  
**edge** 192:20  
**editing** 32:21 280:3  
**education** 95:11  
**educator** 244:3  
**effect** 102:16 235:11  
 243:12  
**effective** 78:16 79:2  
**effects** 49:10 145:17  
**effort** 57:4 168:2

<b>efforts</b> 68:6,7 257:6	<b>emphasizes</b> 82:16	<b>episodes</b> 4:18	<b>everybody's</b> 59:4 130:9
<b>EHR</b> 270:13,18	<b>empirical</b> 144:21 149:3	<b>episodic</b> 13:22 48:19	<b>everyone's</b> 15:14,21
<b>EHRs</b> 100:13 255:1	150:12,16 152:5,10	57:10 80:20	16:6 32:2 281:15
<b>eight</b> 38:21 132:19	173:15 195:12	<b>equal</b> 184:10,14	283:11
271:6	<b>empirically</b> 87:6,6	<b>equals</b> 184:10,12	<b>evidence</b> 19:13,17,18
<b>either</b> 32:3 38:13 54:2	142:22	<b>equated</b> 270:9	21:2,6,10,14,20,21
65:11 82:7 109:19	<b>empirics</b> 94:3	<b>equitable</b> 193:10,15	22:3,16 23:3 69:3,8
114:3 119:1 148:8	<b>employed</b> 122:7	215:2	70:13,20 71:5 82:14
151:20,20 152:4	<b>employers</b> 165:22	<b>equity</b> 221:4 225:7	98:2 194:15
154:18 155:4 159:15	<b>EMR</b> 82:11	227:22 273:18	<b>evidence-based</b> 21:16
168:11 187:17 196:6	<b>encompass</b> 178:5	<b>ER</b> 169:5 241:3,4	<b>evil</b> 238:8
229:12 236:13 248:2	<b>encounter</b> 182:8	<b>Erin</b> 2:10 188:7,11	<b>evolve</b> 25:18 245:13,20
252:3 278:18,22	<b>encounters</b> 119:9	<b>error</b> 63:6,22 66:6	245:22 246:1 247:12
279:11	<b>Encourage</b> 50:14	70:18 85:8,10 88:4,13	<b>evolves</b> 270:21
<b>either/or</b> 165:17 166:3	<b>ended</b> 129:2 202:8,9	164:13 235:5 242:1,3	<b>evolving</b> 248:19 260:6
173:22	<b>endocrinologist</b> 55:6	242:9	<b>exact</b> 63:3 72:19 242:1
<b>elaborated</b> 208:6	111:8,9 231:10,21	<b>errors</b> 63:4	<b>exactly</b> 7:15 34:14
<b>electronic</b> 19:3	244:2	<b>especially</b> 63:12 80:16	40:16 93:16 122:2
<b>element</b> 40:10 139:6	<b>endorsement</b> 283:22	82:22 132:7 196:11	128:20 151:4 187:17
177:6	<b>ends</b> 54:22 190:21	219:17 222:8 281:2	194:11 213:16 216:4
<b>elements</b> 7:3,11 26:20	<b>energy</b> 94:21 95:5	<b>essence</b> 76:10	226:13 248:4 271:1
27:7 38:19 40:4,10,13	284:7	<b>essential</b> 24:6 35:17	272:14
40:20 41:4 42:21,22	<b>enforced</b> 44:3	<b>essentially</b> 12:17 82:9	<b>example</b> 39:14 48:11
43:7 52:13 75:11,12	<b>engaging</b> 5:19	92:6 267:8	54:20 55:9 58:1 66:12
75:16,17,20,22 76:4,7	<b>engineered</b> 63:3	<b>establish</b> 200:1	68:3 93:7,13 106:4
173:15 274:19 276:12	<b>ENM</b> 181:18 213:10	<b>established</b> 43:15	110:1,15 111:5,7
276:20 277:22 281:5	<b>enshrined</b> 257:10	70:15 112:2	114:6 117:16,21
<b>elevates</b> 180:9	<b>ensure</b> 24:9 187:5	<b>estimate</b> 64:7 66:6	118:20 127:12 133:21
<b>eligibility</b> 27:4,5	273:18	<b>estimates</b> 63:2,4,4,18	134:8,9 154:6,7,8
<b>eligible</b> 112:3 116:4	<b>enter</b> 66:4	64:5	157:21 158:3 174:4
137:15 138:12,13	<b>entered</b> 267:8	<b>et</b> 23:3 110:8 116:14	182:3 200:5 201:3
145:12,13	<b>enterprises</b> 63:14	128:5 142:1,11	203:13 208:7 226:7
<b>ELISA</b> 2:9	97:10	176:20 213:13,18	231:8 232:18,19
<b>Elizabeth</b> 1:13 9:18	<b>enthusiasm</b> 148:3	215:21 219:18 239:1	258:16 259:19 266:1
25:6 33:20 54:8 91:7	219:10	270:13	<b>examples</b> 13:19 108:22
95:7 102:10 112:8	<b>enthusiastic</b> 172:4	<b>etcetera</b> 82:3	113:1,6 115:13
134:14 136:5 137:3	174:3	<b>evaluate</b> 94:11 99:6	116:15 123:4,18
147:7 166:22 167:1	<b>entire</b> 136:17 151:6	142:22 146:1 160:13	125:1 135:10 136:14
176:13,13 198:21	<b>entirely</b> 202:17 203:6	207:14 211:22	138:4 149:14 153:12
208:4 211:8 229:8	208:20	<b>evaluated</b> 138:22	154:1 159:11 160:13
231:5 238:19 245:16	<b>entirety</b> 217:16	196:13	166:14 188:14 201:6
249:14 258:18 276:22	<b>entities</b> 205:4	<b>evaluating</b> 100:17	241:9 250:21
<b>Elizabeth's</b> 143:14	<b>entity</b> 119:21 207:1	<b>evaluation</b> 1:13 7:6	<b>Excel</b> 117:21
172:6	209:19 210:15 221:21	21:8,9 51:21 52:8	<b>excellent</b> 66:12 191:12
<b>Elliott</b> 75:2	222:1	80:5	284:9
<b>else's</b> 74:9	<b>environment</b> 276:1	<b>evaluations</b> 144:22	<b>exception</b> 163:15
<b>elusive</b> 166:3	<b>environmental</b> 3:5 7:2	<b>evaluative</b> 91:19	<b>exceptions</b> 164:10
<b>email</b> 16:14	7:14 11:1,15 12:1	<b>evening</b> 33:1	166:8
<b>emailed</b> 170:21	15:1 26:21 37:11	<b>event</b> 48:22 67:10	<b>exciting</b> 4:6 22:10
<b>emailing</b> 100:3	80:13 121:10 276:3	153:20 154:22 167:6	<b>exclusion</b> 237:22
<b>emerged</b> 107:18	<b>environments</b> 78:1	167:6	<b>exclusions</b> 112:5,14,18
<b>emerging</b> 80:10	<b>envision</b> 78:21	<b>events</b> 170:9	116:1 118:1 127:10
<b>Emory</b> 2:4	<b>envisioning</b> 134:20	<b>eventually</b> 165:5	138:16 168:12
<b>emphasis</b> 110:14	157:11	234:16	<b>exclusive</b> 48:15 49:19
<b>emphasize</b> 24:5 25:19	<b>episode</b> 122:6 152:2	<b>everybody</b> 4:4 74:8	<b>exclusivity</b> 39:4 47:15
26:22 33:16 136:13	153:20 154:22 155:12	190:22 198:3 211:7	48:8,12 54:6
228:17 252:22	167:7,14	231:17 232:13 233:22	<b>executive</b> 258:21
<b>emphasized</b> 71:16	<b>episode-based</b> 49:21	259:8 269:18	<b>exercise</b> 131:8 147:1

**exist** 270:5  
**existing** 33:5 43:19  
 61:5 71:5 97:6 206:21  
**expand** 88:1,8 117:8  
**expanded** 92:19 115:15  
 115:16 179:7  
**expect** 20:2 266:7  
**expectation** 67:3  
**expected** 22:7  
**expecting** 6:5  
**experience** 68:4 93:7  
 190:6,10  
**experiment** 96:5  
**experimentation** 67:1  
**expert** 131:19  
**expertise** 98:3  
**experts** 141:11  
**explain** 212:10  
**explaining** 10:13  
 157:15  
**explains** 132:8 241:17  
**explanation** 127:9  
 229:4  
**explanatory** 133:21  
**explicit** 92:14  
**explicitly** 128:4 208:9  
**explore** 147:5 153:14  
 166:18  
**express** 243:18  
**extant** 43:8 53:2  
**extended** 171:7  
**extending** 45:16,18  
**extent** 33:9 65:22 70:13  
 171:11 185:1 202:10  
**external** 35:5  
**extract** 283:15  
**extreme** 168:10 252:13

## F

**face** 24:14 146:21 187:8  
**FACEP** 2:5  
**FACHE** 2:2  
**facilitate** 89:8 181:13  
**facility** 111:10  
**facing** 131:1  
**fact** 14:5 27:20 54:12  
 63:5 132:16 228:2  
 231:11 237:9 249:7  
 268:22  
**factors** 71:4 79:5 97:3  
 116:10  
**fails** 147:21 191:13  
**fair** 73:14 90:14,17  
 94:10,14,17 193:10  
 208:18 215:2 225:18  
 225:19 274:12  
**fairly** 193:13  
**fairness** 24:10 168:15

187:6 202:14 221:4  
 225:7 227:22 242:6  
 259:7,8,11 273:18  
**fall** 110:7 164:14 165:9  
 169:8 230:10 236:15  
**fallen** 228:9  
**falls** 165:5  
**false** 37:19  
**familiar** 20:6 157:16  
 257:16  
**family** 1:14 95:9 240:21  
 241:1  
**famished** 174:11  
**far** 11:17 12:7 23:2 27:1  
 43:2 52:4 88:1,2  
 134:11 141:2,21  
 158:14 204:21 222:4  
 251:3 259:1 281:20  
**farther** 22:15 83:19  
 259:17  
**fascinating** 235:22  
**fashion** 41:14 56:18  
 67:21 267:5  
**fast** 137:20  
**fault** 204:6  
**favor** 34:12 206:13,16  
 209:9 218:20 219:3  
 222:20 247:13 251:14  
 269:21 280:9  
**feasible** 157:10  
**features** 43:18,21  
**federal** 2:15 135:4  
 210:2  
**fee** 204:8 258:12  
**feed** 33:15 283:10  
**feedback** 19:8 150:9  
 272:14 281:7  
**feel** 13:8 14:10 17:11  
 27:16 30:16 34:4,12  
 69:14 82:2 98:7  
 175:19 184:16 193:12  
 193:12,13,19 228:13  
 233:10,17 247:2,21  
 250:10 259:12 265:16  
 265:21  
**feeling** 22:17  
**feels** 29:15 242:4  
**felt** 28:6 197:22  
**fence** 224:5  
**FHFMA** 2:2  
**field** 171:15,16  
**FIESINGER** 1:14 17:19  
 18:22 19:4 22:9 31:5  
 31:16 95:7,17 98:4  
 127:4 140:22 193:6  
 214:21 216:15 238:16  
 239:17,21 256:16  
 258:9 259:15 260:14

272:10  
**figure** 6:21 11:22 16:11  
 64:20 84:14,21  
 125:18 168:3 195:19  
 221:22 226:4 244:12  
**figured** 82:10  
**figuring** 6:15 8:12  
 86:17 161:4 221:6  
**file** 142:7  
**fill** 265:15 269:6  
**final** 11:4 17:16 121:8  
 130:14 167:22 264:13  
 276:9 279:20  
**finalize** 104:13  
**finally** 22:11 49:16 50:1  
 240:3  
**financial** 206:5  
**find** 13:4 57:6,14 58:7  
 64:11,16 66:21 89:13  
 93:6 120:7 164:9  
 171:11 221:3  
**finding** 281:17  
**findings** 89:1  
**fine** 22:2 23:5 191:2  
 220:12  
**fine-tuned** 30:16  
**finger** 223:20  
**finish** 214:15  
**first** 9:22 14:20 23:15  
 23:16 32:20 34:16  
 35:20 53:5,21 70:4,11  
 87:2 88:11 93:5 98:8  
 109:8 112:1 116:18  
 117:13 120:17 124:8  
 130:8 132:14 134:15  
 137:14,20 145:1  
 148:17 170:14 173:10  
 174:15 176:21 177:3  
 178:11 180:17 187:14  
 191:14 201:5 205:14  
 213:22 222:22 228:16  
 229:9 236:9 254:1  
 262:13 267:6 278:8  
**Fisher** 75:2  
**fit** 6:19,21 74:12 120:1  
 120:16 134:4 166:9  
 182:19 243:4  
**fits** 202:11,11  
**fitting** 125:12  
**five** 40:18 44:16 67:2  
 72:10 74:19 75:19  
 80:19 126:3 138:18  
 198:7 209:12 242:15  
 264:6,7 267:20  
**five-year** 115:1  
**fix** 166:18  
**flawed** 252:6  
**fleshing** 173:2

**flexibility** 26:11 49:12  
 272:17  
**flight** 18:2  
**flipping** 59:4  
**Floor** 1:8  
**flow** 79:10 130:12  
**flows** 137:12  
**focus** 27:3 51:1 58:21  
 80:3 118:4,11 163:18  
 181:22  
**focused** 7:21 165:20  
**focusing** 165:10  
**foist** 15:17  
**folks** 12:13 16:12 24:16  
 51:5 64:19 81:1,13  
 89:16 99:22 122:22  
 175:16 197:14,17  
 241:20 277:20  
**follow** 54:3 132:1  
**follow-on** 22:9 281:16  
**follow-up** 55:20  
**followed** 106:19  
**following** 119:3 204:6  
**follows** 48:11,13  
 225:16  
**force** 19:16 20:18  
 266:21  
**forceful** 31:13  
**foreseeable** 236:19  
**forget** 158:21  
**forgiveness** 209:21  
**form** 5:7 33:7 35:6  
 54:15 67:21 269:7  
**format** 50:12  
**formation** 31:18  
**formulate** 19:8 31:19  
**formulated** 144:3  
**Fort** 1:14  
**forth** 20:15 50:12  
 123:21 124:2,3 143:2  
 153:6 175:9 240:14  
 260:12 279:6 282:5  
**Forum** 1:1,8  
**forward** 4:6 5:19 22:6,7  
 22:15 26:4 35:11  
 43:12 50:7 81:10  
 93:13 102:19 175:20  
 210:9 223:9 257:11  
 264:3 272:1 280:18  
**forwarded** 64:18  
**found** 5:18 35:10 37:18  
 38:1 40:18 43:18  
 67:10 123:14 213:19  
**foundation** 6:2  
**four** 4:17 60:1 72:1  
 96:12 108:21 109:7  
 135:13 145:1 152:19  
 154:1 157:12 172:15

202:10 205:17,18  
271:21  
**four-dimensional**  
129:20  
**fourth** 143:7  
**fraction** 145:7  
**fractures** 112:19  
**fragmented** 35:19  
**frame** 6:10,15 7:11 27:1  
45:18 76:1 107:7  
124:13 139:1,7,7  
192:2  
**framed** 147:9  
**framework** 3:16 102:18  
117:4 121:10 122:1  
122:14 123:12 124:22  
134:18 136:10 139:20  
148:6 165:13 172:2  
**frankly** 125:15  
**frequency** 126:6  
**frequently** 75:18 77:13  
**fresh** 282:5,8  
**friends** 19:5  
**front** 12:5 95:9 228:4  
236:22 273:13  
**frustrated** 24:17  
**full** 23:3 273:21 280:15  
**fully** 178:22 219:11  
255:16 266:11  
**fun** 141:12  
**fundamental** 254:15  
255:22 256:10 271:18  
**fundamentally** 266:19  
**funded** 4:22  
**funding** 95:20  
**furnishing** 221:9  
**further** 40:17 50:8  
96:17 131:4,4 178:2,6  
208:6 261:18 280:18  
**further** 253:19  
**future** 54:13 56:4 80:13  
93:10 192:1 243:22  
256:3 271:14  
**fuzzy** 65:3

## G

**gaming** 31:8 32:14  
236:12 237:3,5,8,18  
240:18 241:11  
**gaps** 265:15  
**garner** 250:14  
**gathered** 175:14  
**gauntlet** 175:15  
**Gen** 259:18  
**general** 34:2 53:11  
64:19 101:17,19  
216:10 219:3 253:4  
259:9 265:10

**generalities** 157:22  
**generally** 14:11 123:9  
172:3 212:13 216:12  
254:2  
**generate** 64:5 145:4  
**generated** 69:21  
**Generation** 258:10,13  
**generic** 167:12,20  
168:7 178:16 183:6  
**genesis** 53:12  
**gentleman** 129:1 141:4  
**geographic** 27:2  
112:10  
**gestures** 185:10  
**getting** 11:3 17:14  
37:20 46:10 48:8  
59:16 89:11 94:20  
104:15 110:5 116:15  
125:15 132:10 134:17  
151:9 195:8 200:17  
203:7,15,18 204:2,8  
209:21 227:13 233:15  
240:9 242:7 251:16  
261:18 263:2  
**Gibson** 2:2  
**give** 6:4 7:17 16:1,13  
19:21 56:15,18 60:13  
62:11 63:11 76:5  
83:22 84:1,3 103:13  
113:5 114:5 125:5  
135:10,22 154:13  
174:8 177:8 193:6  
194:15 203:12 232:18  
234:5 244:18 256:20  
**given** 13:9 39:8 42:4  
44:21 55:1 71:1 74:8  
118:8 145:19 153:4  
202:4 214:7 218:10  
226:18 246:13 247:11  
248:18 249:7 260:4  
261:20 264:20 265:20  
270:10 280:14 282:4  
**gives** 27:9 110:1  
**giving** 124:22  
**glad** 57:13,14 131:17  
**glean** 57:17  
**gleaned** 53:15  
**glossary** 29:20 30:8  
102:9  
**glucose** 55:7  
**go** 6:7 7:13,18 8:17 9:4  
9:8,13,18 11:16 17:11  
17:16 23:2,7,11 27:14  
28:14 39:20 51:4 56:6  
58:2 65:3,12 66:2  
68:1 81:2 84:14 88:12  
91:14 94:2 95:15 97:3  
97:13,17 99:8 100:18

101:12 103:11,12  
104:7,11,11 106:11  
107:17 108:3 112:22  
114:8 115:4 122:18  
126:21 135:6,12,14  
136:1 137:19 139:19  
140:4,4 141:21 142:4  
147:2,2,22 148:7,11  
153:17 155:4 158:14  
159:6,13 161:8,9  
164:11 167:1 169:7  
176:1,18 178:11  
179:22 182:10 183:17  
185:16 188:10 193:21  
197:9 198:15 199:19  
201:19 206:7,15  
207:15 209:6 210:22  
211:3 214:10 215:7  
216:13,19 217:12  
219:12,16 220:21  
223:1 224:13 226:14  
229:6 230:17 235:1,3  
236:3 238:14 239:6  
246:7 248:5 249:3  
251:5 252:9 255:9,12  
258:18 266:12 267:22  
268:6,7,18 275:8  
278:22 279:6,12  
**goal** 23:17 24:1 52:6  
53:6 117:15 118:8,21  
120:21 137:20 138:3  
138:6,7,10,12 140:9  
140:10,10,11,17  
152:1 176:21,21  
179:14 185:17,18  
186:11 191:12 192:11  
192:12 193:8 194:2  
196:6 197:14,21  
201:14 214:8 225:11  
226:21 230:4,5,7  
233:19 234:19 253:20  
255:19,20 269:11  
**goal-related** 229:13  
**goals** 23:19 25:1 45:2  
53:5 121:13 136:16  
138:19,20,21 140:16  
150:14 152:9 177:1  
179:20 183:14 185:2  
185:4,21 186:12  
192:9,10,16 226:2,4,5  
226:12,18 227:20  
238:4 245:18,19  
**goes** 15:4 25:15 51:12  
54:21 166:12 180:19  
215:12 222:13 247:8  
253:14 257:5 259:1  
279:21 281:13  
**going** 6:11,13,19 8:17

8:18 9:21 11:4,6,10  
11:11 12:2,20 13:6  
14:2,8,12,14,15,16,21  
14:22 15:2,3 16:9,21  
21:1,2,13,18 22:5  
23:7,11 27:8,12,13,15  
28:4,10 32:3,16 35:11  
45:1 50:2 59:14 62:16  
66:2,20 67:2 72:19  
74:1,2 76:19 79:15,16  
81:14 82:21 85:20,20  
86:10 94:7 96:6,7,16  
98:6 100:20 103:11  
103:17,22 105:13  
111:16 112:20,20,22  
114:14 115:19,21  
116:1 118:14 120:11  
121:19 122:22 125:14  
125:17 126:1 130:21  
135:9,10,11 136:8  
137:18 139:16 141:18  
142:4,17 146:20  
147:14,22 152:21,22  
154:20 155:1,2,19,20  
156:7,8,16,19 157:22  
158:10 159:2 160:22  
164:9,14 166:10,11  
166:18 169:11 174:6  
175:7 176:1 177:2  
181:10 182:12,12,17  
183:12 184:20,22  
185:7 186:19 188:7  
188:22 189:3,5  
192:14 197:22 198:8  
200:7,10 201:21  
202:1,22 204:4,10  
206:11 208:19 211:9  
214:13 216:18,20  
219:10 220:9 225:16  
225:22 226:5,17  
228:21 230:16,22  
232:3,12 233:9  
234:13 237:12 238:5  
239:15 240:4,17  
241:18 242:17 243:20  
244:7,18 245:4 247:6  
250:13,14 251:6  
254:17 257:9,10  
260:2 265:1,3,22  
266:7 268:6 271:4  
274:16 275:7,21  
276:13 277:3,4,10,17  
277:20 278:3,4 280:3  
282:1,3,17 283:8,17  
**gold** 70:19 72:20 84:8  
99:15 227:17 228:3  
228:17 239:1,7 242:5  
246:9,13,20 247:11

248:3,18 260:4,10  
**good** 9:15 10:22 29:19  
 34:8 37:4 41:20 44:18  
 50:4 53:19 54:5 55:15  
 61:8 69:19 73:11,16  
 77:3,12,15 78:17  
 80:15 84:14 85:18,19  
 87:20 90:12 91:2,4  
 93:5 97:16,17,22  
 100:5,7 101:3 102:5  
 106:11 107:5 117:1  
 123:1 127:22 130:5  
 134:9 137:1,5 138:4  
 140:22 148:20 153:10  
 155:6 160:16 165:14  
 166:17 178:20 193:1  
 194:11 195:4,13  
 208:3 212:13 214:1  
 214:16 223:20 241:9  
 242:19 243:6 245:15  
 246:5 248:17 263:14  
 268:11 272:5 274:15  
 280:22 283:5  
**gotten** 40:19 56:17  
 228:6  
**governance** 215:21  
**grade** 19:17  
**grand** 96:5  
**granted** 179:21  
**granular** 214:11 218:21  
 218:21 221:14 259:12  
**graphic** 128:17  
**gray** 60:22 65:8 89:13  
**great** 4:12 5:2 6:12 17:2  
 28:20 32:10,11,20  
 33:14 43:14 50:11  
 60:18 62:17,17 66:14  
 81:14 85:9 91:4 95:8  
 102:21 105:7,19  
 111:13,21 127:1  
 128:12 130:9 141:15  
 165:16 175:19,21  
 186:17 201:2 211:6  
 235:4 240:19 241:5  
 257:22 271:16 284:10  
**greater** 45:22 259:7,11  
**grew** 132:17  
**grid** 170:21  
**grossly** 237:12  
**ground** 92:22 193:9  
**group** 8:10 13:10 34:5  
 35:14 41:21 42:12  
 43:22 50:9 54:8 90:10  
 103:13 110:12 115:2  
 126:7 127:17 132:21  
 135:17 136:4 139:22  
 141:22 145:11 151:10  
 161:16 164:18 172:21

173:17 178:10 214:5  
 215:19 217:1 219:19  
 220:6,12,16 222:6,10  
 222:12 223:21 225:18  
 231:5,20,21,22 232:3  
 235:12 242:15 261:15  
 268:8 277:11 279:15  
 284:14  
**grouped** 231:17  
**groupings** 42:22  
**groups** 168:21 185:18  
 203:13 205:3 220:4  
 232:2 261:22 277:5  
**growth** 69:5,11  
**guarantee** 142:6  
**guess** 11:5 18:11 28:12  
 51:8,15 52:2 56:7  
 61:19 88:17 121:17  
 121:22 149:5,12  
 151:3 155:8 165:18  
 185:14 199:3 201:16  
 206:13 207:11 214:13  
 222:13 232:15 246:19  
 246:19 247:22 248:3  
 252:8,21 259:15  
**guidance** 20:1 21:17  
 22:5 36:15 92:11  
 149:20 165:1  
**guide** 96:19 147:10  
**guidelines** 63:12  
**guiding** 5:6 136:20  
 176:11  
**guts** 74:18  
**guy** 162:3  
**guys** 6:12 7:17 16:2  
 17:20 34:19 107:22  
 112:7 131:10 137:9  
 160:2,7 230:12 234:2  
 244:7 250:6 277:22  
 279:19,22 282:19,20

## H

**half** 77:20,21 244:16  
 271:22 283:1  
**Hamilton** 2:2  
**hammer** 104:12 175:8  
**hamstring** 192:10  
**hand** 18:13,14 107:19  
 212:18 224:2,11  
 273:12  
**handle** 127:21 168:14  
 179:4 215:22  
**handled** 127:11  
**hands** 279:16  
**hang-ups** 133:5  
**happen** 84:17,18 238:5  
 238:5 241:8 275:10  
**happened** 53:16 240:22

**happening** 131:18  
 249:17  
**happens** 56:1 166:6  
**happy** 18:7 52:22 79:19  
 261:2  
**hard** 11:3 18:17 53:8  
 67:15 105:12 163:8,9  
 163:9 191:7 235:2  
 251:17 252:19  
**harnessing** 267:5  
**hash** 279:10  
**hat** 238:8 258:22  
**hate** 268:12  
**Hawaii** 232:20  
**HAWLEY** 1:15 246:8,18  
 247:14,21 249:1  
 264:14  
**head** 11:3 39:18 272:11  
**headed** 159:9  
**headers** 161:13  
**heading** 212:21  
**headings** 37:18  
**heads** 104:21 108:17  
 208:21 245:9  
**headway** 86:15  
**health** 1:15,19,22 2:3  
 2:16 4:16 5:14 25:16  
 29:14 30:22 96:20  
 100:12 135:4 186:3  
 197:17 200:10 216:8  
 245:14,18,20 248:19  
 249:15 250:4 260:5  
 266:20  
**healthcare** 2:1 23:18  
 29:14 35:18 84:15  
 101:11 136:17 141:22  
 178:21 179:5 182:19  
 182:21 183:6 184:2  
**healthier** 178:1  
**HealthPartners** 98:13  
**healthy** 88:7 169:4  
**hear** 19:17 33:14  
 146:16 155:22 162:9  
 181:5 183:10 191:6  
 206:8 207:19 224:3  
 229:17 257:21  
**heard** 51:15 131:22  
 185:18 187:14 191:9  
 195:11 198:14 212:10  
 212:21 250:9 266:10  
**hearing** 35:2 53:22  
 134:15 135:16 168:17  
 170:15 190:1 201:17  
**heart** 129:7 167:14  
 179:18  
**heck** 25:8 245:6  
**held** 281:17  
**Helen** 2:7 20:9 101:3

131:12 163:21 165:15  
 168:17 169:14 173:21  
**Heller** 1:20  
**help** 6:10 17:1 19:8  
 32:9 57:11 89:8  
 130:10 135:9 141:14  
 142:3 148:21 158:11  
 163:12 164:3 165:8  
 178:7,8,21 187:8  
 223:16 260:12 261:22  
 277:6,11  
**helped** 90:6  
**helpful** 6:2 13:5,18  
 50:13,14,16 102:22  
 104:6 116:22 124:20  
 149:18 150:5,13  
 153:3 191:5 224:12  
 229:17,21 266:6  
 273:21 276:13 277:2  
 279:1  
**helps** 179:5 263:18  
**hemoglobin** 233:3,6,14  
 262:20 263:2  
**HERRING** 2:8 274:21  
 275:7 281:13  
**hey** 100:13 141:9 158:1  
**Hi** 5:12  
**Hiding** 29:5  
**hierarchy** 86:18 87:2,7  
**HIEs** 255:2  
**high** 21:20 43:6 91:20  
 163:5 218:19 230:16  
**high-level** 43:9 67:11  
**higher** 219:5 225:19  
**highlight** 109:2 171:1  
 256:5  
**highlights** 45:9 249:2  
**highly** 86:2  
**hip** 157:19 158:5  
**history** 192:21 239:2,17  
**hit** 27:19 91:12 243:16  
**HMO** 82:7 252:11  
**hold** 34:16 244:1,13  
**holding** 145:17 216:22  
 217:9,15 233:22  
**home** 18:2 110:11  
 240:6  
**honest** 111:15 210:19  
**honestly** 68:9 146:11  
**hop** 16:13 279:16  
**hope** 7:21 35:1 121:22  
 136:1 238:4  
**hopefully** 33:14 42:11  
 229:21 259:14  
**hoping** 18:4 56:1  
**horizon** 80:13  
**hospital** 2:3 55:20,22  
 92:4 109:17,19



118:10 119:2,7 122:7  
138:11 139:19 140:11  
140:16,17 155:3  
161:9 208:12 211:17  
226:7  
**hospitalist** 116:7  
151:16 244:2  
**hospitals** 25:9 128:8  
141:7 142:1  
**host** 124:13  
**hour** 103:20 201:22  
244:16  
**hours** 103:16 105:15,15  
**house** 241:2  
**housekeeping** 17:19  
53:22  
**HOUSER** 1:15 85:6  
132:6 133:15,19  
180:18 181:8 193:22  
195:1 216:20 236:7  
237:7 252:19 253:6  
**huge** 57:2 65:8 172:8  
243:21  
**Humana** 1:12  
**humility** 243:18  
**hundreds** 212:2,2,2  
**hurry** 182:15

## I

**I.D** 113:11  
**IBARRA** 2:8 16:15  
105:3 177:15  
**ID** 213:9 214:1,6,9,9  
**idea** 8:6 23:15 26:13  
40:17 59:14 60:18  
64:14 66:8 84:7 85:7  
87:20 90:18 91:4 96:6  
99:4 101:2,2,5 104:1  
105:7 109:1 113:9  
132:6 139:16 141:1  
143:15 148:4 158:7  
162:10 164:6,7  
166:19 167:6 174:3  
176:11,16 183:11  
202:21 206:3 209:1  
210:19,20 212:12,14  
214:16 219:10 220:1  
224:8 226:2 236:12  
243:15 245:10,22  
247:6 249:21 255:16  
265:11 271:16 272:6  
280:22  
**ideal** 26:11 54:10 192:3  
192:6 201:12 205:17  
205:20,21 267:6  
268:14 272:16  
**ideals** 254:19  
**ideas** 8:9 22:12 85:9

102:20 104:4 106:13  
145:15 187:19 235:19  
**identified** 6:18 38:12  
138:13,14  
**identify** 26:6 37:11  
40:21 43:2 179:19  
180:20 183:22 184:2  
184:3 210:11 223:14  
262:13 267:7 272:3,3  
277:8  
**identifying** 40:19 43:5  
181:10,12 183:20  
**ignore** 161:18  
**ill** 155:14 169:5  
**Illinois** 141:5  
**illness** 166:7 167:12  
**illustrate** 162:15,22  
166:9  
**illustrations** 117:2  
**illustrative** 133:12  
166:14 172:9  
**imagine** 64:2 95:15  
**immediately** 273:11  
**impact** 25:12 55:13  
74:22 95:20 97:16  
243:2  
**impacted** 82:1  
**impacting** 96:2  
**impacts** 153:2 195:19  
243:11  
**imperfection** 237:15  
**implement** 68:5 122:4  
144:13 165:2 208:14  
**implementable** 62:8  
67:19 68:2,10,21,21  
**implemented** 41:14  
49:7 52:12,14 58:7,17  
69:10 203:12  
**implementers** 8:1  
**implementing** 168:20  
168:22  
**implication** 77:3  
**implications** 55:11  
**implied** 130:11  
**imply** 196:16  
**implying** 101:16  
**importance** 47:7  
177:19  
**important** 8:19 10:14  
14:9 17:15 21:20 23:1  
26:22 28:10,15 43:12  
44:5 45:7 50:7 63:9  
76:13,14 77:21 80:12  
85:3 89:21 124:11  
136:18 156:22 157:9  
163:19 207:13 227:19  
228:2 237:21 239:5  
242:11 264:20 266:4

270:16 273:4  
**imposed** 207:1  
**impossible** 161:18  
**impressive** 90:15  
**improve** 96:19 216:8  
226:20  
**Improved** 3:14  
**improvement** 109:11  
111:7 113:18 213:18  
217:8  
**improvements** 69:7  
**improving** 69:1  
**in-person** 1:3 276:4,8  
**in-use** 56:15  
**inaccurate** 257:7  
**inactions** 216:2  
**inappropriate** 138:16  
241:7  
**inarticulate** 226:22  
**incented** 51:14  
**incentive** 52:7 203:11  
**incentives** 22:12 97:6  
**incentivize** 55:5  
**inching** 68:8  
**inclination** 176:4  
**include** 7:3 61:6 71:18  
**included** 27:2 100:21  
**includes** 8:4  
**including** 26:6 179:8  
210:10 223:13 254:10  
266:20 270:12 272:2  
**inclusion** 102:10  
112:11  
**inclusion/exclusion**  
127:14  
**inclusions** 112:5,16  
**inconsistency** 253:10  
**inconsistent** 144:18  
**incorporate** 23:21  
162:11 263:8 270:4  
**incorporated** 59:22  
92:9  
**increase** 88:3,4,13  
**increased** 245:13  
**increases** 203:3  
**increasing** 28:2  
**incredible** 73:22  
**Independent** 2:13  
**index** 48:21  
**indirect** 243:11  
**individual** 5:17 25:13  
45:4 63:17 77:17 78:3  
79:5 86:21 119:2  
164:7,10 167:11  
209:21 210:4,22  
211:14,15,16,17,22  
212:13 213:7,21  
214:4 217:6,15

218:17 219:17 221:8  
222:6 223:1 225:18  
226:15  
**individually** 277:6  
**individuals** 63:13  
**infamous** 107:20  
**influence** 200:22  
**influencing** 218:12  
**inform** 171:8 195:21  
263:19  
**informant** 90:2 97:18  
**informants** 90:22,22  
**information** 8:11 21:16  
21:16 30:7 64:9 76:13  
90:12 122:15 216:8  
255:2  
**informs** 225:3  
**inherent** 87:14  
**initially** 27:20  
**inject** 86:17  
**injustices** 223:3  
**Innovation** 2:15  
**inpatient** 169:6  
**input** 13:3,10 15:3  
16:13 17:14 18:4,5,7  
24:13 35:3 50:20  
104:18 117:7 118:16  
138:8 175:21 176:2  
187:7 230:6 277:9  
**instance** 19:16 39:16  
41:5 42:14 44:2,13  
46:10 47:14 55:4 62:4  
111:18 213:6  
**Institute** 1:15  
**institutional** 109:15  
111:10 114:1  
**insurance** 84:18  
**integrate** 60:19  
**integrated** 40:3 179:10  
249:18  
**integrates** 33:7  
**intelligence** 68:9  
**intended** 11:15 67:7,12  
138:3  
**intent** 28:4 51:12,19  
52:5 249:15  
**intentionally** 32:6 54:15  
236:13  
**interact** 142:10 158:18  
**interaction** 87:11  
**interactive** 130:16  
131:13 137:11 156:7  
**interested** 70:11  
**interesting** 20:4 64:14  
84:11 89:11 125:2,8  
131:5,8 139:9,15  
140:3 143:3,4 160:15  
170:22 171:2 206:3

249:10 252:9 263:6  
**interestingly** 42:10  
 166:15  
**interim** 277:17  
**internal** 284:2  
**internally** 215:21  
**interpretation** 69:3  
**interpretations** 66:11  
**interpretative** 131:13  
**interpreted** 178:15  
**interpreting** 212:7  
**interrupting** 100:7  
**interventions** 265:16  
**interviews** 90:2 97:18  
**intimidating** 247:17  
**intriguing** 64:12 101:5  
 166:19  
**introduce** 4:9 261:6  
**introducing** 4:13  
**introduction** 5:11  
**involved** 123:17 200:15  
 202:14  
**Ira** 1:18 34:18 73:18  
 75:6 121:2 125:20  
 153:8 155:7,22  
 160:20 167:3 182:10  
 185:12 217:21 218:1  
 231:3 254:1  
**Ira's** 123:7 130:11  
 133:17 136:14 165:18  
 165:19 168:18 169:2  
 186:17  
**irrelevant** 149:17  
**issue** 6:4 7:11,12 25:15  
 39:3,6,11 44:6 47:3  
 50:2 56:3 83:8 86:1  
 95:22 98:8 110:13  
 143:7 158:4 210:12  
 216:21 222:14 241:4  
 242:16 243:21 245:7  
 250:20  
**issues** 24:16 35:11 37:8  
 43:12 48:22 49:16  
 50:8 72:12 105:11  
 131:9 134:10 141:5  
 145:3,16 151:1  
 158:17 212:6 219:18  
 239:9 282:4  
**item** 206:1  
**iterate** 186:19  
**iteration** 191:15 278:12  
**iterative** 33:17

---

**J**


---

**Jen** 65:15 79:16 170:18  
 183:17 191:8 192:6  
 234:21 235:1 236:2  
 248:5 273:22

**Jennifer** 1:19,20 4:9 5:3  
 257:4  
**Jenny** 1:12 24:11 51:6  
 57:8 87:21 129:13  
 166:22 169:17 183:17  
 185:15 198:20 220:1  
 220:22 251:5 257:6  
 267:12  
**Jenny's** 56:7  
**job** 19:7 32:20  
**join** 258:13  
**joint** 54:10 99:22 111:5  
 111:6 112:15,16  
 117:12,15 122:6  
 151:12,13 162:17  
**joints** 115:22  
**joking** 103:18 188:10  
 266:15  
**Jones** 64:22 100:13  
 156:3 181:19 182:5  
**Jr** 267:22  
**judge** 71:12 72:6,15  
 84:8 198:12  
**judging** 147:18  
**July** 281:14  
**jumbled** 154:10  
**jump** 65:16 136:6  
 191:11 234:22 278:17  
**jumped** 79:17  
**jumping** 127:6  
**June** 1:6 281:15

---

**K**


---

**keep** 14:8 29:9 79:16  
 81:13 105:2,3 121:17  
 158:15 168:4 186:19  
 194:21 195:5 206:11  
 226:6 230:9,15 231:1  
 241:18 250:13 257:19  
 277:17 282:7  
**keeping** 23:4 184:8  
 194:1 206:14 209:9  
 222:21 223:5  
**keeps** 51:9 209:14  
**Keith** 1:16 182:3 209:4  
 227:4,4  
**key** 5:6 8:9 29:22 30:3  
 37:18 38:1,3,4,8 44:6  
 49:1,12 90:2,22 97:17  
 98:18 99:1,14 158:18  
 175:14 272:7  
**keypad** 275:4  
**Kim** 2:8 15:7 90:19,19  
 105:2 177:7 250:7  
**kind** 6:2,4,10 8:6,8 9:9  
 9:13 10:7,19 18:11  
 23:8,8,15 29:8 30:1,9  
 35:8,10,21 36:1 37:4

37:17 38:2,5 39:11,15  
 42:9 43:1,5,9,11  
 44:11 45:4,16 46:22  
 48:10,19 49:3,13,14  
 49:20,22 50:17 52:8  
 53:1,3,9,13 56:8  
 61:10 63:18 65:3  
 67:12 70:18 71:6 76:9  
 77:6 80:10 82:16 88:1  
 90:8,10,11,19 92:21  
 99:13,18 100:22  
 101:19 102:18 118:17  
 119:10,17 124:19  
 131:9 133:5 136:7  
 139:15 143:18 144:7  
 144:8,11,18,19  
 145:12 153:4 162:2  
 167:3 169:19 170:15  
 174:4 176:16,18  
 178:5 187:18 223:6  
 224:4 226:8 230:1  
 231:4 234:1 235:16  
 240:4 241:17 245:3  
 247:2,15 249:2,21  
 253:13 265:10 266:5  
 272:14 277:12 279:10  
 279:21  
**kinds** 22:18 80:4 97:3  
 155:11 157:5  
**kings** 240:2  
**kit** 133:13  
**knee** 167:15  
**knew** 62:6  
**know** 11:2 12:7 13:11  
 15:7 16:3 20:14,18  
 21:20 28:6 29:17 30:9  
 30:15 34:8,8,17 40:9  
 52:3 62:12 65:5 67:5  
 68:14 72:1,18,21 75:5  
 76:17 78:3 88:15,16  
 89:5 90:21 93:21  
 95:22 96:2,8 97:11  
 98:10 103:22 105:12  
 105:21 106:5,11  
 107:1,7,8,15 108:8  
 109:16 114:10,16  
 115:7,10 116:4,8,14  
 119:20,21,21 120:4  
 123:22 124:10 125:12  
 125:14 126:1,4,13,17  
 126:21 128:8 131:6  
 131:18,19 133:2,3,17  
 133:20 134:2,3,4  
 135:18 136:5,10,21  
 137:8,15,22 138:4  
 139:5,6,8 140:9,10,12  
 143:16 144:6,10,15  
 145:15,21,22 146:7,8

146:8,19 147:17  
 148:16 149:1,1,13,13  
 149:15,19,20 150:8  
 151:5,12,14,21 152:3  
 153:5,15,21,22 154:2  
 156:1 158:1,2,4,5  
 161:6,7,14,18,22  
 162:4,7,16 163:8,10  
 164:20 165:22 167:20  
 168:1,13 169:13,20  
 170:16 171:5,12  
 174:13 175:19,21  
 176:9 177:6,14 179:9  
 181:8,14,16,16,18  
 182:4,8,14 183:1,11  
 187:21 189:1,4  
 191:15 192:5 194:10  
 195:20 196:2,3,7  
 199:7,8,12,17,21  
 200:1,3,4,6,16 202:2  
 202:6 204:10,10,14  
 205:10,11,20 207:8  
 207:12 208:13 210:16  
 210:20 211:6,8,16  
 212:1,3,20 214:10,19  
 215:11,13 216:4,18  
 219:13 220:3,4,8  
 221:2 222:5,12,14,15  
 223:15 225:7,13  
 226:9,13 228:6,8  
 229:12,13,20 230:4  
 230:19 231:9,16,19  
 233:2,13,14,20 234:2  
 234:12,15,18 235:12  
 235:18,21 241:5  
 242:13,15 243:5,11  
 243:12,18,19,22  
 244:1,9 246:10,20  
 247:22 248:1,14  
 249:18 251:15 253:13  
 254:7,19 255:3,4,5,5  
 255:21 257:4 258:16  
 259:5 260:17,21  
 262:17 263:18 267:16  
 267:17,20,21,21  
 268:1,13 269:2,3,9,16  
 269:18,21 270:5,6  
 273:21 276:22 277:11  
 277:16,22 278:5,8  
 279:5,22 280:1 281:5  
 281:12 283:16,19  
**knowing** 36:1 240:17  
**knowledge** 91:5,6  
 101:18 137:2  
**knows** 20:9 97:12  
**KOCHER** 1:16 227:6  
**Kristin** 37:14  
**KROPP** 1:17 32:19 60:5

60:10,13,15 222:20 223:18 261:5,13 262:1,10,17,22 263:5 263:9,15 264:2 273:7	281:5 <b>legal</b> 62:11 142:11 <b>legendary</b> 103:22 <b>legislation</b> 240:11 <b>length</b> 88:3 <b>lens</b> 193:18 <b>let's</b> 40:10 54:21 56:5 57:8,9 59:7 75:16 76:17,22 77:1 81:11 81:13 86:18 98:10 100:15 105:1,9 107:16,17 117:11 118:9 124:6 126:20 160:12 161:15 188:2 213:1 231:2 233:21 233:22 234:5 245:11 252:10,12 259:20 <b>level</b> 9:20 10:17 12:21 13:9 19:22 21:2 27:18 37:7,7 44:9,10 45:5 46:2 47:1 58:2 73:22 86:6,20 91:20 96:9 113:12,17 114:2 124:8 127:11,12 135:4 138:9,10 142:2 142:12 148:22 149:19 157:7 163:5 167:11 168:13 188:16 193:9 209:18,19,20 213:14 217:17 218:20,21 219:4,17,19 220:5,12 220:12 221:3,12,20 222:10 224:18,20,22 225:20 226:18 230:2 230:6,16,19 254:11 254:12 267:11 <b>levels</b> 28:2 95:21 124:16 126:12 142:15 179:9 217:2 <b>liability</b> 54:11 <b>liable</b> 199:18 <b>Liaison</b> 2:15 <b>likes</b> 54:10 <b>limit</b> 60:21 <b>limitation</b> 112:10 <b>limitations</b> 19:13 26:3 <b>limited</b> 89:13 <b>Linden</b> 37:14 <b>line</b> 38:11 56:7 109:22 110:6 114:9,20 116:5 133:14 138:10 274:22 <b>lines</b> 33:4 133:17 136:8 198:16 254:8 <b>linked</b> 130:19 <b>linking</b> 186:4 <b>list</b> 17:21 50:22 81:1,15 91:19 102:7 105:20 106:2,7,19 107:5	123:4,5 135:2 139:4 144:1 206:14 207:16 207:17 208:5,7,16 278:9 <b>listed</b> 33:4 79:5 154:16 154:16 <b>listening</b> 88:14 <b>lit</b> 37:17 <b>literally</b> 83:3,14 166:9 211:14 <b>literature</b> 12:6 21:17,21 22:4 38:2 49:4 50:15 52:4 53:9 58:8 60:22 68:19 80:11 89:14,14 101:17 121:11 143:11 144:9 <b>little</b> 17:7 19:19 22:15 22:20 23:16 28:3 29:21 32:7 35:12 37:9 46:12 52:18 53:12,15 56:16 57:11 71:20,20 86:3 87:19 89:20 93:1 100:15 104:1,5 105:12,17 107:16 109:18 117:20 121:5 125:4 126:2 129:12 135:20 141:16 149:3 154:10 156:2,14 157:15 158:4 167:8 171:15 173:8 176:10 178:2,6,14,21 182:9 183:2 186:20 188:13 197:22 198:4 207:18 207:20 210:6 213:4 213:15 216:18 219:9 223:22 232:17 241:14 242:7 244:10 259:11 259:12 261:4 265:22 271:11,22 272:5 281:8 <b>live</b> 141:12 201:22 <b>LLOYD</b> 1:18 56:6,11 58:5,14,17 59:1,6,11 59:17,19 60:1,7,11,14 61:2,7,13,17 99:21 107:20 110:4 119:13 119:16 129:11,19 133:6,16 159:9 185:14 186:10 188:22 190:5,9,15 192:8 202:7 203:8,19,22 213:2 231:4 234:11 266:17 268:18 <b>locked</b> 239:21 <b>locking</b> 266:1,3 <b>locus</b> 27:5 56:3 222:13 225:6 226:17 229:13 <b>logic</b> 67:20 68:8 117:8	118:2,17 121:6 130:13,18 135:14,22 136:11 150:22 156:4 156:16 165:9 274:5,7 283:15,16 <b>logical</b> 79:10 <b>logically</b> 166:2 <b>logistically</b> 281:22 <b>logistics</b> 281:12 282:15 <b>long</b> 81:2 94:13 135:21 174:7 191:18 <b>longer</b> 45:20 105:20 <b>look</b> 4:6 11:4 15:7,13 18:1,18 19:18 27:1,20 29:1 45:19 50:7 52:5 57:8,9 72:22 80:12 83:18 87:4,15 88:10 88:15 91:10 95:20 100:15 117:6,11 118:6 132:14 134:20 135:17 146:21 149:20 161:8 163:3 165:22 166:1 169:7 176:6 181:17 206:19 224:17 244:6,17 256:3 261:2 276:18 277:19 283:14 <b>look-back</b> 88:2 <b>looked</b> 52:4 60:21 98:14 100:10 142:19 143:11 144:9 160:13 242:22 251:15 <b>looking</b> 5:19 6:9 13:14 13:15 15:22 45:19 50:17 51:11 54:12 75:9 76:4 78:2 79:22 88:18 112:15 113:8 114:12 117:7 122:6 132:9 143:12 150:16 164:19 166:16 167:21 179:1 181:17 208:3 213:9 222:5 267:16 273:14 276:15 <b>looks</b> 7:16 <b>loose</b> 30:4 <b>Los</b> 132:18 <b>lose</b> 150:21 151:1 <b>losing</b> 266:18 <b>lost</b> 142:6 205:16 <b>lot</b> 4:19 8:10,12 18:19 19:4 21:3 22:11 26:13 27:17 43:14 48:11 50:16,18 56:8 61:14 70:21 71:3 74:20 75:18 79:22 80:2 83:8 86:5,7 88:6,16 91:5 103:21 104:4 108:15 108:17 110:9 113:7 114:10 117:4 119:8
---	--	---	---

121:21 123:2 126:1  
 127:16 162:9,13  
 166:20 175:20 186:18  
 191:12 193:3 218:15  
 219:6 220:3 222:9  
 223:2 224:1 238:19  
 239:9 243:16 273:10  
**lots** 23:9 47:22 194:11  
**loud** 54:3 229:3  
**love** 17:20 61:4 120:19  
 136:4 143:14 158:22  
 193:19 206:6 247:16  
 264:11 272:20  
**low** 167:15  
**lower** 254:3  
**loyal** 202:4  
**LTACs** 128:7  
**lumped** 246:10  
**lunch** 103:17 104:10  
 159:1,2,6 174:7,9

### M

**MA** 1:15 2:15  
**MACP** 1:11,17  
**MACRA** 79:22 80:18  
 102:16  
**magnify** 87:13  
**major** 120:7 146:12  
 239:18  
**majorities** 39:12  
**majority** 4:17 41:15  
 220:15 222:2  
**making** 13:8 82:16  
 86:15 87:5 93:22  
 114:7 137:14 150:2  
 156:5 160:10 221:21  
 228:3 233:6 269:12  
**man** 109:1  
**manage** 233:12  
**management** 1:21 55:7  
 80:5 230:20,21  
 262:12  
**manager** 2:8 244:3  
**managing** 151:17  
 199:20  
**manipulate** 32:5,6  
**manipulation** 31:8  
 240:17 241:12  
**map** 49:1 239:8  
**marching** 129:8  
**margin** 88:13  
**mark** 18:21  
**marker** 115:1,1  
**markets** 203:10  
**Mass** 64:19  
**Massachusetts** 100:1  
**match** 42:19 99:12  
 116:1 204:17

**matches** 46:11  
**matching** 192:13  
**matter** 56:13 85:12  
 103:8 175:10 243:18  
 284:17  
**matters** 85:13 86:11  
 244:22 256:21  
**Maurer** 37:14  
**MBA** 1:11,17 2:2  
**MD** 1:11,11,13,14,16,17  
 2:5,7  
**mean** 12:11 15:12,16  
 15:17 20:14,16 21:7  
 23:2 29:12 40:1 44:10  
 45:14 64:2 65:7 70:17  
 70:20 74:17 75:15  
 78:12 83:2 88:14  
 90:14 92:19 98:12  
 105:18 107:5 111:6  
 120:6 122:10,21  
 126:15 130:20 138:11  
 139:11 143:20 153:13  
 154:16,17 158:6  
 163:4,5,13 167:4  
 179:3 180:11 186:10  
 187:16 189:5 195:1,3  
 204:16 211:19 216:13  
 225:12 232:14 239:21  
 240:17 246:1,18  
 252:6 253:6 259:1,18  
 261:17 262:5 270:19  
 280:22  
**meaning** 17:22 31:8  
 209:18 215:6 221:7  
 283:21  
**meaningful** 76:19  
**means** 67:19 73:11  
 74:5 108:5 157:3  
 182:20 189:1  
**meant** 35:4 140:15  
**measure** 7:22 8:1 14:4  
 21:8 24:6,15,19 27:2  
 27:3 39:13 42:9 46:15  
 63:6 64:16 70:5 73:4  
 73:9 85:11 86:2,3,7  
 87:11 96:11 109:18  
 111:13,14 121:20  
 126:10 127:12 128:9  
 135:5 145:6,17 154:6  
 156:10 176:14 187:3  
 187:11,13,21 188:3  
 188:17 189:6,12,15  
 189:20 193:17 194:4  
 197:5,15 198:2  
 202:15,22 204:3,12  
 205:1 211:19 233:13  
 237:15 241:6 257:2  
 268:14 283:22 284:1

**measure's** 86:6  
**measured** 202:16,17,19  
 264:21  
**measurement** 2:9 36:3  
 36:9 86:13 113:10  
 164:5 179:11 184:1  
 189:3 227:10  
**measurements** 145:20  
**measures** 21:11 22:7  
 24:7 42:6 45:21 54:13  
 87:15 97:5 98:9 112:9  
 127:15,16,17,19  
 132:15 136:2 144:16  
 146:2,6 147:21 154:3  
 187:4 191:16 192:18  
 205:2 219:1 221:16  
 243:2,3 257:10  
**measuring** 85:8 186:8  
 188:2 189:7,12 199:2  
**mechanism** 217:12  
 257:8 258:6  
**mechanisms** 243:14  
 257:2,20 260:7,8  
 268:20 270:10  
**Medicaid** 2:15 159:22  
**medical** 110:10 231:20  
 231:21,22  
**Medicare** 2:15 73:3  
 95:11 112:12,17  
 159:19 205:7 213:6  
 258:12 269:2  
**Medicine** 2:4  
**MedPAC** 125:4  
**meet** 5:13 14:17 45:2  
 91:22 144:14 191:13  
 191:14,19 192:15  
 197:15  
**meeting** 1:3 3:18 4:4  
 6:6 7:19,21 8:3 9:7  
 10:8 12:14,17 72:4  
 89:8 90:10 144:4  
 148:18 149:22 173:1  
 261:8 263:17 275:10  
 275:14 276:1,4,8,14  
 281:15,16 283:13  
 284:4  
**meetings** 9:12  
**meets** 46:3 197:4  
**Mehrotra** 1:9,11 3:3  
 4:12 5:2 8:16,21 9:5  
 9:15,17 10:17,19 12:4  
 12:9 14:19 15:11,16  
 17:2 18:3 19:9 20:4,9  
 20:12 22:8 23:6 28:8  
 28:21 29:3,18 30:18  
 31:11 32:10 33:13  
 34:11 39:17 40:8 41:1  
 50:10 51:4 52:19

53:19 54:5 55:15  
 57:19 58:12,16,20  
 59:9,12,18,21 62:18  
 64:13 65:17 66:13,16  
 69:12 71:8 73:14 75:6  
 76:1,9,20 78:6 79:15  
 80:15,22 81:6,9 82:15  
 85:3 87:21 89:10  
 90:13 91:3,12 93:4  
 94:20 98:12 100:5  
 101:15,22 102:21  
 103:6,15 105:6  
 106:10,21 107:15  
 110:2 116:17 119:15  
 120:17 122:16 123:1  
 123:13 125:2 127:1  
 128:12 130:5 131:10  
 132:2 134:7 137:3  
 139:9 140:21 142:16  
 144:20 146:15 148:1  
 148:11,13 152:16  
 155:7,22 157:8  
 158:20 159:4 160:15  
 162:9 163:13 165:14  
 166:20 170:12 171:16  
 171:19 173:19 174:10  
 174:16,22 175:4,13  
 177:10,13 178:8,19  
 179:13 180:16 181:5  
 181:15 182:10,14  
 183:8,16 185:11  
 186:8,16 188:10  
 189:22 190:7,14  
 191:5,20 193:1,20  
 194:20 195:5 196:20  
 197:8,16 198:18  
 201:2 205:13 207:19  
 208:18 210:5 212:8  
 213:22 216:9,17  
 217:19 218:1,17  
 219:8 220:17,21  
 222:16 223:19 225:21  
 227:3 228:14 231:2  
 235:1 236:2 237:1  
 238:2 239:12,19  
 241:15 242:19 243:5  
 244:14 246:4,11  
 247:5,16 248:5,17  
 249:11 250:5 251:12  
 252:8,21 253:22  
 255:11 256:13 257:21  
 258:18 260:1,20,22  
 261:9,11 262:4,7,11  
 262:18 263:1,6,13,20  
 264:4,10 265:8  
 267:12 270:7,20  
 271:1,3 272:9,13,20  
 273:3,20 274:9,12

280:6,9 281:9 282:3  
 282:13 283:1,6  
**member** 4:11,15 9:19  
 10:4,21 17:19 18:22  
 19:4,11 22:1,9 27:15  
 28:18 29:5,8 30:6,12  
 30:14 31:5,16 32:19  
 33:21 51:7 53:21 54:6  
 56:6,11 58:5,14,17  
 59:1,6,11,17,19 60:1  
 60:5,7,10,11,13,14,15  
 61:2,7,13,17 62:19  
 65:15,18 66:18 69:20  
 70:3,10 73:19 74:16  
 75:14 76:8,10 77:14  
 78:7 79:20 80:18  
 81:16 82:22 83:6,11  
 85:6 87:22 91:9,13  
 94:9 95:7,17 98:4  
 99:21 102:4 105:18  
 106:17 107:1,20  
 110:4 119:13,16  
 121:4 122:21 123:2  
 123:14 125:11 127:4  
 128:15 129:11,18,19  
 129:21 130:8 132:6  
 133:6,15,16,19 136:7  
 137:4 140:7,22 147:8  
 153:9 154:18 155:8  
 156:18 158:13 159:9  
 160:19 163:4,22  
 167:2 168:16 170:19  
 171:18 178:13 179:3  
 180:2,18 181:8,9  
 182:11,17 183:12,19  
 184:5,19 185:14  
 186:10 188:22 190:5  
 190:9,15 191:10  
 192:8,17 193:6,22  
 195:1,7 196:14,22  
 197:13 198:10,22  
 201:20 202:7 203:5,8  
 203:10,19,21,22  
 204:19 206:13 208:2  
 209:7 211:11 213:2  
 214:21 216:15,20  
 218:3,19 220:2 222:4  
 222:20 223:18 224:14  
 227:2,6 229:9 231:4  
 232:14,21 234:11,21  
 235:4 236:7 237:7  
 238:16 239:17,21  
 241:21 242:22 243:8  
 245:17 246:8,18  
 247:14,21 248:7,22  
 249:1,13 251:6,9,18  
 252:19 253:6 254:5  
 255:18 256:16 258:9

258:17,19 259:15  
 260:14,15,21 261:5  
 261:13 262:1,10,17  
 262:22 263:5,9,15  
 264:2,14 266:17  
 267:15 268:18 269:15  
 270:17,22 271:2  
 272:10 273:1,7 274:2  
 274:10 280:12 281:11  
**members** 9:10 15:18  
 62:4 88:19 101:10  
**members'** 216:1  
**memory** 100:11 187:18  
 257:12  
**mental** 125:16 284:7  
**mention** 79:21 80:9  
**mentioned** 11:9 70:17  
 93:17 102:10 136:11  
 164:12 236:11 276:22  
**menu** 253:15,15  
**merit** 162:13  
**merits** 3:9 55:14  
**MeSH** 37:18  
**messed** 223:12  
**met** 1:8 144:12  
**method** 25:2,5 26:12  
 38:8 52:9 64:16 88:10  
 144:7,13 190:12  
 228:19 264:18 272:18  
 274:4  
**methodological** 65:20  
**methodologies** 150:18  
**methodology** 5:1 66:3  
 227:18,19,20 228:5  
 248:9  
**methods** 7:6 11:6 33:5  
 33:12 37:12 44:1 63:7  
 67:11 100:2 136:21  
 270:9  
**metric** 71:12 72:13 73:3  
 73:7 145:8 188:4  
 198:12  
**metrics** 71:10 72:14,22  
 73:16 144:16 190:3  
**MGH** 66:12  
**mic** 91:12 273:6  
**Michael** 1:11 2:2 34:17  
 130:7 178:12 179:1  
 180:1 196:20  
**Michigan** 1:16 2:16  
 5:16  
**micro-level** 123:19  
**microphone** 54:3  
**mics** 185:12  
**mid-July** 281:14  
**mid-level** 240:12  
**middle** 72:12 92:22  
 96:4

**mike** 12:11 29:2,3,3  
 62:18 107:19 134:14  
 136:5 137:6 164:12  
 236:3 238:14 241:18  
 243:7  
**million** 132:18,19  
**mind** 4:13 5:10 74:5  
 99:1 121:18 142:18  
 153:15 188:21 194:8  
 209:7,14 210:5  
 267:13  
**mindful** 150:6  
**minds** 282:5  
**mine** 189:1 232:6  
**minimum** 39:9,9 42:13  
 42:18 44:13  
**Minnesota** 1:18  
**minor** 110:3  
**minutes** 81:12 103:20  
 148:2 158:22 159:5  
 174:9 175:5 264:5,6,7  
**MIPS** 44:11 79:22 80:16  
 102:16 191:14 234:12  
**misattribution** 258:8  
 260:8  
**misheard** 156:14  
**misjudging** 34:10  
**misleading** 213:15  
**mismatch** 189:10  
**missed** 38:10 57:3  
 127:8  
**missing** 11:19 106:4  
 108:1,3 136:10  
 251:17  
**mistake** 212:9  
**misunderstood** 247:10  
**mix** 70:5 80:14 159:18  
 171:15  
**mix-and-match** 265:5  
**mixed** 237:19  
**mode** 8:14  
**model** 27:3,4 38:18  
 39:19,21 40:1,2,14,17  
 41:12 46:16 50:4,6  
 62:2 66:1 67:4 69:9  
 69:14 71:6 77:2,3,7  
 77:12,16,19 79:4  
 86:21,22 94:19  
 109:14 113:4,12  
 114:11,12,17 118:18  
 122:7 125:16 126:5,9  
 130:18 135:14 136:17  
 143:17 147:11,11,14  
 147:22 164:11 168:18  
 168:19,20 169:8,9,10  
 171:9 190:19,21  
 198:13 200:12 213:17  
 221:17 258:10,15

262:8 274:4,13  
**modeled** 137:12  
**models** 3:14 38:14,20  
 40:18 41:10,15 42:8  
 43:8 49:8 50:12,17  
 56:19 62:4 63:8,17,19  
 63:21 64:3 66:22 76:6  
 78:15,22 92:6,7 96:1  
 96:12 97:10 102:1,11  
 102:13,16,17 111:21  
 120:8 134:1 136:11  
 149:2,4 154:3 165:6  
 169:20 170:4 190:18  
 192:19 203:11,11  
 209:17 212:17 250:2  
**models/approaches**  
 49:6  
**modified** 141:2 216:2  
**moment** 264:20 275:4  
**Monday** 282:22  
**money** 220:9  
**monkey** 282:1  
**month** 232:21  
**months** 45:19 248:22  
**morning** 8:5 10:9 17:10  
 35:13 102:20 108:18  
 123:6 171:22 172:1  
 215:3  
**mortality** 45:22 207:7  
**MOSCOVICE** 1:18  
 73:19 74:16 75:14  
 76:8,10 77:14 123:14  
 155:8 156:18 158:13  
 182:11,17 218:3  
 251:9  
**mother** 272:21  
**move** 13:21 81:10  
 107:21,22 150:20  
 208:1 209:1 236:5  
 241:19 244:14 245:11  
 257:19 280:18 282:7  
**moves** 245:4,5  
**moving** 43:12 50:5  
 93:12 102:19 175:20  
 219:11 232:21 256:17  
**MPH** 1:11,16,18 2:7,8,9  
 2:10,14  
**MPhil** 1:16  
**MS.WILBON** 11:14 12:8  
 15:15,19 18:9,16 29:2  
 81:7  
**MSc** 1:12  
**MSN** 1:19  
**MSSP** 68:13  
**muck** 162:3  
**muddying** 227:8  
**MULDOON** 2:15 13:13  
 150:1 220:19,22

253:16  
**multi-** 125:12  
**multiple** 26:8 39:5 42:3  
 48:7,7,16 51:10,16,22  
 62:3 80:2 95:21  
 113:20 116:14 128:5  
 166:10 167:18 170:3  
 181:3 194:4 200:14  
 205:2,2,5 210:13  
 231:14,14 257:14  
**MUNTHALI** 2:9

---

**N**

---

**N.W** 1:9  
**nail** 235:16  
**nailed** 248:11  
**Nallamotheu** 37:15  
**name** 171:5 223:3  
 269:8  
**narrative** 132:8 142:13  
**narrow** 108:6 231:18  
**narrowly** 178:16  
**Nate** 19:9 53:20 147:6  
 149:2 183:11 249:11  
 250:9  
**Nate's** 22:10  
**NATHAN** 2:4  
**National** 1:1,8,11 23:20  
 34:3 177:2,4,7,16,21  
 183:14 185:2,5,20  
 186:12  
**nature** 53:7 84:12,19  
**nauseam** 190:21  
**near** 243:21  
**near-term** 244:8  
**necessarily** 62:2  
 106:18 109:11 220:2  
 232:9 249:5 264:22  
**necessary** 26:5,11  
 36:11 61:8 143:16  
 179:22 184:22 185:5  
 185:7 210:9 215:18  
 216:6 217:8 218:4,7  
 223:10 11 271:10  
 272:1,17  
**necessity** 248:10 250:2  
**need** 16:4 19:1 21:11  
 29:10,21 44:12 57:16  
 61:21,22 62:1,3 63:1  
 63:5 73:22 76:18  
 78:13,18 94:4 108:12  
 108:13 120:4 128:16  
 129:22 133:13,14  
 141:10 142:9 144:10  
 144:12 159:16 162:15  
 165:4 172:5 183:2  
 190:18 194:8 197:11  
 198:11,12 200:20

204:7,19 210:1 216:2  
 225:8 241:14 242:17  
 244:1 250:2 256:5,8  
 257:8 260:11 264:8  
 273:17 274:6 278:5  
**needed** 26:13 272:14  
**needs** 30:15,16 97:11  
 101:19 127:18 190:19  
 196:9 216:1 234:18  
 248:1,2 257:9 265:2  
 267:10 273:9  
**negative** 104:22  
**negotiate** 66:1,3,10  
**negotiated** 65:21  
 222:10  
**network** 225:1  
**networks** 179:10  
 249:18  
**never** 182:12 215:16  
 216:5 271:5  
**new** 25:16 67:4 156:10  
 191:4 192:18,18  
 240:20 269:12 270:1  
**nice** 22:20 239:7 250:20  
**night** 10:8 141:13  
**nightmares** 163:11  
**nine** 68:7  
**noise** 54:1 198:5  
**non-exclusive** 49:19  
**non-stop** 103:17  
**norm** 15:11  
**normative** 137:14 139:5  
 139:14 148:5 206:18  
 207:16 208:5,16  
 218:7 229:22 230:17  
**norms** 26:5 34:1 210:10  
 223:12 272:2  
**note** 34:20 102:5  
 120:10 122:16 251:13  
**noted** 119:20  
**notes** 119:22 240:1  
 276:18  
**notion** 63:22 94:16  
 164:4,12 225:6,7  
 231:13 241:22  
**novel** 190:18,19  
**NOWAK** 1:19 183:19  
 274:2,10  
**NP** 213:13  
**NPIs** 214:11  
**NQF** 2:7 7:22 15:1 20:5  
 20:13 74:8 92:10,11  
 101:9,10,16 131:7  
 146:1 178:3,4 241:13  
 271:8 274:17 275:14  
 282:6 283:21  
**nuance** 121:21 158:3  
**nuanced** 173:9

**nuances** 124:18 162:22  
 193:11  
**number** 37:22 44:13  
 80:22 83:21 94:6  
 113:11 115:14 138:8  
 138:18 140:3 148:7  
 186:21 187:16 198:9  
 198:17 207:12 209:5  
 210:7,18 213:9  
 219:11 226:1 242:20  
 243:1 244:17,19  
 245:12 250:14 255:12  
 271:16 275:3 276:5  
 276:12 280:16  
**numbers** 45:11 58:10  
 60:12 63:3 145:3  
**numerators** 127:14  
**nurse** 211:16  
**nursing** 111:10

---

**O**

---

**O'ROURKE** 2:10 159:2  
 174:8,14,18 188:12  
 217:21  
**OB** 161:10 240:21  
**OB/GYN** 241:1  
**Objectives** 3:2  
**obligation** 67:17 171:8  
**observation** 83:16  
**obtain** 187:8  
**obvious** 249:21  
**obviously** 24:2 153:13  
**occur** 45:17 53:14  
 220:12 241:10  
**occurred** 150:11 223:4  
 275:16  
**occurring** 152:15  
**ocean** 132:20  
**October** 284:5  
**Officer** 2:7  
**offices** 142:8  
**officially** 56:22,22  
**oftentimes** 268:11  
**oh** 5:7 13:21 15:13 16:9  
 18:16 20:9 28:22,22  
 29:1,3 32:18 58:16  
 59:18,21 65:2 70:2  
 101:3 133:22 148:11  
 152:5 167:1 170:19  
 172:21 174:16 182:4  
 183:10,11,17 188:7  
 197:8 220:21 248:5  
 251:15 262:4 266:15  
 267:20,22  
**okay** 4:15 9:5,15,18  
 10:20 12:9 28:21  
 34:19,19 40:8,18 41:1  
 42:20 51:4 59:18,22  
 70:2,12 71:22 74:21  
 81:13 84:14 91:3  
 96:14 97:1 98:9 99:9  
 103:4 107:20 108:4  
 108:22 111:4,17  
 113:4 114:5 122:3  
 123:13 126:21 138:9  
 145:1 156:17 159:4  
 169:16 174:12,13  
 183:17 186:16,22  
 190:14 193:19 195:5  
 197:8 198:18 201:18  
 203:21 216:16 217:20  
 218:1,16 220:17  
 223:18 229:11 233:11  
 234:3 238:18 240:16  
 241:20 244:15 245:10  
 256:17 259:16,20  
 260:20 264:10,14  
 266:11 271:3,21  
 272:5,9,13 275:7  
 279:20 282:18 283:5  
**old** 141:18  
**old-fashioned** 18:22  
**once** 18:10 51:18 54:17  
 149:1 218:11 240:22  
 255:1  
**one's** 71:11  
**one-** 64:6  
**one-to-one** 48:12  
**ones** 56:15 57:9,10  
 58:7,9,14 74:18 75:17  
 115:6 160:11 172:8  
 172:11 246:13  
**online** 16:14 130:22  
**oops** 223:10  
**open** 50:19 69:2 122:17  
 153:7 274:22 281:6  
 281:21  
**Operator** 174:20 175:2  
 274:21 275:1  
**opinion** 21:19  
**opportunities** 16:22  
 102:14 259:5,5  
**opportunity** 130:15  
 271:12 278:15 279:10  
**opposed** 41:7 117:19  
 139:5 156:12 195:14  
 196:10 219:21 259:8  
**option** 61:15 278:13  
 281:17  
**options** 118:13,19  
 238:20  
**order** 35:20,22 143:7  
 144:11,18,19 148:17  
 173:10,12 211:3,4  
 214:15 216:19 273:18  
 276:14,16,19

**organization** 96:3  
110:11 113:9 164:1  
164:17 170:6 226:19  
**organizational** 102:18  
130:2 157:7  
**organizations** 106:6  
157:6 262:8  
**orient** 12:13  
**orientation** 283:12  
**oriented** 109:9,10  
**original** 249:14,14  
**originally** 258:14  
**orthopedic** 54:21 118:6  
181:19  
**orthopedist** 48:19 55:5  
116:6 151:18 152:8  
**ought** 22:2 55:10  
125:22  
**outcome** 69:19 85:14  
92:16 156:10 185:7  
**outcomes** 1:13 37:6  
48:21 85:18,19 92:3,8  
94:11 201:1 211:20  
**outline** 276:2  
**outpatient** 48:5 140:1  
**outside** 164:14 217:2  
**over-tagging** 113:19  
**overall** 25:13 126:19  
175:19  
**overlap** 130:1 268:11  
**overlapping** 129:17  
197:3  
**overlaps** 262:14  
**oversee** 20:17  
**overseen** 182:2  
**oversimplifying** 237:12  
**overt** 120:3 269:12  
**overtag** 232:12  
**overtagging** 231:13,18  
232:2 243:20  
**overview** 103:13

# P

**P-R-O-C-E-E-D-I-N-G-S**  
4:1  
**p.m** 175:11,12 284:18  
**P4P** 22:12 23:3 96:13  
**PA** 213:13  
**Pabulum** 183:7  
**package** 225:8  
**page** 30:7,14 33:2  
174:4 227:12 275:10  
283:1  
**paid** 165:6 200:7,11,18  
201:8 203:7,15,18  
204:2,8 210:2 261:20  
**pain** 167:15,16  
**painfully** 257:16

**panel** 60:3 64:21 65:1,1  
65:4 68:14 199:7,12  
199:19 200:4,9,13  
201:7 203:6 205:11  
260:17,19  
**panels** 205:5  
**paper** 19:1,3,19 33:10  
45:8 52:16 56:20,21  
64:18 67:10 71:10  
92:5,8,20 98:14  
108:18 115:17 142:19  
148:21 160:2,12  
173:13 204:20 209:16  
213:4,16,19 275:12  
275:17 276:3 278:4  
**papers** 53:11 59:3 69:4  
266:22  
**paradigms** 19:14  
**parameters** 36:17  
198:11  
**paraphrased** 201:11  
**paraphrasing** 32:20  
**pare** 133:18  
**Parenthood** 141:15  
**paring** 105:20  
**parse** 122:14  
**parsing** 6:20  
**part** 12:1,11 21:12 24:6  
31:22 56:13 61:19  
64:9,10 65:19 70:11  
78:16 90:1,1,1,5  
95:11 117:5 119:16  
127:8 131:17 133:7  
134:22 176:15 185:17  
186:5 187:2 191:21  
196:12 198:7 204:17  
207:13 215:22 218:10  
221:16 226:13 227:6  
232:19 247:9 268:19  
269:10,15 270:16  
276:20  
**partially** 200:16  
**PARTICIPANT** 91:2  
103:5  
**participate** 281:19  
**participating** 277:21  
**participation** 28:1  
**particular** 12:19 19:22  
21:7,12 29:20 169:3  
196:8 204:12 253:2  
254:7  
**particularly** 7:10 13:4  
36:2 52:11 134:10  
149:15,16  
**particulars** 132:10  
**parties** 181:3 267:8  
**partners** 197:17  
**parts** 136:11

**party** 180:21 181:1,2  
205:4  
**pass** 278:9  
**passes** 57:16  
**patient** 13:22 24:12  
25:22 27:5 39:8 42:4  
46:8,18 47:18 48:3  
51:18 54:21,22 65:9  
70:1,15 71:1 80:6,19  
82:8,9 92:15 96:3,19  
100:19 128:1,5,17,22  
129:8,14 138:7  
153:20 154:22 155:14  
156:13 159:13,14,14  
159:17 162:7 164:1,7  
165:21 166:9,10,12  
167:7,11,17,20 169:4  
171:1,5 186:5 187:7  
190:5,9 199:20  
200:13 201:7,20  
202:5 208:10 215:7  
216:7 217:16 221:9  
221:13 230:5,20  
232:6 250:15,21  
252:1 256:18 258:10  
258:12 265:2,13  
267:2,18 268:4,13  
**patient's** 47:20 48:2,14  
100:21 173:20  
**patient/one** 47:14  
**patients** 31:19 35:21  
36:2 40:7 42:6 44:13  
44:17 45:12 46:10,12  
46:21 48:8,17 51:16  
51:21 73:5 81:18,19  
82:2,4,18 83:21 84:2  
97:21 99:9 112:21  
119:9 129:10 145:12  
155:11 157:5,19  
161:1,3,8,11,18,20  
162:2 163:6,8 164:20  
166:1,7 167:18 168:8  
169:1 170:9 171:8,12  
199:8,18 200:6  
203:14 204:9 205:7,8  
205:9 220:8 233:12  
233:15 235:9 252:13  
257:6,12 267:17  
**pattern** 57:14 181:17  
**patterns** 86:17 201:21  
**pause** 84:20 198:7  
275:4  
**pay** 54:17 82:1 137:22  
154:9 163:9 200:12  
200:13  
**payer** 68:7 82:7,8,9  
159:14,14 160:3  
164:17 205:12

**payers** 56:17 57:5 59:3  
59:15 62:11 160:6  
221:11  
**payers'** 150:9  
**payment** 27:3,22 51:15  
52:7 54:18 109:12,13  
109:14 126:13 155:13  
164:5 189:16,19  
190:2 200:5,12,21  
202:19 203:3,11  
204:13 209:18 220:7  
221:17 242:16  
**payments** 221:15  
242:13  
**PCMH** 44:11  
**PCMHs** 47:11 58:1  
**PCP** 83:1 154:7 155:3  
181:18 182:1 202:4  
244:2 251:1 252:11  
**PCPs** 47:11 181:22  
**PDF** 130:21 156:8  
**peer** 61:1,9 89:14  
**peer-reviewed** 50:15  
**pen** 19:2  
**pencil** 19:1  
**people** 16:1 18:18,19  
20:2 22:16,18 28:6  
30:16 31:16,22 32:3,5  
50:16 54:14 85:13,17  
85:18 88:19 89:3  
91:21 93:2,9 94:10  
100:3 105:13 114:10  
115:3 120:19 121:2  
122:19 124:18 125:16  
131:2,9 132:18,19  
136:21 142:14,22  
145:7 160:21 161:16  
162:10 164:3,9 165:2  
166:20,22 170:17  
172:3 174:10 178:1  
178:17 180:12 185:11  
186:7,14 188:16  
189:15,17,18,19  
191:19 197:19 199:10  
199:13 202:3 210:13  
214:14 215:19 230:17  
233:15 239:22 243:12  
253:8 255:7 256:14  
258:7 262:21 266:1  
268:2,20 269:3,12  
279:2,16  
**people's** 69:3 104:15  
134:19 146:18 176:19  
210:17  
**perceive** 257:7  
**perceived** 258:7  
**percent** 32:13 40:11  
41:13,13,16,16 42:2,8

42:8,15,17 44:16,20 58:6 72:10,11 77:2,4 82:4,19,20 116:13 143:1,2 163:16,16 165:11,11 166:8 197:21 198:7 203:14 203:16 229:2 234:6 242:14,14,15 256:22 <b>percentage</b> 197:5 204:5 <b>percentages</b> 242:13 <b>perfect</b> 31:10 68:1 99:16 204:16 224:7 257:13,14 282:14 <b>perfectly</b> 108:19 <b>performance</b> 27:22 45:21 51:21 52:7 64:11 73:9 82:1 83:22 84:4 96:16 137:22 145:19 146:19 147:15 147:16 154:9 164:5 <b>performed</b> 37:10 151:18 <b>performing</b> 253:20 <b>period</b> 39:6 45:20 88:3 88:9 92:16 115:11 126:6 175:17 199:9 277:18 <b>periodically</b> 250:3 <b>periods</b> 9:10 <b>Perloff</b> 1:20 4:9,11,15 65:15,18 79:20 80:18 170:19 171:18 191:10 234:21 235:4 248:7 248:22 <b>permission</b> 142:11 <b>person</b> 78:4 100:20 130:2 131:20 147:4 162:4,17,18,19 180:12 216:5 233:6,7 234:5 235:17 269:5 275:14 <b>personal</b> 21:15 247:7 <b>perspective</b> 36:3,10 43:10 69:1 85:16 90:7 114:19 128:9,17 159:13,21 168:20 171:2 200:10 208:10 255:14 266:19 <b>phase</b> 147:15 <b>PhD</b> 1:18,20,22 2:1,2,5 2:13,14,16 <b>phone</b> 4:10 60:11 65:16 170:18 191:8,9 234:22 279:11 280:10 <b>phrase</b> 206:19 215:1 <b>physician</b> 29:16 46:8 48:15 70:16 86:21 119:2 152:6,8 200:13	205:3 210:4,14 213:8 213:10 214:4,5 216:22,22 217:6,12 219:4,17 220:4,6 222:12 232:10,10,17 237:11 <b>physician's</b> 64:21 217:9 <b>physicians</b> 46:11 64:22 88:6 97:21 122:8 141:7,9 151:21 217:1 217:15 220:7 222:6 237:11 <b>physicist</b> 4:16 <b>pick</b> 87:3,3 105:13 111:13 128:1 149:11 154:11 176:12 190:12 191:1 194:5 <b>picked</b> 65:18 110:21 111:19 <b>picking</b> 31:9 <b>picks</b> 129:5 <b>picky</b> 178:13 <b>picture</b> 215:18 <b>piece</b> 19:1 76:13 190:15 190:17 234:7,8 <b>pieces</b> 168:14 <b>pill</b> 141:19 <b>piloting</b> 233:2,8 <b>Pioneer</b> 69:4 <b>peeing</b> 132:20 <b>pitfalls</b> 89:5 <b>place</b> 67:7 116:15 236:8 239:7 240:5 243:14 <b>places</b> 88:18 110:14 142:21 185:1 255:5,6 <b>plain</b> 163:8 <b>plan</b> 6:5 16:2 54:11 83:9,11,12 84:18 104:17 135:4 280:2 283:5 <b>Planned</b> 141:15 <b>plans</b> 83:4 <b>plant</b> 23:11 <b>play</b> 19:6 27:8 63:7 66:11 114:19 128:6 155:20,21 174:1 184:18 198:19 <b>played</b> 90:17 <b>plays</b> 153:12 <b>please</b> 174:21 266:16 275:2 277:19 <b>pleasure</b> 5:13 <b>pluralities</b> 39:11 <b>plurality</b> 40:12 42:14 116:11 <b>plus</b> 58:7 282:22 <b>point</b> 10:22 13:5 14:9	16:20 17:3,18,21 19:10 22:10 24:4,5,10 25:14 26:9 28:15 29:9 29:19 30:6 32:11,12 33:14 52:1 53:5,19 54:5 55:16 59:10 62:17,20 63:15 64:7 64:13 65:16 71:15 73:14,16 76:21 77:10 77:10 79:17 80:15 82:14,15 84:13 85:2,4 87:11 89:11 91:4,18 93:5 97:15 98:18 100:6,8 104:14 110:3 110:22 123:7 124:2 125:9 128:16 129:16 136:14 139:11 152:17 155:22 157:10 162:6 165:14 173:7 178:20 179:18 180:19 183:10 186:5,17 187:14 188:13 190:20 191:16 191:17 193:1,7 197:17,20 201:5 208:18 210:6 211:5,9 211:10 214:1,14,16 217:22 219:15 227:11 228:7 229:7 232:3,11 232:11 234:14,22 235:5 236:10 238:13 242:20 243:6 245:3 246:5,19 247:3,7 248:17 252:9,22 257:22 258:1 259:14 262:20 265:18 267:10 274:13 277:15 <b>point's</b> 132:3 134:7 163:1 <b>pointed</b> 124:14 <b>points</b> 94:2 130:6 204:5 209:12 238:17 266:9 <b>policies</b> 215:21 <b>policy</b> 1:15,21 24:7 49:1 62:13 80:13 149:18 187:3 265:16 <b>policy-writing</b> 258:22 <b>polite</b> 237:3 <b>politicians</b> 142:6,7 <b>pool</b> 112:2,4 <b>poor</b> 46:11 238:12 <b>POPE</b> 1:22 27:15 28:18 81:16 82:22 83:6,11 125:11 153:9 154:18 184:19 206:13 208:2 218:19 243:8 269:15 <b>populate</b> 161:1 162:7 <b>populated</b> 161:10 <b>populating</b> 161:20	<b>population</b> 24:15 112:6 112:19 153:20 155:1 155:15 164:6 167:7 167:22 187:21 188:4 188:5 189:7,8 197:4 199:1 200:10 202:16 202:18 207:2,3,10 215:8 253:12 <b>population-</b> 49:14 <b>populations</b> 187:11 193:17 204:15 <b>position</b> 188:21 <b>positions</b> 113:21 <b>positive</b> 69:8 <b>positives</b> 37:20 <b>possibilities</b> 238:20 <b>possible</b> 63:6 149:9 158:16 196:5 218:22 219:7 229:14 281:22 <b>post</b> 276:6 <b>posting</b> 275:9 <b>potential</b> 17:8 31:21 70:18 98:6 99:15 149:21 221:15 237:5 <b>potentially</b> 90:18 91:15 157:18 168:15 176:7 179:5 181:2,6 217:14 253:18 265:7 282:1 <b>practical</b> 48:9 <b>practice</b> 1:14 30:22 53:4,16 234:6 <b>practices</b> 179:9 <b>pre-work</b> 276:13 <b>preamble</b> 239:2,3 240:6 243:17 245:3 246:2 249:4,9 256:9 273:2 <b>precedent</b> 92:1 <b>precision</b> 114:15 <b>preclude</b> 156:20 <b>predict</b> 32:1 <b>preferable</b> 26:2 250:17 252:17 <b>preferred</b> 92:6 <b>preliminary</b> 43:4 <b>prelude</b> 251:22 <b>Premier</b> 1:18 <b>prescribing</b> 249:5 <b>prescription</b> 55:1 <b>prescriptive</b> 14:1 248:15 259:2,2 <b>present</b> 1:10 2:13,20 121:9 131:20 <b>presentation</b> 71:15 79:11 <b>presented</b> 123:5 131:1 187:19 <b>presenting</b> 112:8 <b>president</b> 2:9 240:2
--	---	---	--



**presiding** 1:9  
**press** 174:21 275:2  
**presumably** 170:2  
**presume** 53:6  
**presumed** 41:7  
**pretty** 23:2 29:12 35:13  
 60:15 91:20 107:4  
 114:2 137:20 146:11  
 153:14 155:5 163:5  
 240:4 259:1 260:14  
 281:4  
**prevailing** 197:2  
**prevalence** 66:21  
**prevalent** 75:21 77:18  
 78:15 120:9,10  
**preventive** 19:16 20:6  
 20:17 129:5  
**preview** 17:3 26:16  
**previous** 123:17  
**previously** 60:3  
**primary** 48:5 55:6 78:12  
 80:20 109:8 110:7,9  
 110:10,12,14 115:18  
 115:18,20 129:2  
 133:11 171:6 199:21  
 231:10 232:1,22  
 233:3 234:3,4  
**prime** 11:21  
**principal** 80:21  
**principally** 106:13  
 253:4  
**Principles** 3:16  
**principle** 6:22 10:15  
 23:16 24:22 34:2  
 63:10 71:18,18  
 106:12,18 107:12  
 117:14 176:7,10  
 180:5,9,14 188:15  
 194:21 196:6,8,10  
 197:12 201:14 206:18  
 207:12 208:16 210:15  
 210:20 212:12,14,19  
 214:7,16 216:10  
 218:6 219:3,22  
 222:21 223:6 224:3  
 224:11 225:8,14,19  
 227:9 228:8 229:4,16  
 230:2 242:3 245:2,5  
 245:15,16 247:8,9  
 248:8,13 249:3 250:1  
 250:1,10 251:8,22  
 252:2 253:2,5 254:13  
 255:15 256:11,20  
 257:1,18 258:4 259:3  
 259:12,16 266:14  
 267:11 269:19 270:14  
 271:17,20 272:5  
 273:5,10,19

**principles** 1:3 5:6 6:1  
 6:16 9:2,3,21 11:1  
 14:22 17:22 18:5 23:8  
 23:13 32:21 33:8,12  
 33:22 35:2,16 43:15  
 49:18 50:21 74:3  
 78:10 83:5 91:15  
 92:10 93:1 98:21  
 104:3,11 105:9 107:3  
 134:21 136:20 159:7  
 175:7 176:2 206:14  
 207:16 208:20 230:14  
 236:5 239:16 240:6,7  
 241:17 244:17 251:9  
 253:15 259:19 266:18  
 271:13 275:17 278:5  
**print** 18:9  
**printed** 18:12  
**prior** 88:6  
**private** 56:17 59:3,14  
 68:6 160:3  
**probably** 4:21 10:12  
 15:21 16:2 27:8 48:1  
 48:9 52:18 53:17 63:6  
 67:22 70:11,13 72:10  
 72:11,16 80:11 82:3  
 83:9 85:10 87:8,19  
 88:19 106:9,10  
 107:12 110:19 126:2  
 134:11 138:2 139:21  
 150:2 152:20 165:2,3  
 165:4 198:3 209:11  
 217:13 227:12 228:8  
 228:12 236:4,17  
 251:7 253:9 254:7  
 256:8 257:15 264:12  
 279:8 280:17  
**problem** 35:22 45:15  
 46:14 58:18 62:8  
 107:21 163:7 169:18  
 202:8 217:5 244:9  
 255:22 256:10  
**problematic** 168:14  
 217:14,14 265:6,7  
**problems** 35:20 163:7  
 235:7 257:15  
**procedure** 118:7  
**process** 14:21 15:5  
 20:13 22:15 24:11  
 33:17 35:4 36:5 53:13  
 81:22 94:7 101:14  
 118:3 132:8 135:7,12  
 136:1 153:10 164:14  
 166:10,11 196:17  
 215:22 226:14 240:5  
 261:15 267:6,7 281:2  
 283:21,22 284:13  
**processes** 193:17

284:3  
**produce** 67:7,15,19  
**produced** 7:1  
**producing** 7:7 67:12  
 68:18  
**product** 6:6,8,16 7:1,13  
 7:18 40:6 108:5  
 277:17  
**products** 17:1  
**profession** 141:6  
**profile** 64:10 73:4 92:3  
**profiling** 44:8 52:8  
 111:8,9  
**profits** 32:1  
**program** 11:10 12:22  
 14:4 24:7 37:7 44:9  
 44:10,11,12,19 45:1,5  
 45:6,6 47:1 49:22  
 51:14,15 53:7,13 69:5  
 69:13 72:9 97:1  
 109:12 122:4 135:5  
 138:20 152:11 156:9  
 170:7 171:9 187:3  
 188:18 190:4,11,13  
 206:20 207:13 213:6  
**programmatic** 39:1  
 44:22 170:10  
**programs** 24:8 38:16  
 49:2 52:12,14 53:3  
 61:5 97:1 99:1,14  
 136:2,12 151:5  
 165:20 168:1 187:4  
 205:3,5,17,22 210:2  
**progress** 32:22 175:20  
**progression** 34:5  
**project** 2:8,8 6:9 9:14  
 36:14 95:11 105:4  
 262:12 275:8,10  
**proliferate** 255:2  
**promise** 50:22  
**prompt** 122:18  
**proportion** 233:16  
**proposal** 225:22  
**proposals** 205:14  
**propose** 103:2 126:15  
 219:10 260:2 264:12  
 271:6  
**proposed** 34:5 37:12  
 41:13 49:7 52:15 56:7  
 56:11 179:1  
**proposing** 59:14  
 165:19 258:5  
**prospective** 39:3 41:8  
 41:17 61:19 101:7  
 110:21 115:8 120:13  
 258:15  
**protective** 89:19  
**prototypical** 162:7

**provide** 18:5,6 21:17,22  
 22:5 36:10 63:21  
 76:15 90:7,11 118:16  
 120:21 149:14,19  
 165:12 221:12  
**provided** 46:19 158:8  
**provider** 24:12 25:13  
 25:22 26:1,7 27:4  
 29:10,12 30:20 34:1,6  
 36:1 37:7 38:22 39:5  
 39:7 40:7 42:1 44:9  
 45:4 46:2,19 47:14  
 48:4,13 51:10,16,19  
 62:9 64:5,17 71:1  
 72:9 82:10,19 85:20  
 86:6,20 99:5 106:6,14  
 116:5 138:8 151:10  
 152:2 156:22 164:18  
 171:6 179:20 186:1,5  
 187:7 199:17,22  
 200:8 203:13 207:6,8  
 208:12 210:4,11  
 211:14 216:11 220:4  
 223:1 229:11 233:3  
 235:8,9,13,13 250:15  
 250:16 251:22 252:14  
 254:11 256:19 265:1  
 267:3 268:13 272:4  
**provider's** 208:10  
 235:14  
**providers** 25:5 26:8  
 30:8 36:5,9 42:3,7  
 44:14,21 45:12 46:21  
 48:7,16 51:10,22  
 54:16 63:17 65:12  
 66:1 73:6 80:4,17  
 81:22 82:4,21 99:9  
 132:22 133:1 138:14  
 140:1 141:22 145:13  
 146:16 151:10 153:2  
 157:2 160:21 168:21  
 171:7 182:22 185:19  
 186:11 200:14 202:1  
 202:13 203:13 205:6  
 205:10 211:22 218:13  
 221:7,7 222:1 232:22  
 235:21 240:12 273:11  
**providers'** 250:21  
**provides** 241:17  
**providing** 221:12  
 231:14  
**proxies** 72:21  
**proxy** 267:1  
**public** 1:15,19 2:16  
 3:12 6:7 8:8,13,18  
 9:10 10:4 15:4 16:17  
 16:19 29:14 81:3  
 104:14 174:14,18,20

174:22 175:2,14,16  
 176:1 274:22 275:5  
 275:16 276:7 278:3  
 281:10,14  
**publically** 92:7  
**publicly** 263:11  
**publish** 50:14  
**published** 16:21 38:13  
 56:22 57:1 58:9,15,18  
 60:21 88:16,17 89:2  
 89:14  
**pull** 106:1 116:3 123:6  
**pulling** 53:11 92:1  
**pulse** 223:20  
**purchasing** 222:9  
**purpose** 12:13,17 24:18  
 27:21 45:7 51:14 52:5  
 124:8 131:3 136:15  
 187:12  
**purposes** 44:19 62:5  
 154:3 194:14 215:11  
 228:20  
**pursue** 98:1  
**pursuing** 102:8  
**push** 75:7 142:12  
 181:16 192:1 258:1  
 281:7  
**pushed** 241:7 244:20  
**pushing** 182:8 194:21  
**pushy** 233:20  
**put** 6:15 8:2,8,14 10:11  
 14:13 15:2 16:8,17  
 17:9,20 32:17 35:5  
 40:5 72:17 75:12 76:5  
 76:18 91:10 92:5  
 104:14 110:19,21  
 114:9,10,22 116:20  
 117:20 119:5,22  
 121:2 147:14 152:11  
 160:11 166:4 171:13  
 172:13,18 173:1  
 175:15 186:3 188:8  
 196:21 198:16 205:14  
 209:15 212:15,16,19  
 224:6 235:2 238:7  
 239:3,4 240:14,15  
 243:14 246:11 247:6  
 247:6 259:18 269:3  
 273:5,6 277:12 279:7  
 279:14,14  
**putting** 127:7 137:7  
 211:7 224:9 230:8  
 249:22 258:20 269:1

---

**Q**


---

**QI** 138:1,2  
**qualitative** 101:13  
**qualitatively** 97:19

**quality** 1:1,8,12 2:9,14  
 21:9 23:20 34:3 48:20  
 49:21,22 63:13,18  
 69:6,7,9,11 70:6,6,7  
 92:3 94:11 96:11  
 109:10 111:7 113:18  
 114:18 127:12,16,19  
 135:5 136:2 137:22  
 154:6 167:21 168:2,5  
 177:2,4,7,16,21  
 183:14 185:2,20  
 186:13 188:3 189:14  
 189:20 190:2,3,3  
 191:16 201:9 202:17  
 202:22 203:2,17  
 204:1,6,11,12 206:6  
 206:22 213:18 217:7  
 221:16 241:6 243:2,3  
 254:15 255:21 256:6  
 271:18

**quantity** 21:9

**question** 9:19 14:20

17:20 21:3,7 33:2,9  
 36:6 54:7 67:15 68:16  
 69:17,17 74:6 77:5,12  
 95:17 96:9 98:1,5  
 106:4 122:17 136:4  
 140:3 149:5 159:10  
 161:12 180:3 195:12  
 195:20 196:4 197:1  
 212:18 214:13 251:4  
 252:2 253:6 278:2  
 280:13 281:1,21

**questions** 9:17 17:17  
 94:4 122:10 127:8  
 137:17 281:5 284:11  
 284:13

**quick** 5:11 17:19 64:13  
 81:2 91:6 117:3  
 119:10 123:3 139:11  
 158:20 209:9 238:2  
 271:7 274:2

**quickly** 171:20 223:2  
 264:15 271:5 274:21  
 275:20 282:6

**quiet** 230:22

**quite** 30:12 42:12 85:11  
 86:8 127:15 128:3  
 180:21 196:19 243:4  
 272:11

---

**R**


---

**Rachel** 37:14

**RACI** 261:4,9 262:2

**RADWIN** 2:1 30:6,14

102:4 128:15 129:18  
 129:21 160:19 163:4  
 192:17 251:18

**raise** 24:3 224:11 253:1  
**raised** 29:9 34:7 144:21  
**raises** 73:21 74:4  
**ramification** 189:16  
**ran** 111:15  
**random** 52:19  
**randomly** 83:14  
**range** 158:16  
**ranges** 164:21  
**rate** 25:8  
**rates** 132:21 139:18  
 241:2  
**rational** 32:2  
**reach** 88:22 140:13  
 277:20 281:3  
**reached** 68:7  
**reaching** 89:7 277:5  
**react** 104:7 117:6  
 120:19 172:21 226:18  
**reacting** 29:10 224:21  
**reaction** 28:9 62:19  
 104:15,19 117:3  
 119:10 134:19 139:12  
 143:9 174:2 176:19  
 210:17 238:3 249:12  
**reactionary** 162:20  
**Reactions** 178:10  
 193:20  
**read** 29:16 30:11 70:20  
 141:12 142:2 184:19  
 184:20 197:6 241:13  
**reader** 118:14 134:12  
**readily** 67:21  
**reading** 243:3  
**readings** 41:18  
**readmission** 45:22  
 111:11 156:10 207:5  
**readmissions** 109:17  
 128:8  
**ready** 159:3  
**real** 46:3 57:22 68:2  
 74:10,17 124:20  
 140:13 252:2 274:2  
 283:12  
**real-time** 18:4 247:16  
**real-world** 188:14  
**realistic** 280:13  
**reality** 192:2 201:17  
 252:11 270:4  
**realize** 205:16 241:8  
**realizing** 232:15  
**really** 12:18 14:8,16,17  
 18:17 23:17 24:5,21  
 25:3,19 29:22 33:16  
 35:17 36:3,4,15,17,20  
 37:19 38:18 42:12,19  
 43:3,14,21 44:4,6  
 45:9,13,20 47:2,11,20

47:21 48:1,4 49:1,4  
 49:13,17 50:2,13,16  
 54:13 55:15 57:14  
 63:15 69:22 70:19,22  
 71:16 73:22 74:2,2,5  
 74:22 75:20 76:16  
 78:13 80:12 82:15  
 84:11,15,19 86:1,10  
 86:16 97:17 98:8 99:1  
 99:2,18 101:6 102:5,8  
 102:19,22 104:11  
 105:22 110:18 114:22  
 116:19,21,21 120:1  
 120:16 123:15,18  
 124:8,17 125:17,21  
 128:18 131:5,7 137:6  
 138:14 139:22 142:9  
 142:12 146:16 153:12  
 153:21 156:22 162:15  
 162:21 167:6 169:17  
 170:20 171:2 175:21  
 178:20 181:10,21  
 183:3 191:22 194:21  
 194:21 195:17 201:3  
 210:7 215:19 218:9  
 221:2 225:5 227:9  
 229:10 230:15 231:6  
 233:7 237:14 242:4  
 243:1 244:8 245:2  
 249:17 261:14 268:3  
 268:4,8 269:21  
 270:15 271:5 273:4  
 276:13,15 277:21  
 283:15  
**reason** 16:16 36:13,14  
 110:16,18 111:2  
 120:4 133:7 181:22  
 182:6 239:4 266:17  
 269:16  
**reasonable** 34:13 89:12  
 91:1 104:19 282:15  
**reasonably** 204:15  
**reasons** 146:22 194:7  
 222:22  
**recall** 69:6  
**recap** 3:18 23:13  
**received** 157:19  
**receiving** 126:11  
 154:19 222:3  
**recognize** 63:5 99:16  
 185:15 236:7 241:15  
 270:11  
**recognizing** 224:7  
 282:14  
**recommendation** 6:22  
 13:9 99:20 154:11,15  
 176:8,12 196:10  
 197:10 218:5 225:15

254:8 256:9 274:14  
**recommendation/ch...**  
 176:16  
**recommendations** 6:19  
 7:22 9:7 12:18 21:6  
 49:18 79:12 98:21,22  
 102:6 104:3 134:22  
 135:1 150:3 196:7  
 219:12 255:10 256:2  
 256:4,5 275:18  
 278:19 279:3,13  
 284:2  
**recommending** 218:9  
**reconcile** 279:4,13  
**reconsider** 248:8  
**reconvene** 7:20  
**record** 103:9 175:11  
 177:17 284:18  
**records** 100:13  
**red** 263:22  
**redo** 146:10  
**reduced** 204:5  
**reduces** 203:2  
**reductions** 69:5  
**reevaluated** 250:2  
**refer** 54:10 125:6 126:5  
 156:4  
**reference** 30:13  
**referenced** 130:19  
**references** 130:19  
 179:8  
**referred** 276:17  
**refine** 17:1 27:9 33:15  
 148:18 191:6 275:11  
 275:17 277:6 278:16  
 281:4  
**refined** 148:4  
**refinement** 10:2,7,11  
 278:6  
**reflect** 9:11 11:12 17:4  
 28:16 33:10 65:11  
 142:17 144:1 150:13  
 176:4 230:5 271:11  
 273:17  
**reflected** 35:16  
**reflecting** 27:10 45:3  
 47:7 53:17  
**reflects** 138:7,19 139:8  
**reform** 245:19  
**reframe** 252:10  
**refresh** 23:9 95:2  
**regard** 67:9  
**regarding** 90:16 105:8  
**regardless** 205:11  
**regards** 243:20  
**regimented** 196:17  
**regular** 248:9  
**regulation** 240:13

**reiterating** 188:21  
**reject** 273:11  
**relatable** 166:6  
**related** 49:13 66:19  
 67:16 105:22 117:22  
 118:7 154:21 248:3  
**relates** 47:5  
**relationship** 65:21  
 80:19 181:21 182:7  
 200:2 270:3  
**relationships** 80:7  
 181:11,12,14 183:21  
 184:18 186:9  
**relative** 55:14  
**relatively** 88:7 101:18  
 145:2  
**relevant** 36:22 37:21  
 41:3 52:1 153:1  
 190:11  
**reliability** 25:12 44:7  
 47:5 49:11 73:6,8  
 89:4 145:8,19 146:4,8  
 146:14 147:2  
**reliable** 219:1  
**rely** 228:3 265:3,4  
**remains** 50:6  
**remark** 160:19  
**remarks** 120:9  
**remember** 24:11 63:1  
 77:1 100:10 105:16  
 140:2 141:19 231:8  
 241:4  
**remind** 273:5  
**reminder** 54:1  
**reminds** 133:19  
**removed** 176:7 254:3  
**removing** 208:19,20  
**repeat** 8:18  
**replace** 268:12  
**replacement** 111:5,6  
 112:16,17 117:12,16  
 122:6 151:13,13  
 157:20 162:17  
**report** 5:18 7:8,8 8:2,4  
 9:13 10:12 11:4,13  
 17:16 30:7,15,20 33:3  
 36:21 72:17 76:14  
 98:14 123:16 125:1,3  
 130:14,21 134:20  
 152:22 157:12 176:5  
 197:18 231:8 276:6,8  
 276:9 281:13  
**reported** 82:6 92:7  
**reporting** 126:13  
 137:22 154:8 220:13  
**reports** 29:19 38:13  
 70:16 123:17  
**represent** 214:3

**representing** 101:10  
**require** 41:22  
**required** 42:3,13,15  
 112:6  
**requirement** 39:10  
 218:8 259:13  
**requirements** 39:9  
**rerun** 58:10  
**research** 1:13 22:11  
 99:6,18 101:6,7  
 195:12 239:9  
**researcher** 4:16 5:15  
**researchers** 52:16  
**reside** 127:12  
**resilient** 32:8  
**resonate** 155:9  
**resonates** 162:10  
**resources** 90:21 119:5  
 226:19  
**respect** 42:13 64:3  
 69:10  
**respond** 18:2 25:5 85:6  
 104:7 119:13 139:12  
 163:4 249:14 251:4  
**responding** 17:13  
**response** 97:21 177:17  
 220:22 238:9 250:19  
**responsibility** 49:21  
 85:19 129:6 179:17  
 182:1 189:19 193:14  
 234:6  
**responsible** 26:1 36:2,9  
 39:8 47:19 48:1,7,14  
 48:17,20 64:15,16  
 72:20 99:5 129:3  
 151:10 179:19 180:21  
 181:1,2,4,6 200:9,17  
 201:8,9 204:1,11  
 215:20 220:14,15  
 222:2 231:11 232:4  
 234:5 250:16 261:17  
 269:5  
**rest** 16:19 95:3 175:6  
**restating** 246:9  
**result** 48:3 67:12 68:18  
 69:21 73:6 79:3  
 194:17 237:9,13  
**resulted** 69:5 71:6  
**resulting** 40:5 49:20  
**results** 3:5 7:5 25:12  
 50:14 67:7 69:6  
 152:10  
**resumed** 103:9 175:11  
**retrospective** 39:3 41:7  
 41:15,19 43:20 61:18  
 62:6,15 115:8 120:13  
 199:9  
**revealing** 240:1

**review** 3:2 5:22 16:5,22  
 23:6 37:17 52:4 53:9  
 58:8 259:6 275:20  
 276:1 280:21  
**reviewed** 22:3 35:2  
 41:5 61:1,9 89:14  
 176:3  
**revise** 245:17  
**revisit** 248:8,20 260:6  
**Revisiting** 3:16  
**rewarding** 51:17  
**rich** 50:18  
**richer** 100:16  
**rid** 48:8 266:10  
**right** 4:3,19 13:14 14:7  
 16:21 18:3 20:5,7  
 23:10,11 30:4 31:11  
 34:22 40:16 41:2 51:1  
 53:10 55:21 56:12  
 58:15,19 59:7,13  
 62:16 65:3 66:14,20  
 66:22 68:3 70:1,1,3,4  
 70:8 71:1,1,21 75:16  
 81:9 82:10 83:2 84:1  
 84:9,13,22 87:16 93:4  
 94:8,9,13 97:4 100:11  
 101:15 103:2,6  
 105:14 106:15 107:15  
 108:9,17 109:4,18,21  
 110:5,20 111:1,8  
 112:10,21 113:14,17  
 113:20 114:4,14,20  
 115:15,17,22 119:17  
 120:20 122:20 123:1  
 124:21 125:3 126:20  
 130:22 133:15 135:18  
 140:7 149:18 151:19  
 154:21 155:1,4 157:1  
 161:17 163:15 170:16  
 171:18,19 172:11  
 173:19 175:4,13  
 180:22 181:15 183:1  
 185:16,17,21 186:3  
 186:13 188:1,20  
 189:4,9,14 191:13  
 192:5,22 193:12  
 194:20 195:10 197:15  
 198:9 201:6,12,17  
 202:19 205:20 206:9  
 207:1,3,4 208:7  
 209:11 216:13 221:20  
 222:4,16 227:13  
 228:17 229:19 232:1  
 233:5 234:14 243:3  
 245:11 247:8 251:12  
 253:22 258:6 264:4  
 267:1,3,15 273:20  
 274:16 281:6,11

283:7 284:15  
**right-hand** 124:1  
**rights** 239:13,20  
**rigor** 20:1  
**rises** 225:19  
**risk** 66:2 68:11 111:4  
 114:11,12,17 119:20  
 159:21  
**risk-bearing** 110:17  
**risk-taking** 209:19  
**RN** 1:19 2:1,10  
**road** 46:4 63:11 141:5  
 178:6 239:8 242:12  
**ROBERT** 1:17 2:2  
**robust** 277:16  
**role** 114:20 214:8  
**role-based** 80:1  
**roles** 90:16  
**roll** 28:19 45:5 107:9  
 205:5  
**room** 1:8 15:12 122:19  
 174:19 239:22 275:15  
 277:10  
**round** 60:21 88:20  
**rounding** 167:4  
**routinely** 262:13  
**row** 108:1,3  
**rows** 13:21 26:17  
 135:18 162:7 230:3  
**rubber** 46:3  
**rule** 14:6 25:2 26:14  
 39:19 47:14 48:4  
 69:14 72:15 75:11  
 89:17 94:8 96:15  
 124:12 138:19 161:2  
 161:5 205:18 219:16  
 228:21 246:16 248:20  
 255:14 260:7  
**rules** 24:13 25:18,20  
 26:10 31:7 44:22 45:4  
 47:8 58:3 70:15 74:1  
 93:19,20 94:6 95:14  
 98:18 145:4,9 146:19  
 161:14,19 206:1  
 212:16 228:19 236:13  
 239:6 240:20 245:12  
 247:12 270:8 272:16  
 273:17 274:3,6,8  
**run** 92:10 93:2,20  
 133:22 209:8 277:13  
**running** 161:6  
**rural** 141:6,7,9 218:14  
**Ryan** 2:16 3:7,10 5:10  
 5:12 34:22 36:8 40:2  
 40:16 41:2 52:10,22  
 56:9 59:5 60:17 61:3  
 61:12,16 62:17 63:15  
 65:13 68:22 69:16

70:2,9,12 73:1 89:22  
 90:5 96:21 143:14  
 145:10 169:16 196:12  
 196:15 223:17 245:21  
**Ryan's** 160:12 274:14

## S

**Sad** 273:8  
**safety** 129:7  
**salient** 153:16  
**Sally** 64:22 158:1  
**sample** 83:17,18 84:6  
 92:15 218:22 219:18  
 235:7  
**sampling** 255:4  
**SAMUHEL** 2:2 10:21  
 29:5,8 30:12 62:19  
 136:7 241:21 242:22  
**savings** 31:21 69:21  
 204:3,4,13 205:7  
 213:6  
**saw** 38:2 49:4 68:19  
 88:6 212:16 231:9  
**saying** 31:13 43:3  
 45:18 57:8,15 61:11  
 71:5,21 75:3,21 77:15  
 77:22 88:2 93:16  
 109:5 121:19 122:2  
 124:5 136:9 137:15  
 137:17 139:6 169:14  
 180:20 184:6 185:3  
 185:15 192:5,9 198:1  
 200:6 201:4 207:22  
 216:14 219:3 220:13  
 220:18 224:1 225:5  
 226:8,11 233:19  
 241:5 246:17,19,21  
 248:11 254:9 258:3  
 259:8 260:10 270:21  
**says** 76:13 99:10 225:9  
**scale** 203:12  
**scan** 3:5 7:2,5,14 11:1  
 11:15 12:1 15:1 37:9  
 37:11 49:4 121:10  
 276:1,3  
**scared** 56:8  
**scenario** 14:5 19:6  
 116:8 122:3 128:1  
 152:4 192:14  
**scenarios** 11:7 68:10  
 78:11 110:6 164:3,10  
 165:7 225:17  
**scene** 270:3  
**schedule** 16:8 81:8  
**schemata** 128:21 129:9  
**SCHMITT** 2:2  
**School** 1:19,20 2:4,16  
**science** 242:1

**scientific** 2:7 114:14,19  
 137:13  
**scientifically** 22:21  
 67:5  
**scope** 23:1,4 74:4,7  
 75:5 89:19 90:1 95:19  
 131:6 132:1  
**score** 25:12 86:6  
 202:22 203:2  
**scores** 86:9  
**Scott** 1:22 215:9,14  
**screen** 18:18 107:22  
**screenings** 200:20  
**screens** 107:18  
**sea** 71:10  
**search** 37:16,17 38:8  
 38:10  
**second** 9:9 24:4 35:22  
 67:17,17 87:3 109:9  
 119:14 144:11 148:22  
 168:13 173:12,12  
 186:22 209:13 242:21  
 261:3 276:7,16,19  
 278:11 284:4  
**secondary** 267:6  
**section** 12:5 240:21  
 269:22  
**see** 15:7 17:10 18:19  
 22:19 29:14 42:21  
 43:1,11 47:3,9 49:6  
 49:12 53:10 56:5,20  
 58:1,10,10,16 71:5  
 74:3 87:3,9 89:15  
 100:8,10 103:6 108:2  
 108:16 111:3,14  
 113:1 114:6 115:3  
 123:15 127:15 128:3  
 131:2 132:1 134:13  
 143:10,15 144:17  
 145:6 146:12,21  
 162:11 166:3,15  
 168:18 169:2 170:11  
 173:21 174:3,4  
 175:16,17 180:16  
 181:18 187:22 191:22  
 193:4 194:12 202:1,1  
 213:1 231:2 243:21  
 244:8 245:8 260:3  
 262:10 263:18 265:10  
 265:19 268:6,6,7  
 269:4 275:21 279:15  
**seed** 23:11  
**seeing** 31:18 50:11  
 53:16 195:10 199:22  
 208:21 221:9 232:16  
 258:11 268:13  
**seeking** 268:5  
**seen** 65:10 223:3 238:3

267:16  
**segment** 28:14  
**select** 12:22 82:8 133:4  
**selected** 187:9  
**selecting** 268:3  
**selection** 132:12  
 250:22 253:3 264:17  
 266:13 270:13 284:1  
**selects** 268:4  
**self-** 250:21 253:2  
 264:16 266:12 270:12  
**self-selection** 26:1,3  
 82:17 250:16 265:2,3  
 265:14  
**semblance** 61:14  
**semi-finalize** 104:13  
**send** 15:3 90:18,20  
 92:2 94:18 230:11  
 277:2 278:16 279:19  
 281:10,20 283:8  
**sending** 282:18  
**Senior** 2:10,10  
**sense** 6:4 7:17 9:16  
 14:13 19:14,21 27:9  
 39:22 47:10,10,12,16  
 47:21,21 48:4,18  
 57:12 72:4 79:12 87:9  
 94:21 100:16 114:7  
 118:1 119:7 134:17  
 141:2 145:5 154:13  
 155:6 161:5,14 164:3  
 166:2 169:12 177:8  
 193:3 194:19 210:22  
 219:19 224:1 270:6  
 271:7,13,15 279:2  
**sensing** 57:20 261:15  
**sensitive** 46:6,9 60:16  
 198:4 240:10  
**sensitivity** 46:4 47:4  
 49:9 62:20 64:4 65:19  
 67:13 85:12 86:3  
 195:15  
**sent** 17:22 137:13  
 261:7 278:11  
**sentence** 9:22 10:12  
 232:17  
**sentences** 10:13 28:13  
**separate** 7:8 9:9 40:20  
 41:9 135:1 207:17  
 215:5 216:3 237:8  
 255:15  
**September** 95:8  
**series** 94:4 137:16,17  
 179:4  
**serious** 13:19 14:2  
**service** 204:9 258:12  
**services** 2:3 5:15 19:16  
 20:17 27:1 80:4,5,7,8

80:8 115:14,15 116:1  
116:12,13 117:22  
118:5 119:6 165:4  
221:9  
**session** 18:11 236:9  
**set** 23:8 30:10 32:17  
94:16 117:20 134:21  
134:22 135:2 137:12  
144:21 160:21 234:3  
240:20 278:11  
**sets** 75:21 79:8  
**setting** 48:5 65:22 94:9  
169:3 191:18  
**settings** 37:3 166:13  
**settle** 228:2  
**setup** 95:8  
**seven** 74:19 92:15  
137:19 271:5  
**shaking** 104:21 208:21  
245:9  
**shape** 33:7  
**share** 18:7 54:16 68:3  
93:6 145:12,13  
**shared** 23:19 34:2,5  
54:19 55:3 142:21  
177:1 179:17 180:4,6  
180:6,7 204:3,4,13  
205:7 213:6 261:4  
**SharePoint** 15:20 16:14  
**sharing** 180:13  
**sheet** 79:6  
**Shield** 1:19 69:10  
232:20  
**Shield's** 257:5  
**shift** 67:2 243:9  
**shoot** 92:22  
**short** 92:19 206:14  
209:10 230:15  
**Shortell** 75:1  
**shortening** 230:12  
**shorter** 8:6  
**shot** 60:13  
**should-consider**  
253:15  
**show** 110:21,22 113:2  
134:3 146:17 199:11  
261:1 279:15  
**showed** 111:19  
**showing** 115:2 120:2  
134:2  
**shown** 268:10  
**shows** 152:5 268:3  
**shudder** 20:19  
**side** 21:8 124:1 167:5  
244:11 269:13  
**sidebar** 125:4 157:15  
160:12 162:8  
**sidebars** 157:19

**sides** 206:8  
**signal** 46:1  
**significant** 250:15  
**similar** 110:13 131:9  
205:21 240:4 241:4  
258:2  
**similarly** 155:2 226:16  
**simple** 68:16 74:1  
92:13 142:9 158:15  
**simplicity** 26:9 142:13  
272:15 273:14  
**simplification** 237:14  
**simplify** 135:19,19  
244:21  
**simply** 55:13 206:19  
**Simultaneous** 65:14  
73:13 75:13 83:10  
272:8 280:11  
**single** 26:6,14 34:1,6  
39:5 46:9 47:19 51:10  
51:19 71:12 80:2  
81:19 101:10 106:5  
116:13 129:14 133:14  
185:6 210:4,11,14  
214:17 215:16 216:12  
216:22,22 223:14  
224:22 228:21 232:17  
234:1 235:9,15,20  
237:10 249:7 252:15  
272:3,4  
**sites** 128:5  
**sitting** 167:2  
**situation** 13:16 19:7  
184:3 244:6  
**situations** 99:2 128:2  
202:3  
**six** 74:19 133:17,17  
228:7 242:14 248:22  
266:11,12 271:5  
**Sixty-** 56:11  
**size** 83:17,18 84:6  
219:18 235:8  
**sizes** 218:22  
**skilled** 111:10  
**skip** 105:16 115:5  
**skipped** 128:13  
**skipping** 212:9  
**slide** 275:19  
**slightly** 76:2 140:8  
209:22 252:10 266:4  
**slippage** 41:11  
**SM** 1:13  
**small** 133:2 217:17  
235:7 277:5,11 278:1  
283:9  
**smaller** 8:6 218:14  
**smart** 67:22  
**Smith** 267:18,19,21

**Smiths** 267:20  
**smoke** 141:18 157:20  
**smoking** 25:7 112:8  
118:22 119:6 122:4  
126:20 132:15,21  
139:17,18 155:16  
168:1 226:7  
**SNF** 114:3 156:10  
157:20 158:2  
**SNFs** 128:7  
**snowball** 38:5  
**Social** 1:20  
**solicit** 150:8  
**solutions** 1:17 242:12  
**solved** 50:2  
**solving** 45:14 258:20  
**somebody** 60:3 85:14  
88:5 108:8 210:21  
244:13 262:19  
**someone's** 41:5 66:4  
**somewhat** 42:7 91:19  
109:1 154:21 193:8  
206:14  
**soon** 142:7  
**Sophia** 2:14 131:18  
150:2 153:6 172:13  
**sorry** 14:7 28:22 56:16  
100:22 106:1 127:4  
139:17 148:10,12  
163:22 174:13 178:13  
191:11 216:19 243:7  
248:6,7 251:15,16  
253:5 273:7 276:18  
**sort** 12:6 13:16,18,21  
14:1,2,2 22:9 27:19  
28:19 32:8 55:9 57:15  
65:5,6 74:13 75:1  
78:8,9,10,11 81:21  
82:13 84:4 85:1  
105:10,19 106:19  
107:7 108:20 109:12  
113:1 119:18 121:7  
121:12 123:3,19,22  
126:8,18 130:12,18  
131:1 137:11 148:15  
148:15,22 149:4,12  
150:10 151:1,2 152:1  
152:15 153:12 154:13  
158:18,18 159:18  
160:5 164:2,6 165:8  
173:9,11 176:5,11,15  
179:6 181:6 183:6  
185:8 193:2 195:17  
195:20 196:3 202:8  
207:14,18 219:5,22  
221:3,8,10,14,19  
222:1 224:16 226:22  
226:22 227:7,10,11

227:14 231:16 236:15  
243:13 244:5 249:6  
254:20 256:2,5  
258:22 260:9 263:10  
264:13 277:3,4,6,16  
277:20 278:9 281:4  
283:12,15  
**sorts** 126:7 249:19  
**sound** 91:1 104:19  
106:12 283:4  
**sounds** 9:15 13:13  
43:13 71:4 82:19 90:3  
91:2 105:7 143:6  
148:3 171:21 172:2  
181:6 195:11 218:5,8  
219:9 246:2 253:22  
254:2 265:21 282:16  
**source** 124:12 139:2  
255:3  
**sources** 25:16 38:12  
70:18 136:16 242:2  
253:18 265:12 270:1  
270:12,18  
**space** 93:12,14 153:14  
153:15  
**spaces** 158:18  
**speak** 54:2 91:1 100:20  
193:22 209:5  
**speaking** 65:14 73:13  
75:13 83:10 272:8  
280:11  
**speaks** 43:6  
**specialist** 233:8  
**specialist-based** 48:6  
**specialists** 47:12,22,22  
116:3  
**specialty** 49:14 78:13  
109:9 110:8 111:6  
112:15 115:20 116:2  
129:3 133:11 161:9  
**specific** 7:21 14:4  
40:21 42:16 46:6,16  
57:9,10,22 61:21 80:4  
98:15 110:16 115:22  
121:20 125:1 144:2  
150:3,15 159:10  
165:7,20 168:7 170:9  
178:15 183:2 256:18  
284:1  
**specifically** 11:5 57:18  
59:15 61:9,18 83:13  
121:19 127:15 206:4  
214:20 215:11,15  
**specification** 24:6  
187:3  
**specificity** 46:5 47:4  
49:9 62:21 64:4 65:19  
67:14 121:6

**specifics** 57:17 159:10  
**specified** 196:18  
**specify** 144:6  
**spectrum** 164:20  
**SPELL** 2:4 19:11 22:1  
     53:21 54:6 147:8  
     183:12 249:13  
**spending** 39:15 42:5,9  
     73:3,3 87:14 113:15  
     113:15,16 245:6  
**spied** 211:11  
**split** 109:20 224:12  
**splitting** 113:14  
**sport** 211:19 212:5  
**spreadsheet** 117:21  
**Sr** 267:22  
**SRIDHARA** 2:5 78:7  
     105:18 106:17 107:1  
     121:4 122:21 123:2  
     163:22 195:7 196:14  
     224:14 227:2 254:5  
     255:18 280:12 281:11  
**Srinivas** 2:5 17:8 34:17  
     78:6 105:13,16 121:1  
     123:20 163:21 193:4  
     195:6 197:1 224:13  
     226:9 254:4 282:3  
**Srinivas'** 125:21  
**stab** 203:20 279:17  
**stability** 114:15  
**stack** 130:21  
**staff** 2:7 15:1,9 33:1  
     271:8 274:17 278:9  
     279:4 282:6  
**stages** 92:2  
**stakes** 27:19 28:2 114:9  
     126:11,14 137:16  
     154:2  
**stand** 248:1,2  
**standard** 70:19 72:20  
     84:9 99:15 227:17  
     228:3,17 239:1,8  
     242:5 246:9,14,20  
     247:11 248:3,18  
     260:4,10  
**standardized** 92:16  
**Standards** 2:14  
**standing** 256:12  
**star** 174:21 275:3  
**start** 14:15 61:8 72:16  
     77:7 97:7 105:9  
     116:15 117:9,13  
     120:2 121:1,18  
     126:20 130:10 142:2  
     177:3,15 185:9  
     199:20 213:9 214:12  
     227:16 228:4 231:13  
     231:18 233:21 276:15

**started** 4:8 5:7,22 12:14  
     37:17 39:20 78:9  
     103:12 105:1 108:15  
     133:20 142:8 148:3  
     192:9 269:16  
**starting** 10:22 51:2 56:6  
     120:7 131:3 156:11  
     157:6 206:15 234:12  
     268:20 277:14  
**state** 12:3,6,12 22:3  
     29:13 54:10,13 135:4  
     137:1 141:6 228:4  
     231:16 240:12 249:20  
     249:21 272:17  
**stated** 138:15 251:21  
**statement** 101:17  
     137:13 184:11,15  
     185:17 246:3 274:3  
**statements** 218:6,7  
**static** 25:15 245:12  
**statistical** 63:7  
**statistician** 62:22  
**statistics** 164:6  
**status** 11:12  
**stay** 23:1 230:22 267:10  
     268:9 273:9  
**stayed** 92:10  
**step** 70:4 87:2 96:17  
     104:10 121:5 147:4  
     217:8 232:5 271:10  
     280:4  
**steps** 3:18 61:22  
     108:20 112:1 145:1  
     148:7 264:8 275:8  
**steroids** 55:1,8  
**stick** 41:12 211:4  
**stop** 107:16 114:6  
     174:6  
**story** 127:22 128:10  
     142:10  
**straightforward** 133:9  
     146:12 149:16  
**strategies** 138:21  
**strategy** 23:20 34:3  
     37:16 38:10,12 177:2  
     177:5,8,16,21 183:15  
     185:2,8,21 186:13  
**stratify** 154:13  
**Straw** 108:22  
**strawman** 279:11  
**Street** 1:9  
**strengths** 102:14  
**strict** 21:9  
**strike** 209:11 251:4  
     269:16  
**striking** 251:14  
**stripe** 101:10  
**strong** 223:1

**strongly** 162:1  
**struck** 250:11 251:5  
**structural** 249:16  
**structure** 7:15 76:18  
     92:18 97:7 155:21  
     161:1,4,11,13,19,21  
     284:4  
**structures** 155:18  
     160:22  
**struggle** 145:22 170:20  
**struggling** 19:11  
     114:13 159:12 176:9  
     210:18 261:13 266:18  
**studies** 52:6 96:14 99:6  
     116:22 135:12 149:21  
     157:12 162:2 163:11  
     172:7 202:10,11  
     242:10 277:13 283:10  
     283:13  
**study** 100:3 109:22  
     110:6 120:14 124:2  
     132:11,13,14 136:15  
     139:16  
**stuff** 22:19,20 50:18  
     52:16 60:19 61:9  
     98:11 130:13 141:12  
     142:20 166:17 239:4  
**stumbled** 109:4  
**style** 125:5  
**sub** 138:16  
**sub-** 230:8  
**subject** 104:18  
**subsetting** 105:20  
**substantial** 281:5  
**success** 93:8  
**successful** 97:10  
**sufficient** 72:10 83:21  
     143:16 218:22  
**sufficiently** 37:21  
**suggest** 183:12 198:15  
     198:15 223:5,7  
     258:19  
**suggested** 236:14  
     263:17  
**suggestion** 132:11  
     208:4  
**suggestions** 149:8  
**suggestive** 98:2  
**suggests** 237:22  
     253:14  
**sum** 68:16  
**summarize** 8:9 49:3  
     134:13 148:2 170:15  
     171:20 173:4,11  
     219:9 283:18  
**summarizes** 7:9  
**summary** 7:5 8:7 51:8  
     102:22 105:19 137:5

    148:14 275:9 283:7  
**super** 91:17 229:16  
**superficial** 142:2  
**supervision** 240:12,13  
**supplement** 61:4  
**supplemental** 7:8  
**supplementing** 38:7  
**supplier** 218:13  
**support** 22:16 78:8  
     183:19 219:1 272:6  
**supporting** 34:2 80:8  
     80:20 178:4  
**supportive** 62:6  
**supports** 139:3 259:14  
**sure** 4:15 5:12 15:12  
     16:8 20:22 21:5 24:12  
     24:13 55:12 74:7 76:2  
     79:20 84:10,14 88:12  
     93:16 94:8,12,14  
     116:2 151:8 152:13  
     159:16 165:17 166:21  
     169:14 175:8 177:5  
     187:17 194:9 196:14  
     197:1 200:18 203:21  
     209:14 227:6 228:4  
     233:6 235:1 236:6  
     237:19 238:6,7  
     241:13 248:4,10  
     250:7 258:4 259:21  
     263:8,20 265:5,9  
     269:11 271:17 277:22  
     279:20  
**surely** 61:3  
**surgeon** 54:21 118:6  
     155:3 181:19 212:1  
**surgery** 151:18  
**surgical** 80:8  
**survey** 269:2  
**surveys** 148:19  
**susceptibility** 237:17  
**suspect** 10:11  
**SUTARIYA** 2:5 66:18  
     69:20 70:3,10 209:7  
**sweat** 98:10  
**switched** 23:16  
**system** 2:1 23:18,18  
     25:16 26:4 30:22  
     31:10 32:5,6,15 35:19  
     47:17 69:19 85:16  
     94:16 100:12 101:12  
     136:17 160:3 168:20  
     176:22 178:14,17,18  
     181:13 182:19,21  
     183:6 186:3 210:8  
     223:9 235:12 245:14  
     245:20 249:15 250:4  
     272:1 273:16,18  
**system-** 69:1

**systems** 36:1 74:11,22  
76:17 248:19,19  
252:4 260:5,5

# T

**T** 66:5

**table** 12:15 13:17 14:13  
17:8,14 19:21 26:18  
58:6,12,21,21 75:7,8  
78:10 103:21 104:1  
105:4 107:17,21  
113:1 116:20 117:11  
119:11 120:1,2,16  
125:13 132:7,9  
134:16 137:7 147:13  
205:14 228:12 230:3

**tabled** 236:10

**tactics** 257:20

**tag** 186:14 188:8 235:2

**tagged** 113:21

**tagging** 231:20

**tags** 121:3

**take** 16:5 26:20 56:14  
57:16 61:22 75:15,17  
95:1,2,3 104:2 112:20  
117:12 121:15 130:17  
141:19 157:11 160:10  
162:11 163:9 164:8  
178:2 186:7 188:15  
193:7 201:6 202:5,22  
203:19 204:3 207:22  
213:12 224:16 228:12  
238:17 244:7 251:13  
252:10 265:18 278:9  
279:17 283:13,20

**taken** 32:13 83:20

132:3 134:8 163:1  
179:21 186:18 232:4  
261:16

**takes** 92:18

**talk** 5:17 21:1 35:9

41:11,20 47:8 90:3  
95:10 99:8 103:22  
126:18 129:12 142:4  
156:4 159:4 161:15  
175:9 199:20 219:12  
256:8 264:8 270:1  
278:17 279:2

**talked** 27:17 28:3 35:12  
41:18 43:15 71:2 79:6  
103:13,21 107:5  
113:7 115:2 126:12  
127:16 129:1 145:10  
148:16 149:2 151:14  
171:4 179:15 180:3  
200:11 229:22 235:6  
235:7 244:10 256:21  
257:6 283:16,17

**talking** 13:17 29:22

30:2 51:9 63:2,2  
67:13 73:16 77:20  
80:3 89:16 101:11  
105:2,3 108:6 112:7  
141:4 143:19 150:11  
153:19 163:20 168:18  
170:2,5 174:11  
197:19 206:17 211:13  
215:10 222:8 235:18  
240:9 242:8 243:1,4  
255:12 262:15 264:16  
268:22

**talking-** 100:4

**target** 113:15,15,16  
179:11

**Taroon** 2:13 153:9

178:20

**task** 19:16 20:17 266:21

**tax** 113:11 213:9 214:1  
214:6,9,9

**taxonomy** 74:11 75:8

75:21 77:16,17 78:2  
85:8 86:14 102:9  
124:6 125:13,17  
126:16,22 129:9  
153:12 154:12

**team** 11:17 37:13 41:18

42:20 68:7 70:3 88:19  
89:12,19 96:19  
211:19 212:5 215:19  
215:20 216:1,11  
232:19 284:9

**team's** 9:1

**team-based** 249:17

**teams** 54:15 89:3

238:18

**tease** 96:10 235:14

**technical** 105:11 144:8

146:13 211:21 212:6  
213:3 230:11 234:8

**technically** 229:14

233:12 234:9

**techniques** 80:3

**technology** 273:8

**teleconference** 2:20

**telephone** 275:3

**tell** 38:17 70:21 83:13  
127:22 128:10 142:10  
201:11

**temperature** 279:22

**temporal** 84:12,19 85:2

**ten** 158:22 159:3,5

163:16

**tend** 41:22

**tendency** 223:1,17,18

272:3

**Tennessee** 160:1

**tension** 19:12 23:22

49:8 161:17 230:14

**tensions** 35:11

**term** 29:10 30:3 31:1,14

114:14 126:4 156:17

183:5 205:20

**termination** 124:12

**terminology** 30:5

193:11 217:3

**terms** 11:7,10 12:2,15

12:18 13:4 17:15 23:2

27:17 29:22 30:1

74:21 76:15 95:4

104:2 107:3 123:20

124:20 129:5 131:7

148:14 149:9 150:3

159:20 171:5 173:2

175:20 194:1,22

196:2 202:17 216:6

217:9 221:6,12 238:8

238:22 239:11 240:8

242:8,16 252:18

261:21 278:6 280:4

283:16

**terrible** 177:14

**test** 62:3 71:19 73:8,15

74:3 77:15 84:22 85:1

144:14 147:16,20,20

149:4 173:16 190:17

190:22 191:3,3 194:1

194:4,9,12,18 195:8,9

234:10 244:4,6

268:20

**tested** 24:8 71:22 187:4

190:19,21 191:2

196:12

**testing** 20:2 22:6 73:20

73:21 74:5 107:7

146:3 147:15,16

190:17 194:6,18

196:16 248:14

**tests** 146:8,9,11 208:5

**text** 117:19

**texting** 142:8

**thank** 4:5 5:2 32:19

33:1 50:9 102:21

116:18 120:17 127:1

127:4 128:12 134:16

137:6 171:18 220:17

236:2 264:2 275:1

284:6,15,15

**thanks** 5:21 10:21

34:22 50:10 51:7 54:4

87:20 127:6 236:1

**theirs** 197:18

**theme** 254:17

**theoretically** 67:14

181:4

**theory** 73:7 86:18 146:7  
179:3

**thing** 31:5 38:18 53:22

57:15 62:10 66:21

73:1,20 79:21 80:14

84:11 89:22 93:17

97:5,5,6,17 98:19

125:15 138:16 142:18

144:19 150:10,12

156:3 159:16 164:2

167:4 168:9 175:14

177:14 181:20 189:14

196:16 211:2 212:21

213:4 214:2,10

219:20 229:11 230:9

231:6 256:9 262:3

264:19 266:13

**things** 11:13,18 14:3

18:18 25:22 43:17

51:8,11 52:3 58:18

61:15,21,22 65:2 67:6

77:19 79:8 84:17,18

85:1,7 89:6 92:13

94:17 96:15 97:3

98:13 108:12,17

109:21 124:11 126:3

126:7 128:3,19

137:19 142:22 143:19

143:20,22 144:12,20

155:3 159:19 162:14

164:14 169:7 170:1

177:11 192:15 196:11

200:21 208:15 214:3

218:3 222:7,17

227:21 228:15 230:1

233:9 234:3 238:7

241:10 244:13 249:19

254:10 255:6 259:21

260:2,12 269:10

270:5 273:19 276:11

277:1 279:7 280:16

**things-you-** 253:14

**think** 4:20 5:4 10:14,21

11:19,20,21 13:7,13

13:17 14:3,8 15:1

17:5,6,12,13,17 18:1

18:3,6,7,14,17,20

19:15 21:2,3,6,11,11

21:18 22:1,5,22 23:3

24:2,11,21 25:6,17

26:16,19 28:3,15,18

28:20,21 29:11,18

30:4,18,22 31:4,12,18

32:1,10,12,21 33:13

33:14,18,20,22 34:15

35:3,13,15 36:13,21

37:3,5,8 39:17 41:19

42:10,17 43:12,17,21

44:4,17 45:3,8,14  
 46:2,6,13 47:2,6,13  
 47:15,20 48:6,8,10,22  
 49:3,8,16 50:1,6,11  
 50:13,16 51:11 53:1,8  
 53:15,17 54:7,18  
 55:16,18,20 56:13,14  
 56:20 57:3,8,16 59:7  
 60:2,17 61:8,20,21  
 62:22 63:5,8 64:11,14  
 64:18 65:6,18,20  
 66:18 67:1,18 68:18  
 69:7,16,22 70:12,18  
 71:2,8,14,19 72:3,3,5  
 76:19,21 77:9 78:13  
 78:16,17,18 80:1,6  
 81:10 83:8 84:2 85:9  
 85:10,11 86:14 87:16  
 87:19 89:12,20 91:7  
 91:17,18,21 92:21  
 93:15,22 94:10,14  
 97:8,15,22 98:4,5,7  
 98:20 99:7,11,17  
 101:4,5 102:7,15,18  
 103:12,20 105:2,19  
 105:21 106:3,8,18  
 107:1,5,9,11 108:12  
 108:20 110:20 111:4  
 115:17 116:19 117:5  
 117:10,14 118:13  
 119:16 120:2 121:5,9  
 121:12,18,20 122:10  
 122:17,20,21 123:2,3  
 123:4,7,10,11,12  
 124:5,7,16,19 125:20  
 125:22 126:3,7  
 128:13,16,20 129:12  
 129:13,18 130:4,10  
 130:20 131:4,7 132:2  
 132:11 133:8,10  
 134:7 136:18,19,22  
 137:4,11 138:2,2  
 139:12 140:4,18,22  
 141:1,2,8 142:3  
 144:10,10 145:10  
 146:11,16 147:1,3  
 148:13,14,17 150:1  
 150:10,13,14 151:19  
 151:21 152:17,19  
 153:5,7,17 154:4,9,18  
 155:5,10,17 156:11  
 156:19,20,22 157:3,9  
 158:6,11,13,19,21  
 159:1,6,15 162:13,21  
 163:1,2,10 164:2,9,12  
 164:15,15,16 165:1,7  
 165:11,12,19 166:12  
 166:17,18,19,22

167:3 168:4,11,16  
 169:13,17 170:4  
 171:6 172:9,21 174:2  
 174:10 175:22 176:14  
 178:19,22 179:5,6  
 180:11,21 182:1  
 183:1,9 184:5,7,21  
 185:3,11,12,16,17  
 186:1,2,17 187:14,15  
 187:16,22 189:1,2  
 190:15 191:4,6,14  
 193:2,16,18 195:8,10  
 195:14,17,22 196:1  
 197:10,11,13 198:13  
 199:4 201:3,4,10,16  
 201:18,20 202:7,7,10  
 202:12 203:5,20  
 204:17,19 205:19  
 206:2 207:17 208:2,3  
 208:4 209:13 210:1  
 210:12 211:11,18  
 213:4,18 214:1,7,8,22  
 215:1,15 216:21  
 218:11 219:14,21  
 220:11 221:1,19  
 222:22 223:6,19  
 224:8,14 225:1,4,6,13  
 226:16 227:2,6,12  
 228:1,1,5,8,14,15  
 229:1,3,3,8,11,15,18  
 230:13 231:4,6 232:8  
 232:14,16 233:4,19  
 234:19 236:4,20  
 237:1,2 238:5,6,10,19  
 238:21 239:5,6 240:8  
 242:3,11,16,19 243:1  
 243:15 244:9,10,20  
 246:4,6,8,16 247:14  
 247:15,15 248:2,3  
 249:1,13 250:14,19  
 251:1 252:4,16,20,22  
 254:6,8,9,13,17  
 255:11,13,18,21  
 256:1,1,10 257:9  
 259:2 260:9 263:14  
 263:16 264:16,21  
 265:6 266:1,5,10,10  
 266:17,20,21 267:10  
 268:14,16,17,19  
 269:15,17 271:9,9  
 272:7 273:9,12,19  
 274:5,9,13 278:18,22  
 279:1,8 280:22  
 281:21 282:8,10  
**thinking** 7:11,12 9:20  
 19:5,19 26:21 28:17  
 31:18,20 33:6 49:17  
 52:18 55:10 62:21

63:16 87:17 89:3  
 95:13,21 96:4,13  
 105:15 123:11 124:21  
 126:19,20 128:22  
 134:18 147:9,9  
 148:16 149:12 150:3  
 151:3 162:14 168:19  
 176:5 182:4,6 193:8  
 196:15 197:3,16  
 200:3 207:4 211:15  
 211:18,21 215:4  
 222:17 227:1 238:10  
 241:12 258:2 260:11  
 262:19 280:1 282:9  
**thinks** 224:10  
**third** 24:22 87:3 109:10  
 143:7 155:14 166:4  
 205:4  
**thorny** 99:3 134:10  
 149:17 152:20 155:15  
**thought** 6:1 20:20  
 27:19 31:5 34:15  
 36:18 37:2 44:3 53:13  
 55:21 72:7 75:7 88:21  
 89:6,7 99:19,21  
 103:19 105:19 107:2  
 107:4 111:12 117:1  
 118:11,15 119:3,4,11  
 127:20,22 132:8  
 135:7 137:10 145:11  
 153:5,10,13 156:6,15  
 170:14 176:3,6,17  
 179:14 182:11 197:9  
 207:11 213:14 222:14  
 244:7 247:7 257:13  
 266:13 271:16,20  
 272:4 273:3  
**thoughtful** 28:3  
**thoughts** 19:8 27:10,13  
 34:16,18 51:6 104:20  
 179:13 244:19  
**thread** 173:20  
**threats** 102:15  
**three** 56:12 67:2 71:22  
 96:12 124:11 138:4  
 160:8,11,13 185:18  
 232:1 236:15 240:2  
 242:14 269:3 282:10  
**three-** 115:1  
**three-and-a-half** 103:16  
**thresholds** 42:16 44:2  
 45:11  
**threw** 9:22  
**throw** 66:8 80:14 127:7  
 171:14 225:22 251:18  
**tie** 153:21 166:16,16  
**tied** 21:6 62:14 109:11  
 221:16 225:11

**tiering** 160:3  
**till** 103:16  
**time** 11:3,21 14:16 15:9  
 15:10,22 16:4 17:9  
 23:9 25:15 26:22 34:7  
 39:6,7,20 40:1 44:20  
 45:18 46:15 53:8  
 77:20,21 81:2,3 84:13  
 84:21 85:2 88:3 95:4  
 95:19 111:16,22  
 115:11 124:12 125:19  
 126:6 129:15 138:22  
 139:7,7 148:18  
 158:20 164:13 172:19  
 175:6,17 176:13  
 191:18 194:3 199:13  
 209:4,10 210:1 245:6  
 245:13,22 246:2  
 247:12 248:16,20,21  
 249:8 251:17 260:6  
 260:12 263:19 264:5  
 264:19 265:17,21  
 270:21 271:4 275:1,6  
 280:21 281:2,8 282:1  
 283:11 284:6  
**timed** 241:3,6  
**timeline** 15:8  
**times** 95:10 109:5  
 129:2 199:10 215:17  
 220:3 222:9 273:15  
 279:6  
**timing** 16:9 39:2 282:14  
**timing's** 16:9  
**TIN** 213:14  
**TINs** 113:11 118:21  
**tiny** 108:1,1  
**today** 5:9,14 6:2,17  
 14:9,10 18:4 21:1  
 29:6 38:11 47:9 56:4  
 68:5,11 79:6 95:4  
 96:8 107:6 145:11  
 166:19 175:22 176:5  
 192:11 210:2 252:14  
 254:20 268:17 270:5  
 270:19 275:13 276:4  
 279:18 280:2 282:19  
**today's** 12:11 269:14  
**told** 68:12 81:22 257:4  
**tolerate** 86:8  
**Tom** 267:21  
**toolkit** 130:16  
**top** 86:20 108:2,16,21  
 124:16 142:12 155:10  
**topic** 8:11  
**topics** 5:20  
**toss** 227:14  
**total** 71:4  
**totally** 87:10 132:16



139:1 216:7 232:15  
**touch** 235:9  
**touching** 119:8 221:8  
**tough** 125:14  
**trace** 137:21  
**track** 110:3,15,16,19  
111:2 114:11 117:12  
118:21 159:19 230:9  
278:10 279:2  
**tracks** 110:17  
**tractability** 44:15  
**traction** 93:8  
**trade-offs** 49:9  
**tradeoffs** 144:2  
**traditional** 38:8  
**tragedy** 244:5  
**trajectory** 128:22  
**transformation** 266:21  
**transitions** 128:7  
**transparency** 117:15  
226:1 238:3 260:16  
**transparent** 25:1 28:5  
62:1 108:13 226:3,12  
260:16  
**treated** 193:13  
**treatment** 167:14,15  
**tree** 154:14  
**tremendous** 75:3  
**trenches** 81:17  
**tried** 42:20 43:1 64:20  
**tries** 76:11 178:2,4  
**triggered** 199:14  
**triple** 177:20,22 178:5  
206:16  
**tripped** 195:8  
**trouble** 32:15 53:22  
57:12 151:4 152:14  
**troubling** 190:16  
**Troy** 1:14 17:18 22:8  
29:2 31:4 95:6 99:12  
100:14 127:3 128:15  
128:20 140:21 193:4  
193:5 202:12 212:11  
214:19 231:3 236:3  
236:11 238:14 243:9  
256:15 273:15  
**Troy's** 99:10 225:4  
243:15 245:3  
**true** 92:10 109:6,6  
267:1  
**truth** 64:15 65:2,11 66:5  
102:2  
**truthiness** 66:14 102:2  
**truths** 66:10  
**try** 16:4 20:2 33:17 35:8  
37:9 41:11 53:6 57:17  
63:11,12 64:16,20  
87:18 95:21 97:18

99:14 100:1 103:20  
104:4,12 108:6 114:8  
118:22 120:2,21  
125:7 126:2 135:19  
137:18 149:6 153:21  
154:12 172:1,7 173:1  
173:10,16,22 186:6  
195:18 200:1 226:4  
231:15 233:22 250:8  
250:12 265:12 279:4  
279:18 283:18  
**trying** 22:18,19 23:21  
31:17 35:5 36:20  
39:21 47:16 51:19  
56:14 68:5,9 73:4  
78:5 89:18 91:9 94:16  
95:12 100:4 104:2  
105:4 106:1 109:20  
113:2 116:14 117:17  
122:3 128:8 133:8  
136:19 138:5 147:3  
148:6 149:6 150:5,22  
151:19 152:12 157:10  
162:21 163:2 164:16  
164:18 165:2,12  
170:20 173:21 181:21  
183:3 186:14 187:18  
188:7,12,15 189:2,6  
191:22,22 196:1  
200:22 201:19 205:5  
206:8 210:12 212:4  
214:22 224:16 225:2  
225:11 229:3 230:13  
231:7 232:8 237:2  
240:5 244:11 245:5  
246:5 251:19 252:22  
255:16 263:10 265:11  
266:2 267:4 270:10  
272:12 284:12  
**Tuesday** 278:15 279:17  
280:10,14,18 282:7  
282:18,22  
**tune** 107:14  
**turn** 5:4 27:12 134:14  
136:5 242:21 274:16  
**turned** 229:10  
**tweak** 147:22 153:6  
**tweet** 172:22  
**two** 6:3 9:9,22 14:20  
42:5 65:5 66:19 68:19  
69:4 71:22 75:10  
78:16 93:18,19 94:5  
95:1,10 105:14,15  
109:7 115:9 118:8  
123:16 128:2 132:18  
133:16 138:8 145:4,9  
145:15 146:19 147:1  
151:5 152:20 158:17

179:20 188:6 190:3,8  
196:2,6 199:15  
200:20 201:13 202:1  
202:21 203:1,1  
205:13 218:3 226:10  
241:9 244:21 247:13  
261:8 262:15 267:8  
273:7 277:13 278:7  
280:15,17,20 282:10  
284:8,10  
**two-day** 6:6  
**two-dimensional**  
125:13  
**two-page** 8:7  
**two-thirds** 271:22  
**type** 38:22 51:14 52:3  
86:20,22 130:16  
138:5 161:13 237:15  
237:18 256:9  
**types** 37:3 66:22 78:14  
157:2 193:17 221:11  
**typical** 37:17 162:2  
163:16 169:4  
**typically** 48:13  
**typing** 231:1

## U

**U.S** 20:6,17  
**ultimate** 253:20  
**ultimately** 6:8 8:3 9:12  
96:18 185:22 189:13  
202:12 261:17 269:5  
269:10  
**unable** 16:16  
**unavoidable** 236:21  
**uncertainty** 85:22 86:1  
86:5,7,8,11,12,13  
87:12,12,13,14  
**uncommon** 163:14  
**unconsciously** 32:4  
**uncoordinated** 35:19  
35:22  
**underlying** 63:7 94:15  
102:2  
**undermine** 46:22  
163:15 168:15  
**undermined** 46:7  
**underneath** 124:9  
246:12 247:8  
**underserved** 218:14  
**understand** 14:21  
29:11 77:22 97:18  
99:17 101:20 121:10  
122:14 142:3 149:6  
156:18 157:17 164:4  
165:5,9 171:12  
227:20 248:10 255:16  
**understanding** 122:1

197:2 213:5 264:18  
**understood** 76:3  
**underway** 49:2  
**unintended** 25:4 31:12  
95:22 236:15,16,20  
236:21 237:2 238:11  
240:18,19 243:10  
**unintentionally** 236:13  
**unique** 235:15  
**unit** 113:6 124:9 126:10  
126:10 130:2 153:19  
154:19,19 157:21  
231:19 232:12 234:17  
**unitive** 106:5  
**units** 154:1  
**University** 1:16,18,21  
2:4,16 5:15  
**unpackage** 228:15  
**unpublished** 81:16  
**unwanted** 236:20  
**urban** 218:12  
**usability** 142:15  
**use** 13:2,16 26:12 27:3  
31:1,9 37:13 43:19  
47:9 52:9 56:12,15  
57:6 58:4,10 64:20  
77:2 78:11,14 79:1,9  
79:14 92:8,15 102:12  
107:8,14 108:10,22  
109:4 114:14 115:18  
115:20,21 121:7,13  
126:4,16,17 128:21  
130:17 137:21 138:3  
138:6 143:1 149:9  
150:4,15 156:7,16  
157:12 160:9 164:2  
165:7 173:20 182:22  
183:5,21 185:19  
186:6 194:10,13  
206:9 214:3 216:8  
218:4 225:13 236:16  
241:7 245:2,19  
250:17 253:18 257:16  
258:5 262:8 265:12  
272:18 274:3 277:8  
279:19 282:17 283:19  
**useful** 17:12 77:10  
93:12,14 102:19  
116:19 118:2 123:15  
125:21 131:8 132:4  
134:18 136:9 147:1  
228:16 270:6  
**user** 95:20 97:16 141:8  
**users** 13:10 157:1  
**uses** 73:9  
**usually** 15:5 164:16  
**Utah** 1:15

V				
<b>VA</b> 2:1 <b>vacation</b> 268:7 <b>vaginal</b> 240:20 <b>valid</b> 187:15 194:15 <b>validate</b> 171:11 <b>validation</b> 170:22 171:4 <b>validity</b> 24:14 25:12 44:8 46:7 47:5 49:11 73:7,8 89:5 114:15 145:19,21 146:3,22 187:9 <b>value</b> 74:17 <b>value-based</b> 35:18 36:11 109:13 <b>values</b> 218:12 <b>variability</b> 43:6 <b>variable</b> 86:3 <b>variation</b> 42:12 49:5 63:20 64:1 235:12 <b>varied</b> 52:13 64:3 <b>variety</b> 125:16 <b>various</b> 11:7 68:6 188:17 213:13 277:7 <b>vary</b> 43:21 121:17 <b>varying</b> 27:18 164:21 <b>vast</b> 4:17 41:14 <b>vastly</b> 45:11 <b>VBAC</b> 241:2 <b>vehemently</b> 129:22 <b>verbally</b> 279:10 <b>versus</b> 6:22 13:22 19:13 26:7 30:21 39:3 39:5,11 49:14,19,22 51:10 52:7 55:11,14 78:12 84:8,15 106:6 120:13 122:8 127:16 133:11 138:3 151:17 152:8 154:22,22 155:1 215:9 225:18 226:7 <b>vibe</b> 136:3 <b>Vice</b> 2:9 <b>video</b> 131:12 174:5 <b>view</b> 16:19 35:10 36:5 169:10 <b>vignette</b> 159:17 <b>Village</b> 1:14 <b>visit</b> 46:9 81:20 181:19 213:11 <b>visits</b> 39:16 40:11 42:5 42:7 143:2 181:18 <b>visual</b> 18:20 <b>voice</b> 54:3 100:21 173:21 224:3 <b>volume</b> 125:15 <b>voluntarily</b> 258:11 <b>vote</b> 208:19 223:22	234:20 244:18 245:8 251:13 278:21 279:11 280:7 <b>votes</b> 271:7 <b>vulnerability</b> 31:7  <th data-bbox="548 338 841 367">W</th> <b>waivers</b> 62:11 142:11 <b>walk</b> 5:5 96:11 128:1 141:14,17 149:19 150:22 215:4 261:11 274:20 <b>want</b> 11:12 13:1,10,21 14:9,17 15:13,17 17:11 19:7,20 21:14 22:13 24:4 26:18 28:12 30:11 31:9,20 33:16 34:14 43:11 45:15 50:5 51:16 54:14,16,17 62:15 65:10 68:12,14 71:18 72:11 75:15,17 76:22 77:5,11 84:7 85:17 87:22 91:8,11 93:10 93:11 95:3 96:18 102:8 104:5 108:2,9 112:18 114:12,16 115:3,7,18,21 116:2 118:11 121:6 122:18 124:6 125:18,19 126:19 131:10,12,16 132:3 134:8,19 136:6 136:13 140:8,12 141:10 147:20 150:2 150:6,8 151:2,8,15 152:10,18,19 153:2,6 153:9 155:16 157:13 158:15,16 159:3 162:10,12,16 163:14 163:14,17 164:2 166:21 168:4,5,6 169:7 173:20 174:3,8 174:9 175:14,22 176:11 178:14 182:22 183:4 186:6 187:1 189:10,17,20 191:10 192:1,4,10 193:12,12 193:13 194:3,10,13 198:18 199:5,5,12,17 200:12,18 202:13,13 205:10,14 206:10,12 208:8 209:14 215:2 215:11 217:19 218:18 219:4,6 220:1,4,8,16 224:4 226:3 227:5,14 230:15 234:4,16 235:5 237:7 238:16 239:4 240:14 241:9	W	241:13,21 245:18 246:15 252:3,6 254:5 256:19 257:1,18 258:19 261:11 265:19 274:20 276:14,15,20 278:19 279:14 281:6 281:18 <b>wanted</b> 4:8 7:17 25:14 66:8 79:18,21 80:9,14 81:1 84:10 85:6 91:13 102:5 114:10 147:5 159:18 163:22 168:9 171:1,14 183:19 191:11,17 193:22 222:18 229:20 233:1 236:8 244:9 261:1 281:3 <b>wanting</b> 217:21 <b>wants</b> 224:22 <b>Washington</b> 1:9 <b>wasn't</b> 52:17 69:17 82:11 101:15 106:7 137:8 187:17 211:13 231:12 241:5 265:9 271:16 <b>water</b> 251:19 <b>waters</b> 227:8 <b>wave</b> 128:11 <b>way</b> 15:21 17:8 25:22 33:7 37:4,20 40:3 42:9 45:14 62:16 64:7 66:4 73:11 76:12 78:14,18 85:21 91:6 96:10,11 97:22 108:2 123:16 139:14,14 140:5,20 142:9 143:15,21 144:8 147:11 152:9 153:14 157:9 159:15 161:15 165:12 166:5 171:7 171:10 194:16 195:10 195:16 207:21 211:21 214:4 215:5 216:13 218:13 246:21,22 247:4,17 249:7 252:3 253:11 257:8 258:20 260:18 278:22 279:12 <b>ways</b> 33:4 40:20 64:2 73:5 87:8 123:16 124:20 127:21 144:3 144:5,6,9 166:6,16 185:16 244:12 247:1 259:21 270:2 278:7 <b>wayside</b> 228:9 <b>we'll</b> 7:7 9:9 11:16 17:4 17:10,13 18:10,20 23:11,12 32:11 46:20 47:8 74:3 81:12 83:21	83:22 84:3 96:14 103:6 104:7,9,15 114:6,7 131:22 135:12,14 157:13,14 158:21 159:4,5,6 172:12,13 173:10,15 173:17 175:5,7,9,17 186:20 195:5 263:20 274:9 275:4 277:5 278:1,11 280:6 282:20 <b>we're</b> 4:21 6:5,8,14,19 7:16 11:11 12:20 14:12,15,21,22 18:4 19:17 21:1 23:7 27:7 28:4 29:22 30:1,4 33:11 34:12 36:13,14 38:7 51:12 53:10 56:1 62:16 63:1,2 67:13 68:4,8 71:21 72:19,21 73:2,4 74:2 76:16 77:17 78:2 79:19,21 80:3,6 81:5 84:10 94:16 96:4 100:4 101:11 103:11,22 105:4,5 112:19,20 113:2 129:21 130:4 131:1,21 135:10 136:19 139:6 143:12 146:5 147:10 148:20 150:11,22 154:8,8 156:16 158:10,13 165:10,12 166:16 170:2,4 172:3 174:6 181:17,21 182:12,17 182:18,20 183:3 184:17 185:3 189:5 191:22 194:22 195:18 196:1 201:19 212:5 216:14 232:12 239:15 239:15 240:4,9 242:8 242:10 244:11,11 248:11 249:22 265:11 265:22 273:14 277:19 278:3 282:17 <b>we've</b> 6:17,18 7:10 10:9 14:10 61:10 71:2 83:19 84:21 90:6 93:19 94:22 98:20 107:5,6 108:21 116:4 126:1 142:19 145:10 148:4,4 182:14 228:1 242:3 243:22,22 244:10 264:5 268:18 283:17 <b>weak</b> 101:18 <b>weaker</b> 252:5 <b>weaknesses</b> 102:14

**web** 276:1  
**web-based** 130:16  
**website** 15:20 141:16  
 241:13  
**Wednesday** 1:5 282:19  
**weeds** 45:16  
**weedy** 145:3  
**week** 16:2,3,10 139:17  
 275:11 282:20,21  
**weekend** 282:21  
**weeks** 172:15 173:17  
 282:10  
**weigh** 170:18 206:7,12  
 217:19,22 227:5  
 229:7 264:11 266:16  
 271:12  
**weighing** 267:13  
**weight** 70:7 109:21  
 152:11  
**weighting** 234:15  
**welcome** 4:3 13:3  
**well-defined** 36:18  
**well-said** 72:7  
**went** 13:19 64:22 82:9  
 100:11,12 103:9  
 116:21 123:19 142:7  
 157:20 175:11 226:5  
 241:2 284:18  
**weren't** 58:8 60:2  
 109:20 114:3 258:14  
**Werner** 37:14  
**what-** 195:16  
**wherewithal** 226:20  
**whichever** 160:2  
**White** 1:22 215:10,14  
**who've** 157:19  
**WILBON** 2:10 5:21 8:20  
 9:3,6,16 10:3,6,18  
 15:6 103:11 278:21  
 280:8 282:16 283:3  
**wild** 74:13  
**willing** 66:4 202:5  
 279:16  
**willy-nilly** 207:15  
**wind** 131:2  
**window** 45:17 48:21  
**wine** 263:22  
**wish** 96:7 183:5 240:15  
**woman** 161:7  
**wonder** 67:9 98:19  
 118:2 130:14 150:19  
 156:1 227:16  
**wondering** 11:5,11 52:2  
 117:5 245:1  
**word** 30:20 31:9 36:6  
 39:21 41:12 91:16  
 93:18 178:17 182:22  
 195:9 214:22 245:19

249:15 251:1,2,10  
**wording** 225:12 254:16  
 272:11 274:11  
**words** 37:18 38:8  
 140:13 183:1 207:2,5  
 218:4 240:14 244:21  
 258:6  
**wordsmith** 189:5  
 193:11 239:10  
**wordsmithing** 182:18  
 195:22 266:5  
**work** 3:2 4:17,19 5:15  
 7:4 9:1,1 11:6,9,10,19  
 14:4,11,14 15:5,17  
 16:10 22:12 44:18  
 52:10 54:14 60:5  
 68:15 73:21 74:7  
 76:16 77:19 79:8,21  
 81:13 83:3 87:6,18  
 88:16 90:2,6,15 97:2  
 99:13 100:22 101:9  
 101:16,19 104:2  
 161:14 164:11 178:3  
 180:8 189:2,17  
 191:13 202:1 205:9  
 205:11 242:9 257:5  
 262:9 277:4,17  
 283:14  
**worked** 67:6,11 68:18  
 69:1,13,13 70:22  
 88:18 116:19 134:16  
 240:3  
**workgroup** 100:1  
 277:11  
**workgroups** 283:9  
**working** 7:16 14:15  
 18:11 72:16 75:1  
 77:17 78:1 88:19 89:4  
 97:3 102:1 127:6  
 137:8 174:9 232:6  
 245:7 258:21 277:1  
 277:16  
**works** 22:19 172:22  
 174:4 203:5  
**world** 57:22 68:2 90:9  
 192:6 201:12 234:12  
 234:13 268:15  
**worried** 85:13 196:3  
 207:20 212:6  
**worries** 235:19  
**worry** 98:10 156:5  
 190:16 195:2 203:16  
 203:17  
**worse** 253:10,13  
**worst** 163:10  
**worth** 102:7  
**wouldn't** 5:10 13:15  
 16:10 46:20 62:15

150:8 188:20 247:6  
**wrap** 6:2 104:16 170:12  
 170:14 264:8 274:17  
 274:18  
**wrapping** 39:18  
**wrench** 282:2  
**wrestled** 215:3  
**write** 15:10 189:4 216:9  
**writing** 71:9 250:8  
**written** 16:10 133:20  
**wrong** 82:21 97:13  
 209:22 212:7 250:22  
 251:1  
**wrote** 124:10 126:4  
 184:6,15

---

**X**


---

**X** 12:22 116:12 118:11

---

**Y**


---

**yada** 141:19,19,19  
**Yale** 1:13  
**yeah** 105:18 106:17,17  
 109:5 129:15 133:6  
 137:4 138:9 140:15  
 147:8 148:15 152:16  
 153:13 155:8 156:18  
 160:19 165:16  
**year** 49:22 84:16 88:5,6  
 88:8,10,12,20 115:9,9  
 151:6,8 153:20,21  
 154:22 155:1 167:7,8  
 167:17,21,22 199:12  
 199:19 240:1  
**years** 4:18 22:11 65:5  
 67:3 88:20 96:7  
 240:22  
**yesterday** 4:6 5:5 12:15  
 17:5,9 25:7 27:11  
 29:9 32:22 34:7 35:14  
 43:13,16 54:8 55:17  
 82:17 108:4,14 109:5  
 113:7 115:2 119:18  
 129:16 131:20 139:17  
 171:22 187:20 188:14  
 191:21 202:9 212:10  
 214:2 217:4 231:7  
 232:9 264:18 275:13

---

**Z**


---



---

**O**


---



---

**1**


---

**1** 3:2 54:8 231:20  
**1's** 34:5  
**1,000** 84:3  
**10** 43:4 64:2,3 84:1,2

88:19 189:15 203:14  
 204:5 220:9 235:9  
**10,000** 215:8  
**10:30** 81:6,7  
**10:47** 103:9  
**100** 32:13 72:11 74:12  
 189:16,18,19 197:21  
 220:8 234:6 256:22  
 266:2  
**103** 3:10  
**1030** 1:8  
**11** 135:18  
**11:00** 81:5,6,12 103:4  
**11:05** 103:10  
**110** 229:1  
**12** 45:19  
**12:14** 175:11  
**12:45** 175:6  
**12:54** 175:12  
**138** 56:7  
**15** 1:6 33:4 240:21  
 264:5  
**15th** 1:8 281:14  
**163** 38:14 41:9 56:9  
**165** 61:10  
**168** 74:12 76:16  
**17** 41:13  
**174** 3:12  
**175** 3:14

---

**2**


---

**2** 3:2 4:4 30:7,14 58:21  
 110:3,15,16 111:2  
 114:11 117:12 118:21  
 129:1 162:3 198:17  
 207:12 209:5 227:11  
 231:21  
**2:30** 103:16 186:21  
 266:3  
**2:35** 284:18  
**20** 44:20 96:6 162:18  
 165:11 166:8  
**200** 134:1 239:22  
**2006** 92:9  
**2016** 1:6  
**21st** 281:15  
**236** 3:16  
**24** 3:3  
**271** 3:18  
**28** 56:1 57:6 58:7  
**2B** 187:16 197:1

---

**3**


---

**3** 28:11 58:13,21 110:19  
 117:14 159:19 226:1  
 231:22 236:10 255:12  
**30** 40:11 42:15,17 55:20  
 96:15 143:1 174:9

175:5  
**30-minute** 174:12  
**300** 95:9  
**31** 33:4 42:8  
**35** 3:7 81:12

---

**4**

---

**4** 242:20 243:1,1 244:19  
**40** 268:1  
**42** 42:8  
**435** 101:9  
**45** 103:19 148:2

---

**5**

---

**5** 43:3 88:19,20 245:12  
**5,000** 215:8  
**50** 143:1 268:1  
**50-plus** 68:4  
**5A** 260:3

---

**6**

---

**6** 33:2 41:16 228:8  
250:14 271:16  
**68** 74:13

---

**7**

---

**7** 33:22 210:7,18 219:11  
**7-1/2** 263:2  
**70** 38:12 40:20 41:12  
**77** 42:2

---

**8**

---

**8** 84:1  
**80** 165:10  
**83** 41:12  
**85-year-old** 269:7  
**850** 84:3  
**86** 77:2,4  
**89** 41:16

---

**9**

---

**9:00** 1:9  
**9:07** 4:2  
**90** 82:3,19,20 163:16  
203:16  
**9th** 1:8

C E R T I F I C A T E

This is to certify that the foregoing transcript

In the matter of: Attribution: Principles and  
Approaches Committee

Before: NQF

Date: 06-15-16

Place: Washington, DC

was duly recorded and accurately transcribed under  
my direction; further, that said transcript is a  
true and accurate record of the proceedings.

  
-----  
Court Reporter

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

[www.nealrgross.com](http://www.nealrgross.com)